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Tumor microenvironment represents an extremely dynamic niche shaped by the 
interplay of different cell types (e.g. tumor cells, stromal cells), their soluble products 
(e.g.cytokines, chemokines and growth factors) and varied physico-chemical 
conditions (e.g low oxygen concentration or hypoxia). Recent studies have identified 
myelomonocytic cells as key players in regulating the tumor microenvironment 
and hence, tumor progression in a variety of cancers. In view of these findings, the 
present book attemps to provide a comprehensive account of the diversity of tumor 
microenvironment across different cancers and how myelomonocytic cells have 
taken the center-stage in regulating this niche to direct cancer progression. A better 
understanding of the myelomonocytic cells and the mechanisms by which they 
regulate cancer progression will open new vistas in cancer therapeutics.
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Tumor microenvironment represents an extremely dynamic and diverse milieu 
consisting of different cell types (e.g. tumor cells, stromal cells), distinct physico-
chemical stimuli (e.g. low oxygen or hypoxia) and a variety of humoral factors such as 
cytokines, chemokines and growth factors. The interplay of these different elements is 
crucial to tumor progression. Therefore, investigating the tumor microenvironment 
has a direct impact on the understanding of the mechanisms which regulate cancer 
progression.  
Myelomonocytic cells have emerged as key players in the tumor microenvironment. In 
particular, tumor associated macrophages (TAMs) have served as the classical 
example of the tumor promoting actions of myelomonocytic cells. These cells 
constitute a major proportion of the inflammatory infiltrates associated with most 
solid tumors and a link between inflammation and cancer. One of the most direct 
evidence for the tumor promoting role of TAMs comes from studies which use 
transgenic approach to modulate TAM numbers in murine tumor models where TAM 
infiltration has been linked to tumor progression, angiogenesis and metastasis.  
Similarly, in many human cancers of the breast, cervix, bladder and prostrate, a high 
TAM density positively correlates with poor prognosis. More recently, other 
myelomonocytic cell types such as blood monocytes, Tie-2-Expressing Monocytes 
(TEMs), Myeloid-Derived Suppressor Cells (MDSCs), and Tumor Associated 
Neutrophils (TANs) have been shown to possess protumoral activity. Inspite of these 
evidences, several aspects of myelomonocytic cell repertoire in the tumor 
microenvironment remains to be understood. For example, the plasticity of these cells 
across different phases of cancer progression, the dialogue between these cells and 
other lymphocytic populations in the tumor tissues, and the possibility of re-
programming the tumor microenvironment by strategies to modulate myelomonocytic 
cells in vivo.  
The objective of this book is to present a comprehensive overview of the dynamic 
interaction between the tumor microenvironment and the myelomonocytic cells that 
leads to cancer progression. The focus is explaining how the tumor microenvironment 
polarizes the myelomonocytic cells to favor tumor growth and how these cells, in turn, 
contribute to the shaping and maintenance of the tumor microenvironment. 
Mechanisms regulating this process at the level of functional phenotypes, 
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cytokine/chemokine circuits and molecular pathways have also been addressed. For 
the reader's ease, the book is divided into three broad sections: section 1 introduces 
some of the basic features of myelomonocytic cells and details the general functions 
and the diversity of these cells in the tumor microenvironment; Section 2 focusses on 
describing the tumor microenvironments of specific cancer types, such as brain cancer, 
liver cancer, oral cancer, lung cancer and melanoma and the role of myelomonocytic 
cells therein; Section 3 focusses on describing some new players (e.g. mesenchymal 
stem cells, microRNAs) and novel approaches (e.g. in vivo imaging) of studying the 
tumor microenvironments. 
In the end, I would like to express my sincere gratitude to Profs Alberto Mantovani, 
Antonio Sica and Ajit Sodhi for mentoring me in the field of macrophage research. I 
am indebted to Saki, for her constant support and encouragement; to Prof. B. Lahiry 
for kindling my curiosity to look into the unknown. I am grateful to all my 
collaborators who have contributed to my research and the generous grant support 
from Biomedical Research Council (A*STAR). Finally, I would like to thank Maja and 
her colleagues at In Tech without whose help the production of this book would not 
have taken place. 
 
Subhra K. Biswas, PhD 
Principal Investigator  
Singapore Immunology Network (SIgN), 
Agency for Science, Technology & Research  (A*STAR), 
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Cell Lineage Commitment and Tumor 
Microenvironment as Determinants for Tumor-
Associated Myelomonocytic Cells Plasticity 
Raffaella Bonecchi1,2, Benedetta Savino1, 
 Matthieu Pesant1 and Massimo Locati1,2 
1Istituto Clinico Humanitas IRCCS, Rozzano, 
2Department of Translational Medicine, University of Milan, Milan, 
Italy 
1. Introduction 
Myelomonocytic cells have long been recognized as key elements in tumor biology, with the 
potential to both elicit tumor and tissue destructive reactions and to promote tumor 
progression. Tumor-associated macrophages (TAM) from established tumors resemble 
alternative-activated macrophages associated with the resolution phase of inflammatory 
reactions and support tumor growth, angiogenesis, tissue remodeling, metastatization, and 
local immunosuppression. On the other hand, myeloid-derived suppressor cells are released 
from bone marrow pools in tumor-bearing animals and operate immunosuppressive 
activities in tumor-draining lymphoid organs, thus contributing to tumor escape from 
immune surveillance. The ambivalent role of myelomonocytic cells in tumor biology reflects 
their extraordinary plasticity. Tumor-derived signals in the local microenvironment have 
long been recognized for their ability to dictate macrophage-polarized activation. More 
recently, different monocyte subsets have been identified in both human and mouse, and 
cell lineage commitment is now emerging as a second element dictating cell functional 
polarization. We will here review current knowledge on the relative contribution of these 
two elements in the plasticity of myelomonocytic cells in the tumor setting. 
2. Macrophage heterogeneity and polarization mechanisms 
It is well established that tumors are environments of deregulated innate and adaptive 
immune responses. In this scenario, several evidences link tumor initiation and progression 
to chronic inflammation and recent findings have started dissecting the underlying cellular 
and molecular mechanisms. Macrophages represent one of the major myelomonocytic-
derived cell types detectable within the tumor (Condeelis & Pollard 2006; Mantovani et al. 
2008). It is now widely documented that tumor-associated macrophages (TAM) infiltration 
and biological activities within the tumor favor tumor growth/development (Pollard 2004; 
Lin et al. 2006; Mantovani et al. 2008), and consistently with this TAM infiltrate is usually 
associated with poor prognosis (Bingle et al. 2002; Lewis & Pollard 2006; Torroella-Kouri et 
al. 2009; Qian & Pollard 2010). 
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In contrast with classically activated macrophages (also known as M1 macrophages), in 
most tumors macrophages present an “alternative” activation state (Elgert et al. 1998). 
Originally based on in vitro studies inspired by the Th1/Th2 paradigma, macrophage 
activation can be schematically reconciled to two main phenotypes (Figure 1). Macrophages 
stimulated with the Th1 cytokine IFNγ and bacterial components such as LPS were named 
classically-activated macrophages or M1. They are characterized by a high production of IL-
12 and IL-23, sustain the Th1 response by producing the chemokines CXCL9 and CXCL10, 
exhibit cytotoxic activity and high phagocytosis capacity, a high production or reactive 
oxygen intermediates (ROI), and display a good antigen presentation capability (Mantovani 
et al. 2002; Gordon 2003; Verreck et al. 2004; Gordon & Taylor 2005; Mantovani et al. 2005; 
Martinez et al. 2006). As a first line of defense against pathogens M1 play an important role 
in protection from viral and microbial infections. By their ability to produce high amounts a 
pro-inflammatory cytokines and mounting an immune response they also limit tumor 
growth/development. At the other extreme of the macrophage polarization spectrum are 
cells exposed to the Th2 prototypical cytokine IL-4, referred to as alternatively-activated 
macrophages or M2 macrophages (Stein et al. 1992). More recently, different forms of 
alternative activation polarization, collectively indicated as M2-like macrophages, have been 
reported as a consequence to activation by other stimuli, including the combination of 
immune complexes and TLR ligands, IL-10, TGF, and glucocorticoids (Mantovani et al. 
2004). In general terms, hallmarks of M2 and M2-like cells are a high expression of negative  
 
Macrophages differentiate from monocytes after M-CSF and/or GM-CSF stimulation. Subsequent 
polarization pathways include classical activation induced by IFNγ and LPS (M1 macrophages) and 
alternative activation triggered by IL-4/IL-13 (M2 macrophages). In the tumoral microenvironment, 
tumor-associated macrophages (TAMs) encounter diverse polarizing stimuli produced by tumoral cells, 
Th2 cells, Treg cells and B cells that skew their activation state to a phenotype resembling M2 
macrophages, leading to tumor promotion/development. 
Fig. 1. Macrophage polarization mechanisms and cancer: a dangerous imbalance. 
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regulators of the inflammatory response, including IL-10 and IL-1 receptor antagonist, and 
scavenger and galactose-type receptors (for example CD36 and the mannose receptor 
MRC1). M2 also produce abundant levels of the chemokines CCL17, CCL22 (Bonecchi et al. 
1998) and CCL18 (Bonecchi et al. 2011) that in turn favor and sustain a Th2 response and 
tumor growth. Furthermore, M1 and M2 have distinct metabolic properties, as 
demonstrated by the dichotomic metabolic pathways of arginine (Munder et al. 1998; Hesse 
et al. 2001) and iron (Recalcati et al. 2010; Cairo et al. 2011). Major functions of M2 are their 
contribution in the clearance of parasites, wound healing and tissue remodeling, 
suppression of T-cell proliferation, pro-tumoral activity by virtue of their immunoregulatory 
and angiogenic abilities (Biswas & Mantovani 2010). 
3. The tumor microenvironment: Macrophage polarity in Tumor-Associated 
Macrophages (TAM) 
Several tumor-microenvironmental signals have been reported to instruct TAM 
polarization, including prostaglandin E2 (Rodriguez et al. 2005; Hagemann et al. 2006; 
Eruslanov et al. 2009; Eruslanov et al. 2010), migration-stimulating factor (MSF) (Solinas et 
al. 2010), and TGF (Flavell et al. 2010). Strong evidence also supports the relevance of M-
CSF as a pro-tumoral factor attracting and triggering a M2-like polarization within the 
tumor. Indeed in human tumors, overproduction of M-CSF is associated with a poor clinical 
outcome in a wide range of cancers and several tumor types feature characteristics of an M-
CSF-induced gene expression signature (Espinosa et al. 2009; Webster et al. 2010). This is 
consistent with transcriptional profiling analysis on in vitro differentiated macrophages, 
which have shown that M-CSF differentiated macrophages exhibit M2-like features, while 
GM-CSF differentiated macrophages exhibit M1-like features (Martinez et al. 2006; 
Fleetwood et al. 2007; Hamilton 2008). Accumulating experimental evidence from murine 
models of cancer further showed the pro-tumoral role of M-CSF. For example transplanted 
tumors’ growth is impaired in M-CSF-deficient mice (Nowicki et al. 1996) and blockade of 
either M-CSF or is receptor leads to impaired tumor growth (Aharinejad et al. 2004; Kubota 
et al. 2009; Priceman et al. 2010). On the other hand, whereas no effect on tumor 
development was observed in the spontaneous mammary cancer model MMTV-PyMT in an 
M-CSF deficient background, the development of metastatic carcinoma was delayed (Lin et 
al. 2001). Angiogenesis is clearly a pro-tumoral feature as it provides the necessary “fuel” 
favoring tumor growth. In this context M-CSF has been shown to exert a pro-angiogenic 
effect in macrophages by inducing the production of VEGF (Curry et al. 2008). 
A second pathway skewing TAM to the M2 phenotype is sustained by the Th2-derived 
cytokines IL-4 and IL-13. In the spontaneous mammary carcinoma model driven by PyMT 
both cytokines have been shown to be responsible for the M2 polarization of TAMs 
(DeNardo et al. 2009). In this model IL-4 derived from CD4+ T cells and IL-13 derived from 
NKT cells instruct TAM an M2-like polarization leading to tumor development. Conversely, 
blockade of IL-4R led to a diminished M2-like gene expression profile and a switch to M1-
associated gene expression, ultimately resulting in increased tumor surveillance. IL-4-
induced M2 polarization of TAM has also been evidenced in a model of pancreatic cancer 
(Gocheva et al. 2010). IL-4 induced the activity of cathepsin in TAM, resulting in increased 
angiogenesis and tumor growth. The contribution of IL-13 to the M2 polarization of TAM 
has been demonstrated in the 4T1 mammary carcinoma model (Sinha et al. 2005). In this 
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context, macrophages from CD1d-deficient mice (that lack NKT cells) show a M1 
tumoricidal phenotype and metastasis resistance. IL-10 is also well known to induce an M2 
phenotype. In tumor, IL-10 produced by Treg cells has been shown to dampen TAM 
capacity to mount a T cell mediated immune response (Kuang et al. 2009). B cells are also a 
source of tumoral IL-10. It has been demonstrated that IL-10 production by B-1 cells induced 
a M2 polarization of TAMs in a B16 melanoma model (Wong, S. C. et al. 2010). Besides the 
contribution of B cells-derived IL-10 in driving M2 polarization of TAM, new evidence 
support that B cells skew TAM to a M2 phenotype via production of T cell-dependent 
autoantibodies against an extracellular matrix component in a K14-HPV16 skin 
carcinogenesis model (de Visser et al. 2005; Andreu et al. 2010). 
Finally, emerging evidence indicate that besides their major role in monocyte recruitment 
chemokines, CCL2 (MCP-1) in particular, may also be involved in macrophage polarization 
in the tumor burden (Roca et al. 2009). Indeed, human CD11b+ peripheral blood 
mononuclear cells induced to differentiate upon CCL2 stimulation upregulated M2 markers 
such as CD14 and CD206 (also known as Mannose Receptor 1). This M2 polarizing effect 
and thus pro-tumoral role of CCL2 is paralleled with the observation that many tumors 
overexpress CCL2 and these high levels have been associated with a bad outcome in cancer 
patients (Qian & Pollard 2010). It was furthermore recently reported in a murine breast-
cancer model that CCL2 induced inflammatory monocytes infiltration in tumors (Qian et al. 
2011). Moreover, tumor cells-derived CCL2 was shown to play a prominent role in 
metastasis development. 
4. Cell lineage commitment: Monocyte subsets 
Experimental evidence highlights that macrophage plasticity depends not only on the 
specific microenvironment encountered upon their extravasation from the circulation, but 
also on the existence of myelomonocytic subsets and lineage-committed TAM 
subpopulations that exploit diverse tumor-promoting activities (Coffelt et al. 2010b; 
Geissmann et al. 2010a; Geissmann et al. 2010b). On the basis of morphology and differential 
expression of antigenic markers, three types of blood monocytes (classical, intermediate, and 
nonclassical) have been described for both human and murine system (Ziegler-Heitbrock et 
al. 2010). In the mouse monocytes, which express CD115 (M-CSF receptor) and CD11b (Mac 
1), are classified based on the expression level of Ly6C (one of the epitopes recognized by 
the anti-Gr-1 monoclonal antibody) in Ly6ChighCD43+ or classical monocytes, 
Ly6ChighCD43++ or intermediate monocytes and Ly6ClowCD43++or nonclassical monocytes. 
These two subsets have been demonstrated to have different functions and migration 
patterns (Auffray et al. 2009), as classical monocytes are CX3CR1lowCCR2+CD62L+ and are 
actively recruited to sites of inflammation whereas nonclassical monocytes were 
CX3CR1hiCCR2-CD62L- and make homing to non-inflamed tissues. Recently, Geissman and 
colleagues demonstrated that the nonclassical monocyte subset constantly patrols the blood 
vessel wall and can be rapidly recruited to sites of inflammation before the arrival of 
classical monocytes (Auffray et al. 2007). The developmental relationship between the two 
monocyte subsets is still unclear. Experimental data suggest the possibility of a common 
precursor that gives rise to both classical and nonclassical monocytes. Adoptive transfer of 
classical monocytes demonstrated that this subset decreased the expression of Ly6C giving 
rise to nonclassical monocytes (Yrlid et al. 2006; Varol et al. 2007; Movahedi et al. 2010). 
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However, the generation of nonclassical monocytes has not been affected by antibody-
mediated depletion or genetic defect in classical monocytes (Scatizzi et al. 2006; Feinberg et 
al. 2007; Mildner et al. 2007; Alder et al. 2008). Monocyte subsets were also identified in the 
human settings, with some consistency and some discrepancies as compared to the murine 
setting. Three human monocyte subsets were defined based on the expression levels of 
CD14 and CD16 (the FcRIII molecule): classical monocytes (CD14++CD16-), intermediate 
monocytes (CD14++CD16+) and non-classical monocytes (CD14+CD16++). Gene expression 
profiles of these subsets indicates that they exhibit common gene expression patterns (at 
intermediate levels mirroring the CD14/CD16 levels) but also display unique features that 
potentially argue for distinct roles of these subsets in the immune process (Wong, K. L. et al. 
2011; Zawada et al. 2011). Classical and non-classical monocytes have both pro-
inflammatory activities for examples in response to LPS challenge but differ in the 
cytokine/chemokine repertoire they produce in response to LPS (Wong, K. L. et al. 2011). 
Moreover, non-classical monocytes show “patrolling” properties and appear to be very 
responsive to virus stimulation (Cros et al. 2010). So far, no specialized function has been 
assigned for intermediate monocytes but it is of note that their frequency is increased in 
cardiovascular diseases (Heine et al. 2008; Rogacev et al. 2011) and HIV (Ellery et al. 2007; 
Jaworowski et al. 2007). Tie2-expressing monocytes (TEM) were found in the nonclassical 
monocyte subset (De Palma et al. 2005). These monocytes play a non-redundant role in 
tumor neovascularization as their selective depletion resulted in reduced tumor 
angiogenesis in murine tumor models. TEM are selectively recruited to tumors by the Tie2 
ligand angiopoietin-2 (ANG-2), which is expressed by tumor endothelium (Venneri et al. 
2007; Coffelt et al. 2010a). Recent results indicate that Tie2 can be expressed also by classical 
and intermediate human monocytes (Zawada et al. 2011). 
A discussed issue about monocyte heterogeneity is about identity and localization of their 
precursors. A compartmental reservoir of extramedullary monocytes has been identified in 
the subcapsular red pulp of the spleen (Swirski et al. 2009). These undifferentiated 
monocytes express Ly6C, rapidly amplified and are recruited to ischemic myocardium 
while their role in the tumor context is still unknown. Mobilization and proliferation of 
precursors in peripheral tissues has been studied as another mechanism to give rise to 
differentiated macrophages (Massberg et al. 2007). CCR2 ligands seem to play a central role 
for the mobilization of committed hematopoietic precursors to peripheral sites where they 
differentiate into M2 repair macrophages (Si et al. 2010). Hematopoietic precursors were 
found also in some tumor bearing-mice models (Kitamura et al. 2007; Deak et al. 2010) and 
probably they contribute to the mature macrophage pool. CD34+ hematopoietic progenitors 
in presence of breast cancer cell culture medium differentiate in CD11b+ myeloid cells that 
seem to be involved in the tumor angiogenesis and in the initiation of premetastatic niche. 
Proangiogenic CD11b+ monocytes have been identified in the blood of tumor-bearing mice 
and cancer patients (Laurent et al. 2011). 
At present our understanding of the relative role of monocyte subsets in tumor infiltration 
and biology is still largely incomplete. Classical monocytes represent one of the cellular 
components of a heterogeneous population of myeloid nature indicated as myeloid-derived 
suppressor cells (MDSC), which also includes immature monocytes and granulocytic cells 
(Sinha et al. 2007; Gabrilovich & Nagaraj 2009; Peranzoni et al. 2010). MDSC are functionally 
defined for their immunosuppressive functions, are expanded both at tumor site and in 
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secondary lymphoid organs in tumor-bearing animals and in cancer patient blood samples, 
where their increase correlated with the clinical cancer stage (Diaz-Montero et al. 2009). 
Recently it has been demonstrated that classical monocytes preferentially infiltrate lung 
tumor metastasis, while nonclassical monocytes are mainly recruited to primary tumor site 
(Qian et al. 2011). 
5. An integrated view 
The different circulating monocyte subsets identified appear to be committed to distinct 
extravascular fates in the tumor microenvironment (Figure 2). Classical monocytes are 
thought to differentiate mainly toward M2-like macrophages (Sinha et al. 2007; Geissmann 
et al. 2010b), and several studies have showed that MDSC in the tumors differentiate into 
immunosuppressive TAM (Kusmartsev & Gabrilovich 2005; Movahedi et al. 2010) and 
tolerogenic dendritic cells (Liu et al. 2009; Augier et al. 2010). Conversely, in TS/A and 4T1 
tumors classical monocytes have been shown to include the precursors of both M1-like TAM 
enriched in hypoxic regions of the tumor and M2-like macrophages (Movahedi et al. 2010). 
As TEM are concerned, it is interesting to note that ANG-2 induces an M2-like phenotype 
(Pucci et al. 2009). However, TEM depletion has no impact on TAM recruitment in murine 
tumor models (De Palma et al. 2005), suggesting that TEM likely represent a sub-population 
of monocytes distinct from TAM precursors. Finally, despite monocytes have long been 
considered the unique precursors of macrophages, local proliferation of tissue-resident 
macrophages has been demonstrated for many populations, as alveolar macrophages 
(Sawyer et al. 1982; Tarling et al. 1987; Landsman et al. 2007), splenic white-pulp and 
metallophilic macrophages (Wijffels et al. 1994), and liver Kupffer cells (Crofton et al. 1978),  
 
Fig. 2. Lineage commitment and tumor microenvironment in the generation of mononuclear 
phagocytes heterogeneity at the tumor site. 
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principally in homeostatic conditions. Of note, Allen and colleagues have also recently 
described IL-4-driven local proliferation of resident macrophages during helminth infections 
(Jenkins et al. 2011). In the context of cancer, it would thus be of great interest to address the 
potential effect of IL-4 on TAM proliferation to get a better insight in de novo recruitment of 
monocytes/macrophages versus local expansion of the existing pool of TAM. 
The two main murine subsets, classical (Ly6Chigh) and non-classical (Ly6Clow) monocytes, 
originate from hematopoietic precursors (HPC) in bone marrow and enter the tumor mass. 
Once in the tumor, exposure of monocytes and macrophages to different stimuli drive their 
polarization and function, resulting in the generation of the heterogeneous infiltrate. It 
remains unknown whether Ly6Clow nonclassical monocytes are generated through a 
Ly6Chigh intermediate (dotted lines). 
6. Conclusion 
Macrophages are heterogeneous and plastic cells of the myelomonocytic lineage which 
adapt to the microenvironmental cues by changing their transcriptional program. Using 
cancer as a paradigm for macrophage polarization leads to the current view that various, if 
not all tumor-associated signals/factors/cytokines/chemokines/growth factors lead to a 
macrophage phenotype closely but at the same time different from the M2 type. Besides 
TAM, in tumors other monocyte/macrophages populations have been described, including 
MDSC, HPC and TEM, which display molecular and functional signatures resembling 
circulating monocytes subsets. 
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1. Introduction 
Myeloid cells are abundant in solid tumors and early infiltrate neoplastic lesions since the 
first stages of tumourigenesis, usually preceding other leukocytes (e.g. lymphocytes). (Clark 
et al., 2007) In the last decades there has been growing evidence that infiltrating T 
lymphocytes (CD3+ CD8+CD45RO+) are associated with favourable prognosis in human 
colorectal cancer (Laghi et al., 2009; Pages et al., 2005) melanoma, ovarian and breast cancer 
(Clemente et al., 1996; Mahmoud et al., 2011; Vesely et al., 2011; Zhang et al., 2003) In 
marked contrast, cells of the innate immunity, like myeloid cells, are most frequently 
associated with poor clinical outcomes. A number of studies have demonstrated that tumor-
associated myeloid cells (TAMCs) have the ability to support tumor cell proliferation and 
invasion, activate the neo-angiogenic switch, and suppress anti-tumor immune responses. 
(DeNardo et al., 2009; Mantovani et al., 2004a; Martinez et al., 2009; Pollard, 2004; Qian and 
Pollard, 2010; Talmadge et al., 2007) Thus, in a simplified scheme, adaptive immunity is 
usually protective and limit tumour progression, while innate immunity favours disease 
development. However, research in recent years have added a further level of complexity, 
as components of the adaptive immunity (e.g. IL-4-producing CD4 T cells and antibody-
producing B cells) have been shown to activate innate immune cells in a pro-tumour 
manner. (DeNardo et al., 2009; Wang and Joyce, 2010)  Therefore, the dynamic interplay 
between tumor-infiltrating cells of the innate and adaptive immunity is of paramount 
importance for the outcome of tumour progression or regression. 
Tumor-associated myeloid cells (TAMCs) include at least four different myeloid 
populations (Figure 1): 1) tumor-associated macrophages (TAMs), considered crucial 
orchestrators of cancer-related inflammation (Mantovani et al., 2008), promoting 
angiogenesis, immunosuppression, tissue remodelling and metastasis (Sica, 2010); 2) the 
angiogenic monocytes expressing the tunica internal endothelial kinase 2 (Tie2), the 
angiopoietin receptor, playing a key role in tumor angiogenesis (De Palma et al., 2005); 3) 
the Ly6G and Ly6C subsets of an heterogeneous population of immature myeloid cells, 
called myeloid-derived suppressor cells (MDSCs) for their ability to suppress T cells  
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Fig. 1. Pathways of differentiation and accumulation of TAMCs. In the bone marrow 
hematopoietic stem cell (HSC) differentiate into common myeloid progenitors (CMPs), which 
can subsequently differentiate into different subsets of circulating myeloid cells: monocytes 
(Mo), Tie2-expressing monocytes (TEM), neutrophils (PMN), and granulocytic and monocytic 
myeloid-suppressor cells (G-MDSC and M-MDSC). Tumors secrete factors which sustain 
myelopoiesis, and promote both the recruitment and pro-tumor differentiation of circulating 
myeloid cells. TAMs are recruited into the tumor site by chemotactic factors (eg. CCL2, CSF-1) 
and represent the prominent phagocytes population orchestrating cancer-related 
inflammation. TEMs derive from circulating Tie2+ monocytes and are recruited in tumors by 
hypoxia-inducible chemoattractants, such as Ang2 and CXCL12. Tumor-associated 
neutrophils (TANs) stem from circulating neutrophils and are recruited in tumors by 
chemokines (e.g. CXCL8). TANs participate in tumor promotion by the expression of crucial 
pro-angiogenic factors. During tumour progression an heterogeneous population of myeloid 
cells (G-MDSC and M-MDSC) accumulate in blood and lymphoid organs. MDSCs may be 
recruited by selected chemoattractants (CCL2, S-100, VEGF, C5a) into the tumor 
microenvironment, where they contribute to suppression of the adaptive immunity.  
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functions, which accumulate mainly in blood and lymphoid organs during tumor 
progression, but may also be recruited to the tumor site (Sica and Bronte, 2007); 4) tumor-
associated neutrophils (TANs) that, despite their short half-life, have been recently proven 
to participate in tumor promotion by the expression of crucial pro-angiogenic factors 
(Fridlender et al., 2009). 
TAMCs originate in the bone marrow where hematopoietic stem cells (HSCs) differentiate 
into common myeloid precursors (CMPs), which subsequently give rise to different subsets 
of circulating cells: immature myeloid cells (IMCs) that can be further subdivided in a 
granulocytic (CD11b+/Ly6G+) and a monocytic (CD11b+/Ly6C+) subpopulation, monocytes 
(CD11b+/Gr1+/F4/80+/CCR2+), Tie2-expressing monocytes (CD11b+/Gr1low/-/Tie2+) and 
neutrophils (CD11b+Ly6G+) (Mantovani et al., 2009). Tumors secrete factors which sustain 
myelopoiesis, promote the recruitment of circulating cells into the tumor mass, and orientate 
their functional differentiation to their own advantage (Mantovani et al., 2009; Sica and 
Bronte, 2007). In addition, Dendritic cells (DCs) also belong to the family of myeloid cells 
stemming from CMPs. Cells with dendritic characteristics are scarcely present in neoplastic 
tissues (Murdoch et al., 2008). Tumor-associated DCs generally show an immature 
phenotype and are poor inducers of effective responses to tumor antigens. The properties of 
these cells have been extensively reviewed elsewhere (Ma et al., 2011; Palucka et al., 2010) 
and are not discussed here. 
2. Pro-tumour functions of tumor-associated myeloid cells 
2.1 Tumor-associated macrophages 
TAMs derive from circulating monocytes which are recruited at tumor sites by a number of 
diverse chemoattractants secreted by tumour and stromal cells. For instance the chemokine 
CCL2 was discovered as a tumour-derived factor inducing chemotaxis in 
monocytes.(Bottazzi et al., 1983; Zachariae et al., 1990) Other chemokines these include : 
CCL3, CCL4, CCL5, CXCL12 (Balkwill, 2004; Konishi et al., 1996; Schioppa et al., 2003). Non-
chemokine chemotactic factors are also important, for instance: urokinase plasminogen 
activator (uPa) (Zhang et al., 2011), M-CSF, TGF; fibroblast growth factor, FGF; vascular 
endothelial growth factor, VEGF) (Joyce and Pollard, 2009; Lin et al., 2002; Sica and Bronte, 
2007) and antimicrobial peptides (-defensin-3, BD-3) (Jin et al., 2010). Many of these 
molecules correlate with TAMs infiltration in different types of tumor, while other (eg. uPa, 
BD-3) are specifically associated with certain types of cancer, prostate and gastric cancer 
respectively (Jin et al., 2010; Zhang et al., 2011).  
Once in tumours, monocytes differentiate to macrophages, primarily because of the 
presence of M-CSF produced by tumour cells, and polarize to tumour-educated 
macrophages by exposure to the local milieu rich in immune-suppressive mediators such as 
IL-10, TGF and VEGF. 
Macrophages are versatile cells that are capable of displaying different functional activities, 
some of which are antagonistic: they can be immuno-stimulatory or immune suppressive, and 
either promote or restrain inflammation. (Auffray et al., 2009; Gordon and Taylor, 2005; 
Hamilton, 2008; Mantovani et al., 2004b; Martinez et al., 2009)  Macrophage heterogeneity has 
been simplified in the macrophage polarization concept where the two extreme phenotypes, 
the M1 and M2 macrophages, have distinct features. (Allavena et al., 2008; Goerdt and 
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Orfanos, 1999; Gordon and Taylor, 2005; Mantovani et al., 1992; Pollard, 2009; Stein et al., 1992) 
M1 or classically–activated macrophages are stimulated by bacterial products and Th1 
cytokines (e.g. IFN); they are potent effectors that produce inflammatory and immuno-
stimulating cytokines to elicit the adaptive immune response, secrete reactive oxygen species 
(ROS) and nitrogen intermediates and may have cytotoxic activity to transformed cells. M2 or 
alternatively activated macrophages differentiate in micro-environments rich in Th2 cytokines 
(e.g. IL-4, IL-13); they have high scavenging activity, produce several growth factors that 
activate the process of tissue repair and suppress adaptive immune responses. (Gordon and 
Martinez, 2010; Mantovani et al., 2005; Qian and Pollard, 2010)  
While this M1 vs M2 dual subsets simplification offers a mechanistic model of the functional 
polarization of macrophages, tissue microenvironments are likely to elicit simultaneous 
activation of different signalling pathways with opposite influence on macrophage 
functions, contributing to the extensive heterogeneity in patterns of gene expression seen in 
macrophages (Gratchev et al., 2008; Murray and Wynn, 2011; Ravasi et al., 2002; Riches, 
1995; Stout et al., 2005; Tannenbaum et al., 1988). This in vivo functional skewing of myeloid 
populations is an emerging paradigm of tumor-mediated immunosuppression, where 
myeloid cell plasticity plays as a double-edged sword (Mantovani and Sica, 2010; Sica and 
Bronte, 2007). In early phases, high production of M1 inflammatory mediators (e.g. tumor 
necrosis factor, TNF; reactive oxygen species, ROS) appears to support neoplastic 
transformation (Sica and Bronte, 2007), whereas in established cancers the expression of M2-
like phenotypes with immunosuppressive, pro-angiogenic and tissue remodelling activities 
promotes immune escape, tumor growth and malignancy (Dinapoli et al., 1996; Mantovani 
and Sica, 2010; Movahedi et al., 2010; Pollard, 2004; Saccani et al., 2006; Sica and Bronte, 
2007; Sica et al., 2008; Sica et al., 2000).  
In molecular profiling studies, murine TAMs from fibrosarcoma showed several features of 
M2 macrophages: arginase-I, YM1, FIZZ1, MGL2, VEGF, osteopontin and MMPs, as well as 
an immunosuppressive phenotype : high IL-10, TGF and  low IL-12, RNI and MHC II, 
which correlate functionally to reduced cytotoxicity and antigen-presenting capacity. 
(Biswas et al., 2006; Hagemann et al., 2009; Ojalvo et al., 2010) Similar findings were found 
in human TAMs from ovarian cancer patients.(Allavena et al., 2010)  We compared the 
expression of  upregulated genes in human TAMs with the profiling of in vitro-polarized 
M1 and M2 macrophages. Several genes (e.g. osteopontin, fibronectin, scavenger and 
mannose receptors)  were similarly upregulated in TAMs and in M2 macrophages. By the 
Principal Component Analysis, the global profiling of TAMs fell much closer to that of M2-
polarized macrophages. (Solinas et al., 2010)   
However, TAMs heterogeneity is starting to emerge, likely depending on the tumour type 
and micro-environmental cues. (Lewis and Pollard, 2006; Movahedi et al., 2010) Notably, 
murine TAMs showed also the expression of typical M1 factors such as IFN-inducible 
chemokines (CCL5, CXCL9, CXCL10, CXCL16). (Biswas et al., 2006; Stout and Suttles, 2005) 
TAMs influence fundamental aspects of tumour biology, as shown in figure 2. Among the 
well documented pro-tumour functions of TAMs is the production of trophic and activating 
factors for tumour and stromal cells (e.g.EGF, FGF, VEGF, PDGF, TGF). These growth 
factors directly promote the proliferation of tumour cells and increase the resistance to 
apoptotic stimuli (Ingman et al., 2006; Kalluri and Zeisberg, 2006; Mantovani et al., 2008; 
Moussai et al., 2011) The cytokine IL-6, released by TAMs, is important to sustain the  
 




Fig. 2. Pro-tumour functions of Tumour-Associated Myeloid Cells (TAMCs). Different 
types of TAMCs promote the progression of tumors. TAMs rescue neoplastic cells from 
apoptotic stimuli and stimulate their proliferation, by producing several growth factors and 
cytokines (e.g.EGF, IL-6). TAMs, TEMs and TAN activate angiogenesis, via VEGF, MMPs 
and other angiogenic factors. TAMs have an intense proteolityic activity and degrade the 
extra-cellular matrix, but also produce matrix proteins, such fibronectin (FN1). TAMs favour 
tumour cell intravasation and dissemination to distant sites. TAMs and MDSC induce 
immune suppression by producing suppressive mediators such as IL-10 and TGF,  
arginase 1 and nitric oxide (NO).  
survival and proliferation of malignant cells in tumours of epithelial and hematopoietic 
origin. (Bollrath et al., 2009; Fukuda et al., 2011; Grivennikov et al., 2009; Lesina et al., ; 
Ribatti and Vacca, 2009)  TAMs are also a major source of proteolytic enzymes that degrade 
the ECM, thus favouring the release of matrix-bound growth factors. (Joyce and Pollard, 
2009; Mantovani et al., 2008)  
TAMs a key effectors of the “angiogenic switch" where the balance between pro- and anti-
angiogenic factors, commonly present in tissues, tilts towards a pro-angiogenic outcome. 
(Baeriswyl and Christofori, 2009; Du et al., 2008; Murdoch et al., 2008; Zumsteg et al., 2009) 
In hypoxic conditions the transcription factor HIF-1alpha induces in TAMs the production 
of VEGF and of the angiogenic chemokine CXCL8. (Lewis et al., 2000)  
TAMs are probably the most active contributors to the incessant matrix remodelling present 
within tumours, as they produce several MMPs and other proteolytic enzymes. (Mason and 
Joyce, 2011) Tumour cells exploit the ECM degradation mediated by TAMs to invade 
locally, penetrate into vessels and disseminate to give distant metastasis. (Wyckoff et al., 
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2007) TAMs aiding cancer cell invasion have been directly visualized in experimental 
tumours in vivo by multiphoton microscopy: by using fluorescently labelled cells Wyckoff 
and colleagues showed that tumour cell intravasation occurs next to perivascular 
macrophages in mammary tumours. (Pollard, 2008; Wyckoff et al., 2007)  Further, it has 
been recently shown that cathepsin protease activity, by IL-4-stimulated TAMs, promotes 
tumour invasion.(Gocheva et al., 2010) IL-4 is produced by tumour-infiltrating CD4 T cells 
and there is mounting evidence of its relevance in the polarization of macrophages with pro-
tumour functions. (DeNardo et al., 2009; Wang and Joyce, 2010) The chemokine CCL18 
produced by TAMs has been recently shown to play a critical role in promoting breast 
cancer invasiveness by activating tumour cell adherence to ECM. (Chen et al., 2011) 
We recently found that human TAMs and in vitro tumour-conditioned macrophages 
express high levels of the Migration Stimulation Factor (MSF), (Solinas et al., 2010) a 
truncated isoform of Fibronectin. (Schor et al., 2003) Macrophage-secreted MSF displays 
potent chemotactic activity to tumour cells in vitro,(Solinas et al., 2010) confirming that the 
pro-invasive phenotype of cancer cells is modulated by macrophage products released in 
the tumour-micro-environment.  
Further support to the concept of a reciprocal interaction between tumour cells and TAMs 
was provided by a recent paper where SNAIL-expressing keratinocytes became locally 
invasive after macrophage recruitment elicited by M-CSF. (Du et al., 2010)  
In line with the above experimental evidence, high numbers of infiltrating TAMs have been 
significantly associated with advanced tumours and poor patient prognosis, in the majority 
of human tumours.(Bingle et al., 2002; Mantovani et al., 2008; Pollard, 2004; Qian and 
Pollard, 2010)  There are, however, notable exceptions to this pro-tumour phenotype, 
probably dictated by their functional polarization. One such exception is human colorectal 
cancer, where some studies reported that TAMs density is associated with better 
prognosis.(Forssell et al., 2007; Ohno et al., 2003; Sconocchia et al., 2011) The localization of 
TAMs within colorectal cancers appears of primary importance: the number of peritumoural 
macrophages with high expression of costimulatory molecules (CD80 and CD86), but not of 
those within the cancer stroma, was associated with improved disease-free survival.(Ohtani 
et al., 1997; Sugita et al., 2002) 
Specific TAMs subsets identified by surface markers may have predictive values: in lung 
adenocarcinoma, the number of TAMs CD204+ (scavenger receptor) showed a strong 
association with poor outcome while the total CD68+ population did not. (Ohtaki et al., 
2010) 
Macrophage-related gene signatures have been identified in human tumours such as 
ovarian and breast cancer, soft tissue sarcoma and follicular B lymphoma; (Beck et al., 2009; 
Finak et al., 2008; Ghassabeh et al., 2006; Lenz et al., 2008) in classic Hodgkin's lymphoma, 
tumours with increased number of CD68+ TAMs were significantly associated with 
shortened progression-free survival. (Steidl et al., 2010) 
Recent addition to the molecular repertoire of TAMs includes semaphorin 4D (Sema4D) 
(Sierra et al., 2008) and growth arrest-specific 6 (Gas6) (Loges et al., 2010), which are 
respectively involved in promoting tumor angiogenesis and cancer cell proliferation.  
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2.2 Tie2-expressing onocytes/macrophages (TEMs)  
Tie2-expressing monocytes/macrophages (TEMs) are a small subset of myeloid cells 
characterized by the expression of the angiopoietin receptor Tie2 and powerful pro-
angiogenic activity (De Palma and Naldini, 2009; De Palma et al., 2005; Murdoch et al., 2007; 
Venneri et al., 2007). They derive from circulating Tie2-expressing monocytes which are 
recruited in tumors by hypoxia-induced endothelial-derived chemotactic factors, such as 
Ang-2 and CXCL12 (Coffelt et al., 2011; Murdoch et al., 2007; Venneri et al., 2007; Welford et 
al., 2011b) The CXCL12-CXCR4 axis is a well known circuit driving accumulation of TAMs 
in hypoxic areas of solid tumors (Schioppa et al., 2003). In addition, it has been 
demonstrated that pharmacological inhibition of CXCR4 is associated with a significant 
reduction of TEM recruitment into mammary tumors (Welford et al., 2011b). Both ablation 
and adoptive transfer studies have demonstrated that TEMs are crucial promoters of tumor 
angiogenesis (De Palma et al., 2005; De Palma et al., 2003; Venneri et al., 2007). In two 
models of mammary tumours and orthotopic human gliomas, Ganciclovir-driven ablation 
of Tie2+ monocytes induced a significant reduction of both tumour mass and vasculature, 
demonstrating their importance in tumour angiogenesis and growth (De Palma et al., 2005; 
De Palma et al., 2003; Venneri et al., 2007). In line, adoptive transfer studies demonstrated 
that subcutaneous co-injection of tumor cells with TEMs increases tumor vascularization 
(De Palma et al., 2005).  
Strikingly, gene expression analysis highlighted that TEMs are highly related to TAMs, but 
express a more pronounced M2-skewed gene signature, with higher expression of M2 genes, 
including arginase 1 (Arg1), scavenger receptors (CD163; Mannose receptor 1, Mrc1; 
Macrophage scavenger receptor 2, Msr2; stabilin-1) and lower levels of pro-inflammatory 
molecules (IL-1; prostaglandin endoperoxide synthase 2/cyclooxygenase 2, PTGS2/COX2; 
IL-12; TNF; inducible nitric oxide synthase, iNOS; CCL5; CXCL10; CXCL11) (Pucci et al., 
2009). These results suggested that Tie2+ monocytes could be a distinct lineage of myeloid 
cells, committed to execute physiologic pro-angiogenic and tissue-remodeling programs, 
which can be co-opted by tumors (Andreu et al., 2010). Noteworthy, human Tie2+ 
circulating monocytes express high levels of pro-angiogenic genes (e.g. VEGF-A; Matrix 
metallopeptidase 9, MMP9; COX2; wingless-related MMTV integration site 5A, WNT5A) 
and are powerful inducers of endothelial cells activation (Coffelt et al., 2010). In agreement, 
sub-cutaneous tumors growing in Ang-2-overexpressing mice showed increased number of 
TEMs associated with enhanced microvessels density (Coffelt et al., 2010). Tie2 engagement 
by Ang-2 in both mouse and human TEMs not only elicits a chemotactic response but also 
enhances their pro-tumoral activities (Coffelt et al., 2010). It was also recently demonstrated 
that Ang-2 levels in 4T1 mammary tumors correlates with both TEM-derived IL-10 and Treg 
infiltration, resulting in suppression of T cells proliferation (Coffelt et al., 2011). In contrast, 
Ang-2 inhibited the expression of M1 cytokines (IL-12 and TNF) in TEMs exposed to 
hypoxia (Murdoch et al., 2007).  
2.3 Myeloid-Derived Suppressor Cells (MDSCs) 
MDSCs represent an heterogenous population of cells whose common characteristics are an 
immature state and the ability to suppress T-cell responses both in vitro and in vivo 
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009).  
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2.2 Tie2-expressing onocytes/macrophages (TEMs)  
Tie2-expressing monocytes/macrophages (TEMs) are a small subset of myeloid cells 
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angiogenic activity (De Palma and Naldini, 2009; De Palma et al., 2005; Murdoch et al., 2007; 
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reduction of TEM recruitment into mammary tumors (Welford et al., 2011b). Both ablation 
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Ang-2 inhibited the expression of M1 cytokines (IL-12 and TNF) in TEMs exposed to 
hypoxia (Murdoch et al., 2007).  
2.3 Myeloid-Derived Suppressor Cells (MDSCs) 
MDSCs represent an heterogenous population of cells whose common characteristics are an 
immature state and the ability to suppress T-cell responses both in vitro and in vivo 
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009).  
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MDSC recruitment and expansion are regulated by several cytokines, chemokines and 
transcription factors (Sica and Bronte, 2007). It has been demonstrated that among 
chemokine receptors, CCR2 plays a pivotal role in the recruitment and turnover of MDSC to 
the tumour site (Sawanobori et al., 2008). Furthermore, the C5a complement component, 
which interacts with a G protein-coupled receptor, has been shown to play a role in MDSC 
recruitment and activation in a cervix cancer model (Markiewski et al., 2008). Some factors 
which are found in the tumour microenvironment, such as pro-inflammatory S-100 proteins, 
are also crucial for MDSC recruitment. Sinha and co-workers demonstrated that MDSCs can 
produce S-100 proteins by themselves, providing evidence for an autocrine loop that 
promotes MDSC recruitment (Cheng et al., 2008; Sinha et al., 2008). 
MDSCs possess several mechanisms for immune suppression: 1) depletion of arginine, 
mediated by Arg1 and iNOS; 2) production of ROS; 3) post-translational modifications of T 
cell receptor (TCR) mediated by peroxynitrite generation; 4) depletion of cysteine; 5) 
production of TGF; 6) induction of Tregs (Bronte et al., 2005; Huang et al., 2006; Movahedi 
et al., 2008; Nagaraj et al., 2007; Srivastava et al., 2010; Terabe et al., 2003; Yang et al., 2006; 
Youn et al., 2008). In healthy individuals, IMCs differentiate in mature granulocytes, 
macrophages or dendritic cells, whereas in pathological conditions they expand into 
MDSCs. MDSCs have been observed in cancer, chronic infectious diseases, and 
autoimmunity. In tumor-bearing mice, MDSCs accumulate within primary and metastatic 
tumors, in the bone marrow, spleen and peripheral blood. In cancer patients, MDSCs have 
been identified in the blood.  
Recent studies have contributed to partially clarify the biology of MDSCs. In mice, two 
major subsets were identified on the basis of their morphology and the expression of Ly6 
family glycoproteins: monocytic MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs). 
M-MDSCs are CD11b+ Ly6G- Ly6Chigh cells with monocyte-like morphology, while G-
MDSCs are CD11b+ Ly6G+ Ly6Clow with granulocyte-like morphology (Ostrand-Rosenberg 
and Sinha, 2009). Cells with similar phenotype, precursors of myeloid cells, are present in 
physiological conditions, but they are devoid of immunosuppressive activity. These cells, 
therefore, should not be named MDSCs (Youn and Gabrilovich, 2010). Other markers of 
MDSC subsets are: IL-4R (CD124), F4/80, CD80, and CSF-1R (CD115) (Sica and Bronte, 
2007). The characterization of MDSCs deeply suffers from the lack of specific markers. 
However, recent characterizations have identified human MDSCs as CD34+ CD33+ CD11b+ 
HLA-DR- cells (Ostrand-Rosenberg and Sinha, 2009). The ability to differentiate into mature 
DCs and macrophages in vitro has been shown to be restricted to M-MDSCs (Youn et al., 
2008). M-MDSC-mediated immune suppression does not require cell-cell contact, but 
utilizes up-regulation of iNOS and Arg1, as well as production of immunosuppressive 
cytokines (Gabrilovich and Nagaraj, 2009). On the contrary, G-MDSCs suppress antigen-
specific responses using mechanisms, including the release of ROS, that require prolonged 
cell-cell contact between MDSC and T cell (Gabrilovich and Nagaraj, 2009). The C5a subunit 
of the complement system appears a key regulator of MDSC functions, by modulating their 
migration and ROS production (Markiewski et al., 2008). 
Several factors produced by tumors have been implicated in the differentiation of MDSCs, 
including granulocyte monocytes-colony stimulating factor (GM-CSF), macrophage- 
monocytes-colony stimulating factor (M-CSF), IL-6, IL-1, VEGF and PGE2 (Gabrilovich and 
Nagaraj, 2009; Marigo et al., 2010). The transcription factor CCAT/enhancer binding protein 
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β (C/EBPβ) proved to be the key player in the process of MDSC development (Marigo et al., 
2010). It has been proposed that two signals are needed for the expansion and function of 
MDSCs: one factor (e.g. GM-CSF) prevents the differentiation in mature myeloid cells, and a 
second signal, provided by pro-inflammatory molecules such as IFNγ, activate MDSCs 
(Condamine and Gabrilovich, 2011).  
A remarkable relation exists between MDSCs and TAMs. MDSCs are able to skew TAMs 
differentiation toward a tumor-promoting type-2 phenotype (Sinha et al., 2007). The cross-
talk between MDSCs and macrophages requires cell-cell contact, then MDSCs release IL-10 
to reduce IL-12 production by macrophages. MDSCs from an IL-1 enriched tumor 
microenvironment produce more IL-10 and are more potent down-regulators of 
macrophage-released IL-12 (Bunt et al., 2009). Circulating MDSCs can differentiate into Gr1- 
F4/80+ TAMs in the tumor site (Kusmartsev and Gabrilovich, 2005) and this conversion is 
driven by tumor hypoxia (Corzo et al., 2010).  
Because of their tumor-promoting activities, MDSCs are associated with type-2 immune 
responses, however accumulating evidence shows that MDSCs have characteristics of both 
M1 and M2 macrophages (Sica and Bronte, 2007). As an example, MDSCs express both Arg1 
and iNOS, where these enzyme are differentially expressed by M1 (iNOS) and M2 (Arg1) 
macrophages. A recent study, investigating the molecular mechanisms behind MDSC 
differentiation, demonstrated an essential role of paired-immunoglobulin receptors (PIRs) in 
the differentiation of M1 or M2 MDSCs (Ma et al., 2011). The balance between PIR-A and 
PIR-B modulates MDSC polarization. In support of this, growth of Lewis lung carcinoma 
was significantly retarded in PIR-B-deficient mice (Lilrb3-/-) and PIR-B-deficient M-MDSCs 
expressed high levels of the M1 molecules iNOS.  
MDSCs contribute to tumor growth also by non-immune mechanisms, including the 
promotion of angiogenesis. MDSCs isolated from murine tumors express high levels of 
metalloproteases, including MMP9 (Murdoch et al., 2008). MMP9 increases the 
bioavailability of VEGF sequestered in the extracellular matrix. Further in the tumor 
microenvironment and in proangiogenic culture conditions, MDSCs acquire endothelial 
markers such as CD31 and VEGF receptor 2 (VEGFR2) and the ability to directly incorporate 
into tumor endothelium (Yang et al., 2004). In agreement, tumor refractoriness to anti-VEGF 
therapy was shown to be mediated by CD11b+GR1+ myeloid cells (Shojaei et al., 2007a; 
Shojaei et al., 2007b). 
2.4 Tumor-Associated Neutrophils (TANs)  
Tumor-associated neutrophils (TANs) have received little interest by immunologists, also 
based on their short life span. However, new evidence contradicts this view, in that 
cytokines like IL-1 or microenvironment conditions such as hypoxia can prolong PMN 
survival (Sica et al., 2011). TANs are present in various tumors, including kidney, breast, 
colon, and lung (Houghton, 2010), and are recruited by locally secreted chemotactic factors. 
As an example, several carcinoma cells produce CXCL8, a prototypic chemoattractant for 
neutrophils (Bellocq et al., 1998). Furthermore, tumor-derived TGF promotes neutrophils 
migration both directly and indirectly, by regulating the expression of adhesion molecules 
in the endothelium (Flavell et al., 2010).  
 
Tumor Microenvironment and Myelomonocytic Cells 
 
24
MDSC recruitment and expansion are regulated by several cytokines, chemokines and 
transcription factors (Sica and Bronte, 2007). It has been demonstrated that among 
chemokine receptors, CCR2 plays a pivotal role in the recruitment and turnover of MDSC to 
the tumour site (Sawanobori et al., 2008). Furthermore, the C5a complement component, 
which interacts with a G protein-coupled receptor, has been shown to play a role in MDSC 
recruitment and activation in a cervix cancer model (Markiewski et al., 2008). Some factors 
which are found in the tumour microenvironment, such as pro-inflammatory S-100 proteins, 
are also crucial for MDSC recruitment. Sinha and co-workers demonstrated that MDSCs can 
produce S-100 proteins by themselves, providing evidence for an autocrine loop that 
promotes MDSC recruitment (Cheng et al., 2008; Sinha et al., 2008). 
MDSCs possess several mechanisms for immune suppression: 1) depletion of arginine, 
mediated by Arg1 and iNOS; 2) production of ROS; 3) post-translational modifications of T 
cell receptor (TCR) mediated by peroxynitrite generation; 4) depletion of cysteine; 5) 
production of TGF; 6) induction of Tregs (Bronte et al., 2005; Huang et al., 2006; Movahedi 
et al., 2008; Nagaraj et al., 2007; Srivastava et al., 2010; Terabe et al., 2003; Yang et al., 2006; 
Youn et al., 2008). In healthy individuals, IMCs differentiate in mature granulocytes, 
macrophages or dendritic cells, whereas in pathological conditions they expand into 
MDSCs. MDSCs have been observed in cancer, chronic infectious diseases, and 
autoimmunity. In tumor-bearing mice, MDSCs accumulate within primary and metastatic 
tumors, in the bone marrow, spleen and peripheral blood. In cancer patients, MDSCs have 
been identified in the blood.  
Recent studies have contributed to partially clarify the biology of MDSCs. In mice, two 
major subsets were identified on the basis of their morphology and the expression of Ly6 
family glycoproteins: monocytic MDSCs (M-MDSCs) and granulocytic MDSCs (G-MDSCs). 
M-MDSCs are CD11b+ Ly6G- Ly6Chigh cells with monocyte-like morphology, while G-
MDSCs are CD11b+ Ly6G+ Ly6Clow with granulocyte-like morphology (Ostrand-Rosenberg 
and Sinha, 2009). Cells with similar phenotype, precursors of myeloid cells, are present in 
physiological conditions, but they are devoid of immunosuppressive activity. These cells, 
therefore, should not be named MDSCs (Youn and Gabrilovich, 2010). Other markers of 
MDSC subsets are: IL-4R (CD124), F4/80, CD80, and CSF-1R (CD115) (Sica and Bronte, 
2007). The characterization of MDSCs deeply suffers from the lack of specific markers. 
However, recent characterizations have identified human MDSCs as CD34+ CD33+ CD11b+ 
HLA-DR- cells (Ostrand-Rosenberg and Sinha, 2009). The ability to differentiate into mature 
DCs and macrophages in vitro has been shown to be restricted to M-MDSCs (Youn et al., 
2008). M-MDSC-mediated immune suppression does not require cell-cell contact, but 
utilizes up-regulation of iNOS and Arg1, as well as production of immunosuppressive 
cytokines (Gabrilovich and Nagaraj, 2009). On the contrary, G-MDSCs suppress antigen-
specific responses using mechanisms, including the release of ROS, that require prolonged 
cell-cell contact between MDSC and T cell (Gabrilovich and Nagaraj, 2009). The C5a subunit 
of the complement system appears a key regulator of MDSC functions, by modulating their 
migration and ROS production (Markiewski et al., 2008). 
Several factors produced by tumors have been implicated in the differentiation of MDSCs, 
including granulocyte monocytes-colony stimulating factor (GM-CSF), macrophage- 
monocytes-colony stimulating factor (M-CSF), IL-6, IL-1, VEGF and PGE2 (Gabrilovich and 
Nagaraj, 2009; Marigo et al., 2010). The transcription factor CCAT/enhancer binding protein 
 
Functions of Diverse Myeloid Cells in the Tumor Micro-Environment 
 
25 
β (C/EBPβ) proved to be the key player in the process of MDSC development (Marigo et al., 
2010). It has been proposed that two signals are needed for the expansion and function of 
MDSCs: one factor (e.g. GM-CSF) prevents the differentiation in mature myeloid cells, and a 
second signal, provided by pro-inflammatory molecules such as IFNγ, activate MDSCs 
(Condamine and Gabrilovich, 2011).  
A remarkable relation exists between MDSCs and TAMs. MDSCs are able to skew TAMs 
differentiation toward a tumor-promoting type-2 phenotype (Sinha et al., 2007). The cross-
talk between MDSCs and macrophages requires cell-cell contact, then MDSCs release IL-10 
to reduce IL-12 production by macrophages. MDSCs from an IL-1 enriched tumor 
microenvironment produce more IL-10 and are more potent down-regulators of 
macrophage-released IL-12 (Bunt et al., 2009). Circulating MDSCs can differentiate into Gr1- 
F4/80+ TAMs in the tumor site (Kusmartsev and Gabrilovich, 2005) and this conversion is 
driven by tumor hypoxia (Corzo et al., 2010).  
Because of their tumor-promoting activities, MDSCs are associated with type-2 immune 
responses, however accumulating evidence shows that MDSCs have characteristics of both 
M1 and M2 macrophages (Sica and Bronte, 2007). As an example, MDSCs express both Arg1 
and iNOS, where these enzyme are differentially expressed by M1 (iNOS) and M2 (Arg1) 
macrophages. A recent study, investigating the molecular mechanisms behind MDSC 
differentiation, demonstrated an essential role of paired-immunoglobulin receptors (PIRs) in 
the differentiation of M1 or M2 MDSCs (Ma et al., 2011). The balance between PIR-A and 
PIR-B modulates MDSC polarization. In support of this, growth of Lewis lung carcinoma 
was significantly retarded in PIR-B-deficient mice (Lilrb3-/-) and PIR-B-deficient M-MDSCs 
expressed high levels of the M1 molecules iNOS.  
MDSCs contribute to tumor growth also by non-immune mechanisms, including the 
promotion of angiogenesis. MDSCs isolated from murine tumors express high levels of 
metalloproteases, including MMP9 (Murdoch et al., 2008). MMP9 increases the 
bioavailability of VEGF sequestered in the extracellular matrix. Further in the tumor 
microenvironment and in proangiogenic culture conditions, MDSCs acquire endothelial 
markers such as CD31 and VEGF receptor 2 (VEGFR2) and the ability to directly incorporate 
into tumor endothelium (Yang et al., 2004). In agreement, tumor refractoriness to anti-VEGF 
therapy was shown to be mediated by CD11b+GR1+ myeloid cells (Shojaei et al., 2007a; 
Shojaei et al., 2007b). 
2.4 Tumor-Associated Neutrophils (TANs)  
Tumor-associated neutrophils (TANs) have received little interest by immunologists, also 
based on their short life span. However, new evidence contradicts this view, in that 
cytokines like IL-1 or microenvironment conditions such as hypoxia can prolong PMN 
survival (Sica et al., 2011). TANs are present in various tumors, including kidney, breast, 
colon, and lung (Houghton, 2010), and are recruited by locally secreted chemotactic factors. 
As an example, several carcinoma cells produce CXCL8, a prototypic chemoattractant for 
neutrophils (Bellocq et al., 1998). Furthermore, tumor-derived TGF promotes neutrophils 
migration both directly and indirectly, by regulating the expression of adhesion molecules 
in the endothelium (Flavell et al., 2010).  
 
Tumor Microenvironment and Myelomonocytic Cells 
 
26
Neutrophils are able to produce various cytokines and chemokines that can influence not 
only immune and antimicrobial responses, but other processes such as hematopoiesis, 
wound healing, and angiogenesis (Cassatella et al., 2009; Mantovani, 2009; Piccard et al., 
2011; Zhang et al., 2009). Despite little attention has been paid to TANs, clinical evidence 
indicates that their presence is a negative prognostic indicator. A correlation between TANs 
infiltrate and poor outcome has been described in renal cell carcinoma, bronchoalveolar cell 
carcinoma, and breast cancer (Jensen et al., 2009; Yang et al., 2005). In agreement, preclinical 
studies experimenting PMN depletion confirmed the detrimental nature of TANs (Pekarek 
et al., 1995; Tazawa et al., 2003).  
Neutrophils contribute to tumor growth by promoting angiogenesis, cell proliferation, and 
metastasis (Houghton, 2010). Similarly to macrophages, a recent report described the 
functional plasticity of neutrophils (Fridlender et al., 2009). The authors investigated the 
effects of SM16, a TGF receptor kinase antagonist in murine lung cancer and mesothelioma 
models using syngeneic tumor xenografts and the orthotopic LSL-K-ras tumor model. 
Depletion of neutrophils by a specific anti-Ly6G antibody resulted in a significantly reduced 
effect of SM16, suggesting that neutrophils participate to the antitumor activity of TGF 
blockade, most likely by the production of oxygen radicals. Also, depletion of neutrophils 
affected the activation of CD8+ CTLs. Fridlender and colleagues propose a new paradigm in 
which resident TANs acquire a protumor phenotype, largely driven by TGF, to become 
“N2 neutrophils”. If TGF is blocked, neutrophils acquire an antitumor phenotype to 
become “N1 neutrophils” (Fridlender et al., 2009).  
It was suggested that N1- and N2-type neutrophils are cells with a different degree of 
activation (i.e. fully activated or weakly activated neutrophils, respectively) rather than two 
alternatively activated cell subtypes (Gregory and Houghton, 2011). It is also object of debate 
the existence of two distinct populations, namely N2-polarized TANs and granulocytic 
MDSCs, that seem to overlap for many characteristics. In the absence of specific markers, it 
cannot be determined if N2 neutrophils within the tumors are granulocytic MDSCs recruited 
from the spleen or whether they are blood-derived neutrophils converted to an N2 phenotype 
by the tumor microenvironment. In support to the existence of N2-polarized TANs, Fridlender 
et al. emphasize that TGF-blockade does not alter blood neutrophils, splenic myeloid cells 
(CD11b+), or splenic MDSCs, selectively acting on the intratumor activation of neutrophils. 
Also, TANs characterized in Fridlender’s study have clear features of mature neutrophils, 
while MDSCs mostly exhibit an immature morphology (Mantovani, 2009).  
3. Therapeutic approaches targeting TAMCs 
The frequent association of TAMCs with poor prognosis makes these cells reasonable 
targets of biological anti-cancer therapies. Further, in the last few years there has been 
increasing evidence that TAMCs are strongly implicated in the failure of conventional 
chemotherapy and anti-angiogenic therapy.(Ferrara, 2010; Welford et al., 2011a) 
Accumulation of myeloid CD11b+Gr1+ cells (including TAMs, MDSC and immature cells) 
in tumours renders them refractory to angiogenic blockade by VEGF antibodies. (Shojaei 
and Ferrara, 2008) This effect was traced to a VEGF-independent pathway driven by the G-
CSF-induced protein Bv8. (Shojaei et al., 2007b) Further, pharmacological inhibition of TEMs 
in tumour-bearing mice markedly increased the efficacy of therapeutic treatment with a 
vascular-disrupting agent.  
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3.1 TAMs and TEMs 
Elimination of TAMs at tumor sites, or inhibition of their survival could result in improved 
prognosis. Earlier and more recent studies of macrophage depletion in experimental settings 
have been successful to limit tumour growth and metastatic spread (Aharinejad et al., 2009; 
Lin et al., 2001; Mantovani et al., 1992), and to achieve better therapeutic responses (De 
Palma et al., 2007; Ferrara, 2010; Gabrilovich and Nagaraj, 2009; Marigo et al., 2008; Welford 
et al., 2011a)  
A number of studies have shown that the bisphosphonate clodronate encapsulated in 
liposomes is an efficient reagent for the depletion of macrophages in vivo. Clodronate-
depletion of TAMs in tumour-bearing mice resulted in reduced angiogenesis and decreased 
tumour growth and metastatization.(Brown and Holen, 2009; Zeisberger et al., 2006)  
Moreover, the combination of clodronate with sorafenib, an available inhibitor of tyrosine 
protein kinases (e.g,VEGFR and PDGFR), significantly increased the efficacy of sorafenib 
alone in a xenograft model of hepatocellular carcinoma. In clinical practice, bisphosphonates 
are employed to treat osteoporosis; current applications in cancer therapy include their use 
to treat skeletal metastases in Multiple Myeloma, prostate and breast cancer. Treatment with 
zoledronic acid was associated with a significant reduction of skeletal-related events and, 
possibly, direct apoptotic effects in tumour cells. (Martin et al., 2010; Morgan et al., ; Zhang 
et al., 2010)  
Our group reported that the anti-tumour agent of marine origin, Trabectedin (Yondelis), 
was unexpectedly found to be highly cytotoxic to mononuclear phagocytes, including 
TAMs. This cytotoxic effect is remarkably selective, as neutrophils and lymphocytes were 
not affected. (Allavena et al., 2005; D'Incalci and Galmarini, 2010)  
A second approach is to inhibit the recruitment of circulating monocytes in tumour tissues.  
The M-CSF receptor (M-CSFR) is exclusively expressed by monocytes-macrophages. In 
patients with advanced tumours, clinical studies are under way to check the feasibility and 
possibly clinical efficacy of inhibitors to the CSF-1R. Among the many chemokines 
expressed in the tumour micro-environment, CCL2 (or Monocyte Chemotactic Protein-1) 
occupies a prominent role and has been selected for therapeutic purposes. Pre-clinical 
studies have shown that anti-CCL2 antibodies or antagonists to its receptor CCR2, given in 
combination with chemotherapy, were able to induce tumour regression and yielded to 
improved survival in prostate mouse cancer models (Li et al., 2009; Loberg et al., 2007; 
Popivanova et al., 2009) 
In the opposite direction, another approach is to exploit the tumor-homing ability of TAMCs: 
after all, they are at the right place at the right time. Indeed, delivery of cytokines and cytotoxic 
proteins to tumors by means of gene modified cells represents a promising strategy to treat 
cancer. It was recently shown that TEMs could be used to deliver interferon-alpha (IFN), a 
potent cytokine with angiostatic and antiproliferative activity (De Palma et al., 2008), thanks to 
the preferential homing of TEMs to the tumors (De Palma and Naldini, 2009). 
A fourth and more recent approach is to 're-educate' TAMs to exert anti-tumour responses 
protective for the host, ideally by using factors able to revert TAMs into M1-macrophages, 
with potential anti-tumour activity. It is becoming accepted that macrophages are flexible 
and able to switch from one polarization state to the other. (Pelegrin and Surprenant, 2009) 
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3.1 TAMs and TEMs 
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proteins to tumors by means of gene modified cells represents a promising strategy to treat 
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potent cytokine with angiostatic and antiproliferative activity (De Palma et al., 2008), thanks to 
the preferential homing of TEMs to the tumors (De Palma and Naldini, 2009). 
A fourth and more recent approach is to 're-educate' TAMs to exert anti-tumour responses 
protective for the host, ideally by using factors able to revert TAMs into M1-macrophages, 
with potential anti-tumour activity. It is becoming accepted that macrophages are flexible 
and able to switch from one polarization state to the other. (Pelegrin and Surprenant, 2009) 
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This was achieved in experimental mouse tumours, by injecting the TLR9 agonist CpG- 
oligodeoxynucleotide (CpG-ODN), coupled with anti-IL-10 receptor.(Guiducci et al., 2005) 
or the chemokine CCL16 (Cappello et al., 2004). CpG-ODN synergized also with an agonist 
anti-CD40 mAb to revert TAMs displaying anti-tumour activity. (Buhtoiarov et al., 2011) A 
remarkable anti-tumour effect of re-directed macrophages has been recently reported in 
human pancreatic cancer with the use of agonist anti-CD40 mAb. (Beatty et al., 2011) Still in 
the same direction, a recent report showed that the plasma protein histidine-rich 
glycoprotein (HRG) known for its inhibitory effects on angiogenesis (Juarez et al., 2002; 
Olsson et al., 2004) is able to skew TAMs polarization into M1-like phenotype by down-
regulation of the placental growth factor (PlGF), a member of the VEGF family. In mice, 
HRG promoted anti-tumour immune responses and normalization of the vessel network. 
(Rolny et al., 2011) 
Direct activation with IFNγ, a prototypical M1-polarizing cytokine, has been shown to re-
educate TAMs (Duluc et al., 2009) and there is evidence for antitumor activity of this 
molecule in minimal residual disease (Mantovani and Sica, 2010). Inhibition of STAT3 
activity, required for IL-10 biological functions and gene transcription, restored production 
of pro-inflammatory mediators (IL-12 and TNF-) by infiltrating leukocytes and promoted 
tumour inhibition (Kortylewski et al., 2005). Recent results suggest that SHIP1 functions in 
vivo to repress M2 macrophage skewing. Consistent with this, Ship1−/− mice display 
enhanced tumor implant growth (Rauh et al., 2005). In agreement, inhibition of the M2 
polarizing p50 NF-B activity resulted in restoration of M1 inflammation and tumor 
inhibition in different cancer mouse models (fibrosarcoma, melanoma)(Saccani A. et al 
Cancer Res 2006) (Porta et al., 2009) 
3.2 MDSC 
The translational potential of MDSC research is dual. The immunosuppressive activity of 
MDSCs could be exploited to inhibit immune responses in autoimmune diseases and organ 
transplantation. Conversely, elimination of MDSCs could be essential in cancer patients 
undergoing active (vaccination) or passive (adoptive transfer of ex-vivo expanded anti-tumor 
T cells) immunotherapy. A possible approach to contrast MDSC pro-tumoral activities 
consists in the promotion of MDSC differentiation into mature cells devoid of suppressive 
activity. Vitamin A represents an interesting candidate to restore immunosurveillance. In 
fact, Vitamin A metabolites stimulate the differentiation of myeloid progenitor cells into 
DCs and macrophages and reduce MDSC accumulation (Gabrilovich et al., 2001; 
Kusmartsev et al., 2003). A clinical trial testing the effects of all-trans-retinoic acid (ATRA) in 
patients with metastatic renal cell carcinoma showed the efficacy of this compound in 
reducing MDSCs in peripheral blood. The decrease in MDSC number correlated with 
improved-antigen-specific T cell responses (Mirza et al., 2006). It has been reported that 
some chemotherapeutic drugs, such as gemcitabine, are able to eliminate MDSCs, without 
affecting T cells, B cells, NK cells, and macrophages (Ko et al., 2007; Suzuki et al., 2005). 
Another strategy is aimed to inhibit MDSC suppressive function. Compounds under 
investigation for this ability belong to COX2 inhibitors, phosphodiesterase 5 (PDE5) 
inhibitors, and NO-releasing non-steroidal anti-inflammatory drugs (NSAIDs) (Gabrilovich 
and Nagaraj, 2009). Preclinical evidence supports the use of IL-1 antagonists in treating 
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human metastatic disease. Blocking IL-1 activity, mainly IL-1β, reduces both metastasis and 
tumor growth (Dinarello, 2010). Recently, it was shown that the effect is also mediated by 
the decrease of MDSC accumulation and suppressive activity (Ostrand-Rosenberg and 
Sinha, 2009). It has also been reported that CD11b+ Gr1+ cells enhance tumor refractoriness 
to anti-VEGF antibody (bevacizumab) treatment (Shojaei et al., 2007a). In this situation, 
MDSCs release the pro-angiogenic protein Bv8 that surrogates VEGF in the stimulation of 
tumor angiogenesis (Shojaei et al., 2007b). Because Bv8 is also important in MDSC 
mobilization and homing to the tumor site, this is an interesting candidate for cancer 
therapy.  
3.3 TANs 
TAN depletion represents a potential therapeutic approach for cancer cure (Tazzyman et al., 
2009). However, since oncologic patients are already immunocompromized individuals, a 
complete ablation of neutrophils is not desirable. Alternatively, given that activated 
neutrophils can kill tumor cells through the release of toxic substances, it would be of 
interest to modulate TAN phenotype, with a switch from N2- towards N1-polarization. 
Nevertheless, this plan would lead to the generation of highly cytotoxic cells and could 
result in excessive tissue damage, potentially lethal. A more manageable therapeutic 
strategy can target neutrophils recruitment to tumors. Inhibition of CXCR2-mediated PMN 
chemotaxis with a specific antibody or a CXCR2 antagonist has been successfully tested in 
pre-clinical experimentation (Gregory and Houghton, 2011). The description of the pivotal 
role of TGF in the promotion of a protumor phenotype of TAN suggests that therapies 
contrasting this cytokine could contribute to re-educate neutrophils in the tumor 
microenvironment (Flavell et al., 2010). Interestingly, a recent study showed that the CCL2-
driven accumulation of TAMs limits the influx of neutrophils in solid tumors by a yet 
unidentified mechanism. If TAMs accumulation is suppressed, neutrophils are recruited to 
the tumor providing a secondary source of MMP-9. Therefore, in the absence of TAMs, 
TANs provide alternative paracrine support for tumor angiogenesis and progression (Pahler 
et al., 2008). Hence, the elimination of TAMs alone may be insufficient to eradicate myeloid 
cell support to tumor growth .  
4. Conclusions 
Recent results indicate that tumour development promotes expansion and functional 
skewing of different myeloid cell populations, leading to accumulation of protumoral 
TAMC populations, which include TAMs, TEMs, MDSCs and TANs. These myeloid cell 
populations display distinct specialized functions, as well as overlapping activities (eg. 
angiogenesis). It is becoming evident that TAMCs appear to constitute a robust pro-tumour 
system and the functional elimination of a single myeloid population may be insufficient to 
eradicate their support to tumor growth. New strategies able to target different myeloid cell 
populations, simultaneously, are therefore desirable. 
New evidence indicates that pathways promoting polarized functions of either 
macrophages (eg. M1 vs M2) or neutrophils (N1 vs N2) may share common constituents. 
(Mantovani, 2009) Understanding of this convergent pathways may offer common target/s 
and strategies to therapeutically affect the pro-tumoral networks established by TAMCs.  
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1. Introduction 
Monocytes are essential components of the innate immune system responsible for 
phagocytosis of pathogens, dead cells, and anti-tumor activities. These cells are involved in 
a remarkably diverse array of homeostatic processes ranging from host defense to tissue 
turnover and are emerging as key players in the pathophysiology of several diseases 
including atherosclerosis, arthritis, obesity, autoimmunity, and cancer. These mononuclear 
blood cells respond to “self” and “non-self” stimulatory signals by mediating immune 
responses, controlling inflammatory cytokines, and accumulating at sites of “danger”. Thus, 
monocytes play a critical role in the protection against invaders. In the case of invader 
“tumors”, monocyte accumulation has been shown to promote neoangiogenesis and tumor 
progression. This paradoxical role of monocytes in normal and tumor development may 
result in the polarized expression of either pro- or anti-tumor functions. Recognition of 
diverse monocyte subsets helps explain the plethora of functions attributed to monocytes in 
acute and chronic inflammatory diseases. Microenvironmental signals, to which monocytes 
are exposed, play a key role in the setting of their phenotype selectively tuning their 
functions. In the tumor microenvironment, recruitment of selected monocyte subsets and 
the inhibition of the apoptotic program promote increase numbers of macrophages in the 
tumor. A complex network of differentiation factors and inflammatory stimuli determine 
monocyte life span by blocking the apoptotic pathway and activating a myriad of survival 
pathways. The present chapter will discuss molecular changes that dictate the fate and 
behavior of monocyte subsets contributing to tumor biology. In addition, we will discuss the 
antagonistic and synergistic interplay of transcriptional and posttranscriptional regulatory 
networks that contribute to the specification of monocytic cell fate and their contribution in 
tumor progression. The recognition of these molecular networks will furnish strategies to 
decrease monocytic cell recruitment, survival at the tumor sites, and facilitate monocytic 
“re-education” programs reestablishing their normal anti-tumor function helping to define 
novel therapeutic strategy against cancer and other inflammatory diseases.  
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2. Monocyte subsets: Molecular and functional heterogeneity 
Heterogeneous populations of monocytes originate from common myeloid precursor cells 
and are responsible for controlling inflammation, tissue repair, stimulating angiogenesis, 
tumor progression, and growth. These populations are dynamic, capable to adapt their 
identity, fate, and immunological function in response to environmental cues. Monocytes 
help to neutralize self or non-self danger signals through innate mechanisms. In this 
defensive reaction, the blood and lymphatic vascular system are essential partners. In 
addition, recruitment of monocytic cells leads to new blood vessel formation or 
angiogenesis, a central feature of tumor growth. Monocytes act as defenders, secreting 
cytokines and in turn modulate other cells of the innate and adaptive immune system trying 
to combat the tumor. Interestingly, cues from the tumor microenvironment promote 
changes in monocytic cells fate and immune function leading to changes in myelogenous 
populations that ensure tumor growth and metastasis, in a co-adaptation process yet not 
well understood.  
The tumor microenvironment is a complex milieu composed of cellular and noncellular 
(matrix) components. Myeloid cells, among others monocytes/macrophages, constitute 
about 50% of the infiltrating cells (Pollard, 2004). The origins and identities of tumor 
infiltrating myeloid cells have been recently uncovered as technical advances helped 
identify these heterogeneous subsets.  
Circulating human and mouse monocytes are broadly classified on the basis of surface 
receptor markers and biological responses into three subtypes. Based on the recently 
approved nomenclature by the Nomenclature Committee of the International Union of 
Immunological Societies (Ziegler-Heitbrock et al., 2010) human monocyte subtypes are 
categorized into “classical” expressing high levels of CD14 and lacking CD16 expression 
(CD14++CD16- or CD16-) constituting 90% of the population and the remaining 10% 
expressing CD14 and CD16 or FcIII receptor (CD14+CD16+). The latest group is further 
subdivided based on the level of CD14 and CD16 expression into “intermediate” 
(CD14++CD16+ or CD16+) and “non-classical” (CD14+CD16++ or CD16++) (Parihar et al., 2010; 
Ziegler-Heitbrock et al., 2010) (Fig. 1). The mouse circulating monocyte counterparts are 
classified into three types based on the expression of the surface glycoprotein Ly6C and the 
transmembrane sialoglycoprotein CD43. These are “classical: Ly6C++CD43+, “intermediate”: 
Ly6C++CD43++ and “non-classical”: Ly6C+CD43++ monocytes (Ziegler-Heitbrock et al., 2010). 
Ly6C is part of the epitope of granulocyte differentiation antigen-1 (Gr-1), also recognized 
by Gr-1 antibodies (Hanninen et al., 1997). Hence, Ly6C++ (Ly6Chigh) monocytes are Gr-1+ 
and Ly6C+ (Ly6Clow) are Gr-1- (Geissmann et al., 2010). Classical mouse monocytes (Ly6Chigh 
CD43+) express CCR2+ and CD62L+ and low levels of the chemokine receptor CX3CR1low, 
whereas non-classical (LY6ClowCD43++) are CX3CR1high but CCR2−CD62L− (Auffray et al., 
2009). Recently, closer association has been shown between the human classical, 
intermediate, and mouse Ly6Chigh, irrespective of CD16 expression while the Ly6Clow 
correspond to non-classical CD14lowCD16++ monocytes (Cros et al., 2010) (Fig. 1). 
Several types of myeloid cells are important components of the tumor stroma contributing 
to diverse tumor-promoting activities including Tumor-Infiltrating Monocytes (TIM) and 
Tumor-Associated Macrophages (TAM) (Hanahan & Weinberg, 2011) (Fig. 1). Circulating  
 




Fig. 1. Role of monocytes and macrophages in tumor progression. Heterogeneous monocyte 
populations arising from a common precursor have been described. Different monocyte 
subsets contribute to the infiltration of myelogenous cells such as TIM, TEM, and TAM into 
the tumor, which in paracrine and autocrine manner contribute to angiogenesis, tumor 
progression, and growth. Plastic behavior of TAMs from M1 to M2 as well as other 
infiltrated monocytes is characterized by distinct cytokine and chemokine profiles 
promoting an anti-tumoral or immunosuppressive environment respectively co-adapting to 
the tumor microenvironment.  
monocytes expressing Tie-2 [angiopoietin-2 (Ang-2)] named TEM, comprised within 
CD14+CD16++ human monocytes and mice Ly6C+ (Ly6Clow) are recruited to the tumor where 
they have been shown to be essential for angiogenesis (Venneri et al., 2007). In a mammary 
adenocarcinoma tumor model the majority of tumor infiltrating monocytes differentiating 
into TAM were Ly6C++ (Movahedi et al., 2010). The tumor environment not only attracts 
myeloid cells but also modulates their fate resulting in a shift in hematopoiesis leading to an 
increase in myeloid cell accumulation in bone marrow, blood, spleen, and at the tumor site 
(Almand et al., 2001; Bronte et al., 2000; Mantovani et al., 2008). 
Monocyte recruitment to the tumor site is greatly influenced by several factors. Among 
others, the prototype CC chemokine MCP-1 (monocyte chemoattractant protein-1; also 
known as CCL2) secreted by malignant cells increases monocyte infiltration (Gu et al., 1999). 
Significantly higher levels of MCP-1 have been reported in patients with primary ovarian 
cancer and melanoma (Negus et al., 1995) and MCP-1 down-regulation decreased monocyte 
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migration in ovarian cancer (Negus et al., 1998). Other chemokines and growth factors such 
as placental growth factor (PGF), TGF-β, PGE-2, CCL3 (MIP-1α), CCL4 (MIP-1β), RANTES 
(also known as CCL-5), and M-CSF, are found at high levels in tumors and contribute to the 
recruitment, survival, and differentiation of monocytes into the tumor (Fig. 1). High M-CSF 
expression is related with TAMs accumulation in breast carcinomas (Tang et al., 1992). 
Vascular endothelial growth factor (VEGF) is also involved in monocyte recruitment into 
tumors (Dineen et al., 2008; Murdoch et al., 2008). Elevated levels of RANTES were reported 
in ovarian cancer  and breast cancer contributed to cancer progression and monocytes 
recruitment (Azenshtein et al., 2002; Negus et al., 1997). 
Thus, secreted factors by tumor-infiltrating monocytes and tumor cells help modulate tumor 
growth and monocyte infiltration and fate determination contributing to tumor growth and 
progression.  
3. Monocytic transcriptomes 
In recent years the improvement in cell isolation techniques has allowed great advances in 
the understanding of transcriptomes in circulating monocytes helping identify unique 
signatures for different monocyte subsets and share remarkably transcriptional similarity 
(Ancuta et al., 2009; Mobley et al., 2007; Zhao et al., 2009). Genome wide studies on 
monocytes transcriptomes suggest that both CD16- and CD16+ monocytes share a common 
precursor (Ancuta et al., 2009). Despite the high similarity on expression profiles, differences 
relate to genes corresponding to cell-cell adhesion, trafficking, inflammation and immune 
responses, cell cycle, signal trasnduction and proliferation. Strict statistical analysis 
indicated as few as ~ 60 differentially expressed genes between monocyte subsets (Ancuta et 
al., 2009). 
Classical monocytes (CD14+CD16-) have higher expression of genes involved in adhesion 
such as CCR2, CD62L and CD11b. In addition, the genes related to inflammation, 
angiogenesis and wound healing are also highly expressed in classical monocytes, revealing 
its implication in tissue repair (Wong et al., 2011). These classical monocytes also  express 
higher level of CD14 and the cytokine IL-8 (Mobley et al., 2007). In these monocytes  all 
phagocytosis enhancing proteins were highly expressed including levels of CD93, the 
receptor for complement component C1q1 (C1q1R), a component of a larger receptor 
complex for C1q complement factor and mannose-binding lectin (MBL2) (Ancuta et al., 
2009). Furthermore, classical monocytes also showed high level expression of 
proinflammatory molecules such as S100A12, S100A9, S1008, and were among the top 50 
most highly expressed genes (Wong et al., 2011). 
CD16+ subsets possess a more differentiated profile with increased expression of 
macrophage and dendritic cell-like genes, probably indicating a more advanced stage of 
differentiation of these cells (Ancuta et al., 2009). These cells express high levels of genes 
involved in antigen processing, antimicrobial activity and host defense. High expression 
of genes encoding defensins, lysosomal proteases including cathepsins and elastase have 
been found (Mobley et al., 2007). Intermediate monocytes (CD14++ CD16+) showed 
enrichment for genes under major histocompatibility complex (MHC) class II processing 
and presenting, these genes mainly includes CD47, HLA-DO and CD40. MARCO 
(macrophage receptor with collagenous structure) is also one of the highly expressed gene 
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in the intermediate subset of monocytes (Wong et al., 2011). CD16+ monocytes express 
higher levels of TNF- and chemokine receptor CX3CR1, CX3CR2 and colony-stimulating 
factor 1 receptor (CSF1R), the receptor for macrophage colony-stimulating factor (M-CSF) 
than classical CD16- monocytes (Ancuta et al., 2009; Wong et al., 2011; Zhao et al., 2009). 
Proteomic analysis also showed small differences with only 235 proteins differentially 
expressed between the monocyte subsets (Martinez, 2009). In addition to CD16, higher 
expression of the hematopoietic cell kinase (HCK) and the tyrosine protein kinase (LYN) 
were observed (Zhao et al., 2009). Interestingly the nonclassical monocytes (CD16++) 
showed the gene enrichment in the category of cytoskeleton rearrangement and 
phagocytosis. Genes related to phagocytosis such as LYN, HCK, ITAM of FCRs, C1QA, 
C1QB and also SLAN were found highly expressed in nonclassical monocytes (Wong et 
al., 2011). In pathological conditions, monocyte functions are finely tuned by the 
microenvironment. In this regard, hypoxic conditions found in tumors affect gene 
expression. Transcriptome analysis of hypoxic primary human monocytes revealed 
modulation of a significant cluster of genes with immunological relevance (Bosco et al., 
2006). These included scavenger receptors: CD163, also found highly upregulated in 
CD16- subsets as well as MARCO , stabilin-1 (STAB1), macrophage scavenger receptor-1 
(MSR1) (Mobley et al., 2007). Toll like receptor-7 (TLR7), immunoregulatory, 
costimulatory, and adhesion molecules: CD32, CD64, CD69, CD89, leukocyte membrane 
Ag (CMRF-35H), integrin β-5 (ITGB5), chemokines/cytokines receptors (CCL23, CCL15, 
CCL8, CCR1, CCR2, RDC1, IL-23A, IL-6ST) were also highly expressed under hypoxia 
(Bosco et al., 2006). Hypoxia also controlled gene expression of chemokine receptors 
including CXCL1, CXCL8, CCL3, CXCR4 (Murdoch et al., 2004). 
Transcriptome studies are unraveling the complexities of the monocyte populations and 
provide evidence of the specialized function of specific subsets. High expression of IL-8 and 
adhesion molecules in CD16- subsets seem to support the role as inflammatory, capable to 
leave the circulation and infiltrate. In addition, high expression of M-CSF in CD16+ support 
their role in driving differentiation of CD16-, a more immature pool that could replenish 
macropahges at inflammatory sites. Studies in gene expression profiles in human monocyte 
subpopulations as part of tumor biology remain scarce and future studies in this area will 
thereby help to understand their specific roles as well as define future approaches to re-
educate monocytes in the tumor microenvironment.  
4. Role of monocyte subsets in tumor progression  
4.1 Monocyte deactivation  
It has been widely accepted that cancer progression is an inherently proinflammatory 
process that involves the activation of the innate and adaptive immune system. During 
tumorigenesis, monocytes are destined to give anti-tumor response of the host and act both 
as cells presenting tumor-associated antigens to tumor-infiltrating lymphocytes and as 
cytotoxic effector cells (Mytar et al., 2003). However, cancer cells have developed 
mechanisms that inhibit immune surveillance (Pardoll, 2003), characterized by the impaired 
ability of monocytes to produce IFN-, TNF-α, IL-12, while enhance IL-10 secretion. IL-10 is 
immunosuppressive, tumor promoting, and inhibits the production of IL-2, IFNγ, IL-12, 
TNF-α, resulting in a reduced Th1 response (Sica et al., 2006). Different studies have 
reported increased IL-10 serum levels in patients with melanoma and other solid tumors 
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migration in ovarian cancer (Negus et al., 1998). Other chemokines and growth factors such 
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(Fortis et al., 1996; Sato et al., 1996). IL-12 plays central role in activating anti-tumor 
immunity by stimulating the production of IFN- and TNF-α necessary for cytotoxic effects. 
In many cancers, for instance in colorectal cancer reduced production of IL-12 was 
accompanied by increased production of IL-10 (O'Hara et al., 1998). Deactivation of 
monocytes can be reversed with Bovis bacillus Calmette-Guerin (BCG), the prototype 
immunomodulator, which inhibits IL-10 production, thus reversing monocyte deactivation 
(Baran et al., 2004).  
Deactivation of TIM is also mediated by other mechanisms. Hyaluronan (HA), an important 
tumor microenvironment matrix structure, produced by tumor cells, is now emerging as a 
key factor in monocyte deactivation and tumor progression (Mytar et al., 2003; Toole, 2004). 
Ligation of CD44 by HA is a proinflammatory event that regulates monocyte adhesion and 
cytokine production and was found to stimulate the expression of IRAK (IL-1 receptor-
associated kinase)-M. High levels of IRAK-M were reported in patients of chronic myeloid 
leukemia and metastasis (del Fresno et al., 2005). Co-culture experiments of CD14+ 
monocytes with a variety of tumor cells show that tumor cells express high level of 
prostaglandin (PG) that also contributes to the downregulation of TNF-α, IL-12, IRAK-1 
interrupting the inflammatory response against cancer progression. These findings strongly 
suggest that the functional activity of monocytes is adversely modified by the local tumor 
microenvironment. Notably, the deactivation mechanisms of monocyte in cancer may not 
just be limited to tumor microenvironment but also players in other inflammatory diseases 
such as atherosclerosis, arthritis, and obesity.  
4.2 Angiogenesis  
Once the tumor cells escape recognition and destruction by infiltrating monocyte, these 
infiltrating cells participate in tumor growth by promoting angiogenesis (Lin et al., 2001), 
an essential process in the tumor progression and growth. High numbers of human 
vascular leukocytes found in human ovarian cancer have been suggested to form 
neovessels in mouse xenotransplantations (Conejo-Garcia et al., 2005). Gr-1+ monocytes 
promote angiogenesis via paracrine mechanisms (Yang et al., 2004). Vascular leukocytes, a 
subset of CD11C+ MHC-II+ dendritic-cell precursors expressing endothelial vascular 
markers VE-cadherin, CD34, and CD146 also contribute to tumor angiogenesis (Conejo-
Garcia et al., 2005; Yang et al., 2004). Circulating TEM derived from non-classical 
monocytes contributes to tumor angiogenesis, migrating towards Ang-2, released at high 
levels by activated endothelial cells and angiogenic vessels at tumor sites (Venneri et al., 
2007). Ang-2 also inhibits TNF-α release (Lewis et al., 2007; Murdoch et al., 2007), 
normally responsible for promoting apoptosis of both tumor and endothelial cells 
(Petrache et al., 2001). Hence, Ang-2-mediated down-regulation of TNF-α may increase 
metastasis and angiogenesis contributing to tumor growth. The molecular basis of factors 
that render proangiogenic activity in TEM are still not well understood. But elimination of 
TEMs in mouse glioma models was shown to reduce tumor growth and vascularity (De 
Palma et al., 2005), supporting the role of TEM in tumor blood vessels formation. In 
human tumor models, CD14+ TIM monocytes can develop endothelial phenotype 
(Schmeisser et al., 2001) and actively participate in neovascularization during tumor 
growth (Urbich et al., 2003).  
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Recent studies indicated that CCL2 synthesized by metastatic tumor cells and by the target-
site tissue stroma is critical for the recruitment of CCR2-expressing monocyte subsets. 
Activation of the CCL2-CCR2 signaling axis promotes extravasation and recruitment of 
inflammatory monocyte subsets into metastatic tumor sites and helps promote 
differentiation of these monoyctes into non-proliferating TAMs (Qian et al., 2011). 
Transcriptome studies in both resident and inflammatory monocytes show higher 
expression of VegfA, a potent angiogenic factor in inflammatory monocytes CD14+CD16- 
subsets, recruited in large numbers to metastatic areas (Qian et al., 2011). Future 
comprehensive trsancriptome analysis in purified monocyte populations under 
pathophysiological conditions should be helpful to gain a further understanding of the 
functional roles of different monocyte populations in tumor progression. 
5. Regulation of monocyte subsets  
5.1 Regulation of survival and cell death of monocytes in tumors 
A complex network of survival and apoptotic pathways determines monocyte fate. Several 
kinases, transcription factors and anti- and pro-apoptotic proteins play key roles in 
determining monocyte survival and cell death. All circulating monocyte subsets have very 
short life span of just few days (Fahy et al., 1999; Zeigler et al., 2003). Inflammatory and 
differentiation stimuli are known to halt apoptosis and inducing prolonged monocyte 
survival. Among others M-CSF, TNF-, and IL-1 promote survival by deactivating the 
apoptotic program lead by caspases (Fahy et al., 1999; Goyal et al., 2002; Kelley et al., 1999). 
The tumor microenvironment characterized by alterations in cytokine, chemokine, and 
growth factor expression contributes to mediate prolonged monocyte survival (Zou, 2005). 
In fact, increase levels of TGF-β, IL-10, and VEGF alter TIM and TEM from anti-tumoral to 
immunosuppressor and proangiogenic in part by switching their cytokine and growth 
factors expressions (Whiteside, 2008) (Fig. 1).  
Among the signaling molecules involved in activation and survival, the phosphatidylinositol 
3-kinase (PI3K)-AKT axis has a central role in regulating a multitude of essential myelogenous 
events, such as differentiation, phagocytosis, oxidative burst, and TLR-mediated responses 
(Franke et al., 1997; Parihar et al., 2010). PI3K activation was also shown to direct infiltration 
(Funamoto et al., 2002; Wang et al., 2002). M-CSF-induced activation of AKT through 
caspase-9 phosphorylation inhibits apoptosis (Kelley et al., 1999), promoting prolonged 
survival and sustaining the differentiation program (Gonzalez-Mejia & Doseff, 2009). In 
addition, PI3K activates protein kinase C (PKC) in monocytes (Herrera-Velit et al., 1997) 
leading to the induction of the activated mitogen-activated protein kinase (MAPK) pathway 
(Rao, 2001), including the extracellular signal-regulated kinase (ERK), the c-JNK and p38 
which are hubs to multiple networks of survival (Parihar et al., 2010). Pro-inflammatory 
mediators induce the PI3K/AKT and MAPK/ERK pathways that in turn are responsible in 
determining the balance of inflammatory versus anti-inflammatory cytokines.  
In the hypoxic regions of a tumor, activation of PI3K/AKT leads to HIF (hypoxia inducing 
factor)-1 activity which in turn regulates tumor growth, angiogenesis, metastasis, and 
monocytes/macrophages recruitment (Semenza, 2003). While the role of HIF-1 in different 
monocyte subsets and macrophages is not fully understood, increased HIF-1 expression in 
TAMs was found to contribute to tumor angiogenesis and invasiveness (Werno et al., 2010).  
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The transcription factor nuclear factor-κB (NF-κB), plays a critical role in tumor biology 
(Karin & Greten, 2005). While in other cell types NF-κB has various tumor-promoting 
functions, in monocytes the activation of NF-κB results in the release of cytokines, such as 
TNF-α and IL-6 which not only trigger prosurvival signals in tumor cells but also support 
growth and progression, and importantly sustain a dysregulated immune function 
(Hagemann et al., 2009; Pikarsky et al., 2004). Activation of NF-κB leads to increase expression 
of angiogenic factors such as VEGF, CXCL1 and CXCL8  and anti-apoptotic molecules 
including the inhibitor of apoptotic proteins (IAPs), and bcl-2 (Richmond, 2002). The relevance 
of the NF-κB signaling pathway is illustrated in a mouse model of colitis associated cancer, 
where deletion of IKK-β reduced the production of tumor promoting paracrine factors and 
subsequently decreased carcinoma growth (Greten et al., 2004). In hepatocellular carcinomas 
the NF-κB activating kinase IKK-β suppresses early chemically-induced liver tumorigenesis by 
inhibiting hepatocyte death and compensatory proliferation. This anti-tumorigenic activity of 
hepatocyte IKK-β was suggested to be due to the induction of NF-κB-dependent pro-survival 
and anti-oxidant genes (He et al., 2010). Deletion of IKK-β in myeloid cells resulted in a 
signicant decrease in tumor size and diminished the expression of proinammatory 
cytokines that may serve as tumor growth factors (Yoshimura, 2006). 
Caspases, the cysteine proteases central to programmed cell death, including “activators” 
(caspases-1, 2, 8, 9, and 10) and ‘executioners’ (caspases-3, 6, and 7) play fundamental roles 
in myelogenous cells through the activation of the extrinsic and intrinsic apoptotic cascade 
(Riedl & Shi, 2004). Fas receptor-induced apoptosis has a key role in monocyte biology as 
both homozygous FasR deficient (lpr/lpr) and heterozygous FasR and Fas ligand deficient 
(lpr/gld)  mice have increased numbers of inflammatory and resident monocytes resulting in 
splenomegaly, lymphadenopathy, and accumulation of tissue macrophages (Ashkenazi & 
Dixit, 1998; Brown et al., 2004). Cytokines, CCL2 and IL-6 abundant in the tumor 
microenvironment have been shown to inhibit caspase-8 and promote enhanced autophagic 
activity to protect the monocytes recruited to the tumor and, at the same time, induce their 
differentiation toward M2-type macrophages (Roca et al., 2009). Futhermore, M-CSF induces 
caspase-9 inhibition leading to reduce apoptosis (Kelley et al., 1999). Several other inhibitors 
of the apoptotic pathways including members of the Bcl-2 family have been characterized 
(Youle & Strasser, 2008) and XIAP also play a crucial role in cell survival and tumor 
development. XIAP directly inhibits activator caspase-9 and also executioner caspases in 
cancer cells and increase expression of XIAP has been reported in monocyte differentiation 
(Sasaki et al., 2000). However, the role of XIAP in different monocyte subsets has not been 
studied. Our studies identified the small heat shock protein (Hsp27) as a direct inhibitor of 
caspase-3 in monocytes. Notably a significant increase in Hsp27 expression was found to be 
required during monocyte-macrophage differentiation (Voss et al., 2007). Hsp27 is highly 
expressed in several tumors and high levels of Hsp27 in plasma have been associated with 
risk of lung cancer  (Wang et al., 2010). Hsp27 was found to have functions in IL-1-induced 
cell signaling and pro-inflammatory gene expression suggesting its ability to modulate 
immunity (Alford et al., 2007). Whether the expression of apoptosis inhibitors such as Hsp27 
is altered in TIM and TAMs have yet to be studied. These findings suggest that anti-
apoptotic factors in plasma can switch monocyte life span contributing to their 
accumulation into tumors. It is possible to hypothesize that monocyte re-education 
programs could target molecular networks involved in shifting survival and cell death 
programs as well as immunoparalysis in monocytes. 
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5.2 Epigenetics and microRNAs regulation in monocytes and macrophages during 
tumor progression  
During hematopoiesis gradual changes in gene expression orchestrate lineage-specification. 
The myelomonocytic lineage originates from a ganulocyte-erythrocyte-megakaryocyte-
macrophage colony-forming unit (GEMM-CFU) that promotes formation of the GM-CFU or 
ganulocyte-macrophage colony-forming unit. GM-CFU under the control of G-MCSF, M-
CSF and IL-3 regulate the differentiation of this progenitor to a monocyte precursor (M-
CFU) that becomes a promonocyte in the bone marrow. Differentiation of precursor cells is 
controlled by transcription factors that regulate differentation and survival. A combination 
of transcription factors including GATA-2, GATA-1, SCL, and members of the homeobox 
proteins (HOXB) control monocyte survival. Repression of GATA-1, SCL, and c-Myc 
expression allows monocytic differentiation (Valledor et al., 1998). Earliest stages of myeloid 
lineage specification involve the activity of Runt-related transcription factor 1 (RUNX1). One 
of the main targets of RUNX1 is PU.1, a member of the ETS (E-twenty six) family 
transcription factor (Olson et al., 1995). PU.1 is key in differentiation by controlling the 
expression of M-CSF and GM-CSF receptors. In addition, PU.1 regulates expression of FC 
receptors involved in phagocytosis. Thus, PU.1 has a critical role in monocytic 
differentiation by regulating expression of molecules essential for differentiation and 
function of monocytic lineages. Intermediate stages of differentiation are regulated among 
others by transcription factor CCAAT enhancer-binding protein (C/EBP) members, c-Myc 
and HOXB7, the latest induced by GM-CSF (Friedman, 2002; Yeamans et al., 2007). In 
addition, c-Jun dimmers (AP-1)  and STAT members contribute to the induction of 
monocytic genes (Friedman, 2002). STAT3 is one of the important transcription factors that 
play an essential role in cell survival, proliferation, and differentiation. Classical monocytes, 
express high levels of AP-1-axis regulated genes, and it has been suggested that this gene 
repertoire may be responsible for the plastic behavior of this monocyte subset to recognize 
self and non-self stimuli (Wong et al., 2011). In non-classical subsets transcription factors 
controlling apoptosis, differentiation, and proliferation were highly expressed, among them 
E2F1, ETS1, and FOXO1, well known to regulate proliferation. Intermediate monocyte 
subsets showed reciprocal increases in transcription factors found in both classical and non-
classical subsets (Wong et al., 2011). 
Epigenetic changes regulated by histone-modifying enzymes such as histone 
acetyltransferases (HATs), histone deacetylases (HDAC), and methylases provide additional 
regulatory mechanisms for monocytic gene expression. Abnormal activity of these enzymes 
leads to changes in gene expression affecting differentiation and apoptosis and causing 
neoplasia and other diseases (Haberland et al., 2009). Acetylation of NF-B induces 
modifications in a temporal manner leading to recruitment of other co-activator and re-
modeling complexes and the induction of inflammatory gene expression (Ito et al., 2000; Lee et 
al., 2006). In monocytes, histone acetylation of the TNF-α promoter has been shown to be 
developmentally regulated and is required for TNF-α expression during acute inflammation 
(Lee et al., 2003). Changes in acetylation of the Decoy Receptor 3 (DcR3) promoter, a member 
of the TNF receptor superfamily, has been reported in tumors affecting expression of MHC 
class II (MHC-II)-dependent antigen presentation (Chang et al., 2008). Recent studies found 
distinct DNA methylation profiles in CD34+ hematopoietic progenitor cells and differentiated 
myeloid cells with pronounced DNA hypomethylation in monocytes (Bocker et al., 2011). 
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The transcription factor nuclear factor-κB (NF-κB), plays a critical role in tumor biology 
(Karin & Greten, 2005). While in other cell types NF-κB has various tumor-promoting 
functions, in monocytes the activation of NF-κB results in the release of cytokines, such as 
TNF-α and IL-6 which not only trigger prosurvival signals in tumor cells but also support 
growth and progression, and importantly sustain a dysregulated immune function 
(Hagemann et al., 2009; Pikarsky et al., 2004). Activation of NF-κB leads to increase expression 
of angiogenic factors such as VEGF, CXCL1 and CXCL8  and anti-apoptotic molecules 
including the inhibitor of apoptotic proteins (IAPs), and bcl-2 (Richmond, 2002). The relevance 
of the NF-κB signaling pathway is illustrated in a mouse model of colitis associated cancer, 
where deletion of IKK-β reduced the production of tumor promoting paracrine factors and 
subsequently decreased carcinoma growth (Greten et al., 2004). In hepatocellular carcinomas 
the NF-κB activating kinase IKK-β suppresses early chemically-induced liver tumorigenesis by 
inhibiting hepatocyte death and compensatory proliferation. This anti-tumorigenic activity of 
hepatocyte IKK-β was suggested to be due to the induction of NF-κB-dependent pro-survival 
and anti-oxidant genes (He et al., 2010). Deletion of IKK-β in myeloid cells resulted in a 
signicant decrease in tumor size and diminished the expression of proinammatory 
cytokines that may serve as tumor growth factors (Yoshimura, 2006). 
Caspases, the cysteine proteases central to programmed cell death, including “activators” 
(caspases-1, 2, 8, 9, and 10) and ‘executioners’ (caspases-3, 6, and 7) play fundamental roles 
in myelogenous cells through the activation of the extrinsic and intrinsic apoptotic cascade 
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activity to protect the monocytes recruited to the tumor and, at the same time, induce their 
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caspase-9 inhibition leading to reduce apoptosis (Kelley et al., 1999). Several other inhibitors 
of the apoptotic pathways including members of the Bcl-2 family have been characterized 
(Youle & Strasser, 2008) and XIAP also play a crucial role in cell survival and tumor 
development. XIAP directly inhibits activator caspase-9 and also executioner caspases in 
cancer cells and increase expression of XIAP has been reported in monocyte differentiation 
(Sasaki et al., 2000). However, the role of XIAP in different monocyte subsets has not been 
studied. Our studies identified the small heat shock protein (Hsp27) as a direct inhibitor of 
caspase-3 in monocytes. Notably a significant increase in Hsp27 expression was found to be 
required during monocyte-macrophage differentiation (Voss et al., 2007). Hsp27 is highly 
expressed in several tumors and high levels of Hsp27 in plasma have been associated with 
risk of lung cancer  (Wang et al., 2010). Hsp27 was found to have functions in IL-1-induced 
cell signaling and pro-inflammatory gene expression suggesting its ability to modulate 
immunity (Alford et al., 2007). Whether the expression of apoptosis inhibitors such as Hsp27 
is altered in TIM and TAMs have yet to be studied. These findings suggest that anti-
apoptotic factors in plasma can switch monocyte life span contributing to their 
accumulation into tumors. It is possible to hypothesize that monocyte re-education 
programs could target molecular networks involved in shifting survival and cell death 
programs as well as immunoparalysis in monocytes. 
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5.2 Epigenetics and microRNAs regulation in monocytes and macrophages during 
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classical subsets (Wong et al., 2011). 
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of the TNF receptor superfamily, has been reported in tumors affecting expression of MHC 
class II (MHC-II)-dependent antigen presentation (Chang et al., 2008). Recent studies found 
distinct DNA methylation profiles in CD34+ hematopoietic progenitor cells and differentiated 
myeloid cells with pronounced DNA hypomethylation in monocytes (Bocker et al., 2011). 
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Interestingly, age-related methylation changes in CD34+ cells were found. Older progenitor 
cells showed a bimodal pattern with hypomethylation of differentiation associated genes 
and de novo methylation events resembling epigenetic mutations, thus providing an 
important insight into the methylation dynamics during differentiation and suggest that 
epigenetic changes contribute to hematopoietic progenitor cell aging (Bocker et al., 2011). 
Induction of inflammatory genes IL-6, IL-8 and IL-12 were found to depend on HAT/HDAC 
activity (Lu et al., 2005; Schmeck et al., 2008). Treatment of monocytic leukemia cell lines and 
patient samples with demethylating and HDAC inhibitors induced reversion to gene profiles 
found in normal subjects, highlighting the role of chromatin remodeling in monocyte behavior 
(Serrano et al., 2008). Treatment of macrophages with broad-spectrum HDACs inhibitors 
showed anti- and pro-inflammatory effects, HDACs suppressed LPS-induced expression of 
the pro-inflammatory MCP-3, and IL-12 but amplified the expression of the pro-atherogenic 
factors Cox-2 (Halili et al., 2010). Dietary compounds with HDAC inhibitory activities, 
including garcinol, curcumin, and anacardic acid, modulate epigenetic status and are being 
investigated as potential anti-cancer agents (Bolden et al., 2006; Inoue et al., 2004). It will be of 
interest to evaluate how these therapies influence monocytes epigenomes. Future studies to 
evaluate the epigenetic dynamics of monocyte subsets will be of great value to further 
understand their unique functional contributions.  
MicroRNAs (miRNAs) are small non-coding RNAs emerging as new post-trancriptional 
regulators and have been found to contribute in several monocyte functions. The overall 
relevance of miRNA in hematopoiesis has been discussed in detail elsewhere (Baltimore et al., 
2008). Based on the epidemiological studies inflammation contributes to 25% of all cancers by 
increasing cancer risk and cancer development (Mantovani et al., 2008). Several miRNAs were 
found to be elevated in inflammation and cancer. In particular, miRNA-155, miRNA-125b, and 
miRNA-21 have emerged as important miRNAs regulating immune responses. MiRNA-155 is 
elevated in leukemia and lymphoma and transgenic mice overexpressing miRNA-155 in B 
cells, develop B-cell leukemia and sustained expression of miRNA-155 in hematopoietic stem 
cells causes myeloproliferative disorders (O'Connell et al., 2008). MiRNA-155 targets among 
others suppressors of cytokine signaling (SOCS1) and SH2-domain-containing inositol-5-
phosphatase 1 (SHIP-1), both negative regulators of TLR signaling in monocyte/macrophage 
inflammatory response. Recent studies showed that tumor environment causes a sustained 
reduction of miRNA-155 in monocytes/macrophages, which in turn activates the C/EBPβ (He 
et al., 2009). C/EBPβ, a member of C/EBP family of leucine zipper transcription factors, plays 
pivotal roles in coordinating the expression of a wide variety of genes that control immune 
responses including COX-2 (Li et al., 2007). C/EBPβ-deficient mice exhibit defects in 
macrophage activation and differentiation (He et al., 2009). Monocytes exposed to tumor 
microenvironment showed C/EBPβ expression inversely correlated with miR-155 expression 
and it was found that miRNA-155 could suppress the C/EBPβ. Furthermore, over-expression 
of miRNA-155 significantly attenuated the cytokine production in tumor-activated monocytes 
(He et al., 2009). Expression of miRNA-146 affects downstream TLR signaling molecules such 
IRAK1 and 2 or TNF receptor-associated factor (TRAF) 6, all involved in the activation of the 
NF-B axis (O'Connell et al., 2010). MiRNA-21 and miRNA-125b are also elevated in 
inflammatory conditions and cancer (Esquela-Kerscher & Slack, 2006).  
Recent studies highlighted different miRNAs profile in circulating monocytes when 
compared with dendritic cells or macrophages (Tserel et al., 2011). However, it is presently 
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unknown whether miRNAs expression is altered in different monocytes subsets in normal 
conditions or in tumorigenesis.  
6. Molecular pathways involved in monocyte fate and re-education 
programming  
Reprogramming implies the conversion of a fully differentiated cell type into another cell 
type without pluripotent intermediate and generally achieved by overexpressing key 
transcription-factors (Zhou & Melton, 2008). Recent studies have reported that various cells 
including fibroblasts can be reprogrammed into blood-cell progenitors (Szabo et al., 2010), 
neurons (Vierbuchen et al., 2010), and cardiomyocytes (Ieda et al., 2010), demonstrating the 
ample applicability of this approach for therapeutic uses.  
Myelomonocytic cells re-education programs have been described. TAMs have been 
suggested to be programmed to specific subtypes such as M1 and M2 upon arrival to the 
tumor microenvironment. It has been shown that administration of GM-CSF in murine 
breast cancer models induces soluble VEGFR-1 resulting in the suppression of VEGF and 
angiogenesis (Eubank et al., 2009). Cytokine-dependent reprogramming using IL-12, which 
impacts innate and adaptive immune systems, has proven the most interesting (Trinchieri, 
1995). IL-12 in its soluble or lipid-encapsulated forms injected into tumor-bearing mice 
resulted in a strong cytotoxic anti-tumor response (Hill et al., 2002), suggesting its capability 
to restore normal immune functions. Inflammatory monocytes expressing high levels of the 
chemokine receptor CCR2 but not CD14-CD16+ were found in increased numbers in several 
chronic inflammatory conditions including atherosclerosis and asthma (Parihar et al., 2010). 
Recent studies showed that administration of lipid nanoparticles containing a CCR2-
silencing short interfering RNA in mice, prevents monocyte accumulation at inflammatory 
sites (Leuschner et al., 2011). Ectopic expression of PU.1 in lymphocytes and neural stem 
cells induced transdifferentiation to the myeloid lineage with functional chemotactic and 
immune functions characteristic of monocytes (Forsberg et al., 2010; Laiosa et al., 2006). 
Transcriptome analysis showed that PU. 1 expression affects chromatin remodeling leading 
to epigenetic changes that ensure macrophage specification (Ostuni & Natoli, 2011). These 
monocytes may serve as vehicles to modulate microenvironments with dysregulated 
immunity such as found in the tumor. Hence, alteration of epigenetic dynamics may also be 
a potential approach to alter monocyte re-programming. It is recognized that macrophages 
adapt in response to the microenvironment (referred to other Chapters in this book). Part of 
this adaptation is based on changes in their transcriptomes (Lawrence & Natoli, 2011). 
However, the molecular mechanisms determining macrophage genetic adaptations remain 
mostly unknown. In the case of monocyte subsets similar studies have not yet been 
conducted. Thus, dissecting the genomic determinants in normal and pathophysiological 
conditions of functional distinct monocyte subsets and TEMs will provide possibilities to re-
educate these cells towards an anti-tumor phenotype, re-establishing apoptotic programs or 
halting their extravasation activities.  
7. Conclusion  
Tumor progression is marked by dynamic changes of the tumor microenvironment from 
early neoplastic events to advanced tumor stages. Recruitment of circulating monocytes to 
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specific tumor sites contributes to progressive modulation of signaling molecules such as 
chemokines, cytokines, growth factors, and transcription factors. Specific contributions of 
different monocyte subsets to the tumor associated myelogenous populations of TEM, TIM, 
and TAMs are starting to emerge. Advances in understanding the molecular networks 
regulating myelomonocytic cells functions and fate provide opportunities to implement re-
education programs to rehabilitate normal anti-tumor monocyte behavior. These strategies 
should help limiting myelomonocytic cell survival, halting recruitment to tumor sites, and 
increasing cytotoxic functions providing novel approaches for cancer treatment. Advances 
in this area will not be limited to tumor biology but will also impact our understanding of 
other chronic inflammatory diseases.  
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specific tumor sites contributes to progressive modulation of signaling molecules such as 
chemokines, cytokines, growth factors, and transcription factors. Specific contributions of 
different monocyte subsets to the tumor associated myelogenous populations of TEM, TIM, 
and TAMs are starting to emerge. Advances in understanding the molecular networks 
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1. Introduction 
Cancer immunotherapies have shown considerable promise in pre-clinical studies, but the 
potency of these interventions has often proved disappointing in vivo. This is in part due to 
tumor infiltration by myeloid cells, which are usually associated with less favorable clinical 
outcomes. In the past decade, several distinct subsets of tumor-infiltrating myeloid cells 
have been described (Movahedi et al., 2010), among which myeloid-derived suppressor cells 
(MDSC) have been subject to particular scrutiny for exerting a critical role in cancer 
progression (Bronte, 2009; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 
2009; Ribechini et al., 2010). MDSC have been studied intensively in the context of cancer, 
and the weight of evidence indicates that these cells accumulate in most human cancers and 
also in experimental animal models with transplanted or spontaneous tumors (Eruslanov et 
al., 2011; Gabitass et al., 2011; Movahedi et al., 2008; Peranzoni et al., 2010; Raychaudhuri et 
al., 2011; Youn et al., 2008). MDSC also have significant roles to play in numerous other 
pathologies, including bacterial infections (Delano et al., 2007), parasitic infections (Brys et 
al., 2005; Goni et al., 2002), chemotherapy outcomes (Angulo et al., 2000), experimental 
autoimmunity (Arora et al., 2011; Kerr et al., 2008; Moline-Velazquez et al., 2011; Zhu et al., 
2007), inflammatory bowel diseases (Haile et al., 2008), obesity (Xia et al., 2011), transplant 
rejection (Hock et al., 2011), and stress responses (Makarenkova et al., 2006). 
MDSC are a heterogeneous population of myeloid lineage cells that comprises progenitor 
cells, immature macrophages, immature granulocytes and immature dendritic cells 
(Gabrilovich and Nagaraj, 2009). MDSC lack specific phenotypic markers of macrophages, 
dendritic cells and monocytes, but instead exist as two morphologically distinct subsets: 
monocytic (MO)-MDSC and granulocytic/polymorphonuclear (PMN)-MDSC (Movahedi et 
al., 2008; Youn et al., 2008). MDSC populations accumulate and become activated in 
response to various factors released by tumor cells and/or by host cells in the tumor 
microenvironment, where they suppress both innate and adaptive anti-tumor immunity 
through a variety of different mechanisms. MDSC are therefore considered to be a major 
contributor to tumor immune evasion. However, the pro-tumor action of MDSC is not 
limited to their direct immunosuppressive properties - these cells have also been shown to 
favor cancer progression by promoting angiogenesis, cancer cell proliferation, invasion, and 
metastasis. The induction of MDSC by pro-inflammatory mediators and by tumor-derived 
soluble factors highlights key contributions from chronic inflammation and from the tumor 
microenvironment to the onset and progression of cancer.  
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In this chapter, we will review the recent literature on MDSC expansion, their role in cancer 
progression, their proposed mechanisms of action, and the therapeutic challenges of targeting 
MDSC. We will focus more specifically on mouse MDSC and their role in melanoma. 
2. Origin, distribution and expansion of MDSC 
Hematopoietic stem cells give rise to myeloid progenitor and precursor cells in bone 
marrow. Then these immature myeloid cells (IMC) migrate into peripheral lymphoid organs 
and differentiate into mature granulocytes, macrophages, or dendritic cells. Various sources 
of immunological stress, including cancer, inflammation, trauma, and autoimmune 
disorder, can inhibit the differentiation of IMC and thus promote the expansion of this 
population. IMC can subsequently become activated by tumor-derived factors and host 
cytokines which results in the generation of MDSC with potent immunosuppressive 
potential (Ribechini et al., 2010). In the steady state, IMC primarily reside in the bone 
marrow, but in pathological settings (cancer being the most well studied), MDSC can be 
detected in the bone marrow, spleen, blood, tumor, and also in lymph nodes (Haile et al., 
2008; Kusmartsev et al., 2005; Serafini et al., 2004; Sinha et al., 2008). 
The expansion, activation and accumulation of MDSC in peripheral tissues can be driven by 
multiple factors produced by tumor cells, tumor stromal cells, or by activated T cells. These 
mediators include prostaglandins; matrix metalloproteinases (MMPs); growth factors such 
as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), vascular 
endothelial growth factor (VEGF), stem-cell factor (SCF); cytokines such as transforming 
growth factor (TGF)-β, tumor necrosis factor (TNF)-α, interferon γ (IFN-γ), IL-1β, IL-4, IL-6, 
IL-10, IL-12, IL-13; chemokines CCL2, CXCL5, CXCL12; and various other pro-inflammatory 
molecules including S100A8/9 proteins, toll-like receptor agonists, tumor-derived exosome-
associated Hsp72, inflammasome component NLRP3, and complement component C5a 
(Chalmin et al., 2010; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha, 2009; 
Ribechini et al., 2010; van Deventer et al., 2010). These agents either promote MDSC 
expansion through the JAK2/STAT3 signaling pathway or induce the activation of MDSC 
via STAT1, STAT6, or through NF-κB-dependent mechanisms (Gabrilovich and Nagaraj, 
2009; Kusmartsev and Gabrilovich, 2006).  
3. Subsets of murine MDSC  
MDSC comprise numerous different types of myeloid precursor cells. In mice, MDSC are 
characterized by the co-expression of surface markers Gr-1 and CD11b. In healthy mice, cells 
with this phenotype constitute around 20-30% of cells in bone marrow, approximately 2-4% of 
cells in the spleen, and fewer still in the lymph nodes (Kusmartsev and Gabrilovich, 2006), 
although the frequency of these cells can increase dramatically in tumor-bearing mice 
(Movahedi et al., 2008). Since Gr-1 antibodies can bind to two separate epitopes, Ly6G and 
Ly6C, it has recently become possible to further delineate MDSC subsets using antibodies that 
specifically target these distinct antigens. The Ly6G molecule is expressed primarily by 
granulocytes, whereas Ly6C is highly expressed by monocytes (Fleming et al., 1993; 
Sunderkotter et al., 2004). Among murine MDSC, the CD11b+Ly6G+Ly6Clow subset (PMN-
MDSC), exhibits a polymorphonulear phenotype, while the CD11b+Ly6G-Ly6Chigh subset 
(MO-MDSC), displays a monocytic phenotype. More recently, some new features of MDSC 
have emerged that provide further insights into the diversity of these cells. Using a simple 
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staining strategy, Greifenberg and colleagues were able to divide mouse splenocytes into six 
distinct sub-populations with regard to their size, granularity, morphology, and relative 
expression of CD11b and Gr-1 (Greifenberg et al., 2009). Among these various populations, Gr-
1lowCD11bhighLy6ChighSSClow and Gr-1highCD11blow (with ring-shaped nuclei) MDSC possessed 
suppressive potential. Additionally, Elkabets et al. identified a novel sub-population of murine 
MDSC that lacks Ly6C expression and predominates during IL-1β-induced inflammatory 
responses. Ly6Cneg MDSC and Ly6Clow MDSC may constitute separate lineages of MDSC, or 
could perhaps represent distinct states of differentiation within a single MDSC lineage 
(Elkabets et al., 2010). In addition to Gr-1 and CD11b, several other surface molecules have 
been reported to discriminate between sub-populations of MDSC, including the co-stimulatory 
molecule CD80 (B7.1) (Yang et al., 2006), macrophage marker F4/80 (Huang et al., 2006), the 
M-CSF receptor (CSF1R/CD115) (Huang et al., 2006), and the α-chain of the receptor for IL-4 
and IL-13 (IL-4Rα/CD124) (Gallina et al., 2006). MO-MDSC express higher levels of F4/80, 
CD115, 7/4, and CCR2 when compared with PMN-MDSC, which suggests a monocytic origin 
for these cells. However, further studies have demonstrated that, although these additional 
markers are undoubtedly expressed by MDSC, they do not specifically define a population of 
immunosuppressive cells (Youn et al., 2008). Indeed, while useful for analytical purposes, the 
Ly6G and Ly6C antibodies are not essential for identifying MDSC populations by flow-
cytometry: differential expression of Gr-1 and F4/80 alone can suffice to distinguish PMN-
MDSC (CD11b+Gr-1highF4/80-) from MO-MDSC (CD11b+Gr-1intF4/80int). The use of Ly6G-
specific antibodies is therefore only required when attempting to isolate a pure PMN-MDSC 
subset from a mixed cell population that also includes MO-MDSC (Toh et al., 2011). A 













Immune suppression via ROS-
mediated mechanisms
Immune suppression via 
arginase and NOS-mediated 
mechanisms
Terminally differentiated Capable in differentiating into macrophages
 
Table 1. Main characteristics of two well-accepted MDSC subsets (Movahedi et al., 2008; 
Youn et al., 2008). It should be noted that some novel sub-populations of MDSC have 
recently been identified.  
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4. MDSC in cancer progression 
There is ample evidence from the literature that MDSC are associated with tumor progression. 
Adoptive transfer of MDSC in murine tumor models has been found to significantly promote 
tumor growth (Balwit et al., 2011; Yang et al., 2004), and administration of MDSC after 5-
Fluorouracil (5FU) injection blunted the anti-tumor effect of 5FU in tumor-bearing mice 
(Vincent et al., 2010). Depletion of Gr-1+ cells in tumor-bearing mice by injection of anti-Gr-1 
antibody strikingly inhibited tumor growth, reduced cancer cell dissemination and metastasis, 
and prolonged survival (Li et al., 2009; Pekarek et al., 1995; Zhang et al., 2009). Treatment of 
tumor-bearing mice with drugs that target MDSC, such as gemcitabine chemotherapeutic 
agent, all-trans-retinoic acid, and phosphodiesterase-5 inhibitors led to delayed tumor 
progression, improved survival, and enhanced efficacy of cancer vaccines and 
immunotherapies (Kusmartsev et al., 2003; Serafini et al., 2006; Suzuki et al., 2005). Reduction 
of murine MDSC numbers has also been shown to facilitate the rejection of established 
metastatic disease after the removal of primary tumors (Sinha et al., 2005). 
5. MDSC use multiple mechanisms to suppress T-cell function  
MDSC use a variety of different mechanisms to suppress anti-tumor immunity. Multiple 
lines of evidence indicate that MDSC are potent inhibitors of both antigen-specific and non-
specific T-cell activation.  
5.1 Arginase 
L-arginine is a conditionally essential amino acid and is primarily metabolized by arginases 
(ARGs) and nitric oxide synthases (NOSs) to produce either L-ornithine and urea, or to 
provide L-citrulline and nitric oxide (NO) (Bogdan, 2001; Morris, 2002; Wu and Morris, 
1998). The suppressive activity of MDSC was initially thought to be associated with the 
metabolism of L-arginine since depletion of this amino acid is accompanied by marked 
suppression of T-cell function and proliferation (Bronte et al., 2003; Bronte and Zanovello, 
2005; Rodriguez et al., 2005; Rodriguez and Ochoa, 2008). L-arginine deprivation has been 
reported to induce T-cell dysfunction via two distinct pathways, the first being loss of CD3ζ 
chain expression by these cells (Ezernitchi et al., 2006; Rodriguez et al., 2004; Rodriguez et 
al., 2002; Rodriguez et al., 2003a). CD3ζ is a key component of the T-cell receptor (TCR) and 
contains three immunoreceptor tyrosine-based activation motifs (ITAM) that generate an 
activation signal in T cells upon antigen recognition (Pitcher and van Oers, 2003). Lack of L-
arginine may therefore decrease the propensity for T cells to become activated by down-
regulating the CD3ζ signal transduction machinery. Alternatively, shortage of L-arginine 
may prevent the up-regulation of cell cycle regulators cyclin D3 and cyclin-dependent 
kinase 4 (CDK4) to arrest T cells in the G0-G1 phase of the cell cycle (Rodriguez et al., 2007). 
MDSC produce high levels of arginase, which depletes L-arginine in the local 
microenvironment, and can also uptake excess arginine through the CAT-2B transporter 
(Rodriguez et al., 2004; Rodriguez et al., 2003b). MDSC may therefore deprive T cells of L-
arginine to limit their proliferative potential, as well as decreasing TCR signaling, to induce 
broad suppression of T-cell function. These mechanisms seem to contribute to the pro-tumor 
function of MDSC, since injection of the arginase I inhibitor N-hydroxy-nor-l-arginine (Nor-
NOHA) in tandem with tumor implantation has been shown to significantly slow the 
growth of lung carcinoma in a dose-dependent manner. However, inhibition of tumor 
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growth upon Nor-NOHA treatment was not observed in tumor-laden SCID mice (severe 
combined immunodeficient animals), suggesting that the anti-tumor effect of arginase 
inhibition was dependent on lymphocyte function (Rodriguez et al., 2004). 
5.2 Nitric oxide 
L-arginine is a substrate for inducible nitric oxide synthase (iNOS) which is highly 
expressed in MDSC. Nitric oxide (NO) production via this pathway is a powerful modulator 
of inflammation and has been reported to preferentially inhibit Th1-mediated immune 
responses (Bauer et al., 1997; Sosroseno et al., 2009). NO potently suppresses T-cell 
activation, proliferation, adhesion, and migration (Bingisser et al., 1998; Bobe et al., 1999; 
Lejeune et al., 1994; Mazzoni et al., 2002; Medot-Pirenne et al., 1999; Sato et al., 2007). It 
suppresses T-cell function through blocking the activation of several important signaling 
molecules in T cells, including Janus-activated kinase 1 (JAK1), JAK3, signal transducer and 
activator of transcription 5 (STAT5), extracellular signal-regulated kinase (ERK), and AKT 
(Bingisser et al., 1998; Mazzoni et al., 2002). NO has also been shown to inhibit MHC class II 
expression and promote T-cell apoptosis (Harari and Liao, 2004; Rivoltini et al., 2002).  
5.3 Reactive oxygen species  
Reactive oxygen species (ROS) have emerged as a potential key mechanism of MDSC-induced 
immunosuppression in tumor-bearing hosts. Hyper-production of ROS is an archetypal 
feature of MDSC in both mouse tumor models and in human cancer patients (Greten et al., 
2011; Kusmartsev et al., 2004; Youn et al., 2008). Elevated ROS production by MDSC is 
mediated primarily by increased NADPH oxidase NOX2 activity (Corzo et al., 2009). In a 
previous report, lack of NOX2 activity abrogated the ability of MDSC to suppress T-cell 
responses (Corzo et al., 2009). Arginases and NOS can also contribute to the generation of ROS 
in MDSC: arginase depletion of L-arginine in the local environment triggers superoxide (O2–) 
generation from iNOS (Bronte et al., 2003; Xia et al., 1998). The unstable O2– anion can then 
react with protons in water to generate hydrogen peroxide. ROS appear then to exert a major 
role in MDSC-mediated T-cell suppression (Kusmartsev et al., 2008; Markiewski et al., 2008; 
Nagaraj et al., 2007) and have been implicated in the inhibition of antigen-specific CD8+ T-cell 
responses in tumor-bearing mice (Kusmartsev et al., 2004). ROS are also thought to play a 
direct role in inducing apoptosis of activated T cells by decreasing Bcl-2 expression (Hildeman 
et al., 2003). Accordingly, inhibition of ROS production in MDSC by the addition of ROS 
scavengers can reverse MDSC-mediated immune suppression and rescues IFN-γ production 
(Kusmartsev et al., 2004; Kusmartsev et al., 2008).  
5.4 Peroxynitrite 
Peroxynitrite (ONOO-) is a reactive nitrogen-oxide species (RNOS) formed from the reaction 
between NO and O2– (Squadrito and Pryor, 1995). A major action of peroxynitrite is the 
modification of proteins by oxidation or nitration of the amino acids tyrosine, cystine, 
methionine, and tryptophan (Gabrilovich and Nagaraj, 2009). MDSC are copious producers 
of peroxynitrite, and increased levels of this species are associated with tumor progression 
(Cobbs et al., 2003; Ekmekcioglu et al., 2000; Nakamura et al., 2006). Hyper-production of 
peroxynitrite during direct contact with T cells allows MDSC to induce nitration of tyrosine 
residues in the TCR and CD8 co-receptor, leading to decreased conformational flexibility of 
the TCR chains and impaired interactions with MHC, thus inhibiting antigen-specific, 
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microenvironment, and can also uptake excess arginine through the CAT-2B transporter 
(Rodriguez et al., 2004; Rodriguez et al., 2003b). MDSC may therefore deprive T cells of L-
arginine to limit their proliferative potential, as well as decreasing TCR signaling, to induce 
broad suppression of T-cell function. These mechanisms seem to contribute to the pro-tumor 
function of MDSC, since injection of the arginase I inhibitor N-hydroxy-nor-l-arginine (Nor-
NOHA) in tandem with tumor implantation has been shown to significantly slow the 
growth of lung carcinoma in a dose-dependent manner. However, inhibition of tumor 
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growth upon Nor-NOHA treatment was not observed in tumor-laden SCID mice (severe 
combined immunodeficient animals), suggesting that the anti-tumor effect of arginase 
inhibition was dependent on lymphocyte function (Rodriguez et al., 2004). 
5.2 Nitric oxide 
L-arginine is a substrate for inducible nitric oxide synthase (iNOS) which is highly 
expressed in MDSC. Nitric oxide (NO) production via this pathway is a powerful modulator 
of inflammation and has been reported to preferentially inhibit Th1-mediated immune 
responses (Bauer et al., 1997; Sosroseno et al., 2009). NO potently suppresses T-cell 
activation, proliferation, adhesion, and migration (Bingisser et al., 1998; Bobe et al., 1999; 
Lejeune et al., 1994; Mazzoni et al., 2002; Medot-Pirenne et al., 1999; Sato et al., 2007). It 
suppresses T-cell function through blocking the activation of several important signaling 
molecules in T cells, including Janus-activated kinase 1 (JAK1), JAK3, signal transducer and 
activator of transcription 5 (STAT5), extracellular signal-regulated kinase (ERK), and AKT 
(Bingisser et al., 1998; Mazzoni et al., 2002). NO has also been shown to inhibit MHC class II 
expression and promote T-cell apoptosis (Harari and Liao, 2004; Rivoltini et al., 2002).  
5.3 Reactive oxygen species  
Reactive oxygen species (ROS) have emerged as a potential key mechanism of MDSC-induced 
immunosuppression in tumor-bearing hosts. Hyper-production of ROS is an archetypal 
feature of MDSC in both mouse tumor models and in human cancer patients (Greten et al., 
2011; Kusmartsev et al., 2004; Youn et al., 2008). Elevated ROS production by MDSC is 
mediated primarily by increased NADPH oxidase NOX2 activity (Corzo et al., 2009). In a 
previous report, lack of NOX2 activity abrogated the ability of MDSC to suppress T-cell 
responses (Corzo et al., 2009). Arginases and NOS can also contribute to the generation of ROS 
in MDSC: arginase depletion of L-arginine in the local environment triggers superoxide (O2–) 
generation from iNOS (Bronte et al., 2003; Xia et al., 1998). The unstable O2– anion can then 
react with protons in water to generate hydrogen peroxide. ROS appear then to exert a major 
role in MDSC-mediated T-cell suppression (Kusmartsev et al., 2008; Markiewski et al., 2008; 
Nagaraj et al., 2007) and have been implicated in the inhibition of antigen-specific CD8+ T-cell 
responses in tumor-bearing mice (Kusmartsev et al., 2004). ROS are also thought to play a 
direct role in inducing apoptosis of activated T cells by decreasing Bcl-2 expression (Hildeman 
et al., 2003). Accordingly, inhibition of ROS production in MDSC by the addition of ROS 
scavengers can reverse MDSC-mediated immune suppression and rescues IFN-γ production 
(Kusmartsev et al., 2004; Kusmartsev et al., 2008).  
5.4 Peroxynitrite 
Peroxynitrite (ONOO-) is a reactive nitrogen-oxide species (RNOS) formed from the reaction 
between NO and O2– (Squadrito and Pryor, 1995). A major action of peroxynitrite is the 
modification of proteins by oxidation or nitration of the amino acids tyrosine, cystine, 
methionine, and tryptophan (Gabrilovich and Nagaraj, 2009). MDSC are copious producers 
of peroxynitrite, and increased levels of this species are associated with tumor progression 
(Cobbs et al., 2003; Ekmekcioglu et al., 2000; Nakamura et al., 2006). Hyper-production of 
peroxynitrite during direct contact with T cells allows MDSC to induce nitration of tyrosine 
residues in the TCR and CD8 co-receptor, leading to decreased conformational flexibility of 
the TCR chains and impaired interactions with MHC, thus inhibiting antigen-specific, 
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cytotoxic T-cell responses (Nagaraj et al., 2007). Peroxynitrite-driven nitration of tyrosine 
residues in human lymphocytes is also able to promote apoptotic cell death by inhibiting 
activation-induced tyrosine phosphorylation in these cells (Brito et al., 1999).  
5.5 Cysteine 
Recent work has demonstrated that murine MDSC block T-cell activation by depleting 
cysteine from the local microenvironment (Srivastava et al., 2010). Cysteine is an essential 
amino acid required for T-cell activation, differentiation and proliferation. Cells generate 
cysteine through two distinct pathways: the cystathionase enzyme can convert intracellular 
methionine into cysteine (Gout et al., 2001; Ishii et al., 2004), or alternatively, the plasma 
membrane cystine transporter xc− can import the oxidized form of the acid (cystine) from the 
extracellular environment. Imported cystine can then be reduced to form cysteine (Arner 
and Holmgren, 2000; Mansoor et al., 1992). Since T cells lack both cystathionase and an 
intact xc− transporter, they are unable to generate cysteine independently. Under 
homeostatic conditions, antigen-presenting cells (APC) provide cysteine to T cells by 
importing cystine, converting it to cysteine, and then exporting the cysteine through their 
plasma membrane ASC transporters (Sato et al., 1987; Angelini et al., 2002). Like T cells, 
MDSC lack cystathionase and depend on extracellular cystine for the synthesis of cysteine, 
but they lack the APC-expressed ASC transporter required to export cysteine. This results in 
MDSC readily importing cystine at a rate similar to that of macrophages and DC, but they 
do not export cysteine. This action depletes the environment of cysteine and results in the 
inhibition of T-cell activation and function (Srivastava et al., 2010).  
5.6 Alternative immunosuppressive mechanisms  
Alternative pathways have been identified through which MDSC might exert their 
suppressive functions. The immunoregulatory cytokine TGF-β has been implicated in 
MDSC function. It is regulated in MDSC by IL-13 and CD4+ CD1d-restricted T cells. 
Blocking IL-13 or TGF-β limited tumor incidence in murine transplanted tumor models 
(Fichtner-Feigl et al., 2008; Terabe et al., 2003). MDSC also have the ability to systemically 
down-regulate CD62L (L-selectin) on T cells in tumor-bearing mice. This action impairs 
naïve CD4+ and CD8+ T-cell homing to lymph nodes. Therefore, these T cells are not able to 
be activated by tumor antigens (Hanson et al., 2009). Down-regulation of CD62L was not 
due to general T-cell activation and could even be observed in tumor-free mice that 
exhibited high numbers of MDSC, (a common profile in aged animals). MDSC also 
constitutively express a disintegrin and metalloproteinase domain 17 (ADAM17, also 
known as TACE/TNFα-converting enzyme) on their cell surface, thus allowing the 
proteolytic cleavage and shedding of the ectodomain of CD62L (Hanson et al., 2009).  
Various reports have demonstrated that MDSC can induce the differentiation of regulatory 
T cells (Treg) in tumor-bearing hosts and indirectly promote immune suppression 
(Gabrilovich and Nagaraj, 2009). Treg induction can occur through diverse pathways that 
depend on the tumor model in use (Bianchi et al., 2011). In a mouse lymphoma model, 
induction of Treg is dependent on arginase and is independent of TGF-β (Serafini et al., 
2008), but in murine ovarian cancer, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
expression on MDSC can mediate Treg induction (Yang et al., 2006). Another study by 
Huang et al. using several murine transplanted tumor models showed that IL-10 and IFN-γ, 
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but not NO, were important factors in MDSC-mediated Treg development (Huang et al., 
2006). A more recent study has also reported that the immune stimulatory receptor CD40 on 
MDSC is required to induce tumor-specific Treg expansion in a mouse colon cancer model 
(Pan et al., 2010). 
5.7 Suppressive mechanisms differ between MDSC subsets 
In addition to morphological and phenotypic distinctions, PMN-MDSC and MO-MDSC also 
exert their suppressive activity by different mechanisms. MO-MDSC express high levels of 
NO and low levels of ROS, and they effectively suppress T-cell function in both antigen-
dependent and independent manners without requiring cell-cell contact. Primarily, MO-
MDSC inhibit T-cell function through NOS-mediated mechanisms since NOS inhibitors are 
able to block this suppressive effect. This pathway is IFN-γ/STAT1-dependent (Movahedi et 
al., 2008; Youn et al., 2008). In contrast, PMN-MDSC produce high levels of ROS but only 
nominal amounts of NO, indicating that ROS are the primary mediators of their suppressive 
functions (Movahedi et al., 2008; Youn et al., 2008). PMN-MDSC generally require antigen-
specific interactions with T cells to mediate suppression (Nagaraj et al., 2007), although it 
has also been reported that PMN-MDSC do not require direct MHC I presentation to exert 
inhibitory effects (Movahedi et al., 2008). In most tumor models, PMN-MDSC are the main 
MDSC subset to be expanded in the peripheral lymphoid organs (Youn et al., 2008), while 
the MO-MDSC population possesses more potent inhibitory activity (Dolcetti et al., 2010; 
Movahedi et al., 2008; Nausch et al., 2008; Priceman et al., 2010). 
Murine splenic MDSC have also been shown to differ from their tumor-derived 
counterparts with regards to T-cell suppression. Tumor MDSC can potently suppress T-cell 
proliferation in both  antigen-specific and non-specific manner, whereas splenic MDSC are 
comparatively weak suppressor cells and exert only antigen-specific T-cell inhibition. This 
functional difference is suggested to be due to the different suppressive mechanisms used 
by splenic and tumor MDSC. Splenic MDSC suppress T cells through ROS production. In 
contrast, at the tumor site, MDSC, as a result of the effect of hypoxia via HIF-1α, 
dramatically up-regulate inos and argI expression and therefore acquire the ability to inhibit 
antigen-nonspecific T-cell functions  (Corzo et al., 2010). 
6. Mechanisms by which MDSC disrupt innate immunity 
In addition to T-cell suppression, MDSC restrict innate responses via their interactions with 
macrophages, NK cells, and NKT cells to further impair anti-tumor immunity. Cross-talk 
between MDSC and macrophages results in increased MDSC production of the type 2 
cytokine IL-10, and decreased macrophage production of type 1 cytokine IL-12, which 
skews tumor immunity towards a tumor-promoting type 2 response (Sinha et al., 2007). 
The role of MDSC in regulating NK-cell function remains controversial. Some studies have 
shown that MDSC impair NK-cell development, IFN-γ production and cytotoxicity against 
tumor cells. This suppression is mediated by membrane-bound TGF-β1 and through down-
modulation of NKG2D (the primary activating receptor for NK cells) (Elkabets et al., 2010; 
Li et al., 2009; Liu et al., 2007; Suzuki et al., 2005). However, in a separate mouse study, MO-
MDSC isolated from RMA-S tumor-bearing mice failed to suppress NK-cell function, and 
instead elicited high production of IFN-γ by these cells. These effects partially depended on 
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cytotoxic T-cell responses (Nagaraj et al., 2007). Peroxynitrite-driven nitration of tyrosine 
residues in human lymphocytes is also able to promote apoptotic cell death by inhibiting 
activation-induced tyrosine phosphorylation in these cells (Brito et al., 1999).  
5.5 Cysteine 
Recent work has demonstrated that murine MDSC block T-cell activation by depleting 
cysteine from the local microenvironment (Srivastava et al., 2010). Cysteine is an essential 
amino acid required for T-cell activation, differentiation and proliferation. Cells generate 
cysteine through two distinct pathways: the cystathionase enzyme can convert intracellular 
methionine into cysteine (Gout et al., 2001; Ishii et al., 2004), or alternatively, the plasma 
membrane cystine transporter xc− can import the oxidized form of the acid (cystine) from the 
extracellular environment. Imported cystine can then be reduced to form cysteine (Arner 
and Holmgren, 2000; Mansoor et al., 1992). Since T cells lack both cystathionase and an 
intact xc− transporter, they are unable to generate cysteine independently. Under 
homeostatic conditions, antigen-presenting cells (APC) provide cysteine to T cells by 
importing cystine, converting it to cysteine, and then exporting the cysteine through their 
plasma membrane ASC transporters (Sato et al., 1987; Angelini et al., 2002). Like T cells, 
MDSC lack cystathionase and depend on extracellular cystine for the synthesis of cysteine, 
but they lack the APC-expressed ASC transporter required to export cysteine. This results in 
MDSC readily importing cystine at a rate similar to that of macrophages and DC, but they 
do not export cysteine. This action depletes the environment of cysteine and results in the 
inhibition of T-cell activation and function (Srivastava et al., 2010).  
5.6 Alternative immunosuppressive mechanisms  
Alternative pathways have been identified through which MDSC might exert their 
suppressive functions. The immunoregulatory cytokine TGF-β has been implicated in 
MDSC function. It is regulated in MDSC by IL-13 and CD4+ CD1d-restricted T cells. 
Blocking IL-13 or TGF-β limited tumor incidence in murine transplanted tumor models 
(Fichtner-Feigl et al., 2008; Terabe et al., 2003). MDSC also have the ability to systemically 
down-regulate CD62L (L-selectin) on T cells in tumor-bearing mice. This action impairs 
naïve CD4+ and CD8+ T-cell homing to lymph nodes. Therefore, these T cells are not able to 
be activated by tumor antigens (Hanson et al., 2009). Down-regulation of CD62L was not 
due to general T-cell activation and could even be observed in tumor-free mice that 
exhibited high numbers of MDSC, (a common profile in aged animals). MDSC also 
constitutively express a disintegrin and metalloproteinase domain 17 (ADAM17, also 
known as TACE/TNFα-converting enzyme) on their cell surface, thus allowing the 
proteolytic cleavage and shedding of the ectodomain of CD62L (Hanson et al., 2009).  
Various reports have demonstrated that MDSC can induce the differentiation of regulatory 
T cells (Treg) in tumor-bearing hosts and indirectly promote immune suppression 
(Gabrilovich and Nagaraj, 2009). Treg induction can occur through diverse pathways that 
depend on the tumor model in use (Bianchi et al., 2011). In a mouse lymphoma model, 
induction of Treg is dependent on arginase and is independent of TGF-β (Serafini et al., 
2008), but in murine ovarian cancer, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
expression on MDSC can mediate Treg induction (Yang et al., 2006). Another study by 
Huang et al. using several murine transplanted tumor models showed that IL-10 and IFN-γ, 
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but not NO, were important factors in MDSC-mediated Treg development (Huang et al., 
2006). A more recent study has also reported that the immune stimulatory receptor CD40 on 
MDSC is required to induce tumor-specific Treg expansion in a mouse colon cancer model 
(Pan et al., 2010). 
5.7 Suppressive mechanisms differ between MDSC subsets 
In addition to morphological and phenotypic distinctions, PMN-MDSC and MO-MDSC also 
exert their suppressive activity by different mechanisms. MO-MDSC express high levels of 
NO and low levels of ROS, and they effectively suppress T-cell function in both antigen-
dependent and independent manners without requiring cell-cell contact. Primarily, MO-
MDSC inhibit T-cell function through NOS-mediated mechanisms since NOS inhibitors are 
able to block this suppressive effect. This pathway is IFN-γ/STAT1-dependent (Movahedi et 
al., 2008; Youn et al., 2008). In contrast, PMN-MDSC produce high levels of ROS but only 
nominal amounts of NO, indicating that ROS are the primary mediators of their suppressive 
functions (Movahedi et al., 2008; Youn et al., 2008). PMN-MDSC generally require antigen-
specific interactions with T cells to mediate suppression (Nagaraj et al., 2007), although it 
has also been reported that PMN-MDSC do not require direct MHC I presentation to exert 
inhibitory effects (Movahedi et al., 2008). In most tumor models, PMN-MDSC are the main 
MDSC subset to be expanded in the peripheral lymphoid organs (Youn et al., 2008), while 
the MO-MDSC population possesses more potent inhibitory activity (Dolcetti et al., 2010; 
Movahedi et al., 2008; Nausch et al., 2008; Priceman et al., 2010). 
Murine splenic MDSC have also been shown to differ from their tumor-derived 
counterparts with regards to T-cell suppression. Tumor MDSC can potently suppress T-cell 
proliferation in both  antigen-specific and non-specific manner, whereas splenic MDSC are 
comparatively weak suppressor cells and exert only antigen-specific T-cell inhibition. This 
functional difference is suggested to be due to the different suppressive mechanisms used 
by splenic and tumor MDSC. Splenic MDSC suppress T cells through ROS production. In 
contrast, at the tumor site, MDSC, as a result of the effect of hypoxia via HIF-1α, 
dramatically up-regulate inos and argI expression and therefore acquire the ability to inhibit 
antigen-nonspecific T-cell functions  (Corzo et al., 2010). 
6. Mechanisms by which MDSC disrupt innate immunity 
In addition to T-cell suppression, MDSC restrict innate responses via their interactions with 
macrophages, NK cells, and NKT cells to further impair anti-tumor immunity. Cross-talk 
between MDSC and macrophages results in increased MDSC production of the type 2 
cytokine IL-10, and decreased macrophage production of type 1 cytokine IL-12, which 
skews tumor immunity towards a tumor-promoting type 2 response (Sinha et al., 2007). 
The role of MDSC in regulating NK-cell function remains controversial. Some studies have 
shown that MDSC impair NK-cell development, IFN-γ production and cytotoxicity against 
tumor cells. This suppression is mediated by membrane-bound TGF-β1 and through down-
modulation of NKG2D (the primary activating receptor for NK cells) (Elkabets et al., 2010; 
Li et al., 2009; Liu et al., 2007; Suzuki et al., 2005). However, in a separate mouse study, MO-
MDSC isolated from RMA-S tumor-bearing mice failed to suppress NK-cell function, and 
instead elicited high production of IFN-γ by these cells. These effects partially depended on 
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the interaction of NKG2D on NK cells with ligand RAE-1 on MDSC. Following activation, 
the NK cells eliminated the MDSC (Nausch et al., 2008). 
7. Non-immunosuppressive pro-tumor functions 
MDSC support for tumor growth does not depend solely on immunosuppression – these cells 
also promote tumor progression by augmenting blood vessel development and enhancing 
tumor-cell invasion and metastasis. In a murine colorectal cancer model (MC26), tumors co-
injected with MDSC from mice bearing large tumors exhibited increased vascular density and 
maturation, as well as decreased necrosis (Yang et al., 2004). Tumor growth was markedly 
facilitated when co-injected with tumor-derived MDSC, but not when co-injected with MDSC 
from normal mice. This increased vasculature was attributed to the production of MMP9, a 
critical mediator of tumor angiogenesis, vasculogenesis, and metastasis. MDSC-derived MMP9 
was shown to increase the bioavailability of VEGF in tumors and promote tumor angiogenesis 
and vascular stability. Accordingly, selective deletion of MMP9 in MDSC completely 
abolished their tumor-promoting activity (Yang et al., 2004). In a separate study using the 
mouse MT1A2 mammary cancer model, it was demonstrated that bone marrow-derived 
CD11b+ myelomonocytic cells significantly contributed to tumor vasculogenesis by producing 
MMP9 (Ahn and Brown, 2008). Various other MMPs, including MMP14, MMP13, and MMP2, 
were also found to be highly expressed in tumor-resident MDSC (Yang et al., 2008). These 
MDSC were recruited to the invasive front of mammary carcinomas with conditional deletion 
of the type II TGF-β receptor gene. The MDSC infiltrate directly facilitated tumor invasion and 
metastasis through enhanced MMP and TGF-β production (Yang et al., 2008). Furthermore, 
Bv8 protein (also known as prokineticin 2, or Prok2) has also been reported to contribute to 
MDSC-dependent tumor angiogenesis. Transplantation of tumor cells in mice resulted in 
significant up-regulation of Bv8 in MDSC, while treatment with neutralizing anti-Bv8 
antibodies suppressed tumor angiogenesis and inhibited tumor growth (Shojaei et al., 2007). In 
addition, murine tumor-associated MDSC were shown to confer tumor resistance to anti-
angiogenic therapy (anti-VEGF antibody) that was mediated by G-CSF and depended on Bv8 
expression. Combining anti-VEGF treatment with anti-Gr-1, anti-G-CSF, or anti-Bv8 antibody 
inhibited growth of refractory tumors more effectively that anti-VEGF therapy alone. Anti-G-
CSF treatment robustly reduced MDSC frequency in refractory tumors, decreased Bv8 levels, 
and inhibited tumor angiogenesis (Shojaei et al., 2009). The tumor microenvironment has also 
been proposed to support MDSC shape change and expression of endothelial markers such as 
VEGFR2 and VE-Cadherin (Yang et al., 2004), which may allow MDSC to differentiate locally 
and directly incorporate into the tumor endothelium to contribute to vascular development.  
Although MDSC up-regulation of proteases seems to be the primary route by which these 
cells promote tumor metastasis, a recent study by Boutte and colleagues also highlighted the 
importance of down-regulating protease inhibitors in tumor dissemination (Boutte et al., 
2011). In this study of transplanted tumors, neutrophilic granule protein (NGP: a cathepsin 
B inhibitor), was down-regulated in MDSC from metastatic tumor-bearing mice compared 
with non-metastatic controls. Up-regulation of NGP in tumors delayed primary tumor 
growth and greatly reduced tumor vasculature, invasiveness, and metastasis.  
MDSC have been further implicated in pre-metastatic niche formation in the lungs of tumor-
bearing mice. The concept of the pre-metastatic niche arises from the observation that many 
tumors have a pre-disposition to metastasize certain organs. Various leukocyte populations 
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and secreted inflammatory factors have been shown to “prepare” distal organs for 
metastatic cells (Hiratsuka et al., 2006; Kaplan et al., 2006; Kaplan et al., 2005), and MDSC 
can infiltrate the lungs of tumor-bearing mice before the arrival of tumor cells. These MDSC 
create a proliferative and immunosuppressive lung environment that is permissive for the 
growth of metastatic tumor cells. Pre-metastatic lungs with elevated MDSC have increased 
levels of basic fibroblast growth factor (bFGF), insulin growth factor 1 (IGF1), IL-4, IL-5, IL-
9, IL-10, and MMP9, whereas IFN-γ is down-regulated in these lungs. Up-regulation of 
MMP9 in pulmonary MDSC drives abnormal vasculature development in the pre-metastatic 
lung (Yan et al., 2010), while myeloid cell-derived S100A8 and S100A9 pre-dispose the lung 
microenvironment towards eventual tumor metastasis (Hiratsuka et al., 2006). 
Finally, our own data reveal that PMN-MDSC promote melanoma cell proliferation by 
secreting soluble factors while also supporting cancer cell dissemination and metastasis by 
inducing epithelial-mesenchymal transition (Toh et al., 2011). These novel MDSC functions 
are discussed in more detail in the subsequent sections.  
8. Melanoma and the immune system 
Malignant melanoma is one of the most immunogenic forms of cancer and hundreds of 
immunotherapeutic trials have been conducted in melanoma patients to date. Substantial 
knowledge has been accumulated on the immunosuppressive pathways at work in 
melanoma and the role played by MDSC in disease progression. Tumor infiltrating 
lymphocytes (TIL) have been correlated with better prognoses and improved five-year 
survival rates (Day et al., 1981), and TIL isolated from melanoma patients are able to lyse 
MHC-matched allogeneic tumors (Degiovanni et al., 1988; Oble et al., 2009). However, the 
prognostic value of TIL is only valid in the early stages of melanoma, since TIL numbers in 
thick lesions do not predict clinical outcomes. Many melanoma-associated antigens are non-
mutated proteins that contribute to melanin synthesis, such as MelanA/MART-1, tyrosinase 
related protein (TRP)-1, TRP-2, gp100 and tyrosinase (Kawakami, 2000). Unfortunately, 
there has been only limited success in vaccinating patients with these antigens (Linette et al., 
2005). Large numbers of MelanA/MART-1 specific T cells have been found in the blood and 
tumors of melanoma patients (Salcedo et al., 2006), but only the circulating T cells were able 
to produce IFN-γ and granzyme B upon antigen stimulation (Zippelius et al., 2004). These 
data indicate potent local immunosuppression at the tumor site which is most likely driven 
by immune cells recruited into the tumor itself. Accordingly, lymphocyte depletion has been 
shown to be effective method of enhancing adoptive T-cell transfer therapy in melanoma 
patients (Hershkovitz et al., 2010). In a clinical trial to test the efficacy of adoptive T-cell 
transfer in combination with lympho-depletion (non-myeloablative chemotherapy; NMC), 
better objective responses and complete remission could be achieved when NMC was 
combined with total body irradiation or high dose irradiation alone (Dudley et al., 2008). 
These findings suggest that tumor-induced immunosuppression does not arise from 
lymphocytes alone but also from myeloid cells. 
To study the complex interactions between tumors and the immune system, investigators 
are progressively turning to transgenic mice that develop spontaneous tumors and replicate 
human cancers more closely than transplanted tumor models. RETAAD mice are transgenic 
for the activated RET oncogene which is specifically expressed in melanocytes of the skin 
and eyes, leading to spontaneous skin tumors and primary uveal melanomas that are 
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the interaction of NKG2D on NK cells with ligand RAE-1 on MDSC. Following activation, 
the NK cells eliminated the MDSC (Nausch et al., 2008). 
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also promote tumor progression by augmenting blood vessel development and enhancing 
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injected with MDSC from mice bearing large tumors exhibited increased vascular density and 
maturation, as well as decreased necrosis (Yang et al., 2004). Tumor growth was markedly 
facilitated when co-injected with tumor-derived MDSC, but not when co-injected with MDSC 
from normal mice. This increased vasculature was attributed to the production of MMP9, a 
critical mediator of tumor angiogenesis, vasculogenesis, and metastasis. MDSC-derived MMP9 
was shown to increase the bioavailability of VEGF in tumors and promote tumor angiogenesis 
and vascular stability. Accordingly, selective deletion of MMP9 in MDSC completely 
abolished their tumor-promoting activity (Yang et al., 2004). In a separate study using the 
mouse MT1A2 mammary cancer model, it was demonstrated that bone marrow-derived 
CD11b+ myelomonocytic cells significantly contributed to tumor vasculogenesis by producing 
MMP9 (Ahn and Brown, 2008). Various other MMPs, including MMP14, MMP13, and MMP2, 
were also found to be highly expressed in tumor-resident MDSC (Yang et al., 2008). These 
MDSC were recruited to the invasive front of mammary carcinomas with conditional deletion 
of the type II TGF-β receptor gene. The MDSC infiltrate directly facilitated tumor invasion and 
metastasis through enhanced MMP and TGF-β production (Yang et al., 2008). Furthermore, 
Bv8 protein (also known as prokineticin 2, or Prok2) has also been reported to contribute to 
MDSC-dependent tumor angiogenesis. Transplantation of tumor cells in mice resulted in 
significant up-regulation of Bv8 in MDSC, while treatment with neutralizing anti-Bv8 
antibodies suppressed tumor angiogenesis and inhibited tumor growth (Shojaei et al., 2007). In 
addition, murine tumor-associated MDSC were shown to confer tumor resistance to anti-
angiogenic therapy (anti-VEGF antibody) that was mediated by G-CSF and depended on Bv8 
expression. Combining anti-VEGF treatment with anti-Gr-1, anti-G-CSF, or anti-Bv8 antibody 
inhibited growth of refractory tumors more effectively that anti-VEGF therapy alone. Anti-G-
CSF treatment robustly reduced MDSC frequency in refractory tumors, decreased Bv8 levels, 
and inhibited tumor angiogenesis (Shojaei et al., 2009). The tumor microenvironment has also 
been proposed to support MDSC shape change and expression of endothelial markers such as 
VEGFR2 and VE-Cadherin (Yang et al., 2004), which may allow MDSC to differentiate locally 
and directly incorporate into the tumor endothelium to contribute to vascular development.  
Although MDSC up-regulation of proteases seems to be the primary route by which these 
cells promote tumor metastasis, a recent study by Boutte and colleagues also highlighted the 
importance of down-regulating protease inhibitors in tumor dissemination (Boutte et al., 
2011). In this study of transplanted tumors, neutrophilic granule protein (NGP: a cathepsin 
B inhibitor), was down-regulated in MDSC from metastatic tumor-bearing mice compared 
with non-metastatic controls. Up-regulation of NGP in tumors delayed primary tumor 
growth and greatly reduced tumor vasculature, invasiveness, and metastasis.  
MDSC have been further implicated in pre-metastatic niche formation in the lungs of tumor-
bearing mice. The concept of the pre-metastatic niche arises from the observation that many 
tumors have a pre-disposition to metastasize certain organs. Various leukocyte populations 
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and secreted inflammatory factors have been shown to “prepare” distal organs for 
metastatic cells (Hiratsuka et al., 2006; Kaplan et al., 2006; Kaplan et al., 2005), and MDSC 
can infiltrate the lungs of tumor-bearing mice before the arrival of tumor cells. These MDSC 
create a proliferative and immunosuppressive lung environment that is permissive for the 
growth of metastatic tumor cells. Pre-metastatic lungs with elevated MDSC have increased 
levels of basic fibroblast growth factor (bFGF), insulin growth factor 1 (IGF1), IL-4, IL-5, IL-
9, IL-10, and MMP9, whereas IFN-γ is down-regulated in these lungs. Up-regulation of 
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and eyes, leading to spontaneous skin tumors and primary uveal melanomas that are 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
72
clinically detectable by four to eight weeks of age. While exophthalmos eventually presents 
in adult RETAAD mice, microscopic eye tumors can be detected as early as ten days after 
birth, and cancer cells disseminate from the primary eye tumor throughout the body within 
three weeks (Eyles et al., 2010; Kato et al., 1998). Disseminated RETAAD cancer cells remain 
dormant for months before developing into cutaneous and visceral metastases, and the 
stepwise evolution of melanoma in these mice closely mimics the histopathology and 
natural history of human cancers (Eskelin et al., 2000; Kato et al., 1998; Kato et al., 2004). The 
RETAAD melanoma model is therefore particularly suitable for dissecting the role of host 




























Fig. 1. Immunosuppressive and non-immunosuppressive tumor-promoting functions of 
MDSC.         : Inhibition.          : Induction or promotion. 
Similar to human melanoma patients, tumors in RETAAD mice grow despite the induction 
of a broad melanoma-specific CD8+ T-cell response (Lengagne et al., 2008). It is surprising 
then that cutaneous tumor cell lines derived from RETAAD mice are still recognized by 
tumor-specific T cells, indicating that they are indeed antigenic (Lengagne et al., 2008). 
Functionally active, melanoma-specific, memory T lymphocytes can be detected at the early 
stages of melanoma progression, in the absence of clinically visible cutaneous tumors 
(Lengagne et al., 2008; Umansky et al., 2008). However, tumor progression continues despite 
the presence of these antigen-specific CD8+ T cells, suggesting that potent suppressive 
mechanisms shield the developing tumor from immune destruction. 
Even though a pathological role for Treg cells has been implicated in several tumor models, 
depletion of Treg in RET transgenic melanoma mice neither delayed nor inhibited tumor 
development (Kimpfler et al., 2009). In RET mice, intra-tumoral dendritic cell (DC) numbers 
correlated with tumor size, and DC from mice with macroscopic tumors secreted 
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significantly less IL-12p70, increased quantities of IL-10, and were impaired in their ability 
to activate T cells. The tolerogenic properties of these DC were mediated by IL-6, VEGF, and 
TGF-β1 secreted in the tumor microenvironment (Zhao et al., 2009). Interestingly, in a 
separate study, IL-6 ablation in RET mice also reduced the incidence and size of tumors (von 
Felbert et al., 2005). Relative aggression of cutaneous tumors in RET mice correlated with 
numbers of tumor-infiltrating CD11b+Gr1low macrophages that displayed an M2-like, pro-
tumor phenotype, characterized by high transcript levels of il10, arginase I, mgl1, fizz1, and 
ccl2. Tumor- and spleen-derived macrophages in these mice were able to potently inhibit T-cell 
function. Surprisingly, depletion of T cells from RET mice resulted in the switching of these 
macrophages towards a M1, anti-tumor phenotype, characterized by secretion of IL-12. In the 
absence of T cells, macrophages in RET mice also displayed reduced ability to support tumor 
growth (Lengagne et al., 2011). In our own laboratory, we have further observed that the 
microenvironment of RETAAD cutaneous tumors supports only limited infiltration of CD4+ 
and CD8+ T cells compared with transplanted B16 tumors (Hong et al., 2011). 
9. MDSC in melanoma 
We have observed that CD11b+Gr1high PMN-MDSC are increased in the spleen and blood of 
RETAAD mice during tumor progression. PMN-MDSC, but not MO-MDSC, preferentially 
accumulate in the primary tumor compared with metastases, which is due to the expression 
of CXCL1, CXCL2 and CXCL5 (chemotactic mediators specific for PMN-MDSC) in the 
primary tumor, but not in metastases. PMN-MDSC notably affect two primary aspects of 
tumor progression – tumor growth and metastasis. In RETAAD mice, depletion of PMN-
MDSC by treatment with anti-Ly6G antibody resulted in a decrease in primary tumor size, 
but failed to diminish cutaneous tumors (which have low infiltrates of PMN-MDSC). 
Furthermore, early depletion of PMN-MDSC (before primary tumor development) resulted 
in decreased proliferation of primary tumors, while in vitro assays demonstrated that the 
ability to induce cancer cell proliferation is specific to PMN-MDSC but not macrophages. 
These data also indicate that PMN-MDSC are able to directly induce tumor cell proliferation 
by secreting a soluble factor (Toh et al., 2011). 
PMN-MDSC also induce epithelial-mesenchymal transition (EMT) which is the first step 
towards metastasis in early stage cancers (Toh et al., 2011). Depletion of PMN-MDSC 
reduced dissemination of tumor cells to distant metastatic sites such as the lungs and the 
tumor-draining lymph nodes. Primary tumor cells in control mice exhibited higher 
expression of mesenchymal markers S100A4 and vimentin compared with mice depleted of 
PMN-MDSC. In vitro, PMN-MDSC were also able to down-modulate E-Cadherin, a classical 
epithelial marker, in both mouse and human melanoma cells. Induction of EMT was 
dependent on TGF-β, epidermal growth factor and hepatocyte growth factor, since blockade 
of these molecules either individually or in combination resulted in partial or complete 
inhibition of EMT (Toh et al., 2011). 
The ability of melanomas to evade immune destruction depends on components of the host 
immune system. While extensive research has already been conducted on immunotherapy 
strategies that enhance T-cell responses against tumors, improving the efficacy of these 
interventions will require a better understanding of the interactions between melanoma cells 
and the immune system, with a particular focus on immunosuppressive MDSC populations. 
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Additional research will also be required to determine whether MDSC are capable of 
inducing cancer cell proliferation and epithelial-mesenchymal transition in other types of 























Fig. 2. Roles of MDSC in the growth, invasion, and metastasis of melanoma. 
10. Therapeutic strategies targeting MDSC 
Recognition that MDSC-mediated immune suppression plays a pivotal role in tumor 
progression highlights these cells as an appealing target for novel cancer treatments. Agents 
that modulate MDSC development, differentiation and recruitment, or block the 
suppressive functions of these cells could represent potent new methods of limiting tumor 
progression, or could perhaps enhance the efficacy of existing therapies. Limiting the 
infiltration and activation of MDSC during chronic inflammation may even reduce the risk 
of de novo tumor development.  
10.1 Promoting MDSC differentiation 
Given the fact that MDSC are immature myeloid cells, a promising approach in cancer 
immunotherapy would be to drive MDSC differentiation into mature populations that no 
longer have suppressive activity. Vitamin A has been identified as a candidate agent that 
possesses this ability, since vitamin A deficiency causes systemic expansion of MDSC in 
mice (Kuwata et al., 2000). Vitamin A metabolites such as retinoic acid have been found to 
favor MDSC differentiation into mature DC, macrophages, and granulocytes. Treatment of 
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mouse or human MDSC with all-trans-retinoic acid (ATRA) in vitro resulted in induction of 
myeloid cell differentiation (Almand et al., 2001; Gabrilovich et al., 2001; Hengesbach and 
Hoag, 2004; Kusmartsev et al., 2008). Using adoptive transfer of MDSC into congenic mice, 
Kusmartsev et al. were able to demonstrate that ATRA also induced rapid differentiation of 
MDSC into mature myeloid cells in vivo (Kusmartsev et al., 2003). In tumor-bearing mice, 
ATRA administration substantially reduced the presence of MDSC and noticeably improved 
CD4+ and CD8+ T-cell-mediated anti-tumor immune responses. Combination of ATRA with 
two different types of cancer vaccines significantly prolonged the anti-tumor effect of the 
vaccination in two different mouse tumor models (Kusmartsev et al., 2003). Moreover, in 
human patients with metastatic renal cell carcinoma, effective concentrations of ATRA were 
shown to eliminate MDSC and improve antigen-specific T-cell responses (Kusmartsev et al., 
2008; Mirza et al., 2006). Vitamin D derivatives have also been reported to drive myeloid 
progenitor cell differentiation both in vitro and in vivo (Duits et al., 1992; Testa et al., 1993). 
25-hydroxyvitamin D3 treatment in patients with head and neck squamous cell carcinoma 
diminished the number of immuno-suppressive CD34+ progenitor cells and improved 
numerous parameters of immune responsiveness (Lathers et al., 2004).  
10.2 Inhibiting MDSC expansion 
As described above, many tumor-derived factors can induce the development and 
expansion of MDSC from hematopoietic precursors (see also section 2). Neutralization of 
these mediators is therefore another attractive strategy for novel cancer therapies. For 
example, stem-cell factor (SCF) has been identified as a vital mediator of MDSC expansion 
and accumulation, since SCF knockdown using silencing RNA decreased MDSC frequency 
and reversed tumor-specific T-cell tolerance in the mouse MCA26 colon cancer model. 
Blocking SCF interactions with its receptor, c-kit, by the use of specific antibodies 
dramatically reduced the MDSC population and prevented tumor-specific T-cell anergy, 
Treg development, and tumor angiogenesis, resulting in tumor regression and enhanced 
efficacy of immune-activating cancer therapy (Pan et al., 2008). Another study also reported 
that melanoma development is restrained in RET-transgenic mice with impaired c-kit 
function, or when RET mice are treated with anti-c-kit antibody. Although the authors 
attributed this phenomenon to the direct function of c-kit in tumor cells, we cannot exclude 
the possibility that the suppression of tumor development was due to attenuated MDSC 
expansion caused by c-kit impairment (Kato et al., 2004). 
MMP9 inhibition is another logical therapeutic approach in cancer therapy due to the MDSC 
requirement for MMP9 in supporting their expansion and function. In a spontaneous mouse 
mammary tumor model, treatment with a MMP9 inhibitor (amino-biphosphonate) was 
shown to significantly reduce MDSC expansion and impair tumor growth, while 
simultaneously enhancing tumor necrosis and improving the anti-tumor responses induced 
by immunotherapy (Melani et al., 2007). Finally, targeting the intracellular signaling 
pathways that are involved in MDSC expansion is also a promising strategy. Using selective 
STAT3 inhibitors, such as JSI-124 (cucurbitacin I), or tyrosine kinase inhibitors, such as 
sunitinib, can augment anti-tumor immune responses by reducing the presence of MDSC. 
Sunitinib combination therapy with IL-12 and 4-1BB activation significantly improved the 
long-term survival rate of mice bearing MCA26 colon tumors (Ko et al., 2009; Nefedova et 
al., 2005; Ozao-Choy et al., 2009). In a more recent study, treating mice with docetaxel anti-
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mitotic, chemotherapeutic reagent was found to polarize MDSC towards a M1-like 
phenotype by inhibiting STAT3 activation, and consequently restored CD4+ and CD8+ T-cell 
function to reduce 4T1-Neu tumor burden (Kodumudi et al., 2010).  
10.3 Eliminating MDSC 
Direct elimination of MDSC can be achieved with chemotherapeutic drugs such as 
gemcitabine, which dramatically and specifically reduces MDSC numbers in tumor-bearing 
mice, but spares CD4+ T cells, CD8+ T cells, NK cells, macrophages, and B cells. This 
beneficial loss of MDSC is also accompanied by an increase in the anti-tumor activity of the 
preserved CD8+ T-cell and NK-cell pool (Suzuki et al., 2005). Treatment with 5-fluorouracil 
(5FU) has also been shown to induce selective apoptosis of MDSC, thereby decreasing the 
burden of these cells in murine spleen and tumor beds, but without depleting host T cells, 
NK cells, dendritic cells, or B cells. The elimination of MDSC by 5FU treatment also 
increased IFN-γ production by tumor-specific CD8+ T cells and promoted T-cell–dependent 
anti-tumor responses (Apetoh et al., 2011; Vincent et al., 2010).  
10.4 Blocking MDSC suppressive function 
Another approach to restricting MDSC support for tumor progression is to block the 
immunosuppressive function of these cells. Since ARG1 and NOS2 are the primary 
mediators of MDSC immunosuppression, these enzymes are the most likely targets for 
novel therapeutic interventions. Various different drugs including nitro-aspirin, COX-2 
inhibitors, and phosphodiesterase-5 (PDE5) inhibitors have been shown to profoundly 
inhibit both ARG1 and NOS2 activity in MDSC. By removing MDSC suppressive mediators, 
these drugs exhibited a potent ability to restore anti-tumor immune responses and delayed 
tumor progression in several mouse models (De Santo et al., 2005; Serafini et al., 2006; 
Talmadge et al., 2007; Zea et al., 2005). Interestingly, in addition to inhibiting MDSC 
function, COX2 inhibitors also blocked the systemic development of MDSC as well as CCL2-
mediated accumulation of these cells in the tumor microenvironment in a mouse model of 
glioma (Fujita et al., 2011). 
11. Conclusion 
In recent years, it is becoming increasingly apparent that the immuno-suppressive 
mechanisms operating in cancer patients significantly contribute to tumor progression and 
attenuate the efficacy of immunotherapies. The tumor microenvironment incorporates 
several distinct immunosuppressive cell populations that play dominant roles in this 
process. MDSC are a heterogeneous population of immature myeloid cells that possess 
potent ability to inhibit immune responses. These MDSC also have the capacity to promote 
angiogenesis, cancer cell proliferation, and epithelial-mesenchymal transition, and thus 
enhance cancer growth, invasion, and metastasis. Controlling the expansion and 
accumulation of MDSC or blocking their suppressive functions represents promising novel 
approaches in cancer therapy. However, vital questions remain to be answered if this 
potential is to be fully realized. What is the predominant mechanism driving the 
differentiation and activation of MDSC? Which mechanisms primarily contribute to the 
suppressive activities of MDSC? What are the dynamics of MDSC migration into tumor 
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tissues and peripheral lymphatic organs, and which factors affect their trafficking? Do 
different subsets of MDSC differ in their function, and does this difference depend on the 
cancer sub-type? Are there better specific markers that would allow investigators to identify 
functional MDSC and distinguish various subpopulations of MDSC (particularly in 
humans)? Solving these questions will advance our understanding of the critical role of 
MDSC in cancer and could aid the development of novel interventions for cancer treatment.  
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burden of these cells in murine spleen and tumor beds, but without depleting host T cells, 
NK cells, dendritic cells, or B cells. The elimination of MDSC by 5FU treatment also 
increased IFN-γ production by tumor-specific CD8+ T cells and promoted T-cell–dependent 
anti-tumor responses (Apetoh et al., 2011; Vincent et al., 2010).  
10.4 Blocking MDSC suppressive function 
Another approach to restricting MDSC support for tumor progression is to block the 
immunosuppressive function of these cells. Since ARG1 and NOS2 are the primary 
mediators of MDSC immunosuppression, these enzymes are the most likely targets for 
novel therapeutic interventions. Various different drugs including nitro-aspirin, COX-2 
inhibitors, and phosphodiesterase-5 (PDE5) inhibitors have been shown to profoundly 
inhibit both ARG1 and NOS2 activity in MDSC. By removing MDSC suppressive mediators, 
these drugs exhibited a potent ability to restore anti-tumor immune responses and delayed 
tumor progression in several mouse models (De Santo et al., 2005; Serafini et al., 2006; 
Talmadge et al., 2007; Zea et al., 2005). Interestingly, in addition to inhibiting MDSC 
function, COX2 inhibitors also blocked the systemic development of MDSC as well as CCL2-
mediated accumulation of these cells in the tumor microenvironment in a mouse model of 
glioma (Fujita et al., 2011). 
11. Conclusion 
In recent years, it is becoming increasingly apparent that the immuno-suppressive 
mechanisms operating in cancer patients significantly contribute to tumor progression and 
attenuate the efficacy of immunotherapies. The tumor microenvironment incorporates 
several distinct immunosuppressive cell populations that play dominant roles in this 
process. MDSC are a heterogeneous population of immature myeloid cells that possess 
potent ability to inhibit immune responses. These MDSC also have the capacity to promote 
angiogenesis, cancer cell proliferation, and epithelial-mesenchymal transition, and thus 
enhance cancer growth, invasion, and metastasis. Controlling the expansion and 
accumulation of MDSC or blocking their suppressive functions represents promising novel 
approaches in cancer therapy. However, vital questions remain to be answered if this 
potential is to be fully realized. What is the predominant mechanism driving the 
differentiation and activation of MDSC? Which mechanisms primarily contribute to the 
suppressive activities of MDSC? What are the dynamics of MDSC migration into tumor 
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tissues and peripheral lymphatic organs, and which factors affect their trafficking? Do 
different subsets of MDSC differ in their function, and does this difference depend on the 
cancer sub-type? Are there better specific markers that would allow investigators to identify 
functional MDSC and distinguish various subpopulations of MDSC (particularly in 
humans)? Solving these questions will advance our understanding of the critical role of 
MDSC in cancer and could aid the development of novel interventions for cancer treatment.  
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Monocytes and macrophages are myeloid cells which originate in the bone marrow and are 
essential in the primary defence against infection by bacteria, viruses and other pathogens. 
These cells circulate as monocytes in the bloodstream before undergoing extravasation and 
migration into adjacent tissues, where they differentiate into resident macrophages. 
Considerable monocyte extravasation occurs at the initial stages of inflammation, wound 
healing, tumour onset and various other diseases in response to chemotactic signals. In 
many instances these inflamed and/or diseased tissues have been shown to include areas of 
extremely low oxygen tension, termed hypoxia, by the measurement of oxygen 
concentrations using microelectrodes, use of hypoxic cell markers and/or expression of 
specific hypoxia-upregulated proteins. Such hypoxic areas are evident in the majority of 
malignant human cancers, including those of the breast, brain, cervix, head/neck, and soft 
tissue sarcomas (Raleigh et al., 2001; Vaupel et al., 1989), and are caused by an inability of 
the supporting vasculature to keep up with the oxygen demands of the rapidly increasing 
tumour mass (Shannon et al., 2003; Vaupel et al., 2005).  
As with inflammation, extensive monocyte extravasation is also an early event in cancer 
development. Infiltrated monocytes differentiate into tumour-associated macrophages 
(TAMs), a process which is driven by tumour-secreted chemoattractants (Murdoch et al., 
2004). Moreover, TAMs accumulate in high numbers within hypoxic areas, which drives a 
change in their gene expression through the modulation of such transcription factors as 
hypoxia-inducible factors (HIFs) 1 and 2 (Burke et al., 2003; Talks et al., 2000), activating 
transcription factor-4 (ATF-4), and early growth response-1 (egr-1) (Elbarghati et al., 2008). 
Subsequently, a wide panel of protumour genes are upregulated by hypoxic macrophages 
which could support tumour growth, survival and metastasis (Fang et al., 2009). This is 
thought to explain the correlation between high numbers of TAMs and poor patient 
prognosis in many types of human tumours (Fujimoto et al., 2000; Hamada et al., 2002; 
Hanada et al., 2000; Heidl et al., 1987; Leek et al., 1996; Lissbrant et al., 2000; Salvesen and 
Akslen, 1999). 
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2. Hypoxia as an important microenvironmental signal for ‘educating’ 
macrophages in tumours 
2.1 Monocyte infiltration into tumours 
The mechanisms by which immune cells are recruited into tumours have been well studied, 
revealing crucial roles for several chemokines and cytokines in the extravasation and 
infiltration of these cells, including monocytes, from the blood vessels and into the tumour. 
The chemokine-driven migration of leukocytes is followed by regulation of tumour growth, 
angiogenesis and metastasis, through alterations in the tumour environment (Balkwill, 2003; 
Strieter et al., 2004; Vicari and Caux, 2002). 
Perhaps the most important monocyte chemoattractants upregulated by tumours are the 
chemokines, CCL2 and CCL5 (also known as MCP-1 and RANTES, respectively), which are 
synthesised by several cell types including tumour cells, fibroblasts, endothelial cells and 
TAMs themselves. Correlation between the expression of CCL2 and the accumulation of 
TAMs within breast (Ueno et al., 2000), ovarian (Negus et al., 1997), esophageal and 
squamous cell (Ohta et al., 2002), non-small cell lung cancer (Arenberg et al., 2000), and also 
glioblastoma (Leung et al., 1997), underscore the importance of this chemokine in monocyte 
recruitment into tumours. In addition, Bottazzi et al. (1992) demonstrated that when the 
CCL2 gene was transferred to a murine melanoma and subsequently grown in vivo, 
infiltration of monocytes increased, as evidenced by a doubling of TAM numbers. However, 
the phenotype of these TAMs may have been anti-tumoural since these CCL2-producing 
tumours exhibited reduced tumour growth and increased overall survival. 
The effects of CCL2 and CCL5 on human monocytes are not just limited to their direct 
chemotactic capabilities; both ligands are also known to support monocytes in the 
production of additional chemoattractants and tumour-promoting molecules – for example, 
analysis of CCL5-induced monocyte gene expression by oligonucleotide array revealed that 
CCL2, CCL3, CCL4, CXCL8, and CCR1 were consistently induced, suggesting a role for 
CCL5 in leukocyte recruitment into the tumour. This correlates with the finding that CCL3 
and CCL4 are expressed in certain human tumours (Scotton et al., 2001), and that CXCL8 
drives adhesion of monocytes to vascular endothelium as part of monocyte recruitment 
(Gerszten et al., 1999). 
The cytokines CSF-1 (colony-stimulating factor-1) and VEGF (vascular endothelial growth 
factor) are also known to be monocyte chemotactic proteins, and are produced by a variety 
of cell types, including monocytes and macrophages. By crossing CSF-1 knock-out mice 
with mice which form spontaneous mammary tumours, Lin et al. (2001) demonstrated the 
importance of this cytokine in the recruitment of monocytes into tumours, since tumours in 
the daughter mice showed reduced TAM numbers and slower tumour progression. These 
features could be reversed by the introduction of CSF-1 by targeted gene expression, 
confirming that this cytokine is important for TAM infiltration and tumour progression. 
The growth factor, VEGF, is best characterised as an angiogenic factor which functions as a 
potent and specific mitogen for endothelial cells. In the majority of tumour types tested, 
VEGF mRNA expression is upregulated within the tumour (Ferrara and Davis-Smyth, 1997), 
primarily by tumour cells and TAMs (Lewis et al., 2000), rather than endothelial cells. The 
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inverse is true for mRNA expression of VEGF receptors, VEGF-R1 and -R2 (Brown et al., 
1993; Plate et al., 1994; Plate et al., 1992), consistent with the hypothesis that VEGF 
predominantly acts as a paracrine factor to induce angiogenesis. Further studies suggested 
the expression of this growth factor by infiltrating lymphocytes (Freeman et al., 1995), and 
its role as a chemoattractant for monocytes and macrophages through VEGF-R1 was 
discovered (Barleon et al., 1996; Sawano et al., 2001), verified by the fact that murine 
macrophages lacking VEGF-R1 (from a model of embryonic angiogenesis) exhibited 
reduced migration in Boyden chambers in response to VEGF (Hiratsuka et al., 1998). 
Immunohistochemistry in surgically resected breast tumour samples showed that increased 
VEGF within tumours was associated with higher numbers of TAMs (Leek et al., 2000). 
These findings suggest that VEGF is not only important for angiogenesis, but also for the 
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Fig. 1. Tumour hypoxia drives monocyte infiltration, polarization and transcription of 
hypoxia-regulated genes. a. Tumours and infiltrated macrophages secrete chemoattractants, 
resulting in the recruitment of monocytes from the blood. Hypoxic conditions commonly 
found within tumours enhance the polarisation of macrophages toward a protumour 
phenotype, which leads to the upregulation of a wide array of tumour-supporting genes 
(such as those shown in the figure) and the downregulation of MHC II. Almost all murine 
TAMs derive from a population of monocytes defined by Ly6ChiCX3CR1lo expression, which 
continuously seed tumours. Two types of murine TAMs, MHC IIhi and MHC IIlo, have been 
shown to be located in normoxic and hypoxic areas of tumours, displaying M1 and M2 
characteristics, respectively. TIE2-expressing macrophages (TEM) are recruited in response 
to release of Ang2 (as well as upregulation of Tie-2) by the hypoxic core. TEMs associate 
with blood vessels and promote tumour angiogenesis. Monocyte/macrophage-derived 
factors in black, tumour-derived factors in blue. b. Hypoxic conditions result in the 
stabilisation of HIF-1α and -2α in macrophages, which are then able to bind to a 
constitutively expressed common β subunit, located in the nucleus. The active transcription 
factors then bind to HREs in a variety of genes (shown at bottom left) which regulate the 
immunosuppressive and protumoural functions of macrophages.  
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Fig. 1. Tumour hypoxia drives monocyte infiltration, polarization and transcription of 
hypoxia-regulated genes. a. Tumours and infiltrated macrophages secrete chemoattractants, 
resulting in the recruitment of monocytes from the blood. Hypoxic conditions commonly 
found within tumours enhance the polarisation of macrophages toward a protumour 
phenotype, which leads to the upregulation of a wide array of tumour-supporting genes 
(such as those shown in the figure) and the downregulation of MHC II. Almost all murine 
TAMs derive from a population of monocytes defined by Ly6ChiCX3CR1lo expression, which 
continuously seed tumours. Two types of murine TAMs, MHC IIhi and MHC IIlo, have been 
shown to be located in normoxic and hypoxic areas of tumours, displaying M1 and M2 
characteristics, respectively. TIE2-expressing macrophages (TEM) are recruited in response 
to release of Ang2 (as well as upregulation of Tie-2) by the hypoxic core. TEMs associate 
with blood vessels and promote tumour angiogenesis. Monocyte/macrophage-derived 
factors in black, tumour-derived factors in blue. b. Hypoxic conditions result in the 
stabilisation of HIF-1α and -2α in macrophages, which are then able to bind to a 
constitutively expressed common β subunit, located in the nucleus. The active transcription 
factors then bind to HREs in a variety of genes (shown at bottom left) which regulate the 
immunosuppressive and protumoural functions of macrophages.  
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2.2 Monocyte infiltration into areas of hypoxia  
Following their infiltration into tumours, macrophages have been shown to accumulate 
specifically in hypoxic areas, a phenomenon which is thought to be guided by hypoxia-
induced chemoattractants and maintained by the suppression of TAM motility in these 
areas by hypoxia (reviewed by Murdoch et al. (2004)). As would be expected, these 
oxygen-deprived regions of tumours have been found to have elevated levels of VEGF, 
produced by both tumour cells and macrophages (Brown et al., 1995; Lee et al., 1998; 
Lewis et al., 2000). In addition, VEGF expression in a murine model of Lewis lung 
carcinoma was shown by immunohistochemistry to correlate with pimonidazole stained 
areas, a marker for hypoxia (Kim et al., 2001). As mentioned previously, this factor is a 
chemoattractant for monocytes and macrophages and therefore is likely to play a major 
role in the accumulation of TAM at these sites (Lewis et al., 2000). However, it is worth 
noting that there is not always a correlation between hypoxia and VEGF expression in 
human tumours (Janssen et al., 2002; Raleigh et al., 1998). Matschurat and colleagues 
(2003) found that another monocyte chemotactic, EMAP II, is expressed at high levels in 
perinecrotic areas of methylcholanthrene fibrosarcomas and B16 murine melanomas in an 
inactive form, pro-EMAP II. Additionally, they showed that hypoxic tumour cell 
supernatants in vitro demonstrated an increase in EMAP II at the protein level, which was 
not supported by an induction at the mRNA level. This suggests that the active protein 
can be induced under hypoxia without the need for transcription, possibly through 
cleavage of pre-EMAP II to its active form by proteases released from necrotic cells 
(Zhang and Schwarz, 2002), providing a rapid mechanism for EMAP II upregulation and 
subsequent macrophage infiltration. This effect explains why macrophages are found at 
sites positive for EMAP II expression in uveal melanoma (Clarijs et al., 2003). 
Also known to be regulated by hypoxia are endothelins, a family of secretory vasoactive 
peptides involved in vasoconstriction. They also have co-mitogenic functions, enhancing the 
effects of other such growth factors as PDGF by initiating intracellular signalling through 
endothelin receptors, ET-RA and ET-RB. Studies of endothelin regulation under hypoxic 
conditions demonstrated a co-localisation of hypoxia and endothelin ET-2 expression in 
murine mammary tumours (Grimshaw et al., 2002a). This is significant since ET-2 is thought 
to bind to ET-RB on macrophages and act as a chemoattractant, explaining the correlation 
seen between ET-2 expression and ET-RB-positive macrophages in breast tumours 
(Grimshaw et al., 2004; Grimshaw et al., 2002b). Furthermore, ET-1 (which acts through 
endothelin-1 receptor A) was recently shown to enhance the invasion and migration of both 
tumour cells and macrophages. The contribution of these factors to metastasis was 
supported by the finding that tumour expression of ET-1 and activity of its receptor are 
required for the development of lung metastases, through a process which is dependent on 
macrophage infiltration of the lung (Said et al., 2011). 
More recently, Wang et al. (2012) identified stromal-derived factor-1 (SDF-1/CXCL12) as a 
tumour-derived chemoattractant and survival factor for TAMs. In a murine glioma model 
they showed that SDF-1kd tumours have a different association of TAMs with hypoxia, 
implying that the secretion of this factor by tumour cells is critical for the accumulation of 
TAM in hypoxic areas of murine glioma. This factor is known to bind to its receptor, CXC 
receptor 4 (CXCR4), which is upregulated through a HIF-1-dependent mechanism in 
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monocytes and macrophages (as well as endothelial cells and tumour cells). Therefore, SDF-
1 and its receptor, CXCR4, are very important for the chemotaxis of TAMs to hypoxic 
tumour sites (Schioppa et al., 2003). 
It has been suggested that the accumulation of infiltrating macrophages in tumours, 
primarily in hypoxic regions, is not just due to chemoattraction, but also to their retention in 
these areas. Downregulation of chemokine release by tumour cells, and of chemokine 
receptors by TAMs in hypoxia, effectively dampens TAM motility, thus causing large 
numbers of macrophages to be trapped in these sites. For example, the expression of CCR2 
(the receptor for CCL2/MCP-1) and chemotactic responses to CCL2 in vitro were markedly 
higher for TAMs isolated from ovarian carcinomas than monocyte-derived macrophages in 
culture (Negus et al., 1998; Sica et al., 2000).  
When cultured with human tumour ascites, the chemotactic response of fresh monocytes to 
CCL2 was greatly diminished, accompanied by a reduction in CCR2 mRNA levels. 
Furthermore, inhibition of TNF-α restored CCR2 mRNA expression in monocytes cultured 
in the presence of ascitic fluid, demonstrating that defective CCR2 expression in TAM may 
be regulated, at least in part, by this cytokine in tumours (Sica et al., 2000). Therefore, it is 
possible that macrophage TNF-α production within hypoxic areas of tumours (Guida and 
Stewart, 1998; Hempel et al., 1996; Scannell et al., 1993) may lead to a downregulation of 
CCR2 expression on TAMs, decreasing their responsiveness to chemotactic ligands. 
An increase in TNF-α expression is also believed to induce mitogen-activated protein kinase 
phosphatase 1 (MKP-1) (Grimshaw and Balkwill, 2001), a molecule which dephosphorylates 
extracellular signal-regulated kinase (ERK) 1/2, and p38 mitogen activated protein kinase 
(p38 MAPK) (Franklin and Kraft, 1997; Sun et al., 1993). Intracellular signalling via p38 
MAPK and ERK1/2 is required for the chemotactic response of monocytes and monocytic 
cell lines to hypoxia-regulated chemokines (Ashida et al., 2001; Wain et al., 2002). Therefore, 
TNF-α may be an important factor in the hypoxic tumour environment for the suppression 
of macrophage migration, via a downregulation of CCR2 and an upregulation of MKP-1 
(Figure 1a).  
3. Hypoxia and its impact on macrophage function 
For a long time it has been known that macrophages can be stimulated by environmental 
signals to exhibit a wide array of phenotypes (Nibbering et al., 1987; Ogle et al., 1994; van 
Furth, 1980). Two main polarization phenotypes of macrophages have been recognized. 
These include the classically activated (M1) and alternatively activated (M2) macrophage 
phenotypes. M1 macrophages are induced by interferon gamma (IFN-γ) and 
lipopolysaccharide (LPS). These macrophages upregulate pro-inflammatory cytokines (e.g. 
IL-12, IL-23, TNF, CXCL10), co-stimulatory molecules, produce reactive nitrogen and 
oxygen intermediates (RNI/ROI), and very little anti-inflammatory cytokines (e.g. IL-10). 
These cells promote inflammation, apoptosis, and microbicidal activity. Conversely, M2 
macrophages are induced by IL-4 and IL-13,  promote angiogenesis, cell proliferation and 
other tissue remodelling and protumoral functions. These cells are characterized in general 
by an IL-12loIL-10hi phenotype, upregulate chemokines like CCL17, CCL18 and CCL22, 
various scavenging receptors and the production of Arginase I. Although the M1-M2 
nomenclature is a useful one when assessing the phenotype of macrophages, it is however, 
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2.2 Monocyte infiltration into areas of hypoxia  
Following their infiltration into tumours, macrophages have been shown to accumulate 
specifically in hypoxic areas, a phenomenon which is thought to be guided by hypoxia-
induced chemoattractants and maintained by the suppression of TAM motility in these 
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TAM in hypoxic areas of murine glioma. This factor is known to bind to its receptor, CXC 
receptor 4 (CXCR4), which is upregulated through a HIF-1-dependent mechanism in 
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an over-simplification. Not all macrophage fit into these two distinct populations, and so 
further sub-populations have been defined (Mantovani et al., 2004).  
Recently, subsets of differentially polarized TAMs with distinct functions were described by 
Movahedi et al. (2010) in murine mammary tumours. Their findings showed that almost all 
TAMs from these tumours were derived from Ly6ChiCX3CR1lo monocytes, where Ly6C is a 
monocyte/macrophage differentiation antigen regulated by IFN-γ, and CX3CR1 is a 
receptor for CX3CL1, a chemokine involved in the adhesion and migration of leukocytes. 
Notably, they found that hypoxic areas had higher numbers of M2-like TAMs, which 
increased as the tumour progressed (in certain tumours), and were shown to have potent 
proangiogenic effects in vivo. This also correlated with the expression of major 
histocompatibility complex II (MHC II), whereby MHC IIhi macrophages resided in 
normoxic areas and displayed an M1-like phenotype, and MHC IIlo macrophages resided in 
hypoxic areas and displayed a more M2-like phenotype (Figure 1a). Expression of  M1 
molecules like Nos2 (iNOS), interleukin (Il)-1β, Il-6, Il-12β and Ptgs2 (or cycloxygenase 2, 
COX2) were reported in MHC IIhi monocytes at the RNA or protein level. By comparison, 
MHC IIlo monocytes expressed such M2-related molecules such as macrophage mannose 
receptor (MR), scavenger receptor 1 (SR-A), arginase-1 (ARG-1), CD163, stabilin-1 (STAB-1), 
and interleukin-4Rα (IL-4Rα) (Movahedi et al., 2010). Fitting with their M2-like phenotype 
and localisation in areas of hypoxia, MHC IIlo TAMs were found to have significantly 
elevated proangiogenic activity in vivo. The phenotypic similarity between MHC IIhi TAMs 
and IKKβ-deficient macrophages implies that differences in these MHC IIhi and MHC IIlo 
TAM subsets may be driven by NF-κβ activity (Movahedi et al., 2010). 
Another monocyte population, thought to be distinct from MHC IIlo TAMs, are the Tie2-
expressing monocytes (TEMs) (Figure 1a). Originally identified in tumour-bearing mice, 
these monocytes circulate in the mouse blood as Tie2+CD11b+CD45+ cells. They comprise a 
small monocyte subset which migrate towards angiopoietin-2 (Ang-2), a TIE2 ligand that is 
primarily released by vascular endothelial cells; this is thought to be a possible mechanism 
by which TEMs are recruited to tumours (Venneri et al., 2007), and more specifically, to 
highly vascularised areas (De Palma et al., 2003) (Figure 1a). Their role in the promotion of 
angiogenesis was confirmed by De Palma et al. (2005), who found that selective depletion of 
TEMs in a murine cancer model resulted in the inhibition of tumour angiogenesis and 
growth. Furthermore, TEM depletion was found to increase the efficacy of vascular-
disrupting agent (VDA) therapy of tumours, suggesting that the action of these cells 
counteracts the antitumour effects of VDAs (Welford et al., 2011). Understanding more 
about monocyte subsets uncovers new possibilities for targeting specific subpopulations, 
which could alter the overall balance of TAM phenotypes. Repolarisation of TAM from an 
M2- to an M1-like phenotype could restore their antitumour effects, leading to a better 
patient prognosis. 
The implications of macrophage plasticity in cancer biology have gathered increasing 
interest, both in terms of the phenotypes driven by the tumour microenvironment, and more 
specifically, by the hypoxic tumour environment. Biswas and colleagues (2008) reviewed the 
experimental evidence demonstrating that TAMs initially have an M1-like phenotype in 
areas of chronic inflammation where tumours commonly develop. These, however, respond 
to secreted cytokines, chemokines, growth factors and stress signals in the (hypoxic) tumour 
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microenvironment, to express more of an M2-like phenotype in established tumours. This 
suggests a “re-education” of macrophages, which are recruited by the tumour, initially 
expressing an M1-like phenotype (thus promoting an inflammatory response); however, 
their residency within tumours leads to their polarisation and differentiation into M2-
skewed TAMs, where their re-educated phenotype is one which promotes angiogenesis, 
tissue remodelling, immunosuppression and cell proliferation (Biswas et al., 2008).  
One important feature of the tumour environment which brings about this phenotypic 
change in macrophages is hypoxia. Hypoxic regions of tumours commonly form due to the 
leaky and disorganised nature of tumour blood vessels, meaning that the rapid tumour cell 
proliferation often surpasses the ability of the poorly-formed vasculature to deliver required 
oxygen and nutrients (Shannon et al., 2003; Vaupel et al., 2001). Studies with human breast 
carcinomas (Leek et al., 1999) or animal tumours (Collingridge et al., 2001) have shown that 
hypoxic tumours contain higher numbers of TAMs. A positive correlation that is also seen 
between hypoxia and TAM numbers in secondary liver tumours that form as metastases 
from breast and colorectal tumours (Stessels et al., 2004). There is an inverse relationship 
between TAM infiltration and patient prognosis seen in many human cancers (Fujimoto et 
al., 2000; Hamada et al., 2002; Hanada et al., 2000; Heidl et al., 1987; Leek et al., 1996; 
Lissbrant et al., 2000; Salvesen and Akslen, 1999), which implies that these macrophages 
adopt a pro-tumoural phenotype, contrasting with their more classic role as pathogen and 
tumour killing cells and with their ability to initiate an immune response.  
4. Molecular pathways mediating the effects of hypoxia on macrophages 
4.1 Transcription factors HIFs 1 and 2 
The best understood transcription factors mediating the response of macrophages to 
hypoxia are the hypoxia-inducible factors (HIFs) 1 and 2 (Burke et al., 2003; Fang et al., 2009; 
Talks et al., 2000) (Figure 1b). Both HIFs are heterodimers consisting of an individual α 
subunit and a common β subunit which is constitutively expressed. HIF-1α and HIF-2α are 
tightly controlled, such that, in the presence of oxygen they are quickly degraded by the 
ubiquitin-proteasome pathway within the cytoplasm. However, hypoxic stress causes an 
increase in production and stabilisation of these subunits, which are then able to complex 
with the β subunit within the nucleus and bind to hypoxic response elements (HREs) of 
certain oxygen-sensitive genes to drive transcription (Jiang et al., 1996; Semenza, 2002). The 
hypoxia-responsive genes regulated by HIFs are known to be involved in tumour 
proliferation, metabolism, angiogenesis, apoptosis and metastasis (reviewed by (Harris, 
2002)). The data supporting the expression of HIFs by macrophages, especially TAMs, is 
currently unclear. Talks et al. (2000) showed that hypoxia predominantly upregulates HIF-
2α in the pro-monocytic cell line, U937, and the HIF over-expression studies by White et al. 
(2004), suggested that HIF-2 might be more important for macrophage pro-angiogenic 
responses to hypoxia. In contrast, human macrophages exposed to tumour-specific levels of 
hypoxia in vitro, as well as those in hypoxic areas of several human tumours in vivo, were 
shown to be capable of inducing high levels of HIF-1 as well as HIF-2 (Burke et al., 2002). 
Recently, Fang et al. (2009) demonstrated that 18 hour exposure of human macrophages to 
hypoxia induces expression of VEGF, IL-1β, IL-8, adrenomedullin, CXCR4, and 
angiopoietin-2. Induction of these genes suggests a potent, pro-tumoural macrophage 
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phenotype. Using small interfering RNA (siRNA), this gene expression was shown to be 
mediated via HIF-1 and 2 signalling, thus implicating these transcription factors in the 
generation of the hypoxia-driven, tumour-promoting macrophage phenotype.  
Both HIF-1 and 2 bind to the HRE sequence contained in the promoter region of the VEGF 
gene and cause its upregulation (Ema et al., 1997; Flamme et al., 1997; Tian et al., 1997). 
Evidence that TAMs themselves upregulate VEGF in poorly vascularised tumour areas 
(Lewis et al., 2000) suggests that hypoxia, at least in part, causes TAMs to align with 
tumour cells in their pro-angiogenic function to increase the supply of oxygen to these 
areas. Interestingly, the binding of HIF-1 and 2 to the promoter region of VEGF in GM-
CSF-cultured macrophages is thought to have antagonistic effects on angiogenesis, 
whereby HIF-1 induces VEGF production and HIF-2 induces the production of the soluble 
VEGF receptor, sVEGFR-1, in low oxygen conditions. The secretion of sVEGFR-1 is able to 
neutralise VEGF biologic activity, inhibiting its angiogenic effect; this indicates that the 
binding of these two transcription factors may have opposing effects on the regulation of 
angiogenesis (Eubank et al., 2011). 
Less is known about the third member of the HIF family, HIF-3α, which shows high 
similarity to HIFs 1 and 2 and also forms heterodimers with the same β subunit. However, 
experiments so far show that this factor lacks the C-terminal transactivation domain (CTAD) 
(Gu et al., 1998), and acts as a dominant-negative regulator of the HIF pathway by 
antagonising the effects of HIFs 1 and 2 (Makino et al., 2001). HIF-3 was found to be 
constitutively expressed in monocyte-derived macrophages (MDMs), and was not 
responsive to hypoxic conditions in either monocytes or MDMs (Elbarghati et al., 2008). 
However, it was found to be hypoxia-responsive in lung epithelial cells (A549) at both the 
mRNA and protein level (Li et al., 2006), and so it is clear that further investigation into this 
transcription factor, with regards to its expression and importance, is needed. 
HIFs are not the only hypoxia-responsive transcription factors. Both activating transcription 
factor-4 (ATF-4) and early growth response-1 (Egr-1) are upregulated in response to hypoxia 
in several murine and human tumour cell types (Ameri et al., 2004; Yan et al., 1999) and 
macrophages (Elbarghati et al., 2008), respectively. Both ATF-4 and Egr-1 proteins were 
found to be transiently upregulated in macrophages following a short hypoxic incubation, 
but there was no induction seen in monocytes. Interestingly, hypoxic treatment caused Egr-1 
protein accumulation in macrophages in both the nucleus and the cytoplasm, in contrast to 
HIFs 1 and 2, and ATF-4 (Elbarghati et al., 2008), and is thought to play a role in monocyte 
differentiation into macrophages. Kharbanda et al. (1991) showed that M-CSF-stimulated 
monocytes demonstrate a dose-dependent increase in EGR-1 mRNA levels, and that 
inhibition of monocyte differentiation with dexamethasone also abolishes this EGR-1 
induction. Therefore, since hypoxia increases the levels of Egr-1 protein, it is possible that 
hypoxia accelerates the differentiation of monocytes into TAMs (Elbarghati et al., 2008). This 
is also supported by the work of Oda and colleagues (2006), who demonstrated an increase 
in the expression of HIF-1α and HIF-1β in differentiating THP-1 cells and human monocytes 
from peripheral blood. RNA interference studies determined that, although HIF-1α is not 
essential for macrophage differentiation, it is, however, required for macrophage functional 
maturation. These findings further suggest that macrophage differentiation may be 
facilitated by hypoxia.  
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Various experimental methods have been used to identify HIF targets, including loss of 
expression in HIF-null cells (Fang et al., 2009; Semenza, 2003), targeting transcribed HIF 
using siRNA treatment (Fang et al., 2009; Kamlah et al., 2009; Krishnamachary et al., 2003), 
overexpression of HIFs using expression vectors or induced gene expression in von Hippel-
Lindau (VHL)-null cells (Wykoff et al., 2000), or by the identification of HREs and HIF 
binding sites within gene promoter regions (Benita et al., 2009; Hirani et al., 2001; Semenza 
and Wang, 1992; Zhang et al., 2006). Both HIF1 and 2 were shown to regulate hypoxic MDM 
induction of VEGFA, GLUT-1, CXCR4, IL-1β, IL-8, and ADM (Fang et al., 2009) (Figure 1b), 
validating other reports of these as HIF target genes (Benita et al., 2009; Hirani et al., 2001; 
Semenza, 2003; Zhang et al., 2006). 
Evidence that hypoxia induces a protumour phenotype in TAMs is not just limited to 
observed changes in RNA and protein expression; functional studies with hypoxic or HIF-
expressing TAMs have also confirmed this phenotypic shift in macrophages. TAM-induced 
endothelial cell migration and tubule formation, reported by Chen et al. (2011), confirms the 
angiogenesis-promoting actions of TAM suggested by RNA and protein expression. More 
specifically, HIF-1α has been implicated in these protumour functional effects of TAMs. 
Doedens et al. (2010) report a dose-dependent suppression of T-cell proliferation by 
macrophages, demonstrating this immunosuppressive effect to be enhanced under hypoxia 
in a HIF-1α-dependent manner.  
4.2 HIF relation with other pathways 
It is clear that hypoxia drives a tumour-promoting phenotype in macrophages – it does this 
through the activation of hypoxia-responsive transcription factors, predominantly HIF-1 
and 2, and their crosstalk with other signalling pathways. One such example is Toll-like 
receptor (TLR) signalling; TLR receptors are known to activate the innate immune system 
upon recognition of various pathogen-associated molecular patterns (PAMPs), including 
Lipopolysaccharide (LPS), bacterial DNA, and double-stranded RNA (Kaisho and Akira, 
2006). In humans there are 10 functional members of the TLR family (TLR1-TLR10), of 
which, TLR4 is possibly the most involved in macrophage hypoxic response. This particular 
receptor recognises LPS, but has more recently been shown to be a receptor for certain 
endogenous molecules associated with damaged cells and tissues (Zhang and Mosser, 2008). 
In their study of the relationship between hypoxic stress and TLR activity of macrophages, 
Kim et al. (2010) showed that hypoxia (and the hypoxia mimetic, CoCl2) increased TLR4 
messenger RNA and protein expression in the murine macrophage cell line, RAW264.7. This 
was unique to TLR4 and not seen with any of the other TLRs. Through the manipulation of 
macrophage HIF-1α gene expression, they demonstrated that hypoxic upregulation of TLR4 
was dependent upon HIF-1 signalling, as well as showing that overexpression of HIF-1α 
enhanced TLR4 expression. Using chromatin immunoprecipitation (ChIP) they discovered 
that HIF-1α binds to the TLR4 promoter under hypoxic conditions, and the resultant 
induction of TLR4 in these macrophages increased the expression of interleukin-6 (IL-6), 
cyclooxygenase-2 (COX-2) and interferon-inducible protein-10 (IP-10) (Kim et al., 2010). 
Therefore, it is likely that, at sites which are challenged by hypoxic stress, macrophages 
upregulate TLR4 and become more sensitive to infection and inflammatory signals. 
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phenotype. Using small interfering RNA (siRNA), this gene expression was shown to be 
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Various experimental methods have been used to identify HIF targets, including loss of 
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In addition to HIF-1α regulating TLR4, Sumbayev (2008) demonstrated that the inverse is 
also true. In human myeloid cells, TLR4 signalling (induced by the gram-negative bacterial 
ligand, LPS), activates crosstalk of HIF-1α and apoptosis signal-regulating kinase 1 (ASK1) 
pathways. Through the activation of p38 mitogen-activated protein kinase (p38 MAPK), 
ASK1 was found to stabilise HIF-1α, and knockdown of HIF-1α led to a reduced TLR4-
dependent induction of pro-inflammatory cytokines. Similarly, TLR7 and 8 (involved in the 
recognition of viral single-stranded RNA) were also found to induce HIF-1α, although ASK1 
was not found to be involved (Nicholas and Sumbayev, 2009). 
Evidence has been given for the role of HIFs 1 and 2 in these pro-tumour actions of TAM in 
hypoxic areas, but more recently it has emerged that HIF-1 may also be responsive under 
normoxic conditions. Such stimuli as LPS, cytokines (e.g. TNFα), growth factors, insulin, 
thrombin and vasoactive peptides cause HIF-1α stabilisation in normoxia, via nuclear factor-
kappa B (NF-κB) signalling. This key transcription factor was shown by Rius et al. (2008) to 
be upregulated following a 2-4h exposure of murine bone marrow-derived macrophages 
(BMDMs) to low oxygen. They also demonstrated that basal levels of NF-κB were required 
for the accumulation of HIF-1α protein in hypoxic cells, using macrophages from an IKK-
beta knock-out (IKKβ-/-) mouse. This implies that IKKβ, an important activator of NF-κB 
through phosphorylation-induced degradation of IkB inhibitors, has important 
contributions to macrophage response to hypoxia. Since NF-κB has a crucial and well 
characterised role in inflammation, IKKβ represents a significant molecule which may link 
the hypoxic response to innate immunity and infection (Rius et al., 2008). 
5. Hypoxia, macrophage function and tumour progression 
By contributing to angiogenesis, metastasis, invasion, immunosuppression, chemo- and 
radio-resistance, and altering metabolism, macrophages are known to greatly influence the 
survival and progression of cancer (see Biswas et al. (2008)). This phenotype of TAMs is also 
known to be influenced by hypoxia, which induces a distinct protumour phenotype. 
Expression of various growth factors, including fibroblast growth factor 2 (FGF2), platelet-
derived growth factor (PDGF), placental growth factor (PGF), and hepatocyte growth factor 
(HGF), have been found to be upregulated in vitro by macrophages under hypoxia (White et 
al., 2004). These factors, in addition to VEGF, function as tumour cell mitogens and support 
tumour growth in hypoxic regions (Fang et al., 2009; Lewis et al., 2000). 
Another key process in tumour progression is angiogenesis. The expression of VEGF (a 
potent mitogen and well characterised pro-angiogenic factor) by hypoxic macrophages has 
been discussed previously. However, other key proteins reported by White and colleagues 
(2004) include CXCL8, angiopoietin, cyclooxygenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS), all of which were identified in cDNA arrays as genes that are 
transcriptionally upregulated in primary macrophages under hypoxia. Induction of these 
genes by macrophages is likely to be crucial for tumour angiogenesis. 
Additionally, hypoxic TAMs also release tissue factor (CD142) (Compeau et al., 1994) and 
macrophage inhibitory factor (MIF) (Schmeisser et al., 2005), which are thought to be 
involved in invasion and metastasis. Tissue factor expression by hypoxic TAMs (as well as 
tumour cells, endothelial cells and fibroblasts), induces the production of thrombin, which 
in turn promotes tumour cell metastasis (Versteeg et al., 2004). Furthermore, MIF has been 
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shown to promote tumour cell motility in a murine colon cancer cell line in vitro and in vivo 
(Sun et al., 2005). These factors may act indirectly through matrix metalloproteases (MMPs), 
such as MMP-9, which is stimulated by MIF and degrades the basement membrane and 
extracellular matrix (ECM) (Hagemann et al., 2004). This weakens the attachment of tumour 
cells to these structural supports and enables their subsequent invasion and metastasis. 
Further evidence of MMP induction comes from a co-culture of macrophages with tumour 
cells in hypoxia, which revealed an upregulation of macrophage MMP-7 production in low 
oxygen conditions in vitro and human tumours (Burke et al., 2003). 
Finally, the hypoxic phenotype of TAMs also includes various immunosuppressive 
functions which are achieved through several mechanisms; these include the expression of 
immunosuppressive factors prostaglandin E2 (PGE2) and IL-10 (Ertel et al., 1993; Murata et 
al., 2002), whose presence within the tumour microenvironment can downregulate the 
tumouricidal abilities of TAMs. In addition, PGE2 and IL-10 inhibit the functions of T cells 
and other effector cells of the immune system (Elgert et al., 1998), which combined with 
hypoxic inhibition of macrophage phagocytosis and presentation of antigens (Leeper-
Woodford and Mills, 1992; Murata et al., 2002), suppresses the triggering of an adaptive 
immune response directed toward the tumour. Doedens et al. (2010) recently reported 
hypoxia- and HIF-1α-dependent suppression of T-cell proliferation by macrophages. 
Hypoxia, therefore, drives the macrophage towards a protumour phenotype which 
regulates tumour growth, angiogenesis, invasion, metastasis and immunosuppression.  
6. Targeting tumour hypoxia for therapy 
Under the stresses associated with hypoxia in areas of tumour ischemia (predominantly low 
oxygen and low glucose concentrations), tumour cells are forced to respire anaerobically 
and reduce their proliferation. This challenges many conventional cancer therapies such as 
chemotherapy, since their mechanism of action relies on the rapidly replication of tumour 
cells. In addition to this, the poorly developed tumour vasculature, which contributes to the 
development of hypoxia in the first place, also impedes the delivery of drugs to these areas 
of the tumour.  
In light of this, antiangiogenic “vessel normalizing” strategies are being developed which 
aim to improve tumour vasculature for better anticancer treatment and reduced metastasis. 
Rolny and colleagues (2011) demonstrated that histidine-rich glycoprotein (HRG), a host-
derived factor, is able to significantly reduce hypoxia and to polarise TAMs away from a 
protumour phenotype. 
The concept of delivering a prodrug systemically - for subsequent activation in specific areas 
of the body - has been applied to cancer biology, but is most often limited by the level of 
expression of the activating enzyme at the target site. Rather than hypoxia inhibiting cancer 
therapy, some recent therapeutic strategies have focussed on utilising cellular responses to 
these harsh conditions, twinned with the prodrug therapeutic design, to creatively activate 
cytotoxic agents within the hypoxic tumour microenvironment. Griffiths et al. (2000) made 
use of macrophage accumulation in areas of low oxygen to deliver gene therapy to 
pathological hypoxia. They genetically modified macrophages to express the enzyme 
cytochrome p450 under hypoxic conditions, which when expressed, converts the 
systemically administered pro-drug cyclophosphamide into its active form exclusively in 
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these areas and causes tumour cell death. This system was then adapted further to deliver 
an oncolytic adenovirus to these areas by co-transducing macrophages with a hypoxia-
regulated E1A/B construct, as well as an E1A-dependent virus which can only proliferate 
within a prostate-tumour (using a prostate-specific promoter) (Muthana et al., 2011). E1A/B 
proteins were only synthesised once the host cell (the macrophage) had infiltrated into areas 
of extreme hypoxia in tumours. This then subsequently activated the proliferation of the 
oncolytic adenovirus and its release. The virus then infected and killed surrounding prostate 
tumour cells – in both hypoxic and non-hypoxic areas of tumours. This three-step process 
(the homing of macrophages to hypoxic sites, hypoxia-responsive proliferation of the 
adenovirus, and the limiting of viral replication to within prostate tumour cells), makes this 
system very specific for killing tumour cells within the hypoxic areas prostate tumours 
(Muthana et al., 2011). This hypoxia-based therapy was seen to eradicate both primary and 
secondary tumours in mice. 
It has been suggested that the best use of this therapy would be in combination with 
conventional therapies, since this could potentially eliminate both the slower proliferating 
(hypoxic) and the highly proliferating areas of the tumour. Using a mathematical model, 
Owen et al. (2011) predict that the use of a macrophage-based, hypoxia-responsive therapy 
immediately before or during conventional chemotherapy would produce significant 
antitumour effects. 
7. Concluding remarks 
Macrophage accumulation in tumours is known to correlate with poor patient prognosis in 
the majority of cancer types (Fujimoto et al., 2000; Hamada et al., 2002; Hanada et al., 2000; 
Heidl et al., 1987; Leek et al., 1996; Lissbrant et al., 2000; Salvesen and Akslen, 1999). This can 
be explained by the tumour-promoting phenotype of TAMs, induced by the tumour 
microenvironment. Here we have reviewed how hypoxia, a key component of many 
malignant tumours (Raleigh et al., 2001; Vaupel et al., 1989), is centrally involved in the 
polarisation of TAMs. The shift in TAM phenotype under hypoxia has been shown not just 
at the expression level, but also at a functional level as well. In many of these reports, the 
HIF-1 transcription factor was found to be crucially important. Studies with HIF-1α 
knockout mice have revealed its role, not just in regulating responses to pathological 
hypoxia, but also to physiological low oxygen conditions as part of normal oxygen 
homeostasis. It is possible that HIF-1 signalling (including its activation of other pathways), 
is a major factor in determining the polarisation and function of macrophages in different 
environments (Dehne and Brune, 2009). 
With considerable assistance from hypoxic, M2-like TAMs, tumour cells in hypoxic areas 
have the necessary support and drive to migrate and invade into adjacent tissues, evade the 
immune system and prevent a targeted adaptive immune response, and travel through the 
vasculature to form metastases at secondary sites. This has large implications in cancer 
therapy, especially since hypoxic tumour cells are less affected by most conventional 
therapeutic strategies. Inefficient targeting of such tumour cells is likely to contribute to the 
well-documented relapse in many chemotherapy- and radiotherapy-treated cancer patients; 
therefore, more creative and innovative therapeutic methodologies need to be developed 
based on our continually growing understanding of tumour hypoxia, to enhance patient 
long-term survival. 
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Heidl et al., 1987; Leek et al., 1996; Lissbrant et al., 2000; Salvesen and Akslen, 1999). This can 
be explained by the tumour-promoting phenotype of TAMs, induced by the tumour 
microenvironment. Here we have reviewed how hypoxia, a key component of many 
malignant tumours (Raleigh et al., 2001; Vaupel et al., 1989), is centrally involved in the 
polarisation of TAMs. The shift in TAM phenotype under hypoxia has been shown not just 
at the expression level, but also at a functional level as well. In many of these reports, the 
HIF-1 transcription factor was found to be crucially important. Studies with HIF-1α 
knockout mice have revealed its role, not just in regulating responses to pathological 
hypoxia, but also to physiological low oxygen conditions as part of normal oxygen 
homeostasis. It is possible that HIF-1 signalling (including its activation of other pathways), 
is a major factor in determining the polarisation and function of macrophages in different 
environments (Dehne and Brune, 2009). 
With considerable assistance from hypoxic, M2-like TAMs, tumour cells in hypoxic areas 
have the necessary support and drive to migrate and invade into adjacent tissues, evade the 
immune system and prevent a targeted adaptive immune response, and travel through the 
vasculature to form metastases at secondary sites. This has large implications in cancer 
therapy, especially since hypoxic tumour cells are less affected by most conventional 
therapeutic strategies. Inefficient targeting of such tumour cells is likely to contribute to the 
well-documented relapse in many chemotherapy- and radiotherapy-treated cancer patients; 
therefore, more creative and innovative therapeutic methodologies need to be developed 
based on our continually growing understanding of tumour hypoxia, to enhance patient 
long-term survival. 
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1. Introduction  
Approximately 90% of cancer-related death is caused by metastasis. The increased motility 
and invasiveness of metastatic tumor cells is reminiscent of events that occur at the 
epithelial-mesenchymal transition (EMT), which is a characteristic that occurs during 
embryonic development, tissue remodeling, wound healing and metastasis. Interestingly, 
EMT is a dynamic process and mainly occurs at the edges of wounds during healing and at 
the invasive fronts of metastatic tumors, which suggest that EMT is influenced by stimuli 
that emanate from the inflammatory microenvironment. The tumor microenvironment 
consists of many kinds of cells including infiltrated inflammatory cells, such as neutrophils, 
lymphocytes, macrophages and myeloid derived suppressor cells (MDSC). These infiltrated 
immune cells secrete cytokines, chemokines and growth factors, such as TNF-α, TGF-β, IL-6, 
fibroblast growth factor (FGF) and epidermal growth factor (EGF). These growth factors 
contribute significantly to the invasive and metastatic traits of cancer cells by inducing EMT. 
Here, we discuss new insights into the molecular pathways and key regulators that link 
inflammatory tumor microenvironment to EMT and metastasis. 
2. Cancer and immunity: Immunity’s roles in tumor suppression and 
promotion 
One of the most challenging questions in immunology is to understand how the immune 
system affects cancer development and progression. In recent years, after a long eclipse, 
different lines of work have lead to a renaissance of the inflammation-cancer connection 
(Balkwill and Mantovani 2001; Coussens and Werb 2002; Mantovani, Allavena et al. 2008). It 
is now believed that the immune system plays a dual role in cancer: on one hand , it can 
function as an extrinsic tumor suppressor (Dighe, Richards et al. 1994; Kaplan, Shankaran et 
al. 1998; Smyth, Thia et al. 2000; Girardi, Oppenheim et al. 2001; Shankaran, Ikeda et al. 2001; 
Street, Trapani et al. 2002) by destroying cancer cells or inhibiting their outgrowth; on the 
other hand, the immune system can also promote tumor progression by establishing 
conditions within the tumor microenvironment that facilitate tumor outgrowth (Schreiber, 
Old et al.). Inflammatory responses play decisive roles at different stages of tumor 
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development, including initiation, promotion, malignant conversion, invasion, and 
metastasis (de Visser, Eichten et al. 2006; Grivennikov, Greten et al. 2010). 
3. EMT and metastasis 
Epithelial-mesenchymal transition (EMT) is a phenotypic conversion during embryonic 
development when tissue remodeling and cell migration shape the future organism, such as 
in embryonic development and wound healing. During EMT, epithelial cells lose the 
adherent junctions that keep them in contact with their neighbors. They gain a mesenchymal 
cell phenotype that enables them to break through the basal membrane and migrate over a 
long distance, a result of profound changes in their cytoskeleton architecture and gene 
expression profile (Kalluri and Neilson 2003). This concept was pioneered by the seminal 
study from Elizabeth Hay using chick primitive streak formation as a model in 1967 (Hay 
1995). Hay realized that an epithelial phenotypic conversion was of crucial importance 
during gastrulation and cell migration in the early vertebrate embryo. She proposed that 
differentiated epithelial cells could undergo a dramatic "transformation" into mesenchymal 
cells (Greenburg and Hay 1988; Hay 1995). However, this "transformation" is reversible: 
mesenchymal cells can revert back to epithelial cells through a reverse process called 
mesenchymal-epithelial transition (MET). As a result, the term “transition” is now used. 
EMT does not only occur during embryonic development or as a physiological response to 
injury. It is also an important element in cancer progression and other pathologies that 
involve organ degeneration, such as fibrosis. At the cellular level, pathological EMTs are 
very similar to physiological EMTs in that they are governed by similar signaling pathways, 
regulators, and effective molecules. 
From a clinical perspective, metastasis is the most critical aspect of tumorigenesis: we have 
already addressed that more than 90% of cancer mortality is caused by metastasis. Aberrant 
control of epithelial proliferation and angiogenesis underlie the initiation and growth of 
primary carcinomas (Hanahan and Weinberg 2011). However, additional steps must be 
completed before a metastatic tumor is successfully established. The spread of malignant 
cells consists of a series of steps, all of which are thought to be important for metastatic 
outgrowth in different organs. Basically, these steps include local invasion toward and entry 
into blood vasculature (intravasation), survival within the circulation system, arrest in 
distant capillary beds or “homing” to distal organs, exit from blood vasculature 
(extravasation), and eventual outgrowth and re-establishment of malignant growths in 
secondary locations (Woodhouse, Chuaqui et al. 1997; Chambers, Naumov et al. 2001; Fidler 
2003; Hanahan and Weinberg 2011). 
3.1 Classification of EMT into three different subtypes 
Based on recent intensive study in this field, EMT can be divided into three subtypes, which 
have different biological functional consequences (Kalluri 2009; Kalluri and Weinberg 2009; 
Zeisberg and Neilson 2009). Type 1 EMT occurs during implantation, embryo formation, 
gastrulation, and neural crest migration, which describes the transition of epithelial cells to 
generate diverse mesenchymal cell types. These primary mesenchymal cells can revert back 
to form secondary epithelia in mesodermal and endodermal organs through MET. Type 2 
EMT occurs during wound healing, tissue regeneration and organ fibrosis, which is usually 
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associated with injury and chronic inflammation. Type 2 EMT ceases once inflammation is 
attenuated, but if inflammation persists, this type of EMT will eventually lead to tissue 
fibrosis and organ destruction. Unlike Type 1 EMT, these mesenchymal cells have no 
potential to undergo MET and turn back to epithelial cells. Type 3 EMT occurs during tumor 
progression, which describes how neoplastic cells at the invasive front of primary tumors 
undergo a transition to acquire increased motility and invasive ability, enabling them to 
invade and metastasize through the blood stream or lymph node system, eventually 
generating life-threatening metastatic lesions at distant organs. 
Because studies of EMT often involve various model systems ranging from different 
epithelial cell types to assorted stimulations, it is important to use validated biomarkers to 
examine the phenotypic conversion during all three classes of EMT. Common biomarkers 
include cell-surface and extracellular molecules, cytoskeletal proteins and specific 
transcription factors. For example, down-regulation of E-cadherin is a hallmark of EMT, and 
loss of E-cadherin expression facilitates the induction of EMT (Huber, Kraut et al. 2005). E-
cadherin is a cell-cell adhesion molecule that participates in homotypic, calcium-dependent 
interactions to form epithelial adherent junctions (Cowin, Rowlands et al. 2005; Junghans, 
Haas et al. 2005). In addition, E-cadherin repressors, such as Snail, Slug, Twist and ZEB1/2, 
are commonly used as EMT markers. Snail is the first described E-cadherin repressor and is 
also the common downstream target of various signaling pathways that lead to EMT. 
Vimentin, an intermediate filament mainly expressed in fibroblasts, endothelial cells and 
hematopoietic cells, is also commonly used as an indicator for Type 3 EMT, since expression 
of vimentin in tumor cells correlates with their invasiveness and metastatic potential. 
Furthermore, differential expression of integrin is also used as a biomarker of EMT, since 
integrins modulate the interaction of cells with extracellular matrix (ECM). For example, 
increased expression of α5 integrin is commonly found in Type 2 and Type 3 EMT (Qian, 
Zhang et al. 2005; Davidson, Marsden et al. 2006; White, Blanchette et al. 2007). 
3.2 Type1 EMT in the formation of mesoderm and neural crest 
EMT is crucially important to tissue morphogenetic events during embryonic development, 
such as the mesoderm formation, neural crest formation, heart valve development, and 
secondary palate formation. Without EMT, development cannot proceed through the 
blastula stage. Mesoderm formation and neural crest development represent the major EMT 
programs that occur during early embryonic development; the resulting mesenchymal and 
neural crest cells act as progenitors and further differentiate into various cell types via MET. 
For example, gastrulation EMT produces the mesoderm, giving rise to muscle, bone and 
connective tissues, whereas neural crest delamination EMT gives rise to glial and neuronal 
cells, adrenal glandular tissues, pigment-containing cells of the epidermis and skeletal and 
connective tissues. The heart valve development and secondary palate formation occur in 
relatively well-differentiated epithelial cells that are destined to become defined 
mesenchymal cells types.  
The formation of mesoderm from the primitive ectoderm during gastrulation is the classic 
example of EMT. Gastrulation, observed in all metazoans, is accompanied by drastic 
morphogenic changes from a single epithelial layer (the epiblast) into three embryonic germ 
layers, the ectoderm, mesoderm, and endoderm, to form a complex three-dimensional 
multilayered embryo (Shook and Keller 2003). In chicken and mouse embryo, Wnt and TGF-
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associated with injury and chronic inflammation. Type 2 EMT ceases once inflammation is 
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undergo a transition to acquire increased motility and invasive ability, enabling them to 
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neural crest cells act as progenitors and further differentiate into various cell types via MET. 
For example, gastrulation EMT produces the mesoderm, giving rise to muscle, bone and 
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relatively well-differentiated epithelial cells that are destined to become defined 
mesenchymal cells types.  
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example of EMT. Gastrulation, observed in all metazoans, is accompanied by drastic 
morphogenic changes from a single epithelial layer (the epiblast) into three embryonic germ 
layers, the ectoderm, mesoderm, and endoderm, to form a complex three-dimensional 
multilayered embryo (Shook and Keller 2003). In chicken and mouse embryo, Wnt and TGF-
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β signaling provide the initial induction signals for EMT, while the FGF signal is necessary 
to maintain the EMT regulatory network during mesoderm formation. All these signaling 
events activate the expression of Snail, which represses the expression of E-cadherin and 
other tight junction components (such as claudins, occludins, and Crumbs) and promotes 
cell migration. In Snail knock-out mice the cells that form are unable to migrate, although 
mesoderm specification is not affected.  
Neural crest formation is another example of Type 1 EMT in embryogenesis where 
premigratory neural crest cells form at the border of the neural plate and non-neural 
ectoderm as a result of signals emanating from these two tissues. Interestingly, similar 
signaling pathways operating during EMT at gastrulation are used in the neural crest 
formation. Indeed, a combination of Wnt, FGF, and TGF-β (mainly BMP) induce the 
expression of Snail, Sox and forkhead box D3 transcription factors (Villanueva, Glavic et al. 
2002). In addition, experimental evidence shows that Notch signalling pathway plays an 
important role in neural crest formation through induction of Slug in frog and chick embryo 
(Nieto 2002). The combination of these transcription factors generates the full spectrum of 
phenotypic changes associated with EMT and primes the precursor cells to become 
migratory neural crest cells. These neural crest cells are equipped with the ability to migrate 
over extraordinarily long distances in the embryo, prior to their reaggregation via MET for 
further differentiation. 
3.3 Type 2 EMT in tissue and organ fibrosis 
3.3.1 Implications of EMT in fibrosis 
Re-epithelization, tissue regeneration and organ fibrosis constitute Type 2 EMT. Organ 
fibrosis is mediated by inflammatory cells and fibroblasts, which deposit collagens, elastin, 
tenacin and other matrix molecules. Fibrosis-associated Type 2 EMT specifically occurs in 
kidney, liver, lung and intestine (Zeisberg, Tarnavski et al. 2007). A series of typical 
experiments has shown that EMT is an important process during tissue injury that leads to 
organ fibrosis. In terms of EMT proteomes, fibroblast-specific protein 1 (FSP1, also known 
S100A4 and MTS-1), α-SMA (smooth muscle actin) and collagen I are reliable markers to 
characterize the mesenchymal products generated by EMTs in the development of fibrosis 
in various organs. TGF-β1, as the major pro-fibrotic cytokine, induces many of the central 
processes involved in fibrosis, including differentiation of fibroblast to myfibroblasat, ECM 
deposition and EMT. TGF-β not only contributes to pulmonary and hepatic fibrosis, but also 
plays a key role in cardiac fibrosis (Gressner, Weiskirchen et al. 2002; Willis and Borok 2007; 
Zeisberg, Tarnavski et al. 2007). TGF-β induces EMT via both a Smad2/3-dependent 
pathway and a MAPK-dependent pathway. The relevance of TGF-β-induced EMT for 
progression of organ fibrosis was recently further elucidated using BMP-7 as an intracellular 
competitor of TGF-β signaling in mouse models of kidney, liver, billiard tract, lung and 
intestinal fibrosis (Zeisberg, Bottiglio et al. 2003; Zeisberg, Hanai et al. 2003). The function of 
TGF-β in fibrosis is highlighted by the finding that Smad3-/- mice are resistant to the 
induction of several fibrotic diseases (Flanders 2004). TGF-β levels are also over-produced 
and are associated with functional impairment in patients with fibrotic pulmonary diseases 
such as idiopathic pulmonary fibrosis (Salez, Gosset et al. 1998). Clinical studies have also 
demonstrated the correlation between fibrosis and EMT (Rastaldi, Ferrario et al. 2002). 
Using immunohistochemistry and in situ hybridization, an EMT was demonstrated with the 
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expression of several markers of tubular phenotype transition, such as cytokeratin, 
vimentin, α-SMA and zona occludens (ZO-1) in 133 kidney biopsies (Rastaldi, Ferrario et al. 
2002). Similarly, an expression pattern of EMT was found in areas of fibrosis in the colon in 
patients with Crohn’s disease (Bataille, Rohrmeier et al. 2008).  
3.3.2 Re-epithelialization of wounded skin 
Re-epithelialization recapitulates several aspects of EMT. Re-epithelialization requires 
epithelial cells at the edge of wounded tissue to loosen their cell–-cell and cell–-ECM 
contacts and assume a migratory phenotype, reminiscent of EMT. Slug has a crucial role in 
wound-healing, which is expressed in keratinocytes at the boundary of wounds. 
Importantly, epithelial cell outgrowth from skin explants was markedly reduced in Slug 
knockout mice, whereas overexpression of Slug in cultured human keratinocytes result in 
increased cell spreading and desmosomal disruption (Savagner, Kusewitt et al. 2005). 
Arnoux et al further found that EGF can activate Erk5, which specifically enhances Slug 
promoter activity and controls wound healing in keratinocyte-derived HacaT cells in vitro 
(Arnoux, Nassour et al. 2008). However, it should be noted that not all features of EMT are 
seen. First, the migrating keratinocytes remain part of a cohesive cell sheet since they retain 
some intercellular junction. Second, the epithelial cells do not actually become mesenchymal 
(i.e., interstitial) cells. They retain epithelial characteristics. Once wound closure is complete, 
the involved epithelial cells revert to their tissue-specific, differentiated state. 
3.4 Type 3 EMT in cancer metastasis 
Cancer metastasis is believed to consist of four distinct steps: invasion, intravasation, 
extravasation and metastatic colonization (Chambers, Groom et al. 2002; Pantel and 
Brakenhoff 2004). During invasion, tumor cells lose cell-cell adhesion, gain mobility and 
leave the site of the primary tumor to invade adjacent tissues. In intravasation, tumor cells 
penetrate through the endothelial barrier and enter systemic circulation through blood and 
lymphatic vessels. In extravasation, cells that survive anchorage-independent growth 
conditions in the bloodstream attach to vessels at distant sites and leave the bloodstream. 
Finally, in metastatic colonization, tumor cells form macrometastases in the new host 
environment (Chambers, Groom et al. 2002; Pantel and Brakenhoff 2004). All of these steps, 
from initial breakdown of tissue structure through increased invasiveness, and ultimately 
distribution and colonization throughout the body, are characteristics of the developmental 
process at EMT/MET. The similarity of genetic controls and biochemical mechanisms 
underlying the acquisition of the invasive phenotype, and the subsequent systemic spread 
of the cancer cells, highlights that tumor cells usurp this developmental pathway for their 
metastatic dissemination. We will further discuss this type of EMT, with more detail on how 
it is regulated by different signaling pathways and molecular in various tumor 
microenvironments.   
3.5 Molecular regulation of EMT 
The hallmark of EMT is the loss of E-cadherin expression, an important caretaker of the 
epithelial phenotype. Loss of E-cadherin expression is often correlated with the tumor grade 
and stage, because it results in disruption of the cell-cell adhesion and an increase in nuclear 
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β signaling provide the initial induction signals for EMT, while the FGF signal is necessary 
to maintain the EMT regulatory network during mesoderm formation. All these signaling 
events activate the expression of Snail, which represses the expression of E-cadherin and 
other tight junction components (such as claudins, occludins, and Crumbs) and promotes 
cell migration. In Snail knock-out mice the cells that form are unable to migrate, although 
mesoderm specification is not affected.  
Neural crest formation is another example of Type 1 EMT in embryogenesis where 
premigratory neural crest cells form at the border of the neural plate and non-neural 
ectoderm as a result of signals emanating from these two tissues. Interestingly, similar 
signaling pathways operating during EMT at gastrulation are used in the neural crest 
formation. Indeed, a combination of Wnt, FGF, and TGF-β (mainly BMP) induce the 
expression of Snail, Sox and forkhead box D3 transcription factors (Villanueva, Glavic et al. 
2002). In addition, experimental evidence shows that Notch signalling pathway plays an 
important role in neural crest formation through induction of Slug in frog and chick embryo 
(Nieto 2002). The combination of these transcription factors generates the full spectrum of 
phenotypic changes associated with EMT and primes the precursor cells to become 
migratory neural crest cells. These neural crest cells are equipped with the ability to migrate 
over extraordinarily long distances in the embryo, prior to their reaggregation via MET for 
further differentiation. 
3.3 Type 2 EMT in tissue and organ fibrosis 
3.3.1 Implications of EMT in fibrosis 
Re-epithelization, tissue regeneration and organ fibrosis constitute Type 2 EMT. Organ 
fibrosis is mediated by inflammatory cells and fibroblasts, which deposit collagens, elastin, 
tenacin and other matrix molecules. Fibrosis-associated Type 2 EMT specifically occurs in 
kidney, liver, lung and intestine (Zeisberg, Tarnavski et al. 2007). A series of typical 
experiments has shown that EMT is an important process during tissue injury that leads to 
organ fibrosis. In terms of EMT proteomes, fibroblast-specific protein 1 (FSP1, also known 
S100A4 and MTS-1), α-SMA (smooth muscle actin) and collagen I are reliable markers to 
characterize the mesenchymal products generated by EMTs in the development of fibrosis 
in various organs. TGF-β1, as the major pro-fibrotic cytokine, induces many of the central 
processes involved in fibrosis, including differentiation of fibroblast to myfibroblasat, ECM 
deposition and EMT. TGF-β not only contributes to pulmonary and hepatic fibrosis, but also 
plays a key role in cardiac fibrosis (Gressner, Weiskirchen et al. 2002; Willis and Borok 2007; 
Zeisberg, Tarnavski et al. 2007). TGF-β induces EMT via both a Smad2/3-dependent 
pathway and a MAPK-dependent pathway. The relevance of TGF-β-induced EMT for 
progression of organ fibrosis was recently further elucidated using BMP-7 as an intracellular 
competitor of TGF-β signaling in mouse models of kidney, liver, billiard tract, lung and 
intestinal fibrosis (Zeisberg, Bottiglio et al. 2003; Zeisberg, Hanai et al. 2003). The function of 
TGF-β in fibrosis is highlighted by the finding that Smad3-/- mice are resistant to the 
induction of several fibrotic diseases (Flanders 2004). TGF-β levels are also over-produced 
and are associated with functional impairment in patients with fibrotic pulmonary diseases 
such as idiopathic pulmonary fibrosis (Salez, Gosset et al. 1998). Clinical studies have also 
demonstrated the correlation between fibrosis and EMT (Rastaldi, Ferrario et al. 2002). 
Using immunohistochemistry and in situ hybridization, an EMT was demonstrated with the 
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expression of several markers of tubular phenotype transition, such as cytokeratin, 
vimentin, α-SMA and zona occludens (ZO-1) in 133 kidney biopsies (Rastaldi, Ferrario et al. 
2002). Similarly, an expression pattern of EMT was found in areas of fibrosis in the colon in 
patients with Crohn’s disease (Bataille, Rohrmeier et al. 2008).  
3.3.2 Re-epithelialization of wounded skin 
Re-epithelialization recapitulates several aspects of EMT. Re-epithelialization requires 
epithelial cells at the edge of wounded tissue to loosen their cell–-cell and cell–-ECM 
contacts and assume a migratory phenotype, reminiscent of EMT. Slug has a crucial role in 
wound-healing, which is expressed in keratinocytes at the boundary of wounds. 
Importantly, epithelial cell outgrowth from skin explants was markedly reduced in Slug 
knockout mice, whereas overexpression of Slug in cultured human keratinocytes result in 
increased cell spreading and desmosomal disruption (Savagner, Kusewitt et al. 2005). 
Arnoux et al further found that EGF can activate Erk5, which specifically enhances Slug 
promoter activity and controls wound healing in keratinocyte-derived HacaT cells in vitro 
(Arnoux, Nassour et al. 2008). However, it should be noted that not all features of EMT are 
seen. First, the migrating keratinocytes remain part of a cohesive cell sheet since they retain 
some intercellular junction. Second, the epithelial cells do not actually become mesenchymal 
(i.e., interstitial) cells. They retain epithelial characteristics. Once wound closure is complete, 
the involved epithelial cells revert to their tissue-specific, differentiated state. 
3.4 Type 3 EMT in cancer metastasis 
Cancer metastasis is believed to consist of four distinct steps: invasion, intravasation, 
extravasation and metastatic colonization (Chambers, Groom et al. 2002; Pantel and 
Brakenhoff 2004). During invasion, tumor cells lose cell-cell adhesion, gain mobility and 
leave the site of the primary tumor to invade adjacent tissues. In intravasation, tumor cells 
penetrate through the endothelial barrier and enter systemic circulation through blood and 
lymphatic vessels. In extravasation, cells that survive anchorage-independent growth 
conditions in the bloodstream attach to vessels at distant sites and leave the bloodstream. 
Finally, in metastatic colonization, tumor cells form macrometastases in the new host 
environment (Chambers, Groom et al. 2002; Pantel and Brakenhoff 2004). All of these steps, 
from initial breakdown of tissue structure through increased invasiveness, and ultimately 
distribution and colonization throughout the body, are characteristics of the developmental 
process at EMT/MET. The similarity of genetic controls and biochemical mechanisms 
underlying the acquisition of the invasive phenotype, and the subsequent systemic spread 
of the cancer cells, highlights that tumor cells usurp this developmental pathway for their 
metastatic dissemination. We will further discuss this type of EMT, with more detail on how 
it is regulated by different signaling pathways and molecular in various tumor 
microenvironments.   
3.5 Molecular regulation of EMT 
The hallmark of EMT is the loss of E-cadherin expression, an important caretaker of the 
epithelial phenotype. Loss of E-cadherin expression is often correlated with the tumor grade 
and stage, because it results in disruption of the cell-cell adhesion and an increase in nuclear 
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β-catenin (Cowin, Rowlands et al. 2005; Junghans, Haas et al. 2005). Several transcription 
factors have been implicated in the regulation of EMT, including zinc finger proteins of the 
Snail/Slug family, the basic helix-loop-helix factor Twist, E12/E47, Goosecoid, δEF1/ZEB1 
and SIP1 (Nieto 2002; Yang, Mani et al. 2004; Hartwell, Muir et al. 2006). These factors act as 
a molecular switch of EMT program by repressing a subset of common genes that encode 
cadherins, claudins, integrins, mucins, plakophilin, occludin and ZO1 to induce EMT. For 
example, Snail expression is associated with E-cadherin repression in metastasis; it also 
correlates with tumor recurrence and poor prognosis in various cancers (Elloul, Elstrand et 
al. 2005; Moody, Perez et al. 2005; Bruyere, Namdarian et al. 2009). In addition, extensive 
crosstalk among these transcription factors forms a signaling network that is responsible for 
establishing and maintaining mesenchymal cell phenotypes. Furthermore, some of these 
transcription factors, including Snail, play an important part in overcoming oncogene-
induced senescence (Ansieau, Bastid et al. 2008), inhibiting tumor immunosuppression 
(Kudo-Saito, Shirako et al. 2009) and generating tumorigenic cancer stem cells (Mani, Guo et 
al. 2008). These transcription factors communicate and respond to extracellular signals such 
as growth factors, cytokines and hypoxia from their microenvironment to induce EMT.  
Many signaling pathways trigger EMT in both embryonic development and in normal and 
transformed cell lines. The signaling pathways include those triggered by different members 
of the TGF-β superfamily, Wnts, Notch, EGF, FGF and many others (Fig.1). 
 
Fig. 1. Overview of the Molecular regulation of EMT. 
TGF-β is a primary inducer of EMT. It not only contributes to EMT during embryonic 
development, but also induces EMT during tumor progression in vivo (Zavadil and Bottinger 
2005). Overexpression of Smad2 and Smad3 result in increased EMT in a mammary epithelial 
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model (Valcourt, Kowanetz et al. 2005). Knockout of Smad3 blocks TGF-β-induced EMT in 
primary tubular epithelial cells; the reduction of Smad2 and Smad3 function is associated with 
the decreased metastatic potential of breast cancer cell lines in a xenograft model (Zavadil, 
Cermak et al. 2004). It is interesting that SMAD3 and SMAD4 interact and form a complex 
with Snail, targeting the promoters of CAR (a tight-junction protein) and E-cadherin during 
TGF-β-inducing EMT in breast epithelial cells (Vincent, Neve et al. 2009). Bos et al identified 
that TGF-β primed cancer cells for lung metastasis through angiopoietin-like 4 via Smad 
signaling pathway (Bos, Zhang et al. 2009). In contrast, inhibition of TGF-β or TGF-β receptor 
reduces the invasive and metastatic activities of cancer cells. TGF-β can also downregulate 
various epithelial molecules, including E-cadherin, ZO-1 and several specific keratins; it also 
upregulates certain mesenchymal proteins such as fibronectin, fibroblast specific protein 1, α-
smooth muscle actin and vimentin. In addition, TGF-β cooperates with numerous kinases such 
as RAS, MAPK, and p38MAP, to promote EMT (Zavadil and Bottinger 2005; Buijs, Henriquez 
et al. 2007). More specifically, p38 MAPK and RhoA mediate an autocrine TGF-β-induced 
EMT in NMuMG mouse mammary epithelial cells (Bhowmick, Ghiassi et al. 2001). ECM 
molecules, such as integrin β1 and Fibulin-5, augment TGF-β-induced EMT in a MAPK-
dependent mechanism (Bhowmick, Ghiassi et al. 2001; Lee, Albig et al. 2008). Constitutive 
activation of Raf enhances the function of TGF-β in inducing EMT via MAPK in MDCK cells 
(Janda, Lehmann et al. 2002). TGF-β also induces EMT through changes in the expression of 
certain cell polarity molecules. For example, TGF-β can induce phosphorylation of Par6, which 
in turn stimulates binding of Par6 to E3 ligase Smurf1. The Par6-Smurf1 complex then 
mediates the localized ubiquitination of RhoA to disrupt tight junctions during EMT 
(Ozdamar, Bose et al. 2005). TGF-β can also downregulate Par3 expression to destroy cell 
polarity (Wang, Nie et al. 2008). It is interesting to note that Abl can inhibit TGF-β-mediated 
EMT in normal and metastatic mammary epithelial cells (MECs) (Allington, Galliher-Beckley 
et al. 2009). Furthermore, TGF-β can cooperate with other oncogenic pathways, such as Notch, 
Wnt/β-catenin and NF-κB, to maintain the mesenchymal phenotype of invasive/metastatic 
tumor cells (Nawshad, Lagamba et al. 2005; Zavadil and Bottinger 2005; Neth, Ries et al. 2007). 
The Wnt/β-catenin pathway has a particularly tight link with EMT (Li, Hively et al. 2000). 
On one hand, β-catenin is an essential component of adherent junctions, where it provides 
the link between E-cadherin and α-catenin and modulates cell-cell adhesion and cell 
migration. On the other hand, β-catenin also functions as a transcription cofactor with T cell 
factor (TCF). Nuclear translocation of β-catenin can activate expression of Slug, thus 
inducing EMT. Expression of β-catenin in oocyte induces a premature EMT in the epiblast, 
concomitant with Snail transcription. Interestingly, Snail is a highly unstable protein and is 
dually regulated by protein stability and cellular location. We showed that GSK-3β binds 
and phosphorylates Snail at two consensus motifs to dually regulate the function of this 
protein: phosphorylation at the first motif regulates its ubiquitination mediated by β-Trcp, 
and phosphorylation at the second motif controls its subcellular localization (Zhou, Deng et 
al. 2004). Thus, Wnt can suppress the activity of GSK-3β, and it stabilizes the protein level of 
Snail and β-catenin to induce EMT and cancer metastasis (Yook, Li et al. 2005; Yook, Li et al. 
2006). Meanwhile, Snail can functionally interact with β-catenin to increase Wnt-dependent 
target gene expression, promoting EMT (Stemmer, de Craene et al. 2008). Increasing 
evidence indicates that Wnt signaling is strongly associated with human basal-like breast 
cancer. Inhibiting Wnt signaling through LRP6 reduces the capacity of cancer cells to self-
renew and colonize in vivo. It also results in the re-expression of breast epithelial markers 
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β-catenin (Cowin, Rowlands et al. 2005; Junghans, Haas et al. 2005). Several transcription 
factors have been implicated in the regulation of EMT, including zinc finger proteins of the 
Snail/Slug family, the basic helix-loop-helix factor Twist, E12/E47, Goosecoid, δEF1/ZEB1 
and SIP1 (Nieto 2002; Yang, Mani et al. 2004; Hartwell, Muir et al. 2006). These factors act as 
a molecular switch of EMT program by repressing a subset of common genes that encode 
cadherins, claudins, integrins, mucins, plakophilin, occludin and ZO1 to induce EMT. For 
example, Snail expression is associated with E-cadherin repression in metastasis; it also 
correlates with tumor recurrence and poor prognosis in various cancers (Elloul, Elstrand et 
al. 2005; Moody, Perez et al. 2005; Bruyere, Namdarian et al. 2009). In addition, extensive 
crosstalk among these transcription factors forms a signaling network that is responsible for 
establishing and maintaining mesenchymal cell phenotypes. Furthermore, some of these 
transcription factors, including Snail, play an important part in overcoming oncogene-
induced senescence (Ansieau, Bastid et al. 2008), inhibiting tumor immunosuppression 
(Kudo-Saito, Shirako et al. 2009) and generating tumorigenic cancer stem cells (Mani, Guo et 
al. 2008). These transcription factors communicate and respond to extracellular signals such 
as growth factors, cytokines and hypoxia from their microenvironment to induce EMT.  
Many signaling pathways trigger EMT in both embryonic development and in normal and 
transformed cell lines. The signaling pathways include those triggered by different members 
of the TGF-β superfamily, Wnts, Notch, EGF, FGF and many others (Fig.1). 
 
Fig. 1. Overview of the Molecular regulation of EMT. 
TGF-β is a primary inducer of EMT. It not only contributes to EMT during embryonic 
development, but also induces EMT during tumor progression in vivo (Zavadil and Bottinger 
2005). Overexpression of Smad2 and Smad3 result in increased EMT in a mammary epithelial 
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model (Valcourt, Kowanetz et al. 2005). Knockout of Smad3 blocks TGF-β-induced EMT in 
primary tubular epithelial cells; the reduction of Smad2 and Smad3 function is associated with 
the decreased metastatic potential of breast cancer cell lines in a xenograft model (Zavadil, 
Cermak et al. 2004). It is interesting that SMAD3 and SMAD4 interact and form a complex 
with Snail, targeting the promoters of CAR (a tight-junction protein) and E-cadherin during 
TGF-β-inducing EMT in breast epithelial cells (Vincent, Neve et al. 2009). Bos et al identified 
that TGF-β primed cancer cells for lung metastasis through angiopoietin-like 4 via Smad 
signaling pathway (Bos, Zhang et al. 2009). In contrast, inhibition of TGF-β or TGF-β receptor 
reduces the invasive and metastatic activities of cancer cells. TGF-β can also downregulate 
various epithelial molecules, including E-cadherin, ZO-1 and several specific keratins; it also 
upregulates certain mesenchymal proteins such as fibronectin, fibroblast specific protein 1, α-
smooth muscle actin and vimentin. In addition, TGF-β cooperates with numerous kinases such 
as RAS, MAPK, and p38MAP, to promote EMT (Zavadil and Bottinger 2005; Buijs, Henriquez 
et al. 2007). More specifically, p38 MAPK and RhoA mediate an autocrine TGF-β-induced 
EMT in NMuMG mouse mammary epithelial cells (Bhowmick, Ghiassi et al. 2001). ECM 
molecules, such as integrin β1 and Fibulin-5, augment TGF-β-induced EMT in a MAPK-
dependent mechanism (Bhowmick, Ghiassi et al. 2001; Lee, Albig et al. 2008). Constitutive 
activation of Raf enhances the function of TGF-β in inducing EMT via MAPK in MDCK cells 
(Janda, Lehmann et al. 2002). TGF-β also induces EMT through changes in the expression of 
certain cell polarity molecules. For example, TGF-β can induce phosphorylation of Par6, which 
in turn stimulates binding of Par6 to E3 ligase Smurf1. The Par6-Smurf1 complex then 
mediates the localized ubiquitination of RhoA to disrupt tight junctions during EMT 
(Ozdamar, Bose et al. 2005). TGF-β can also downregulate Par3 expression to destroy cell 
polarity (Wang, Nie et al. 2008). It is interesting to note that Abl can inhibit TGF-β-mediated 
EMT in normal and metastatic mammary epithelial cells (MECs) (Allington, Galliher-Beckley 
et al. 2009). Furthermore, TGF-β can cooperate with other oncogenic pathways, such as Notch, 
Wnt/β-catenin and NF-κB, to maintain the mesenchymal phenotype of invasive/metastatic 
tumor cells (Nawshad, Lagamba et al. 2005; Zavadil and Bottinger 2005; Neth, Ries et al. 2007). 
The Wnt/β-catenin pathway has a particularly tight link with EMT (Li, Hively et al. 2000). 
On one hand, β-catenin is an essential component of adherent junctions, where it provides 
the link between E-cadherin and α-catenin and modulates cell-cell adhesion and cell 
migration. On the other hand, β-catenin also functions as a transcription cofactor with T cell 
factor (TCF). Nuclear translocation of β-catenin can activate expression of Slug, thus 
inducing EMT. Expression of β-catenin in oocyte induces a premature EMT in the epiblast, 
concomitant with Snail transcription. Interestingly, Snail is a highly unstable protein and is 
dually regulated by protein stability and cellular location. We showed that GSK-3β binds 
and phosphorylates Snail at two consensus motifs to dually regulate the function of this 
protein: phosphorylation at the first motif regulates its ubiquitination mediated by β-Trcp, 
and phosphorylation at the second motif controls its subcellular localization (Zhou, Deng et 
al. 2004). Thus, Wnt can suppress the activity of GSK-3β, and it stabilizes the protein level of 
Snail and β-catenin to induce EMT and cancer metastasis (Yook, Li et al. 2005; Yook, Li et al. 
2006). Meanwhile, Snail can functionally interact with β-catenin to increase Wnt-dependent 
target gene expression, promoting EMT (Stemmer, de Craene et al. 2008). Increasing 
evidence indicates that Wnt signaling is strongly associated with human basal-like breast 
cancer. Inhibiting Wnt signaling through LRP6 reduces the capacity of cancer cells to self-
renew and colonize in vivo. It also results in the re-expression of breast epithelial markers 
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and repression of EMT transcription factors Slug and Twist (DiMeo, Anderson et al. 2009). 
How the synergistic activation of Snail and β-catenin by the Wnt signaling pathway, 
enhancing EMT and metastasis, remains to be further defined. 
Notch is an evolutionarily conserved signaling pathway that regulates cell fate specification, 
self-renewal and differentiation in embryonic and postnatal tissues. Four Notch (Notch 1−4) 
and five ligands (Jagged1, 2 and Deltalike1, 3, 4) have been identified. Notch signaling is 
normally activated followed by ligand-receptor binding between two neighboring cells. 
Notch undergoes intramembrane cleavage by γ-secretase, and its intracellular domain 
(NICD) is released and translocates to the nucleus to activate gene transcription by 
associating with Mastermind-like 1 (MAM) and histone acetyltransferase p300/CBP. 
Alteration of Notch signaling has been associated with various types of cancer in which 
Notch can act as an oncogene or as a tumor suppressor, depending on the cellular context. 
The first observation that Notch pathway is required for EMT was derived from cardiac 
valve and cushion formation at heart development (Timmerman, Grego-Bessa et al. 2004). 
This implies that Notch, acting through a similar mechanism, induces EMT during tumor 
progression and converts polarized epithelial cells into motile and invasive ones (Grego-
Bessa, Diez et al. 2004). Indeed, overexpression of Jagged1 and Notch1 induces the 
expression of Slug and correlates with poor prognosis in various human cancers (Leong, 
Niessen et al. 2007). Slug is essential for Notch-mediated EMT by repressing E-cadherin 
expression, which results in β-catenin activation and resistance to anoikis. Inhibition of 
Notch signaling in xenografted, Slug-positive/E-cadherin-negative breast tumors promotes 
apoptosis and inhibits tumor growth and metastasis (Leong, Niessen et al. 2007). In 
addition, Notch signaling deploys two distinct mechanisms that act in synergy to control the 
expression of Snail (Sahlgren, Gustafsson et al. 2008). First, Notch directly upregulates Snail 
expression by recruiting the Notch intracellular domain to the Snail promoter. Second, 
Notch potentiates hypoxia-inducible factor 1α (HIF-1α) recruitment to the lysyl oxidase 
(LOX) promoter and elevates the hypoxia-induced upregulation of LOX, which stabilizes 
the Snail protein. Thus, Notch signaling is required to convert the hypoxic stimulus into 
EMT, and it increases the invasiveness of tumor cells. In addition, the Notch signaling 
pathway is involved in the acquisition of EMT phenotype of gemcitabine-resistant (GR) cells 
in pancreatic cancer (Wang, Li et al. 2009). Down-regulation of Notch signaling is associated 
with decreased invasive behavior of GR cells. Moreover, Notch signaling leads to the 
increased expression of vimentin, ZEB1, Slug, Snail, and NF-κB, and it results in EMT. Thus, 
inhibition of Notch signaling by novel therapeutic strategies can be clinically important in 
overcoming drug resistance and EMT phenotype of tumor cells. 
The Hedgehog (Hh) signaling pathway was first identified in a large screen for Drosophila 
genes required for patterning of the early embryo (Hooper and Scott 2005; Jacob and Lum 
2007). The Hh ligands, Sonic-, Desert-, and Indian Hh in vertebrates and Hh in Drosophila, 
are secreted proteins that undergo several posttranslational modifications to gain full 
activity. Key effectors of Hh signaling include zinc-finger proteins of the Gli1-3 transcription 
factors. Hh signaling can initiate cell growth, cell division, lineage specification and axon 
guidance and can also function as a survival factor. Activation of Hh signaling also leads to 
EMT. In mouse epidermal cells or in rat kidney epithelial cells immortalized with 
adenovirus E1A, Gli1 rapidly induces transcription of Snail and promotes EMT (Li, Deng et 
al. 2006; Li, Deng et al. 2007). Targeted expression of Gli1 in the epithelial cells of mammary 
gland of mice induces the expression of Snail, resulting in the disruption of the mammary 
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epithelial network and alveologenesis during pregnancy (Fiaschi, Rozell et al. 2007). In 
addition, Hedgehog signals induce JAG2 up-regulation for Notch-CSL-mediated Snail 
expression; on the other hand, Hedgehog induces TGF-β1 secretion to induce ZEB1 and 
ZEB2 expression through TGF-β and NF-κB pathways. Conversely, blocking Hedgehog 
signaling by inhibitor cyclopamine suppresses pancreatic cancer invasion and metastasis by 
inhibiting EMT (Feldmann, Dhara et al. 2007). The crosstalk between the Hh and EMT also 
presents in human esophageal squamous cell carcinoma (ESCC) (Isohata, Aoyagi et al. 
2009). Hh and EMT signaling genes are co-expressed on the undifferentiated esophageal 
epithelial cells and in most ESCCs. These findings suggest that mesenchymal gene 
expression is maintained or strengthened through Hh signaling in cancer cells. 
3.6 Microenvironmental regulation of EMT/metastasis 
Metastasis is a multi-step process that requires cancer cells to escape from the primary 
tumor, survive in circulation, seed at distant sites and grow. Each of these processes 
involves rate-limiting steps influenced by non-malignant cells of the tumor 
microenvironment (Joyce and Pollard 2009), composed of multiple cell types, such as stroma 
fibroblasts, epithelial cells, and a variety of bone marrow-derived cells (BMDCs) including 
macrophages, myeloid-derived suppressor cells (MDSCs), and so on. In this surrounding 
environment, a variety of stromal cells are recruited to tumors, not only enhance growth of 
the primary tumor, but also to facilitate its metastatic dissemination to distant organs (Tse 
and Kalluri 2007; Lunt, Chaudary et al. 2009). 
Recent work has indicated that EMT is a dynamic process controlled by signals that cells 
receive from their microenvironment. By adopting a mesenchymal phenotype through EMT, 
individual carcinoma cells can infiltrate adjacent tissues, cross endothelial barriers, and 
enter the circulation through blood and lymphatic vessels. Once the tumor cells reach their 
secondary tissues or organs, they no longer encounter the signals they experienced in the 
primary tumor, and they can revert to an epithelial state via a mesenchymal-epithelial 
transition (MET). Consistent with this notion, EMT commonly occurs at the invasive front 
(tumor-stromal boundary) of many invasive carcinomas (Christofori 2006; Franci, Takkunen 
et al. 2006). These observations indicate that EMT is triggered by cellular signals from 
microenvironment. These immune and inflammatory cells secrete cytokines, chemokines, 
and growth factors, which play essential roles for supporting tumor progression and 
metastasis. Because it is analogous with the role of inflammation in mediating wound 
healing, we hypothesize that the migratory and invasive ability of tumor cells at the invasive 
front is initiated and propelled by an inflammatory microenvironment through the 
induction of EMT. 
4. The role of inflammatory cells and cytokines in EMT/metastasis 
4.1 Tumor-Associated Macrophages (TAMs) 
Consistent with our hypothesis, a high content of inflammatory cells, particularly tumor-
associated macrophages, is commonly found at the invasive fronts of advanced carcinoma 
(Condeelis and Pollard 2006). Macrophages are key cells in chronic inflammation. M1 
macrophages are involved in Type 1 reactions and are classically activated by microbial 
products, killing microorganisms and producing reactive oxygen and nitrogen 
 
Tumor Microenvironment and Myelomonocytic Cells 118 
and repression of EMT transcription factors Slug and Twist (DiMeo, Anderson et al. 2009). 
How the synergistic activation of Snail and β-catenin by the Wnt signaling pathway, 
enhancing EMT and metastasis, remains to be further defined. 
Notch is an evolutionarily conserved signaling pathway that regulates cell fate specification, 
self-renewal and differentiation in embryonic and postnatal tissues. Four Notch (Notch 1−4) 
and five ligands (Jagged1, 2 and Deltalike1, 3, 4) have been identified. Notch signaling is 
normally activated followed by ligand-receptor binding between two neighboring cells. 
Notch undergoes intramembrane cleavage by γ-secretase, and its intracellular domain 
(NICD) is released and translocates to the nucleus to activate gene transcription by 
associating with Mastermind-like 1 (MAM) and histone acetyltransferase p300/CBP. 
Alteration of Notch signaling has been associated with various types of cancer in which 
Notch can act as an oncogene or as a tumor suppressor, depending on the cellular context. 
The first observation that Notch pathway is required for EMT was derived from cardiac 
valve and cushion formation at heart development (Timmerman, Grego-Bessa et al. 2004). 
This implies that Notch, acting through a similar mechanism, induces EMT during tumor 
progression and converts polarized epithelial cells into motile and invasive ones (Grego-
Bessa, Diez et al. 2004). Indeed, overexpression of Jagged1 and Notch1 induces the 
expression of Slug and correlates with poor prognosis in various human cancers (Leong, 
Niessen et al. 2007). Slug is essential for Notch-mediated EMT by repressing E-cadherin 
expression, which results in β-catenin activation and resistance to anoikis. Inhibition of 
Notch signaling in xenografted, Slug-positive/E-cadherin-negative breast tumors promotes 
apoptosis and inhibits tumor growth and metastasis (Leong, Niessen et al. 2007). In 
addition, Notch signaling deploys two distinct mechanisms that act in synergy to control the 
expression of Snail (Sahlgren, Gustafsson et al. 2008). First, Notch directly upregulates Snail 
expression by recruiting the Notch intracellular domain to the Snail promoter. Second, 
Notch potentiates hypoxia-inducible factor 1α (HIF-1α) recruitment to the lysyl oxidase 
(LOX) promoter and elevates the hypoxia-induced upregulation of LOX, which stabilizes 
the Snail protein. Thus, Notch signaling is required to convert the hypoxic stimulus into 
EMT, and it increases the invasiveness of tumor cells. In addition, the Notch signaling 
pathway is involved in the acquisition of EMT phenotype of gemcitabine-resistant (GR) cells 
in pancreatic cancer (Wang, Li et al. 2009). Down-regulation of Notch signaling is associated 
with decreased invasive behavior of GR cells. Moreover, Notch signaling leads to the 
increased expression of vimentin, ZEB1, Slug, Snail, and NF-κB, and it results in EMT. Thus, 
inhibition of Notch signaling by novel therapeutic strategies can be clinically important in 
overcoming drug resistance and EMT phenotype of tumor cells. 
The Hedgehog (Hh) signaling pathway was first identified in a large screen for Drosophila 
genes required for patterning of the early embryo (Hooper and Scott 2005; Jacob and Lum 
2007). The Hh ligands, Sonic-, Desert-, and Indian Hh in vertebrates and Hh in Drosophila, 
are secreted proteins that undergo several posttranslational modifications to gain full 
activity. Key effectors of Hh signaling include zinc-finger proteins of the Gli1-3 transcription 
factors. Hh signaling can initiate cell growth, cell division, lineage specification and axon 
guidance and can also function as a survival factor. Activation of Hh signaling also leads to 
EMT. In mouse epidermal cells or in rat kidney epithelial cells immortalized with 
adenovirus E1A, Gli1 rapidly induces transcription of Snail and promotes EMT (Li, Deng et 
al. 2006; Li, Deng et al. 2007). Targeted expression of Gli1 in the epithelial cells of mammary 
gland of mice induces the expression of Snail, resulting in the disruption of the mammary 
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epithelial network and alveologenesis during pregnancy (Fiaschi, Rozell et al. 2007). In 
addition, Hedgehog signals induce JAG2 up-regulation for Notch-CSL-mediated Snail 
expression; on the other hand, Hedgehog induces TGF-β1 secretion to induce ZEB1 and 
ZEB2 expression through TGF-β and NF-κB pathways. Conversely, blocking Hedgehog 
signaling by inhibitor cyclopamine suppresses pancreatic cancer invasion and metastasis by 
inhibiting EMT (Feldmann, Dhara et al. 2007). The crosstalk between the Hh and EMT also 
presents in human esophageal squamous cell carcinoma (ESCC) (Isohata, Aoyagi et al. 
2009). Hh and EMT signaling genes are co-expressed on the undifferentiated esophageal 
epithelial cells and in most ESCCs. These findings suggest that mesenchymal gene 
expression is maintained or strengthened through Hh signaling in cancer cells. 
3.6 Microenvironmental regulation of EMT/metastasis 
Metastasis is a multi-step process that requires cancer cells to escape from the primary 
tumor, survive in circulation, seed at distant sites and grow. Each of these processes 
involves rate-limiting steps influenced by non-malignant cells of the tumor 
microenvironment (Joyce and Pollard 2009), composed of multiple cell types, such as stroma 
fibroblasts, epithelial cells, and a variety of bone marrow-derived cells (BMDCs) including 
macrophages, myeloid-derived suppressor cells (MDSCs), and so on. In this surrounding 
environment, a variety of stromal cells are recruited to tumors, not only enhance growth of 
the primary tumor, but also to facilitate its metastatic dissemination to distant organs (Tse 
and Kalluri 2007; Lunt, Chaudary et al. 2009). 
Recent work has indicated that EMT is a dynamic process controlled by signals that cells 
receive from their microenvironment. By adopting a mesenchymal phenotype through EMT, 
individual carcinoma cells can infiltrate adjacent tissues, cross endothelial barriers, and 
enter the circulation through blood and lymphatic vessels. Once the tumor cells reach their 
secondary tissues or organs, they no longer encounter the signals they experienced in the 
primary tumor, and they can revert to an epithelial state via a mesenchymal-epithelial 
transition (MET). Consistent with this notion, EMT commonly occurs at the invasive front 
(tumor-stromal boundary) of many invasive carcinomas (Christofori 2006; Franci, Takkunen 
et al. 2006). These observations indicate that EMT is triggered by cellular signals from 
microenvironment. These immune and inflammatory cells secrete cytokines, chemokines, 
and growth factors, which play essential roles for supporting tumor progression and 
metastasis. Because it is analogous with the role of inflammation in mediating wound 
healing, we hypothesize that the migratory and invasive ability of tumor cells at the invasive 
front is initiated and propelled by an inflammatory microenvironment through the 
induction of EMT. 
4. The role of inflammatory cells and cytokines in EMT/metastasis 
4.1 Tumor-Associated Macrophages (TAMs) 
Consistent with our hypothesis, a high content of inflammatory cells, particularly tumor-
associated macrophages, is commonly found at the invasive fronts of advanced carcinoma 
(Condeelis and Pollard 2006). Macrophages are key cells in chronic inflammation. M1 
macrophages are involved in Type 1 reactions and are classically activated by microbial 
products, killing microorganisms and producing reactive oxygen and nitrogen 
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intermediates. In contrast, M2 cells (tumor associated macrophage; TAM) are important 
components of infiltrated leukocytes in most malignant tumors. They are involved in Type 2 
reactions, tune inflammation and adaptive immunity, promote cell proliferation by 
producing growth factors and enhance angiogenesis, tissue remodeling, and repair. 
Macrophage directly influences the behavior and function of tumor cells and has been 
regarded as an “obligate partner for tumor-cell migration, invasion and metastasis” 
(Condeelis and Pollard 2006). Clinical studies indicate a correlation between TAM density 
and poor prognosis (Pollard 2004). For example, in PyMT-induced mammary tumors, 
macrophages are present in the areas of basement membrane breakdown during the 
development of “early-stage” metastatic lesions and systemic depletion of macrophages 
results in reduced formation of lung metastasis (Lin, Nguyen et al. 2001). TAMs produce a 
wide variety of growth factors (such as FGF, HGF, EGF, PDGF and TGF-β and cytokines 
[such as TNFα, interleukin-6, interleukin-1, and interferons]) to stimulate the growth, 
motility, and invasiveness of tumor cells. TAMs also produce many proteases, ranging from 
uPA to a variety of matrix metalloproteinases, to degrade the basement membrane in order 
to create a channel for tumor cell invasion. In our recent study, we found that the 
EMT/invasiveness of tumor cells was dramatically enhanced when they were co-cultured 
with macrophages or macrophage-conditioned medium (Wu, Deng et al. 2009). We showed 
that this effect, mainly mediated by the secretion of TNFα from macrophages as 
neutralization of TNFα by TNFα antibody, greatly suppressed macrophage-mediated tumor 
cell invasion and metastasis(Wu, Deng et al. 2009). Consistent with our finding, Hagemann 
et al found that co-culturing macrophages with tumor cells enhanced their invasive ability 
in a manner dependent on TNFα and matrix metalloproteinases (MMP)(Hagemann, Wilson 
et al. 2005). Interestingly, expression of Snail in the non-metastatic breast cancer cell lines 
MCF7 and T47D, which contain little endogenous Snail, greatly increased the invasiveness 
of these cells by inflammation, indicating that Snail, through the induction of EMT, is critical 
for mediating inflammation-induced invasion/metastasis of breast cancer cells. Knockdown 
Snail expression significantly inhibited cell migration and invasion induced by 
inflammatory cytokines; it also suppressed inflammation-mediated breast cancer metastasis 
in animal model. Thus, macrophages, the major inflammatory component of the stroma in 
malignancies, facilitate angiogenesis, extracellular matrix breakdown, invasion, and 
metastasis through multiple mechanisms. 
4.2 T-reg cells  
Regulatory T cells (Treg), which include many populations that differ in phenotype, 
cytokine secretion profile and suppressive mechanism (Maloy and Powrie 2001; Shevach 
2002; Wood and Sakaguchi 2003), were reported to interact with tumor cells, promoting 
rather than inhibiting cancer development and progression. High Treg levels have been 
found in peripheral blood, lymph nodes, and tumor specimens from patients with different 
types of cancer (Wang 2008). Treg have been characterized by the constitutive expression of 
Forkhead box P3 (FoxP3), glucocorticoid-induecd THFR family-related receptor (GITR), 
cytotoxic T lymphocyte associated antigen 4 (CTLA-4), and high levels of the alpha chain of 
the IL-2 receptor (CD25). It was found that Treg numbers were significantly higher in 
patients with metastatic cancer compared to healthy donors (Audia, Nicolas et al. 2007; 
Watanabe, Oda et al. 2010). 
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The level of FoxP3, an indicator of Treg activity, might also be an indicator of breast 
tumorigenesis (Gupta, Joshi et al. 2007). It has been demonstrated that high numbers of 
FoxP3-positive Tregs were present in high-grade tumors, increasing the risk of 
relapse/metastasis (Bates, Fox et al. 2006). Interestingly, the FoxP3 transcription factor, 
recently found to be expressed in tumor cells, can regulate a large number of genes. Besides, 
FoxP3 binds to the gene region upstream of the transcriptional start site of CCR7 and 
CXCR4 (Zheng and Rudensky 2007), two chemokine receptors recently reported to play an 
important role in cancer invasion and metastasis (Kodama, Hasengaowa et al. 2007; Pitkin, 
Luangdilok et al. 2007). Thus, FoxP3 expressed in breast cancer cells might influence 
metastasis by modulating the expression of these chemokine receptors or other genes, which 
encode cell surface or secrete molecules that regulate the response of tumor cells to the 
microenvironment (Merlo, Casalini et al. 2009). 
Recently, it has been demonstrated that pulmonary metastasis of breast cancer requires 
recruitment and expansion of Treg that promote escape from host protective immune cells. 
Arya Biragyn’s group reported that the primary role of tBregs (tumor-evoked Bregs) in lung 
metastases of breast cancer in the mouse 4T1 model is to induce TGF-β–dependent 
conversion of FoxP3+ Tregs from resting CD4+ T cells. In the absence of tBregs, 4T1 tumors 
cannot metastasize into the lungs efficiently due to poor Treg conversion, which suggest 
that tBregs must be controlled to interrupt the initiation of a key cancer-induced- 
immunosuppressive event that is critical to support cancer metastasis.(Olkhanud, 
Damdinsuren et al. 2011) 
Tregs were selectively recruited within lymphoid infiltrates and activated by mature 
dendritic cells likely through the recognition of tumor-associated antigen presentation, 
which result in the prevention of effector T cell activation, immune escape, and ultimately, 
tumor progression (Gobert, Treilleux et al. 2009). Treg depletion may become a successful 
anticancer strategy, and Treg manipulation in terms of frequency and functional activity 
should be added to the therapeutic regimen to enhance tumor immunity in humans (Wolf, 
Wolf et al. 2003). 
4.3 Myeloid-Drived Suppressor Cells (MDSC) and others 
Myeloid-derived suppressor cells (MDSC) are present in many cancer patients and mice 
with transplanted or spontaneous tumors (Young and Lathers 1999; Almand, Clark et al. 
2001). MDSC, characterized as CD11b+ Gr-1+ in mice, can be recruited and activated by 
multiple factors, such as VEGF, IL-1β and IL-6, many of which are associated with chronic 
inflammation (Gabrilovich and Nagaraj 2009). Recent studies indicated that these cells also 
have a crucial role in tumor progression. MDSCs can directly incorporate into tumor 
endothelium. They secret many pro-angiogenic factors as well. In addition, they play an 
essential role in cancer invasion and metastasis through inducing the production of matrix 
metalloproteinases (MMPs), chemoattractants and creating a pre-metastatic environment. 
Recruitment of MDSCs further produces pro-inflammatory factors, resulting in the 
amplification of the pro-inflammatory response. MDSCs not only suppress the adaptive 
immune responses but also regulate innate immune responses by modulating the cytokine 
production of macrophages (Sinha, Clements et al. 2007), thus directly facilitating 
metastasis. Recent studies have shown a close correlation between the level of MDSCs and 
cancer stage, metastatic tumor burden, and responsiveness to chemotherapy (Diaz-Montero, 
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intermediates. In contrast, M2 cells (tumor associated macrophage; TAM) are important 
components of infiltrated leukocytes in most malignant tumors. They are involved in Type 2 
reactions, tune inflammation and adaptive immunity, promote cell proliferation by 
producing growth factors and enhance angiogenesis, tissue remodeling, and repair. 
Macrophage directly influences the behavior and function of tumor cells and has been 
regarded as an “obligate partner for tumor-cell migration, invasion and metastasis” 
(Condeelis and Pollard 2006). Clinical studies indicate a correlation between TAM density 
and poor prognosis (Pollard 2004). For example, in PyMT-induced mammary tumors, 
macrophages are present in the areas of basement membrane breakdown during the 
development of “early-stage” metastatic lesions and systemic depletion of macrophages 
results in reduced formation of lung metastasis (Lin, Nguyen et al. 2001). TAMs produce a 
wide variety of growth factors (such as FGF, HGF, EGF, PDGF and TGF-β and cytokines 
[such as TNFα, interleukin-6, interleukin-1, and interferons]) to stimulate the growth, 
motility, and invasiveness of tumor cells. TAMs also produce many proteases, ranging from 
uPA to a variety of matrix metalloproteinases, to degrade the basement membrane in order 
to create a channel for tumor cell invasion. In our recent study, we found that the 
EMT/invasiveness of tumor cells was dramatically enhanced when they were co-cultured 
with macrophages or macrophage-conditioned medium (Wu, Deng et al. 2009). We showed 
that this effect, mainly mediated by the secretion of TNFα from macrophages as 
neutralization of TNFα by TNFα antibody, greatly suppressed macrophage-mediated tumor 
cell invasion and metastasis(Wu, Deng et al. 2009). Consistent with our finding, Hagemann 
et al found that co-culturing macrophages with tumor cells enhanced their invasive ability 
in a manner dependent on TNFα and matrix metalloproteinases (MMP)(Hagemann, Wilson 
et al. 2005). Interestingly, expression of Snail in the non-metastatic breast cancer cell lines 
MCF7 and T47D, which contain little endogenous Snail, greatly increased the invasiveness 
of these cells by inflammation, indicating that Snail, through the induction of EMT, is critical 
for mediating inflammation-induced invasion/metastasis of breast cancer cells. Knockdown 
Snail expression significantly inhibited cell migration and invasion induced by 
inflammatory cytokines; it also suppressed inflammation-mediated breast cancer metastasis 
in animal model. Thus, macrophages, the major inflammatory component of the stroma in 
malignancies, facilitate angiogenesis, extracellular matrix breakdown, invasion, and 
metastasis through multiple mechanisms. 
4.2 T-reg cells  
Regulatory T cells (Treg), which include many populations that differ in phenotype, 
cytokine secretion profile and suppressive mechanism (Maloy and Powrie 2001; Shevach 
2002; Wood and Sakaguchi 2003), were reported to interact with tumor cells, promoting 
rather than inhibiting cancer development and progression. High Treg levels have been 
found in peripheral blood, lymph nodes, and tumor specimens from patients with different 
types of cancer (Wang 2008). Treg have been characterized by the constitutive expression of 
Forkhead box P3 (FoxP3), glucocorticoid-induecd THFR family-related receptor (GITR), 
cytotoxic T lymphocyte associated antigen 4 (CTLA-4), and high levels of the alpha chain of 
the IL-2 receptor (CD25). It was found that Treg numbers were significantly higher in 
patients with metastatic cancer compared to healthy donors (Audia, Nicolas et al. 2007; 
Watanabe, Oda et al. 2010). 
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The level of FoxP3, an indicator of Treg activity, might also be an indicator of breast 
tumorigenesis (Gupta, Joshi et al. 2007). It has been demonstrated that high numbers of 
FoxP3-positive Tregs were present in high-grade tumors, increasing the risk of 
relapse/metastasis (Bates, Fox et al. 2006). Interestingly, the FoxP3 transcription factor, 
recently found to be expressed in tumor cells, can regulate a large number of genes. Besides, 
FoxP3 binds to the gene region upstream of the transcriptional start site of CCR7 and 
CXCR4 (Zheng and Rudensky 2007), two chemokine receptors recently reported to play an 
important role in cancer invasion and metastasis (Kodama, Hasengaowa et al. 2007; Pitkin, 
Luangdilok et al. 2007). Thus, FoxP3 expressed in breast cancer cells might influence 
metastasis by modulating the expression of these chemokine receptors or other genes, which 
encode cell surface or secrete molecules that regulate the response of tumor cells to the 
microenvironment (Merlo, Casalini et al. 2009). 
Recently, it has been demonstrated that pulmonary metastasis of breast cancer requires 
recruitment and expansion of Treg that promote escape from host protective immune cells. 
Arya Biragyn’s group reported that the primary role of tBregs (tumor-evoked Bregs) in lung 
metastases of breast cancer in the mouse 4T1 model is to induce TGF-β–dependent 
conversion of FoxP3+ Tregs from resting CD4+ T cells. In the absence of tBregs, 4T1 tumors 
cannot metastasize into the lungs efficiently due to poor Treg conversion, which suggest 
that tBregs must be controlled to interrupt the initiation of a key cancer-induced- 
immunosuppressive event that is critical to support cancer metastasis.(Olkhanud, 
Damdinsuren et al. 2011) 
Tregs were selectively recruited within lymphoid infiltrates and activated by mature 
dendritic cells likely through the recognition of tumor-associated antigen presentation, 
which result in the prevention of effector T cell activation, immune escape, and ultimately, 
tumor progression (Gobert, Treilleux et al. 2009). Treg depletion may become a successful 
anticancer strategy, and Treg manipulation in terms of frequency and functional activity 
should be added to the therapeutic regimen to enhance tumor immunity in humans (Wolf, 
Wolf et al. 2003). 
4.3 Myeloid-Drived Suppressor Cells (MDSC) and others 
Myeloid-derived suppressor cells (MDSC) are present in many cancer patients and mice 
with transplanted or spontaneous tumors (Young and Lathers 1999; Almand, Clark et al. 
2001). MDSC, characterized as CD11b+ Gr-1+ in mice, can be recruited and activated by 
multiple factors, such as VEGF, IL-1β and IL-6, many of which are associated with chronic 
inflammation (Gabrilovich and Nagaraj 2009). Recent studies indicated that these cells also 
have a crucial role in tumor progression. MDSCs can directly incorporate into tumor 
endothelium. They secret many pro-angiogenic factors as well. In addition, they play an 
essential role in cancer invasion and metastasis through inducing the production of matrix 
metalloproteinases (MMPs), chemoattractants and creating a pre-metastatic environment. 
Recruitment of MDSCs further produces pro-inflammatory factors, resulting in the 
amplification of the pro-inflammatory response. MDSCs not only suppress the adaptive 
immune responses but also regulate innate immune responses by modulating the cytokine 
production of macrophages (Sinha, Clements et al. 2007), thus directly facilitating 
metastasis. Recent studies have shown a close correlation between the level of MDSCs and 
cancer stage, metastatic tumor burden, and responsiveness to chemotherapy (Diaz-Montero, 
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Salem et al. 2009). MDSCs from mammary carcinoma can promote tumor invasion and 
metastasis (Bunt, Yang et al. 2007). In Tgfbr2-decificent mice, MDSCs are concentrated at the 
invasive tumor front and facilitate tumor cell invasion and metastasis through chemokine 
receptors CXCR2 and CXCR4 (Yang, Huang et al. 2008). It has been recently found that 
MDSCs accumulated in pregnant mice and exerted an inhibitory effect on NK cell activity, 
and decreased NK cell activity is responsible for the observed increase in metastasis during 
murine gestation, providing a candidate mechanism for the enhanced metastatic tumor 
growth observed in gestant mice.(Mauti, Le Bitoux et al. 2011) 
In addition to macrophages and MDSC, fibroblasts/myofibroblasts comprise another major 
component of tumor stroma. These cancer-associated fibroblasts (CAF) share a lot of 
characteristics with activated fibroblasts in wound healing and promote tumor progression. 
Recent studies have demonstrated that CAF are important in tumor cell migration and 
metastasis. CAF isolated from metastatic breast cancer produce elevated levels of IL-6 and 
enhance cancer cell invasiveness (Studebaker, Storci et al. 2008). Similarly, De Wever et al 
found that the invasive growth of breast and colon cancer cells could be stimulated using 
myofibroblasts isolated from surgical colon cancer specimens (De Wever, Westbroek et al. 
2004). In addition, CAF in pancreatic ductal adenocarcinoma are responsible for a poorly 
vascularized architecture that imposes a barrier for drug delivery and spurs metastasis 
(Olive, Jacobetz et al. 2009). Furthermore, fibroblasts promote tumor cell proliferation and 
metastasis through the production of several growth factors, cytokines, chemokines, and 
matrix metalloproteinases (MMPs). MMPs derived from tumor cells and stromal 
components are regarded as major players in assisting the metastasis of tumor cells. For 
example, transgenic expression of MMP3 stimulates expression of Snail through the 
increased cellular reactive oxygen species, inducing down-regulation of E-cadherin and 
increased tumor progression (Radisky, Levy et al. 2005). Besides, Reisfeld’s group 
demonstrated recently that CAF are key modulators of immune polarization in the tumor 
microenvironment of a 4T1 murine model of metastatic breast cancer. Elimination of CAF in 
vivo by a DNA vaccine targeted to fibroblast activation protein results in a shift of the 
immune microenvironment from a Th2 to Th1 polarization. This shift is characterized by 
increased protein expression of IL-2 and IL-7, suppressed recruitment of tumor-associated 
macrophages, myeloid derived suppressor cells, T regulatory cells, and decreased tumor 
angiogenesis and lymphangiogenesis. (Liao, Luo et al. 2009) 
Neutrophils are also noted as important cells in the tumor inflammatory microenvironment. 
CXCR2 can induce the expression of matrix metalloproteinase 9 (MMP9) and vascular 
endothelial growth factor (VEGF) to recruit neutrophils (Albini, Mirisola et al. 2008). This 
subsequently leads to endothelial cell invasion and blood vessel formation.  On the other 
hand, there are reports demonstrated that neutrophils accumulate in the lung prior to the 
arrival of metastatic cells in mouse models of breast cancer. Those tumor entrained 
neutrophils (TENs) inhibit metastatic seeding in the lungs by generating H2O2. TENs are 
present in the peripheral blood of breast cancer patients prior to surgical resection but not in 
healthy individuals. Thus, whereas tumor-secreted factors contribute to tumor progression 
at the primary site, they concomitantly induce a neutrophil-mediated inhibitory process at 
the metastatic site. These neutrophils acquire a cytotoxic phenotype and provide anti-
metastatic protection by eliminating disseminated tumor cells. Although the neutrophils are 
eventually outcompeted by continued influx of metastatic cells, infusion of exogenous 
neutrophils effectively blocks metastasis and therefore represents a potential therapeutic 
strategy for management of micro-metastatic disease.(Granot, Henke et al. 2011) 
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Taken together, all of these infiltrated inflammatory cells secret different cytokines, 
chemokines, and other factors to influence the tumor cell migration and invasion and 
contribute to inflammation-mediated metastasis. 
4.4 Cytokines 
TNF-α, a key inflammatory cytokine, plays a central role in tumor progression. Constitutive 
expression of TNF-α from the tumor microenvironment is a characteristic of many 
malignant tumors and its presence is often associated with poor prognosis. Several lines of 
evidence point to the tumor-promoting effects of TNF-α in inflammation-driven 
tumorigenesis. First, overexpression of TNF-α confers migratory and invasive properties of 
many tumor cell lines (Rosen, Goldberg et al. 1991). Second, TNF-α and TNF-α receptor 1 
(TNFR1) knock-out mice are resistant to chemical-induced-carcinogenesis in skin and liver 
metastasis in an experimental colon cancer model (Knight, Yeoh et al. 2000; Arnott, Scott et 
al. 2004). Third, various tumor-promoting effects of TNF-α are further confirmed in 
enhancing tumor cell motility, activating oncogenic pathways, and triggering EMT. TNF-α 
can also promote breast cancer cell migration through up-regulating LOX (Liang, Zhang et 
al. 2007). Endogenous TNFα contributes to the growth and invasiveness of primary 
pancreatic ductal adenocarcinoma, and anti-TNFα inhibit metastasis of these tumors 
(Egberts, Cloosters et al. 2008). Using RNA interference technology, Kulbe et al 
demonstrated that tumor growth and dissemination were significantly inhibited when 
TNFα production was blocked (Kulbe, Thompson et al. 2007). In addition, TNF-α can up-
regulate SELECTIN and VCAM1 on endothelial cells that promote tumor cell adhesion and 
migration (Mannel, Orosz et al. 1994; Stoelcker, Hafner et al. 1995). Furthermore, TNF-α 
enhances the invasive property of cancer cells by inducing EMT through Snail or 
ZEB1/ZEB2 (Chua, Bhat-Nakshatri et al. 2007; Chuang, Sun et al. 2008). In our recent study, 
we found that inflammatory cytokine TNF-α is the major signal to induce Snail stabilization 
and EMT induction (Wu, Deng et al. 2009). We showed that TNF-α greatly enhanced the 
migration and invasion of tumor cells by inducing EMT program through NF-κB-mediated 
Snail stabilization. Knockdown of Snail expression not only inhibits TNF-α-induced cancer 
cell migration and invasion in vitro but also suppresses LPS-mediated metastasis in vivo. 
Furthermore, knockdown of Snail expression not only blocks metastasis that is intrinsic to 
the metastatic breast cancer cells but also greatly suppresses inflammation-accelerated 
metastasis. Collectively, our study indicates that Snail stabilization and EMT induction 
mediated by the inflammatory cytokine TNF-α are critical for metastasis. Our study 
provides a plausible molecular mechanism for tumor cell dissemination and invasion at the 
tumor invasive front.  
In fact, under hypoxic and inflammatory conditions, the tumor microenvironment generates 
and sustains a tumor-promoting cytokine network for facilitating tumor growth and 
metastasis. For example, the production of TGF-β from myeloid cells, mesenchymal cells, 
and cancer cells is significantly enhanced in a hypoxic or inflammatory state. TGF-β is a 
multifunctional growth factor with a complicated dual role in tumorigenesis(Leivonen and 
Kahari 2007). At the early stages of tumor formation, TGF-β acts as a tumor suppressor by 
inhibiting proliferation and inducing apoptosis of tumor cells. At the later stages of 
tumorigenesis, TGF-β functions as a tumor promoter by increasing tumor growth, survival, 
motility, and invasion. TGF-β has also been shown to induce EMT in normal mammary 
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Salem et al. 2009). MDSCs from mammary carcinoma can promote tumor invasion and 
metastasis (Bunt, Yang et al. 2007). In Tgfbr2-decificent mice, MDSCs are concentrated at the 
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murine gestation, providing a candidate mechanism for the enhanced metastatic tumor 
growth observed in gestant mice.(Mauti, Le Bitoux et al. 2011) 
In addition to macrophages and MDSC, fibroblasts/myofibroblasts comprise another major 
component of tumor stroma. These cancer-associated fibroblasts (CAF) share a lot of 
characteristics with activated fibroblasts in wound healing and promote tumor progression. 
Recent studies have demonstrated that CAF are important in tumor cell migration and 
metastasis. CAF isolated from metastatic breast cancer produce elevated levels of IL-6 and 
enhance cancer cell invasiveness (Studebaker, Storci et al. 2008). Similarly, De Wever et al 
found that the invasive growth of breast and colon cancer cells could be stimulated using 
myofibroblasts isolated from surgical colon cancer specimens (De Wever, Westbroek et al. 
2004). In addition, CAF in pancreatic ductal adenocarcinoma are responsible for a poorly 
vascularized architecture that imposes a barrier for drug delivery and spurs metastasis 
(Olive, Jacobetz et al. 2009). Furthermore, fibroblasts promote tumor cell proliferation and 
metastasis through the production of several growth factors, cytokines, chemokines, and 
matrix metalloproteinases (MMPs). MMPs derived from tumor cells and stromal 
components are regarded as major players in assisting the metastasis of tumor cells. For 
example, transgenic expression of MMP3 stimulates expression of Snail through the 
increased cellular reactive oxygen species, inducing down-regulation of E-cadherin and 
increased tumor progression (Radisky, Levy et al. 2005). Besides, Reisfeld’s group 
demonstrated recently that CAF are key modulators of immune polarization in the tumor 
microenvironment of a 4T1 murine model of metastatic breast cancer. Elimination of CAF in 
vivo by a DNA vaccine targeted to fibroblast activation protein results in a shift of the 
immune microenvironment from a Th2 to Th1 polarization. This shift is characterized by 
increased protein expression of IL-2 and IL-7, suppressed recruitment of tumor-associated 
macrophages, myeloid derived suppressor cells, T regulatory cells, and decreased tumor 
angiogenesis and lymphangiogenesis. (Liao, Luo et al. 2009) 
Neutrophils are also noted as important cells in the tumor inflammatory microenvironment. 
CXCR2 can induce the expression of matrix metalloproteinase 9 (MMP9) and vascular 
endothelial growth factor (VEGF) to recruit neutrophils (Albini, Mirisola et al. 2008). This 
subsequently leads to endothelial cell invasion and blood vessel formation.  On the other 
hand, there are reports demonstrated that neutrophils accumulate in the lung prior to the 
arrival of metastatic cells in mouse models of breast cancer. Those tumor entrained 
neutrophils (TENs) inhibit metastatic seeding in the lungs by generating H2O2. TENs are 
present in the peripheral blood of breast cancer patients prior to surgical resection but not in 
healthy individuals. Thus, whereas tumor-secreted factors contribute to tumor progression 
at the primary site, they concomitantly induce a neutrophil-mediated inhibitory process at 
the metastatic site. These neutrophils acquire a cytotoxic phenotype and provide anti-
metastatic protection by eliminating disseminated tumor cells. Although the neutrophils are 
eventually outcompeted by continued influx of metastatic cells, infusion of exogenous 
neutrophils effectively blocks metastasis and therefore represents a potential therapeutic 
strategy for management of micro-metastatic disease.(Granot, Henke et al. 2011) 
 
Tumor Inflammatory Microenvironment in EMT and Metastasis 123 
Taken together, all of these infiltrated inflammatory cells secret different cytokines, 
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Snail stabilization. Knockdown of Snail expression not only inhibits TNF-α-induced cancer 
cell migration and invasion in vitro but also suppresses LPS-mediated metastasis in vivo. 
Furthermore, knockdown of Snail expression not only blocks metastasis that is intrinsic to 
the metastatic breast cancer cells but also greatly suppresses inflammation-accelerated 
metastasis. Collectively, our study indicates that Snail stabilization and EMT induction 
mediated by the inflammatory cytokine TNF-α are critical for metastasis. Our study 
provides a plausible molecular mechanism for tumor cell dissemination and invasion at the 
tumor invasive front.  
In fact, under hypoxic and inflammatory conditions, the tumor microenvironment generates 
and sustains a tumor-promoting cytokine network for facilitating tumor growth and 
metastasis. For example, the production of TGF-β from myeloid cells, mesenchymal cells, 
and cancer cells is significantly enhanced in a hypoxic or inflammatory state. TGF-β is a 
multifunctional growth factor with a complicated dual role in tumorigenesis(Leivonen and 
Kahari 2007). At the early stages of tumor formation, TGF-β acts as a tumor suppressor by 
inhibiting proliferation and inducing apoptosis of tumor cells. At the later stages of 
tumorigenesis, TGF-β functions as a tumor promoter by increasing tumor growth, survival, 
motility, and invasion. TGF-β has also been shown to induce EMT in normal mammary 
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epithelial cells and breast cancer cell lines (Miettinen, Ebner et al. 1994) (Forrester, Chytil et 
al. 2005). As we mentioned in part-2.5 (Molecular regulation of EMT), TGF-β plays an 
important role in the process of EMT. 
IL-6 is another important inflammatory cytokine linking inflammation and cancer. IL-6 
transmits its signal through a common signaling receptor, gp130, expressed in many cell 
types. IL-6 binds to the sIL-6R receptor (gp80, present either on the cell surface or in 
solution), which then induces dimerization of gp130 chains, resulting in activation of the 
associated Janus kinases (JAKs). JAKs phosphorylate gp130, leading to the recruitment and 
activation of the STAT3 and STAT1 transcription factors, as well as other molecules (SHP2, 
Ras-MAPK, and PI3K) (Mumm and Oft 2008). The role of IL-6 in accelerating tumorigenesis 
is becoming clear as exogenous administration of IL-6 to mice during tumor initiation 
results in an increase in tumor burden and multiplicity (Grivennikov, Karin et al. 2009). IL-6 
also enhances tumor proliferation in tumor-initiating intestinal epithelial cells (IECs) 
through NF-κB-IL-6-STAT3 cascade (Bollrath, Phesse et al. 2009; Bromberg and Wang 2009; 
Grivennikov, Karin et al. 2009). IL-6 can also act as an inducer of EMT in breast cancer cells. 
Ectopic expression of IL-6 in breast adenocarcinoma cells exhibits an EMT phenotype 
characterized by suppressing E-cadherin expression and inducting vimentin, N-cadherin, 
Snail and Twist (Sullivan, Sasser et al. 2009). In addition, IL-6 also synergizes with EGF in 
inducing EMT through the activation JNK2/STAT3 in ovarian carcinomas (Colomiere, 
Ward et al. 2009). 
The interleukin-1 (IL-1) also promotes inflammatory processes and augments metastasis. 
There are two forms of IL-1 protein, IL-1α and IL-1β, and one antagonistic protein IL-1 
receptor antagonist (IL-1ra). IL-1β is active solely in its secreted form, whereas IL-1α is 
active mainly as an intracellular precursor. IL-1 is abundant at tumor sites, where it affects 
the process of carcinogenesis, tumor growth and invasiveness, and the patterns of tumor-
host interactions (Apte, Krelin et al. 2006). Genetic ablation of IL-1β in mice results in the 
absence of metastatic tumors in vivo (Voronov, Shouval et al. 2003). Liver metastasis can be 
almost completely inhibited in mice with deletion of the interleukin-1β converting enzyme, 
which is required for the processing of IL-1β (Vidal-Vanaclocha, Fantuzzi et al. 2000). IL-1β 
also directly induces uPA expression and NF-κB activation, which results in the migration of 
A549 cells (Cheng, Hsieh et al. 2009). 
Together with chemotaxis, chemokines, a family of inducible chemo-attractant cytokines 
that regulate the chemotaxis of tumor cells and other cell types, are thought to be involved 
in every crucial step of tumor cell dissemination (Roussos, Condeelis et al. 2011). 
Chemotaxis of carcinoma cells and tumor-associated inflammatory and stromal cells is 
mediated by chemokines, chemokine receptors, growth factors and growth factor receptors. 
Chemotaxis helps to shape the tumor microenvironment. Directional migration to a 
chemokine source is evident both in vitro and in vivo for most cells of the tumor 
microenvironment. The most common chemokine receptor detected in cancer cells is 
CXCR4; another common one is CCR7 (Muller, Homey et al. 2001; Lazennec and Richmond 
2010). In standard chemotaxis assays in vitro, CXCR4-positive cancer cells can migrate in a 
directional manner toward CXCL12, whereas CCR7-expressing cancer cells can migrate 
towards CCL21 (Kodama, Hasengaowa et al. 2007; Pitkin, Luangdilok et al. 2007). Recently, 
it has been reported that the recruitment of inflammatory monocytes, which express CCR2, 
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is dependent on CCL2 synthesized by both the tumor and the stroma, facilitating breast-
tumor metastasis; the same is true for the subsequent recruitment of metastasis-associated 
macrophages and their interaction with metastasizing tumor cells (Qian, Li et al. 2011). 
5. Summary 
Every year about 500,000 people in the United States die as a result of cancer, among which 
90% exhibit systemic disease with metastasis. That’s why it is so important to understand 
the mechanism behind EMT and metastasis. Based on thousands of studies in this field in 
recent years, significant progress has been made regarding our understanding of EMT and 
metastasis, which point out that EMT is the most critical mechanism implicated in tumor 
metastasis and recurrence. It is now quite clearly that solid tumors are not simply clones of 
cancer cells. A variety of stromal cells in the surrounding environment are recruited to 
tumors, which including mesenchymal supporting cells (e.g. fibroblasts), cells of the 
vascular system, and cells from immune system, such as TAMs, Treg, MDSC, Neutrophils 
and so on. The dynamic interaction which exists between cancer cells and the inflammatory 
microenvironment not only enhances growth of the primary cancer but also facilitates its 
metastatic dissemination to distant organs. There are many evidences show that the 
induction of EMT is dependent on the signals that cells received from their 
microenvironment, and the crosstalk between inflammation and metastasis has an un-
replaceable role in each step for the successful establishment of a metastatic tumor (Fig. 2). 
 
Fig. 2. Tumor Inflammatory Microenvironment in EMT and Metastasis. 
Understanding how inflammatory microenvironment is maintained and how it contributes 
to the tumor progression and metastasis will be crucial for understanding tumor biology as 
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Understanding how inflammatory microenvironment is maintained and how it contributes 
to the tumor progression and metastasis will be crucial for understanding tumor biology as 
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well as the development of new effective cancer prevention and therapy. Hopefully, with 
recent research illuminating the involvement of infiltrated inflammatory cells and many 
kinds of cytokines in tumor progression and EMT/Metastasis, a more comprehensive view 
of how cancer cells spreads to different organs in a specific manner will emerge in the near 
future. However, we have to realize that several challenges still need to be addressed about 
how to translate these basic findings into clinical practice and find novel treatment strategies 
targeting the inflammatory microenvironment which could efficiently kill both primary and 
metastatic tumor cells. 
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1. Introduction 
The lung tumor microenvironment consists of tumor cells, stroma, blood vessels, immune 
infiltrates and the extracellular matrix. Genetic alterations in oncogenes and tumor 
suppressor genes or epigenetic changes in the tumor that modulate tumor growth and 
invasion into the surrounding tissue orchestrate the persistence of inflammatory infiltrates. 
These cellular infiltrates modulate tumor development and progression. The infiltrates vary 
by size and composition in diverse tumor types and at different stages of tumor 
development. The lung tumor programs the cellular infiltrates and dysregulates 
inflammation to sustain tumor growth, progression and hypo responsiveness of the tumor. 
Characterization of the complex interactions among the infiltrates and lung cancer will aid 
in defining their role in tumor progression. This understanding will be important for the 
development of novel anticancer therapies. Although this is not a trivial undertaking, the 
information garnered will take us a step closer to personalized medicine. If we know an 
individual’s lung tumor inflammatory infiltrates, we will be able to predict the risk of tumor 
progression and then give specific treatment to reprogram the tumor microenvironment to 
control the disease.  
Contributing to the inflammatory infiltrates are members of the innate system including 
natural killer cells (NK) and the cells of the myelomonocytic lineage consisting of immature 
macrophages, granulocytes, dendritic cells (DC) as well as myeloid cells at earlier stages of 
differentiation (Sica and Bronte 2007; Talmadge 2007; Gabrilovich and Nagaraj 2009; 
Peranzoni et al. 2010). The down regulation of MHC expression by tumors enables them to 
evade T cell immune responses. The presence of NK cells in the infiltrates can contribute to 
antitumor activity because NK effectors recognize tumor targets independent of MHC 
expression (Moretta et al. 2001). However, there is usually a paucity of NK cells in the tumor 
microenvironment suggesting evasion mechanisms preventing their recruitment. 
Macrophages in the tumor microenvironment play an important modulatory role in the 
generation of anti tumor responses. The production of chemotactic factors such as CCL2, 
VEGF and M-CSF (Condeelis and Pollard 2006; Sica et al. 2008) in the tumor 
microenvironment recruits macrophages. The type of macrophages infiltrating the tumor 
correlates with favorable or unfavorable prognoses (Lewis and Pollard 2006). The M1 
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macrophages have potent antigen presentation function and stimulate Type 1 immune 
responses that lead to tumor rejection, tissue destruction, and host defense. M1 macrophage 
density in the tumor islets is positively associated with extended survival of non-small cell 
lung cancer (NSCLC) patients (Ma et al. 2010). The M1 macrophages produce high levels of 
IL-12, CXCL10 and inducible nitric oxide synthase (iNOS) (Mantovani et al. 2007). In 
contrast, M2 macrophages are thought to promote tumor formation by enhancing wound 
healing and tissue remodeling via inhibition of Type1 immune responses by IL-10 and TGFβ 
secretion. The M2 macrophages express high levels of IL-10 and arginase that suppress 
antitumor immune responses (Mantovani et al. 2002; Mantovani et al. 2005; Mantovani et al. 
2007; Sinha et al. 2007). These macrophages increase metastatic potential by increasing 
tumor cell migration, invasion and angiogenesis. The tumor microenvironment also consists 
of T and B lymphocytes of the adaptive immunity. The phenotypes of the T and B subsets 
evoked in chronic inflammatory state of the tumor microenvironment are regulatory in 
nature and dampen immune responses against the tumor. B cells and antibodies have a key 
role in orchestrating macrophage-driven, tumor-promoting inflammation (Andreu et al. 
2011), suggesting that modulating the pathways involved might be of therapeutic benefit in 
cancers driven by chronic inflammation.  
Lung cancers contain a significant population of tumor infiltrating myeloid cells that 
promote tumor growth by suppressing the immune system. In this review we will focus on 
the interaction between lung cancer and myeloid derived suppressor cells (MDSC) that 
suppress antitumor immune responses and contribute to tumor progression. 
2. Immune modulation in the lung tumor microenvironment by myeloid 
derived suppressor cells 
2.1 Myeloid mediated downregulation of immune responses in the tumor 
microenvironment 
MDSC are a heterogeneous population of immature myeloid cells (IMC) that consists of 
myeloid progenitors and precursors of macrophages, granulocytes and DC. In tumors 
immature myeloid cells are partially blocked at the immature state and do not 
differentiate into mature myeloid cells that results in an expansion of this population. The 
activation of these cells in cancer results in the upregulated expression of immune 
suppressive factors such as arginase and iNOS and an increase in the production of nitric 
oxide (NO) and reactive oxygen species (ROS). These expanded IMC populations with 
immune suppressive activity; are collectively known as MDSC. Investigations on diverse 
tumor types have demonstrated that MDSC accrual in the tumor microenvironment is 
dependent on tumor derived soluble factors including growth factors, cytokines and 
chemokines. Granulocyte macrophage colony stimulating factor (GM-CSF) supports the 
survival and expansion of MDSC in the tumor microenvironment (Serafini et al. 2004). 
The sources of GM-CSF are tumors or activated immune effectors such as T, NK and DC. 
IL-1β has been demonstrated to accumulate MDSC in tumors of mice (Lu et al. 2011). 
Tumor derived PGE2 has also been shown to cause an accumulation of MDSC in lung 
cancer (Zhang et al. 2009). MDSC accumulation and immune suppression, provides one of 
the mechanisms through which inflammation can contribute to lung cancer development 
and progression. 
 




Fig. 1. Modulation in the balance of immune effectors and suppressors in the lung tumor 
microenvironment. The lung tumor microenvironment has increased myelomonocytic and T 
regulatory immune suppressors and decreased immune effectors (NK, DC, CD4T, CD8T 
and M1) that promote tumor growth kinetics and progression.  
2.2 Molecular mechanisms of myeloid derived suppressor cell mediated T cell 
inactivation 
MDSC suppress immune responses to newly displayed tumor antigens and promote tumor 
progression and the metastatic potential of the tumor. MDSC suppress T cell activation in 
tumor tissues and draining lymph nodes through several mechanisms. MDSC use two 
enzymes involved in L-arginine metabolism to control T-cell responses: Arginase which 
depletes the milieu of L-arginine and iNOS which generates NO. L-arginine is essential for T-
cell function, including the optimal use of IL-2 and the development of a T-cell memory 
phenotype. MDSC arginase 1 gene (ARG1) is induced by cytokines such as TGFβ and IL-10 
within the tumor microenvironment. The MDSC mediated depletion of arginine suppresses 
CD4 and CD8 T cell activation. IFNγ and TNFα in the tumor microenvironment induce iNOS 
in MDSC releasing NO which blocks the phosphorylation and activation of several targets in 
the IL-2 receptor signaling pathway and induces T-cell apoptosis (Mazzoni et al. 2002).  
Cysteine another essential amino acid for T cell activation is depleted by MDSC. T cells lack 
the enzyme to convert methionine to cysteine and the membrane transporter to import 
cystine for intracellular reduction to cysteine. T cells obtain their cysteine from extracellular 
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Fig. 1. Modulation in the balance of immune effectors and suppressors in the lung tumor 
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sources. During normal antigen processing and presentation activity, DC and macrophages 
synthesize cysteine from methionine and import extracellular cystine for cysteine 
conversion. Cysteine is then exported by antigen presenting cells (APC) during antigen 
presentation, and imported by T cells. Like T cells, MDSC are unable to convert methionine 
to cysteine and are dependent on importing cystine for conversion to cysteine. In the tumor 
microenvironment MDSC are present in high concentration and import most of the 
available cystine that deprive DC and macrophages. Since MDSC do not export cysteine, 
they deprive T cells of cysteine that is necessary for synthesizing proteins required for T cell 
activation (Srivastava et al. 2010). 
MDSC mediated down regulation of T cell L-selectin (CD62L) further impairs T cell activity. 
CD62L is a plasma membrane molecule necessary for homing of naive T cells to lymph 
nodes for activation by tumor antigens. MDSC down-regulate CD62L on naive T cell that 
reduces T cell capacity to migrate to lymph nodes (Hanson et al. 2009).  
MDSC-produced ROS and peroxynitrite in the tumor microenvironment inhibit CD8+ T 
cells by catalyzing the nitration of the T cell receptor and thereby preventing T cell-peptide-
MHC interactions. MDSC also down-regulate the T cell receptor-associated ζ chain, a 
phenomenon common in cancer patients (Nagaraj et al. 2009). In the absence of the zeta 
chain, T cells are unable to transmit the required signals for activation.  
2.3 Cellular mechanisms of myeloid derived suppressor cell mediated immune 
suppression  
MDSC impair T cell activation by directly inducing T regulatory cells (Treg) through the 
production of IL-10 and TGFβ, or arginase that is independent of TGFβ. The Treg cells 
actively down regulate the activation and expansion of antitumor reactive T cells (Boon et al. 
1994; Sakaguchi 2000; Li et al. 2007) and NK cells (Smyth et al. 2006). MDSC affect tumor 
immunity by polarizing T cells towards a tumor-promoting type 2 phenotype by producing 
IL-10 and down-regulating macrophage production of IL-12 (Sinha et al. 2007). The 
suppressive activity of MDSC on T cells can be antigen-specific or non-specific and can vary 
depending on the MDSC subpopulation. MDSC impair NK cells by inhibiting their 
cytotoxicity ability and IFNγ production (Liu et al. 2007; Li et al. 2009).  
2.4 Lung cancer genetic signatures as drivers of immune suppression  
Our laboratory has been evaluating tumor signatures that maintain tumor growth kinetics 
through the modulation of immune activity (Huang et al. 1996; Huang et al. 1998). Many 
tumors, including lung cancer, have the capacity to promote immune tolerance and escape 
host immune surveillance (Chouaib et al. 1997; Smyth and Trapani 2001). Tumors utilize 
numerous pathways to inhibit immune responses including the elaboration of immune 
inhibitory cytokines. In addition to directly secreting immunosuppressive cytokines, lung 
cancer cells may induce host cells to release immune inhibitors (Huang et al. 1996; Huang et 
al. 1998; Alleva et al. 1994; Maeda et al. 1996; Halak et al. 1999). In previous studies, we 
found an immune suppressive network in non-small cell lung cancer (NSCLC) that is due to 
over expression of tumor cyclooxygenase 2 (COX-2) (Huang et al. 1998; Stolina et al. 2000), 
which is constitutively expressed in a variety of malignancies. We and others have reported 
that COX-2 is constitutively elevated in human NSCLC frequently (Hida et al. 1998; Huang 
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et al. 1998; Hida et al. 2000; Hosomi et al. 2000). Although multiple genetic alterations are 
necessary for lung cancer invasion and metastasis, COX-2 may be a central element in 
orchestrating this process (Hida et al. 1998; Huang et al. 1998; Wolff et al. 1998; Achiwa et al. 
1999; Hosomi et al. 2000; Riedl et al. 2004). Over expression of COX-2 is associated with 
apoptosis resistance (Tsujii and Dubois 1995; Lin et al. 2001), angiogenesis promotion (Tsujii 
et al. 1998; Masferrer et al. 2000), enhanced tumor invasion and metastasis (Tsujii et al. 1998; 
Dohadwala et al. 2001; Dohadwala et al. 2002) and decreased host immunity (Huang et al. 
1998; Stolina et al. 2000; Sharma et al. 2003). In murine lung cancer models, we found that 
specific genetic or pharmacological inhibition of COX-2 reduced tumor growth (Stolina et al. 
2000). In other related studies, we documented that COX-2 inhibition prevented tumor-
induced suppression of DC activities (Sharma et al. 2003). In recent studies, we have 
demonstrated that treatment of mice with a COX-2 inhibitor, promoted a Type 1 cytokine 
response, inducing IFNγ, IL-12 and CXCL10 and augmented the vaccination response to 
tumor challenge (Sharma et al. 2005).  
Tumor COX-2 can also modulate MDSC activity through ARG1 in lung carcinoma. MDSC 
producing high levels of arginase block T cell function by depleting arginine. Until recently, 
the mechanism that induces ARG1 in MDSC in cancer was unknown. Rodriguez PC et al, 
utilizing the mouse Lewis lung carcinoma (3LL, that spontaneously arose in the C57BL/6 
mice), showed that ARG1 expression was independent of T cell-produced cytokines but 
rather tumor derived PGE2 maintained ARG1 expression in MDSC. 3LL tumor cells 
constitutively express COX-1 and COX-2 and produce high levels of PGE2. Genetic or 
pharmacological inhibition of COX-2 but not COX-1 blocked ARG1 induction in vitro and in 
vivo. Signaling through the PGE2 receptor E-prostanoid 4 expressed in MDSC induced 
ARG1. Furthermore, blocking ARG1 expression using COX-2 inhibitors elicited a 
lymphocyte-mediated antitumor response. These results demonstrate a new pathway of 
prostaglandin-induced immune dysfunction and provide a novel mechanism that can help 
explain the antitumor benefits of COX-2 inhibitors (Rodriguez et al. 2005) that targets the 
major immune suppressive pathways mediated by MDSC.  
The complex nature of interactions between MDSC and Treg cells are yet to be fully defined 
however it is evident that MDSC promote T reg development in vivo. Tumor-reactive T cells 
have been shown to accumulate in lung cancer tissues but fail to respond because of 
suppressive tumor cell-derived factors (Yoshino et al. 1992; Batra et al. 2003) and because 
high proportions of NSCLC tumor infiltrating lymphocytes are CD4+CD25+ T reg cells 
(Woo et al. 2001). CD4+CD25+ T regulatory (Sakaguchi et al. 2001) cells play an important 
role in maintenance of immunological self-tolerance. T regulatory cell activities increase in 
lung cancer, and appear to play a role in suppressing antitumor immune responses. Treg 
cells actively down regulate the activation and expansion of self-reactive lymphocytes 
(Sakaguchi 2000). Given that many tumor–associated antigens recognized by autologous T 
cells are antigenically normal self-constituents, Treg cells engaged in the maintenance of self 
tolerance may impede the generation and activity of antitumor reactive T cells (Boon et al. 
1994; Sakaguchi 2000). Thus, reducing the number of Treg cells or abrogating their activity 
within the tumor environment may induce effective tumor immunity in otherwise non-
responding hosts by activating tumor-specific as well as nonspecific effector cells (Shimizu 
et al. 1989; Onizuka et al. 1999; Sutmuller et al. 2001). In recent studies we have 
demonstrated that tumor COX-2 expression contributes to decreased host antitumor 
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immune responses by impacting the frequency and activity of CD4+CD25+FOXP3+ T reg 
cells (Baratelli et al. 2005; Sharma et al. 2005). Definition of the pathways controlling Treg 
cell activities will enhance our understanding of limitation of the host antitumor immune 
responses. We demonstrated that lung tumor-derived COX-2/PGE2 induced expression of 
the Treg cell-specific transcription factor, Foxp3, and increased Treg cell activity. 
Assessment of E-prostanoid (EP) receptor requirements revealed that PGE2-mediated 
induction of Treg cell Foxp3 gene expression was significantly reduced in the absence of the 
EP4 receptor and ablated in the absence of the EP2 receptor expression. In vivo, COX-2 
inhibition reduced Treg cell frequency and activity, attenuated Foxp3 expression in tumor-
infiltrating lymphocytes, and decreased tumor burden. Transfer of Treg cells or 
administration of PGE2 to mice receiving COX-2 inhibitors reversed these effects. Our 
studies were the first documentation that COX-2 inhibition down regulated tumor induced 
T regulatory cell activity leading to the restoration of antitumor responses.  
2.5 Lung cancer snail knockdown reduces MDSC and increases CD107a activated 
effector T cells in the tumor microenvironment  
We are defining genetic programs in lung cancer that modulate tumor growth and 
metastases. Cancer cells acquire the ability to progress, invade and metastasize by 
undergoing the process of epithelial-mesenchymal transition (EMT), by activating 
transcription factors (for example, Snail, Twist, Zeb, Slug) that repress E-Cadherin, a 
transmembrane glycoprotein essential for epithelial cell-cell adhesion (Bussemakers et al. 
1993; Cano et al. 2000). These transcriptional repressors are normally active during 
embryogenesis where they program EMT to enable various morphogenetic steps. EMT is 
involved in tumor progression (Thiery 2002; Jeanes et al. 2008). Snail expression in primary 
NSCLC has been associated with a shorter overall survival (Yanagawa et al. 2009). Tumor 
Snail expression has recently been demonstrated to be important in EMT induced 
metastases in melanoma (Kudo-Saito et al. 2009). We are evaluating the mechanistic role of 
tumor snail expression that modulates tumor growth and metastases in immune competent 
mice. Our data (AACR Abstract: Frontiers in Basic Cancer Research, September 14-18 2011., 
San Francisco) demonstrates that tumor snail expression alters tumor growth and metastasis 
by impacting MDSC in the tumor microenvironment. 3LL, 3LL Snail knockdown and 3LL 
control vector cells were implanted in C57BL/6 mice. Compared to controls, 3LL Snail 
knockdown mice had (i) decreased MDSC, (ii) reduced MDSC as well as the non MDSC 
populations intracellular expression of ARG1 in the tumors, (iii) increased expression of the 
CD107a cytolytic marker in tumor infiltrating CD8 T cells and (iv) increased tumor 
infiltrates of CD4 and CD8 T lymphocytes that elaborated enhanced IFNbut reduced levels 
of IL-10 and (v) augmented the frequencies of innate NK effectors and DC. Accompanying 
the inflammatory signature, Snail knockdown cells demonstrated reduced subcutaneous 
tumor growth and lung metastases. Current experiments are mechanistically delineating the 
genetic program(s) induced by tumor Snail knockdown that alter the balance and activity of 
immune effectors and suppressors in the tumor and the impact of adoptive transfer of 
MDSC on tumor growth kinetics of Snail knockdown cells. An adequate understanding of 
the genetic signatures in the tumor and tumor-host interactions that induce immune evasion 
and promote tumor growth, invasion and metastases will be crucial for the development of 
effective therapies for lung cancer.  
 




Fig. 2. MDSC accumulation in Lung cancer suppresses antitumor activity  MDSC are 
recruited to and expanded in the tumor through the induction/production of COX-2, PGE2, 
and Snail in lung cancer. T cell activation is suppressed by MDSC mediated: (i) deprivation 
of L-arginine and cysteine from the environment, (ii) production of ROS and peroxynitrite, 
(iii) down regulation of CD62L and the T cell receptor-associated  chain and (iv) the 
induction of Tregs through MDSC IL-10 and TGF production. MDSC suppresses NK cell 
cytotoxicity, NK IFNproduction and induces tumor associated macrophages with a type 2 
phenotype. MDSC expansion and IL-10 production inhibits DC antigen presentation.  
2.6 Impact of depleting Gr1 or Ly6G myelomonocytic cells on lung cancer growth 
kinetics 
Increases in MDSC evoke strong natural suppressive activity in cancer patients (Young et al. 
1997; Kusmartsev et al. 1998) or tumor-bearing mice (Kusmartsev and Ogreba 1989; Subiza 
et al. 1989; Young et al. 1997). It has been demonstrated that Gr1+CD11b+ immune 
suppressive cells are capable of inhibiting the T cell proliferative response induced by 
alloantigens (Schmidt-Wolf et al. 1992), CD3 ligation (Young et al. 1996), or various 
mitogens (Sugiura et al. 1988; Angulo et al. 1995), and can also inhibit IL-2 utilization 
(Brooks and Hoskin 1994) as well as NK cell activity (Kusmartsev et al. 1998). These studies 
indicate that progressive tumor growth is associated with the down-regulation of T cell 
responses and that the Gr1+CD11b+ myeloid cells are involved in negative 
immunoregulatory mechanisms in the tumor bearing host. In murine tumor models there is 
an increase in the MDSC populations in the tumors, spleens, bone marrow and blood as the 
tumor progresses. In the 3LL lung cancer model as the tumors progress the frequency and 
activity of immune suppressive cells are enhanced in the tumor microenvironment. We have 
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found that tumors have as much as 45% infiltrates that are predominantly of the Gr1+ 
CD11b+ immature myeloid phenotype. As has been recently reported for glioblastoma 
(Fujita et al. 2011) and colon (Mundy-Bosse et al. 2011) murine cancer models, we evaluated 
the contribution of the Gr1 and Ly6G expressing myelomonocytic cells on 3LL tumor 
growth kinetics in C57BL/6 mice, by depleting cells expressing these markers with anti-Gr1 
(RB6-8C5) or anti-Ly6G (1A8) administered every other day via i.p route starting on day 5 
post tumor inoculation. Compared to isotype matched control antibody, the anti-Gr1 
antibody or anti-Ly6G led to a significant decrease in the Gr1hiCD11b expressing myeloid 
subset and a subsequent increase in the CD107a expressing CD3T lymphocytes and NK cells 
in the tumors respectively. Accompanying the decrease in the Gr1hiCD11b expressing 
myeloid subset was a 8 fold decrease in tumor weight. While the anti-Gr1 antibody reduced 
both Gr1hi and Gr1lo, the anti-Ly6G antibody reduced the Gr1hi subset only. Both these 
antibodies depleted the Ly6G expressing cells. Although these depletion antibodies impact 
other Gr1 or Ly6G expressing monocytes, our data suggests that the broad targeting of 
MDSC along with other myeloid cell types is beneficial in eliciting anticancer effects. This 
data is consistent with studies by several groups (Fujita et al. 2011; Mundy-Bosse et al. 2011). 
It would be interesting to evaluate the impact of MDSC depletion on DC and tumor 
associated macrophages (TAM) functional activity. This may resolve further compensatory 
pathways of immune suppression. Currently we are evaluating strategies that target the 
myeloid suppressor subsets in combination with various immune potentiating strategies to 
increase the antitumor benefit. 
2.7 Critical role of antigen presentation in lung cancer: T-cell tolerance versus T-cell 
priming 
Effective antitumor responses require antigen processing cells (APCs), lymphocyte and NK 
effectors, as well as the elaboration of effector molecules that promote antitumor activity. 
Although lung cancer cells express tumor antigens, the limited expression of MHC antigens, 
defective transporter associated with antigen processing (TAP) and lack of costimulatory 
molecules, make them ineffective APCs (Restifo et al. 1993). Many tumors, including lung 
cancer, have the capacity to promote immune tolerance and escape host immune surveillance 
(Chouaib et al. 1997; Smyth and Trapani 2001). Tumors utilize numerous pathways to inhibit 
immune responses, including reduction in APC activity. The accumulation of MDSC in the 
tumor microenvironment negatively impacts DC and their APC activity. 
The central importance of functional APCs in the immune response against cancer has been 
well defined (Huang et al. 1994). The study revealed that even highly immunogenic tumors 
require host APCs for antigen presentation. Thus, host APCs, rather than tumor cells, 
present tumor antigen. This is consistent with a study indicating that CD8+ T-cell responses 
can be induced in vivo by professional APCs that present exogenous antigens in a MHC I-
restricted manner (Albert et al. 1998). This has been referred to as cross-priming or 
representation and may be critical for effective antitumor responses (Bevan 1995). DCs have 
been demonstrated to be the host APC responsible for cross-priming by presenting epitopes 
obtained from apoptotic cells (Castellino and Germain 2006). 
However, in tumor-bearing hosts, there is a state of T-cell unresponsiveness (Staveley-
O'Carroll et al. 1998; Cuenca et al. 2003; Willimsky and Blankenstein 2005). The dominant 
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mechanism underlying the development of antigen-specific T-cell unresponsiveness is 
thought to be through tumor-antigen processing and presentation by APCs (Sotomayor et 
al. 2001). The intrinsic APC capacity of tumor cells has little influence over T-cell priming 
versus tolerance, an important decision that is regulated by bone marrow-derived APCs. 
DCs, macrophages and B cells are all bone marrow-derived cells that express both MHC and 
the costimulatory molecules CD80 and CD86 and present tumor antigens to antigen-specific 
T cells. 
Several studies have shown that DCs play a critical role leading to T-cell tolerance versus T-
cell priming (Fuchs and Matzinger 1996; Belz et al. 2002; Munn et al. 2002; Steinman et al. 
2003), which is dictated by the environmental context in which the DCs encounter the 
antigen. Antigen capture by DCs in an inflammatory context triggers their maturation to a 
phenotype capable of generating strong immune responses, whereas antigen capture in a 
noninflammatory environment leads instead to the development of T-cell tolerance. The 
tumor microenvironment not only fails to provide the inflammatory signals needed for 
efficient DC activation, but also inhibits DC differentiation and maturation through IL-10 
(Gerlini et al. 2004) and VEGF (Gabrilovich et al. 1996). DCs, which are pivotal for T-cell 
priming, remain immature and become dysfunctional in hosts bearing growing tumors, 
acquiring tolerogenic properties that induce T-cell tolerance to tumor antigens. Immature 
DCs (iDCs) have little or no expression of costimulatory molecules such as CD80, CD86 and 
CD40 on their surface and produce little or no IL-12, which is required to support T-cell 
proliferation. iDCs are unable to induce antitumor immune response but can induce T-cell 
tolerance. If APCs fail to provide an appropriate costimulatory signal for T cells, tolerance or 
anergy can develop. The importance of restoring APCs with immune-stimulating activity in 
the tumor microenvironment is crucial. In a recent study ectopic lymph node or tertiary 
lymphoid structures were retrospectively identified within human non-small-cell lung 
cancer specimens and demonstrated that there is a correlation of cellular content with 
clinical outcome (Dieu-Nosjean et al. 2008). The density of DC-Lamp, indicating mature DCs 
within these structures, is a predictor of long-term survival within their selected lung cancer 
patient population. The authors observed that a low density of tumor-infiltrating CD4+ and 
T-bet+ T lymphocytes present in tumors poorly infiltrated by DC-Lamp+ mature DCs 
appears to provide additional supporting evidence for the prognostic importance of an 
adaptive immune reaction to a solid tumor. 
We have previously demonstrated that elements from the tumor microenvironment can 
suppress DC function. We found that bone marrow derived DCs stimulated with GM-CSF 
and IL-4 in the presence of tumor supernatants (TSNs) failed to generate antitumor 
responses and caused immunosuppressive effects that correlated with enhanced tumor 
growth. Functional analyses indicated that TSNs cause a decrement in DC capacity to 
process and present antigens, induce alloreactivity and secrete IL-12. The TSNs caused a 
reduction in cell surface expression of CD11c, DEC205, MHC I antigen, MHC II antigen, 
CD80 and CD86, as well as a reduction in TAP 1 and 2 proteins (Sharma et al. 2003). 
2.8 IL-7/IL-7R-Fc promotes the M1 macrophage phenotype in lung cancer 
Although tumor growth and invasion leads to inflammatory responses, the immune system 
generally develops tolerance to cancer. One way to induce potent immune responses against 
tumors is to activate key innate and immune effector mechanisms. Toward this end, we are 
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found that tumors have as much as 45% infiltrates that are predominantly of the Gr1+ 
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evaluating the utility of chimeric c homeostatic cytokine, IL-7/IL-7R-Fc, to restore host 
APC and T cell activities dysregulated in cancer patients (Almand et al. 2000; Zou 2005). It is 
evident from previous studies that intratumoral infiltration by relatively high numbers of 
activated T lymphocytes (Johnson et al. 2000; Hiraoka et al. 2006) and APC (Dieu-Nosjean et 
al. 2008) leads to better prognosis in lung cancer patients. 
We evaluated the utility of chimeric c homeostatic cytokine, IL-7/IL-7R-Fc, to restore host 
APC and T cell activities in lung cancer (Andersson et al. 2011). Utilizing murine lung cancer 
models we determined the antitumor efficacy of IL-7/IL-7R-Fc. IL-7/IL-7R-Fc 
administration inhibited tumor growth and increased survival in lung cancer. 
Accompanying the tumor growth inhibition were increases in APC and T cell activities. In 
comparison to controls, IL-7/IL-7R-Fc treatment of tumor bearing mice led to increased: i) 
tumor macrophage infiltrates characteristic of M1 phenotype with increased IL-12, iNOS but 
reduced IL-10 and arginase, ii) frequencies of T and NK cells, iii) T cell activation markers 
CXCR3, CD69 and CD127,low and iv) effector memory T cells. IL-7/IL-7R-Fc treatment 
abrogated the tumor induced reduction in splenic functional APC activity to T responder 
cells. Our findings demonstrate that IL-7/IL-7R-Fc promotes the afferent M1 macrophage 
phenotype and the efferent (CXCR3/CXCR3 ligand biological axis) limbs of the immune 
response for sustained antitumor activity in lung cancer. IL-7/IL-7R-Fc provides the cues 
that address the deficits in the lung tumor microenvironment to achieve the requirements for 
the inhibition of tumor growth kinetics by: (i) generating sufficient numbers of T cells 
systemically (ii) increasing the activated T cell infiltrates in the tumor and (iii) activating the 
innate and immune cells in the tumor to manifest antitumor benefit. Although IL-7/IL-7R-Fc 
is potent at reducing tumor growth kinetics, it does not lead to complete tumor eradication. 
This may in part be due to the presence of MDSC in the tumor microenvironment that 
dampens the antitumor activity of IL-7/IL7R-Fc and remains to be resolved.  
2.9 Drug targets impacting myeloid derived suppressor cells 
Several pharmacological approaches that target MDSC are currently being explored in a 
variety of tumor models. The drugs can be divided into classes based on their ability to 
control: (i) MDSC differentiation into mature DC and macrophages capable of APC activity 
(ATRA and Vitamin D3); (ii) MDSC maturation from precursors [(STAT 3 inhibitors, 
Tyrosine Kinase inhibitors (TKI) (Sunitinib and Sorefnib), Bevacizumab, Anti-BV8 mAb, 
Amino-Biphosphonates and MMP9 inhibitors]; (iii) MDSC accumulation (Gemcitabine, 5-
Fluorouracil (5-FU), CXCR2 and CXCR4 antagonists) and (iv) MDSC function [(ROS 
scavengers and ARG and NOX inhibitors (Nitroaspirin, PDE-5, COX-2 inhibitors and 
Cytokines)] (Ugel et al. 2009).  
Gabrilovich et al demonstrated that differentiating MDSC to DC and macrophages by using 
all-trans retinoic acid (ATRA) reduced MDSC numbers and augmented the responses to 
cancer vaccines. ATRA induced differentiation of MDSC primarily via neutralization of high 
ROS production in these cells. The mechanism involves specific up-regulation of glutathione 
synthase and accumulation of glutathione in the MDSC and could be used in developing 
and monitoring therapeutic application of ATRA (Nefedova et al. 2007). 
Recent advances in targeted therapy for cancer have provided small-molecule kinase 
inhibitors that recognize specific targets on the surface or inside cancer cells. These 
 
Lung Tumor Microenvironment and Myelomonocytic Cells 
 
147 
inhibitors have shown efficacy against several hematopoietic malignancies and solid 
tumors. Most drugs generally have inhibitory effects on several kinases, including tyrosine 
kinases (TK) that are critical for the survival, proliferation, migration and invasion of tumor 
cells. With regards to the effects of TKI on tumor immunity, some studies have 
demonstrated the immune stimulatory effects of the TKI (eg imatinib) (Wang et al. 2005) 
whereas others report the immune suppressive effects of the same inhibitor (Seggewiss et al. 
2005).  
Administration of sunitinib, a receptor TKI, has been shown to reduce the frequency of 
MDSC and reversing T cell immune suppression in the peripheral blood of patients with 
metastatic renal cell carcinoma (RCC) and in several murine tumor models. However 
sunitinib has variable impact at reducing MDSC and restoring T cell activity in the tumor 
microenvironment that seems to be tumor dependent. The authors suggest that the 
persistence of MDSC in the tumor following sunitinib treatment in RCC may in part be due 
to increased GM-CSF expression by the tumors that prolong the survival of MDSC and 
protect from sunitinib through pSTAT5 pathway. The authors contend that GM-CSF 
mediated MDSC survival in patient tumors is supported by the observation that GM-CSF 
produced by RCC cultures protect MDSC from sunitinib induced cell death. However, 
tumors transduced with GM-CSF in several tumor models have been shown to lead to 
strong immune dependent rejection. It would be interesting to see in these models the 
activity of MDSC in the tumor microenvironment of the GM-CSF secreting tumors. 
Additionally, an alternate explanation for the persistence of MDSC may be associated with 
increased expression of proangiogenic proteins, such as MMP9, MMP8 and IL-8 produced 
by tumor stromal cells or infiltrating MDSC (Ko et al. 2010; Finke et al. 2011). More studies 
are required to evaluate the role of TKI (sunitinib, sorafenib, imatinib and dasatinib) on 
MDSC activity in the tumor microenvironment and tumor immunity in several tumor 
models and in clinical samples. 
GW2580, a selective molecule kinase inhibitor of colony stimulating factor 1 receptor 
(CSF1R), blocks the recruitment of CSF1R expressing TAMs as well as MDSC in different 
tumor models without having an impact on tumor burden (Priceman et al. 2010). PLX3397, 
another TKI of CSF1R, has also been used to efficiently deplete CD11b+Ly6G-
LY6ClowF4/80+ TAMs (70%) without altering the presence of granulocytic MDSC. The 
treatment of mammary tumor bearing mice with PLX3397 led to a decrease in tumor burden 
(DeNardo et al. 2011).  
Studies by Ping Ying Pan et al have demonstrated that the expression of c-kit ligand [(stem 
cell factor, (SCF)] by tumor cells may be important for MDSC accumulation in tumor-
bearing mice, and that blocking the c-kit ligand/c-kit receptor interaction can reverse MDSC 
mediated immune suppression. Mice bearing tumor cells with SCF siRNA knockdown 
exhibited significantly reduced MDSC expansion and restored proliferative responses of 
tumor-infiltrating T cells. The blockade of SCF receptor (ckit)–SCF interaction by anti-ckit 
prevented tumor-specific T-cell anergy, Treg development, and tumor angiogenesis. The 
authors found that the prevention of MDSC accumulation in conjunction with immune 
activation therapy showed synergistic therapeutic effect when treating mice bearing large 
tumors. Their data suggests that modulation of MDSC development may be essential to 
enhance immune therapy against advanced tumors (Pan et al. 2008). 
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N-acetyl cysteine (NAC) has been proposed as an anti-tumorigenic agent because of its 
ability to reduce the oxidative stress that promotes genetic instability. NAC treatment of 
mice with progressively growing tumors have demonstrated therapeutic efficacy (Gao et al. 
2007). NAC may have the additional benefit of facilitating T cell activation by increasing 
extracellular pools of cysteine in the presence of high levels of MDSC in cancer patients. 
Although NAC targets the cysteine pathway of MDSC mediated T cell suppression, MDSC 
production of arginase and nitric oxide, can still maintain the suppressive effects of MDSC. 
However, administration of NAC, an already FDA-approved drug, in combination with 
other agents that block other MDSC suppressive pathways (ARG1 and NO), maybe more 
effective at inhibiting MDSC and facilitate the treatment of cancers.  
COX-2 is required for PGE2 synthesis; drugs that specifically block COX-2 and reduce PGE2 
delay tumor growth by reducing MDSC accumulation. Therefore, inhibition of PGE2 
biosynthesis in tumor-bearing mice blocks MDSC generation and subsequently retards 
tumor progression (Rodriguez et al. 2005; Sinha et al. 2007). 
Studies have demonstrated that the chemotherapeutic agent, gemcitabine, enhances T cell 
responsiveness by reducing the number of MDSC levels in the spleens of murine lung 
cancer models. In this study, gemcitabine, was administered at a dose similar to the 
equivalent dose used in patients, was able to specifically reduce the number of MDSC found 
in the spleens of animals bearing large tumors without significant reductions in CD4+ T 
cells, CD8+ T cells, NK cells, macrophages, or B cells. The loss of MDSC was accompanied 
by an increase in the antitumor activity of CD8+ T cells and activated NK cells. Since all 
measurements on MDSC frequency and activity in this study was performed from the 
spleens of tumor bearing animals it is not clear from this work as to the extent of depletion 
of MDSC from the lung tumor microenvironment following gemcitabine treatment and 
restoration of immune responses in the tumor microenvironment. The authors did observe 
however, that combining gemcitabine with cytokine immunogene therapy using IFN-β 
markedly enhanced antitumor efficacy leading to a greater reduction in tumor burden than 
when either therapy was administered singly (Suzuki et al. 2005). 
3. Conclusion and future perspectives 
Lung cancer is the most common cause of cancer mortality worldwide for both men and 
women, causing approximately 1.2 million deaths per year (Jemal et al. 2009). With the 
existing therapeutic efforts, the long-term survival for lung cancer patients remains low with 
only 15% surviving for 5 years following diagnosis. Therefore, new therapeutic strategies 
are needed. One such approach is the development of immune therapy for lung cancer. 
Immune approaches for lung cancer remain attractive because although surgery, 
chemotherapy and radiotherapy alone or in combination produce response rates in all 
histological types of lung cancer, relapse is frequent. Immunologic targeting of lung cancer 
has the potential for nontoxic and specific therapy. Strategies that harness the immune 
system to react against tumors can be integrated with existing forms of therapy for optimal 
responses toward this devastating disease. Immune therapy for lung cancer has potential; 
however, there have not been improvements in survival with previous regimens. Tumor-
induced immune suppression may have contributed to the limited efficacy of the 
approaches. 
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Lung cancer growth and invasion into surrounding tissue promotes an inflammatory 
response that is important for tumor development and progression. Dysregulated 
inflammation in cancer leads to hypo responsiveness of the tumor. MDSC play a major role 
of suppressing T cell activation in the lung tumor microenvironment and sustain overall 
tumor growth, proliferation and metastases. Regulating MDSC recruitment, 
differentiation/expansion and inhibiting MDSC suppressive function will serve as a 
multifaceted approach to control lung cancer. Although the broad targeting of MDSC along 
with other myeloid cell types with anti-Gr1 or anti Ly6G mAbs alone is beneficial in eliciting 
anticancer effects, the benefit of chemotherapeutic agents that regulate MDSC are evident 
only when combined with immune therapy and not when administered alone. Cancer 
immune therapy offers an attractive therapeutic addition, delivering treatment of high 
specificity, low toxicity and prolonged activity. Despite the identification of a repertoire of 
tumor antigens, hurdles persist for immune-based therapies. Tumor-induced immune 
suppression may be contributing to the limited efficacy of the current approaches. Effective 
immunotherapeutic strategies for lung cancer will result from a basic understanding of the 
mechanisms that sustain tumor growth kinetics. Strategies that reprogram the tumor niche 
could alter the inflammatory infiltrate in the lung tumor microenvironment making it 
permissive for immune destruction of tumors. It is likely that combination therapies that 
focus on methods to address the immune deficits in the lung cancer microenvironment will 
be required to develop effective therapies for this disease. Targeting MDSC induced 
immune suppression is at the forefront of these therapeutic approaches. The future of 
immune therapy for lung cancer holds promise with novel combined approaches that 
simultaneously downregulate MDSC suppressor pathways, restore APC immune-
stimulating activity, and expand tumor-reactive T cells with c homeostatic cytokines such 
as IL-7, IL-15 and IL-21 to generate effective therapy. The optimal way to integrate novel 
immune targeted combinations will be the major focus of future studies and will require a 
coordinated and cooperative multidisciplinary effort by the international scientific 
community. Objective lung cancer regressions and extensions in survival should be 
correlated with multiple predictive and prognostic molecular and cellular biomarkers of 
response. This information will prove useful in improving therapy. 
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ability to reduce the oxidative stress that promotes genetic instability. NAC treatment of 
mice with progressively growing tumors have demonstrated therapeutic efficacy (Gao et al. 
2007). NAC may have the additional benefit of facilitating T cell activation by increasing 
extracellular pools of cysteine in the presence of high levels of MDSC in cancer patients. 
Although NAC targets the cysteine pathway of MDSC mediated T cell suppression, MDSC 
production of arginase and nitric oxide, can still maintain the suppressive effects of MDSC. 
However, administration of NAC, an already FDA-approved drug, in combination with 
other agents that block other MDSC suppressive pathways (ARG1 and NO), maybe more 
effective at inhibiting MDSC and facilitate the treatment of cancers.  
COX-2 is required for PGE2 synthesis; drugs that specifically block COX-2 and reduce PGE2 
delay tumor growth by reducing MDSC accumulation. Therefore, inhibition of PGE2 
biosynthesis in tumor-bearing mice blocks MDSC generation and subsequently retards 
tumor progression (Rodriguez et al. 2005; Sinha et al. 2007). 
Studies have demonstrated that the chemotherapeutic agent, gemcitabine, enhances T cell 
responsiveness by reducing the number of MDSC levels in the spleens of murine lung 
cancer models. In this study, gemcitabine, was administered at a dose similar to the 
equivalent dose used in patients, was able to specifically reduce the number of MDSC found 
in the spleens of animals bearing large tumors without significant reductions in CD4+ T 
cells, CD8+ T cells, NK cells, macrophages, or B cells. The loss of MDSC was accompanied 
by an increase in the antitumor activity of CD8+ T cells and activated NK cells. Since all 
measurements on MDSC frequency and activity in this study was performed from the 
spleens of tumor bearing animals it is not clear from this work as to the extent of depletion 
of MDSC from the lung tumor microenvironment following gemcitabine treatment and 
restoration of immune responses in the tumor microenvironment. The authors did observe 
however, that combining gemcitabine with cytokine immunogene therapy using IFN-β 
markedly enhanced antitumor efficacy leading to a greater reduction in tumor burden than 
when either therapy was administered singly (Suzuki et al. 2005). 
3. Conclusion and future perspectives 
Lung cancer is the most common cause of cancer mortality worldwide for both men and 
women, causing approximately 1.2 million deaths per year (Jemal et al. 2009). With the 
existing therapeutic efforts, the long-term survival for lung cancer patients remains low with 
only 15% surviving for 5 years following diagnosis. Therefore, new therapeutic strategies 
are needed. One such approach is the development of immune therapy for lung cancer. 
Immune approaches for lung cancer remain attractive because although surgery, 
chemotherapy and radiotherapy alone or in combination produce response rates in all 
histological types of lung cancer, relapse is frequent. Immunologic targeting of lung cancer 
has the potential for nontoxic and specific therapy. Strategies that harness the immune 
system to react against tumors can be integrated with existing forms of therapy for optimal 
responses toward this devastating disease. Immune therapy for lung cancer has potential; 
however, there have not been improvements in survival with previous regimens. Tumor-
induced immune suppression may have contributed to the limited efficacy of the 
approaches. 
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Lung cancer growth and invasion into surrounding tissue promotes an inflammatory 
response that is important for tumor development and progression. Dysregulated 
inflammation in cancer leads to hypo responsiveness of the tumor. MDSC play a major role 
of suppressing T cell activation in the lung tumor microenvironment and sustain overall 
tumor growth, proliferation and metastases. Regulating MDSC recruitment, 
differentiation/expansion and inhibiting MDSC suppressive function will serve as a 
multifaceted approach to control lung cancer. Although the broad targeting of MDSC along 
with other myeloid cell types with anti-Gr1 or anti Ly6G mAbs alone is beneficial in eliciting 
anticancer effects, the benefit of chemotherapeutic agents that regulate MDSC are evident 
only when combined with immune therapy and not when administered alone. Cancer 
immune therapy offers an attractive therapeutic addition, delivering treatment of high 
specificity, low toxicity and prolonged activity. Despite the identification of a repertoire of 
tumor antigens, hurdles persist for immune-based therapies. Tumor-induced immune 
suppression may be contributing to the limited efficacy of the current approaches. Effective 
immunotherapeutic strategies for lung cancer will result from a basic understanding of the 
mechanisms that sustain tumor growth kinetics. Strategies that reprogram the tumor niche 
could alter the inflammatory infiltrate in the lung tumor microenvironment making it 
permissive for immune destruction of tumors. It is likely that combination therapies that 
focus on methods to address the immune deficits in the lung cancer microenvironment will 
be required to develop effective therapies for this disease. Targeting MDSC induced 
immune suppression is at the forefront of these therapeutic approaches. The future of 
immune therapy for lung cancer holds promise with novel combined approaches that 
simultaneously downregulate MDSC suppressor pathways, restore APC immune-
stimulating activity, and expand tumor-reactive T cells with c homeostatic cytokines such 
as IL-7, IL-15 and IL-21 to generate effective therapy. The optimal way to integrate novel 
immune targeted combinations will be the major focus of future studies and will require a 
coordinated and cooperative multidisciplinary effort by the international scientific 
community. Objective lung cancer regressions and extensions in survival should be 
correlated with multiple predictive and prognostic molecular and cellular biomarkers of 
response. This information will prove useful in improving therapy. 
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1. Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and 
characterized by progressive development, high postsurgical recurrence and extremely poor 
prognosis [1–3]. The dismal outcome has been attributed to the highly vascular nature of 
HCC, which increases the propensity to spread and invade into neighboring or distant sites 
[4, 5]. Therefore, it is considered an urgent task to identify key prognostic factors of HCC 
and to elucidate the mechanisms of disease progression. 
HCC is usually present in inflamed fibrotic and/or cirrhotic liver with extensive leukocyte 
infiltration [6, 7]. Thus, the immune status at different tumor sites can largely influence the 
biological behavior of HCC [6, 8, 9]. Several recent studies have shown that high infiltration 
of intratumoral regulatory T cells is associated with reduced survival and increased 
invasiveness in HCC [10, 11]. These findings are in accordance with the general view that 
the tumor microenvironment induces tolerance [12–14]. However, there is substantial 
evidence that the inflammatory response associated with cancers can also promote HCC 
progression by stimulating angiogenesis and tissue remodeling [6, 15, 16]. These findings 
strongly indicate that, besides inducing immune tolerance, HCC may also reroute the pro-
inflammatory immune response into a tumor-promoting direction. 
Macrophages (Mφs) constitute a major component of the leukocyte infiltrate in tumors. 
These cells are derived from circulating monocytes, and, in response to environmental 
signals, they acquire special phenotypic characteristics with diverse functions [17–19]. 
Recent studies have found that tumor environments co-opt the normal development of Mφs 
to dynamically activate the recruited monocytes in different niches of HCC. The malignant 
cells can thereby avoid initiation of potentially dangerous Mφ functions and create favorable 
conditions for tumor progression [20, 21]. Notably, the density of activated monocytes in the 
peritumoral stroma is selectively associated with vascular invasion and poor prognosis in 
HCC patients, whereas the increased infiltration of suppressive Mφs in the cancer nests is 
only correlated with the reduced survival of patients [22]. Thus, immune functional data of 
activated monocytes/Mφs in distinct cancer environments are essential for understanding 
their roles and potential mechanisms in HCC immunopathogenesis. 
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In this chapter, we will summarize the current knowledge about the tumor immune 
microenvironment of HCC and the role of monocytes/Mφs in HCC progression, paying 
particular attention to the tissue micro-localization and phenotype of these cells. Additionally, 
we will describe the poly-directional communications between monocytes/Mφs and other 
stroma cells, including cytotoxic T cells, regulatory T cells, TH17/TC17 cells as well as 
neutrophils, and how activated monocytes in HCC repurpose the inflammatory response 
away from antitumor immunity and toward tissue remodeling and pro-angiogenic pathways. 
Finally, possible implications for the design of novel monocyte/Mφ-based immunotherapeutic 
strategies will be discussed. 
2. Immune microenvironments of human HCC 
After several decades of neglect, tumor microenvironments are once again an area of active 
research interest in cancer [23–25]. The biology of cancer cannot be understood simply by 
underlining the significance of the malignant cells but instead must encompass the 




Fig. 1. Infiltration patterns of immune cells in HCC samples. Paraffin-embedded HCC 
sections were stained with indicated antibodies. The micrographs show the stained 
peritumoral stroma (A) and cancer nest (B). 
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Human HCC microenvironments, composed of non-cancer cells and their stroma (Figure 1), 
are now recognized as a major factor influencing the disease progression [6, 21]. Although 
normal stromal environment is non-permissive for HCC progression, hepatoma cells can 
modulate adjacent stroma to generate a supportive microenvironment. This includes the 
ability to alter the ratios of effectors to regulatory T cells and to affect the functions of APCs 
and the expression of co-signaling molecules, which in turn creates an immunosuppressive 
network to promote tumor progression and immune evasion [10, 21, 26]. However, there is 
also emerging evidence that the pro-inflammatory response at the tumor stroma can be 
rerouted in a tumor-promoting direction [15, 16]. These observations suggest that different 
tumor microenvironments can create either immune suppression or activation at distinct 
sites to promote tumor progression. 
2.1 Immune responses against HCC 
In HCC, several lines of evidence have suggest a positive role of immune system, e.g., by 
controlling hepatoma growth [7, 27–29]. Indeed, data from clinical investigations have 
revealed that HCC patients with an increased intratumoral accumulation of cytotoxic CD8+ 
T lymphocytes had a superior 5-year survival rate and a prolonged recurrence-free survival 
after liver resection [11, 30]. In contrast, HCC-infiltrating CD4+ T lymphocytes exhibited a 
CD25highFoxp3+ phenotype that was a predictor of poor overall survival of patients, 
indicating distinct roles of different tumor-infiltrating lymphocyte subsets in HCC [10, 11]. 
The important role of CD8+ T cells in HCC control is further supported by studies in 
hepatoma-bearing mice; and interferon (IFN)-γ, perforin and granzyme B produced by 
CD8+ T cells had been shown to be several major effector mechanisms for apoptosis of 
hepatoma cells [21, 31, 32]. 
Of note, the tumor-specific antigens (TSAs) in HCC patients are currently still under 
investigation. At present, several tumor-associated antigens (TAAs) of HCC have been 
identified, which has been recently introduced [7, 33]. In brief, several shared tumor 
antigens could also be recognized as antigens targeted by cytotoxic CD8+ T cells in HCC, 
e.g., human telomerase-reverse transcriptase (hTERT) or NY-ESO-1. Expression of these 
antigens has been reported for other malignancies as well. Other antigens are expressed 
specifically in HCC and are also recognized by cells of the immune system, e.g., α-
fetoprotein (AFP) or Glypican-3. The latter two antigens belong to the family of oncofetal 
antigens that are expressed only during ontogenesis. Although the exact mechanisms 
underlying are not yet clear, re-expression of such antigens is often observed in HCC. Thus, 
further research is also required to determine the frequency, immunodominance and 
strength of the immune responses induced against different TAAs. 
Besides tumor-specific cytotoxic CD8+ T cells, the natural killer (NK) cells have also been 
implicated in a successful immune response against HCC, e.g., by direct lysis of malignant 
cells [34]. Indeed, an increased preoperative NK cell activity that related to the expression of 
perforin and granzyme B was correlated with prolonged recurrence-free survival in HCC 
patients [35]. Contrarily, the NK cell dysfunction was shown to predict the poor survival of 
HCC patients after resection [36]. Other studies also showed that the stimulation of antigen-
present cells (APCs) or natural killer T cells (NKT cells) can lead to an activation of NK cells 
and clearance of hepatoma cells in mice [37, 38]. 
Increased levels of B cells have been observed in several types of human tumor, and studies 
in mice indicate that, depending on microenvironment, tumor-infiltrating B cells are capable 
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In this chapter, we will summarize the current knowledge about the tumor immune 
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Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma 
 
159 
Human HCC microenvironments, composed of non-cancer cells and their stroma (Figure 1), 
are now recognized as a major factor influencing the disease progression [6, 21]. Although 
normal stromal environment is non-permissive for HCC progression, hepatoma cells can 
modulate adjacent stroma to generate a supportive microenvironment. This includes the 
ability to alter the ratios of effectors to regulatory T cells and to affect the functions of APCs 
and the expression of co-signaling molecules, which in turn creates an immunosuppressive 
network to promote tumor progression and immune evasion [10, 21, 26]. However, there is 
also emerging evidence that the pro-inflammatory response at the tumor stroma can be 
rerouted in a tumor-promoting direction [15, 16]. These observations suggest that different 
tumor microenvironments can create either immune suppression or activation at distinct 
sites to promote tumor progression. 
2.1 Immune responses against HCC 
In HCC, several lines of evidence have suggest a positive role of immune system, e.g., by 
controlling hepatoma growth [7, 27–29]. Indeed, data from clinical investigations have 
revealed that HCC patients with an increased intratumoral accumulation of cytotoxic CD8+ 
T lymphocytes had a superior 5-year survival rate and a prolonged recurrence-free survival 
after liver resection [11, 30]. In contrast, HCC-infiltrating CD4+ T lymphocytes exhibited a 
CD25highFoxp3+ phenotype that was a predictor of poor overall survival of patients, 
indicating distinct roles of different tumor-infiltrating lymphocyte subsets in HCC [10, 11]. 
The important role of CD8+ T cells in HCC control is further supported by studies in 
hepatoma-bearing mice; and interferon (IFN)-γ, perforin and granzyme B produced by 
CD8+ T cells had been shown to be several major effector mechanisms for apoptosis of 
hepatoma cells [21, 31, 32]. 
Of note, the tumor-specific antigens (TSAs) in HCC patients are currently still under 
investigation. At present, several tumor-associated antigens (TAAs) of HCC have been 
identified, which has been recently introduced [7, 33]. In brief, several shared tumor 
antigens could also be recognized as antigens targeted by cytotoxic CD8+ T cells in HCC, 
e.g., human telomerase-reverse transcriptase (hTERT) or NY-ESO-1. Expression of these 
antigens has been reported for other malignancies as well. Other antigens are expressed 
specifically in HCC and are also recognized by cells of the immune system, e.g., α-
fetoprotein (AFP) or Glypican-3. The latter two antigens belong to the family of oncofetal 
antigens that are expressed only during ontogenesis. Although the exact mechanisms 
underlying are not yet clear, re-expression of such antigens is often observed in HCC. Thus, 
further research is also required to determine the frequency, immunodominance and 
strength of the immune responses induced against different TAAs. 
Besides tumor-specific cytotoxic CD8+ T cells, the natural killer (NK) cells have also been 
implicated in a successful immune response against HCC, e.g., by direct lysis of malignant 
cells [34]. Indeed, an increased preoperative NK cell activity that related to the expression of 
perforin and granzyme B was correlated with prolonged recurrence-free survival in HCC 
patients [35]. Contrarily, the NK cell dysfunction was shown to predict the poor survival of 
HCC patients after resection [36]. Other studies also showed that the stimulation of antigen-
present cells (APCs) or natural killer T cells (NKT cells) can lead to an activation of NK cells 
and clearance of hepatoma cells in mice [37, 38]. 
Increased levels of B cells have been observed in several types of human tumor, and studies 
in mice indicate that, depending on microenvironment, tumor-infiltrating B cells are capable 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
160 
of being pro- or anti-tumorigenic [39, 40]. The role of B cells in human HCC is unclear thus 
far. B cell-derived autoantibodies against several antigens have been described in mouse 
models of HCC as well as in HCC patients [41, 42]. Additional studies showed that 
monoclonal antibodies against Glypican-3 were able to induce antibody-dependent cellular 
cytotoxicity (ADCC) and thus lysis of human hepatoma cells in vitro and in mice [43]. 
However, the importance of ADCC and antibodies in general in the natural immune 
response against HCC has not been investigated so far. 
2.2 Immune responses promote HCC progression 
Although immune system can exhibit vigorous anti-hepatoma activities in vitro, HCC-
specific immune responses fail to control tumor progression in most patients. Clinical and 
experimental studies have demonstrated that the growth of HCC is closely associated with 
impaired differentiation and maturation of APCs, particularly Mφs and dendritic cells (DCs) 
[20, 44, 45]. Also, phenotypic and functional analyses of APCs from HCC patients have 
revealed that tumor cells or tumor-derived factors do favor differentiation of monocytes into 
tumor-associated Mφs (TAMs) [20] or tolerogenic semi-mature DCs (TDCs) [46]. Also, such 
abnormal development of APCs in the HCC microenvironment could intensely impact the 
infiltration and function of other immune cells in tumor in situ, which will be expounded in 
the 3rd section of this chapter.  
Suppression of immune responses by regulatory T (Treg) cells is one of the major 
mechanisms for the induction and maintenance of self-tolerance [12, 13]. Recent studies 
reported increased numbers of Treg cells in the peripheral blood and tumor-infiltrating 
lymphocytes (TILs) in patients with ovarian or liver cancers, which impaired cell-mediated 
immunity and promoted disease progression [10, 11, 47, 48]. Experimental depletion of Treg 
cells in several types of tumor-bearing mice could successfully improve tumor clearance and 
enhance the efficacy of immunotherapy [49, 50]. In parallel, depletion of CD4+CD25+ Treg 
cells could effectively enhance T-lymphocyte and NK-cell effector function in advanced 
stage HCC patients [51, 52]. These data together suggest that Treg cells may impair cell-
mediated immune responses to HCC. At present, the precise underlying mechanism by 
which Treg cells accumulate at the tumor site in HCC patients is also unknown. 
A direct role in HCC progression has also been shown for other cells of the immune system. 
For example, high infiltration of intratumoral neutrophils has been shown to predict a reduced 
recurrence-free survival time of HCC patients after liver resection [53]. Of note, neutrophils at 
the tumor edge induced angiogenesis progression and thus indirectly enhanced cancer growth 
[9]. This observation becomes especially intriguing in light of the finding that peritumoral 
neutrophils can be recruited by the pro-inflammatory cytokine interleukin (IL)-17. IL-17 is 
produced by T cells, termed TC17 or TH17, in the CD8+ or CD4+ T cell compartment in tumor 
environments, respectively [54, 55]. Indeed, IL-17-producing cells accumulate in tumors from 
patients with HCC and that their levels are positively correlated with microvessel density in 
tissues and poor survival in HCC patients [56]. It should be noted that, in several types of 
human cancer, high level of IL-17 in tumors in situ can predict improved survival of patients 
and associates with increased infiltration of cytotoxic CD8+ T cells [57, 58]. Therefore, a better 
understanding of the network of tumor immune environments might provide a novel strategy 
for the rational design of anticancer therapies. 
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3. Polarization of monocytes in HCC microenvironments 
APCs are critical for initiating and maintaining tumor-specific T-cell responses [21, 46]. DCs 
are considered the most effective APCs for primary immune responses [59]; Mφs markedly 
outnumber other APCs and represent an abundant population of APCs in solid tumors [60]. 
Monocytes can give rise to either DCs or Mφs in human tumors. In HCC patients, increased 
HLA-DR+ monocytes in liver are associated with metastatic phenotype [6]. Thus, 
polarization of monocytes in the cancer environments is essential for understanding their 
roles in HCC immunopathogenesis. 
3.1 Differentiation of monocyte-derived Mφs in HCC microenvironments 
Mφs are essential components of host defense and act as both APCs and effector cells [19]. 
Under the influence of local conditions, they acquire specialized phenotypic characteristics 
with diverse functional programs [16–18]. Mφs constitute a major component of the leukocyte 
infiltrate of tumors, and the TAMs are derived almost entirely from circulating blood 
monocytes [17–19]. Mφs in normal or inflamed tissues exhibit spontaneous antitumor activity, 
whereas TAMs are polarized M2 cells that suppress antitumor immunity and promote tumor 
progression [61]. Those findings agree with clinical studies showing that a high density of 
TAM is associated with poor prognosis in most solid tumors [22, 62]. Although the precise 
underlying mechanisms are not yet clear, it is generally assumed that the tumor 
microenvironment is critical determinants of the phenotype of local Mφs. Tumor-derived 
factors, including IL-10 and transforming growth factor (TGF)-β, “educate” the newly 
recruited monocytes to take on a M2 phenotype and perform a protumoral role [63, 64]. In 
contrast, over-expression or local delivery of IL-12 can reestablish the antitumor activity of 
Mφs, and in that case a high density of TAMs is correlated with a marked reduction in tumor 
growth [65, 66]. Such opposing effects of Mφs on tumor progression indicate that selective 
modulation of Mφ polarization might serve as a novel strategy for cancer therapy. However, 
such an approach is hampered by the fact that the mechanisms by which tumor 
microenvironments educate Mφs to perform specific tasks have not been fully elucidated. 
In HCC patients, soluble factors derived from hepatoma cells, including extracellular matrix 
components hyaluronan fragments [20], effectively induced the formation of TAMs. 
Interestingly, kinetic analysis revealed 2 opposing functional stages in the TAM life cycle: 
monocytes are rapidly activated during a narrow time window, 4 to 16 hours after their first 
exposure to hepatoma cell culture supernatants, and afterward the same cells become 
exhausted and their production of cytokines is extinguished, with the exception of IL-10 [20, 
21]. Because TAMs are derived from blood monocytes, such sequential pre-activation and 
exhaustion of cells may reflect a novel immune-escape mechanism by which tumors 
dynamically regulate the functions of migrating monocytes at distinct tumoral sites. More 
precisely, this means that during their first exposure to the tumor microenvironment, the 
newly recruited monocytes may be transiently activated while they are approaching the 
stroma surrounding the tumor, with the aim of minimizing their potential to damage tumor 
cells. Thereafter, when these Mφs are in close proximity to the tumor cells, they become 
exhausted and thus fail to mount an effective antitumor immune response. This notion is 
supported by the observations in human HCC tissues, indicating that most CD68-positive 
cells are smaller and show high expression of HLA-DR in the peritumoral stromal region, 
whereas they exhibit a HLA-DRlowIL-10high phenotype in the cancer nest (Figure 3 in Ref. 20). 
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Of note, similar activation patterns of monocytes/Mφs were detected in ovarian and lung 
cancer [20, 67]. 
Monocytes/Mφs in the peritumoral stroma of HCC had an activated phenotype with 
increased expression of HLA-DR, CD80, and CD86 [6]. Data from in vivo observations 
showed that such tumor-activated monocytes also expressed significant level of B7-H1 (PD-
L1) [8, 21]; and autocrine TNF-α and IL-10, but not IFN-γ, released from activated 
monocytes, stimulated monocyte B7-H1 expression [21, 68]. Furthermore, in vitro study 
using recombinant TNF-α and IL-10 indicated that IL-10 was essential for B7-H1 induction 
and that pro-inflammatory TNF-α acted synergistically with anti-inflammatory IL-10 to 
enhance B7-H1 expression on monocytes. In addition, a positive correlation between IL-17-
producing cells and B7-H1-expressing Mφs was also observed in the peritumoral stroma of 
HCC tissues (Figure 1 in Ref. 8). Although culture supernatants derived from hepatoma 
cells also induced B7-H1 expression on monocytes, IL-17 additionally increased hepatoma-
mediated monocyte B7-H1 expression. Similar regulatory effect of IL-17 on APCs was also 
observed in hepatitis [69]. These findings reveal a fine-tuned collaborative action between 
different types of immune cells in the peritumoral stroma of HCC, which reroutes the 
monocyte inflammatory response into immunosuppression. 
TAMs in the cancer nests of HCC exhibited an exhausted suppressive phenotype; they are 
strongly impaired with regard to various functions related to inflammation [20, 21]. 
However, in contact with autologous T cells, these suppressive Mφs recuperate their 
capabilities to produce low level of IL-12 in tumors, and thereby activate T cells to produce 
IFN-γ, which in turn leads to IDO expression in Mφs and ultimately impairs the antitumor T 
cell immunity (Zhao Q, et al. J Immunol. doi: 10.4049/jimmunol.1100164). These findings 
give important new insights into the collaborative action of tumor stroma cells that is 
exercised to counteract the normal development of Mφs in distinct HCC environments. 
3.2 Differentiation of monocyte-derived DCs in HCC microenvironments 
DCs are the most potent “professional” APCs, and they are responsible for integrating a 
variety of incoming signals and orchestrating the immune response [59]. Bidirectional 
interactions between DCs and T cells initiate either an immunogenic or a tolerogenic 
pathway, both of which play crucial roles in autoimmune diseases and tumor immunity [70, 
71]. It is generally assumed that these two contrasting functions of DCs are associated with 
the maturation stages of the cells: fully mature DCs (mDCs) are efficient activators of naive 
T cells, whereas immature DCs (iDCs) have been implicated for anergy induction. 
Furthermore, an intermediate stage of maturation was recently described in which the cells 
are referred to as semi-mature DCs [72]. These DCs expressed high levels of MHC class II 
and co-stimulatory molecules, even though they exhibited an IL-12lowIL-10high phenotype 
[73]. It was also observed that the semi-mature DCs can induce tolerance by generating 
regulatory T cells and/or T cell anergy [74]. 
In HCC patients, soluble factors derived from hepatoma cells drove human monocytes to 
become tolerogenic DCs (TDCs) that exhibited a semi-mature phenotype with a 2- to 5-fold 
increase in expression of CD83, CD86, and HLA-DR, and a distinctive IL-12lowIL-10high 
cytokine production profile [46]. Upon encountering T cells, the TDCs triggered rapid 
down-regulation of CD3ε and TCR-α/β and subsequent apoptosis in autologous T cells. 
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Consistent with these results, accumulation of immunosuppressive DCs coincided with 
CD3ε down-regulation and T cell deletion in the cancer nests of human HCC tumors (Figure 
2 and 4 in Ref. 46). The impaired T cell function was mediated by factor(s) released by live 
TDCs after direct interaction with lymphocytes. Also, the TDC-induced effect on T cells was 
markedly reduced by blocking of NADPH oxidase but not by inhibition of arginase, 
inducible NO synthase (iNOS), indoleamine 2, 3-dioxygenase (IDO), or IFN-γ. These 
observations indicate that tumor microenvironments educate DCs to adopt a semi-mature 
phenotype, which in turn aids tumor immune escape by causing defects in the CD3/TCR 
complex and deletion of T cells. In addition, besides triggering T cell apoptosis, hepatoma-
exposed DCs also play an important role in expanding intratumoral Treg cells [45]. 
4. Cross talks between monocytes/Mφs and other stroma cells in HCC 
tissues 
Tumor progression is now recognized as the product of evolving crosstalk between different 
cell types within the tumor and its stroma [23, 24]. HCC environments can alter the normal 
development of Mφs that is intended to trigger transient early activation of monocytes in 
the peritumoral region, which in turn induces formation of suppressive TAMs in the cancer 
nests [20, 21]. In this section, we will describe several recent findings about the cross talks 
between monocytes/Mφs and other stroma cells, paying particular attention to the tissue 
micro-localization and phenotype of these cells in HCC.  
4.1 Activated monocytes in the peritumoral stroma of HCC foster immune privilege 
and disease progression through B7-H1 
B7-H1 is a cell-surface glycoprotein belonging to the B7 family of co-signaling molecules 
with a profound regulatory effect on T cell responses [75]. Studies in mouse models have 
revealed that expression of B7-H1 helped dormant tumor cells to evade cytotoxic T cell 
responses [14]. In human HCC, B7-H1+ monocytes/Mφs and CD8+ T cells were both 
accumulated in the peritumoral stroma of HCC tissues, which suggests that these 
monocytes/Mφs promote tumor progression by impairing T cell immunity (Figure 1, 3-5 in 
Ref. 21). Supporting this hypothesis, a significantly larger portion of the tumor-infiltrating 
cytotoxic T cells was found to express the B7-H1 receptor PD-1 [8, 21, 68]. Moreover, HCC-
infiltrating T cells co-cultured with HCC-derived monocytes exhibited an impaired 
production of IFN-γ, and blockade of B7-H1 by pre-incubation of tumor monocytes with the 
mAb MIH1 could markedly enhance the ability of tumor T cells to produce that cytokine. 
Consistent with these data, only PD-1+ cytotoxic T cells isolated from HCC tissues exhibited 
attenuated production of IFN-γ, IL-2, and TNF-a as well as low cytotoxic potential [21]. 
These findings, together with regulatory mechanism of B7-H1 in monocytes/Mφs (Section 
2A), suggest that there is a fine-turned collaborative action between immune activation and 
immunosuppression in tumor microenvironments. Soluble factors derived from hepatoma 
cells [21], as well as IL-17 released by TH17 and TC17 [54, 55], can trigger transient 
activation of newly recruited monocytes in the peritumoral stroma area of HCC, and 
thereby induce the monocytes to produce significant amount of cytokines, including TNF-α, 
IL-23, IL-1β, and IL-10, which in turn leads to the expression of B7-H1 protein on their 
surface and ultimately impairs the antitumor T cell immunity. 
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Tumor progression is now recognized as the product of evolving crosstalk between different 
cell types within the tumor and its stroma [23, 24]. HCC environments can alter the normal 
development of Mφs that is intended to trigger transient early activation of monocytes in 
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infiltrating T cells co-cultured with HCC-derived monocytes exhibited an impaired 
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thereby induce the monocytes to produce significant amount of cytokines, including TNF-α, 
IL-23, IL-1β, and IL-10, which in turn leads to the expression of B7-H1 protein on their 
surface and ultimately impairs the antitumor T cell immunity. 
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4.2 Activated monocytes in the peritumoral stroma of HCC promote expansion of 
memory IL-17-producing T cells 
Although cancer patients exhibit a generalized immunosuppressive status, substantial 
evidence indicates that the inflammatory reaction at a tumor site can promote tumor growth 
and progression. HCC is usually derived from inflamed cirrhotic liver with extensive 
leukocyte infiltration. Recent study has shown that TH17 cells were highly enriched in HCC 
and their levels were positively correlated with micro-vessel density in tissues and poor 
survival in HCC patients [56]. In contrast to the classical TH17 cells that hardly express IFN-
γ, almost half of the IL-17-producing CD4+ T cells we isolated from HCC tissues were able to 
simultaneously produce IFN-γ, suggesting that the tumor microenvironment can 
profoundly determine the phenotype of such cells [54–56]. In addition, the IL-17-producing 
cells often predominantly accumulate in the peritumoral stroma rather than in the cancer 
nests of HCC [54, 55]. A significant correlation between the levels of CD68+ cells and IL-17+ 
lymphocytes was found in the peritumoral stroma of HCC (Figure 1 in Ref. 54). However, 
there was no such correlation in intratumoral tissue, suggesting that Mφs in different parts 
of HCC play disparate roles in IL-17-producing T cell expansion.  
Most of the CD68+ cells in the peritumoral stroma had a smaller volume and showed 
marked expression of HLA-DR, which implies that they were newly recruited and activated 
monocytes. In contrast, most Mφs in the cancer nests were negative for HLA-DR (Figure 2). 
Accordingly, hepatoma-activated monocytes were significantly superior to the suppressive 
tumor Mφs in inducing expansion of both TH17 (CD4+ IL-17-producing T cells) and TC17 
(CD8+ IL-17-producing T cells) cells from circulating memory T cells in vitro with 
phenotypic features similar to those isolated from HCC, and these monocytes secreted a set 
of key pro-inflammatory cytokines, including IL-1β, IL-6, and IL-23, that triggered 
proliferation of functional TH17 cells. In addition, inhibition of monocytes/Mφs 
inflammation in liver markedly reduced the level of tumor-infiltrating IL-17+ cells and 
tumor growth in vivo [54]. Therefore, the pro-inflammatory IL-17-producing cells are  
 
Fig. 2. Distinct activation patterns of monocytes/Mφs in HCC samples. Adjacent sections 
of paraffin-embedded HCC samples were stained with an anti-CD68 (A) or anti-HLA-DR 
(B). The micrographs at higher magnification show the stained cancer nest (1), peritumoral 
stroma (2), and adjacent normal tissue (3). 
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generated and regulated by a fine-tuned collaborative action between different types of 
immune cells in distinct HCC microenvironments, and allow the inflammatory response of 
activated monocytes to be rerouted in a tumor-promoting direction. Selectively modulating 
the “context” of inflammatory response in tumors might provide a novel strategy for 
anticancer therapy. 
4.3 Peritumoral neutrophils link inflammatory response to disease progression by 
fostering angiogenesis in HCC 
Most monocytes/Mφs in the peritumoral stroma of HCC exhibit an activated phenotype 
that favors the generation of IL-17-producing cells in the same area, and their levels were 
correlated with disease progression in HCC patients [54]. Interestingly, another important 
myeloid cell population, namely tumor-associated neutrophils (TANs), was also enriched 
predominantly in the peritumoral stroma of HCC tissues, and their levels were well 
correlated with IL-17-producing cell density in the same area (Figure 2 in Ref. 9). Data from 
both clinical sample analysis and experimental studies showed that functional IL-17+ cells in 
the peritumoral stroma stimulated epithelial cells to produce CXC chemokines that induced 
neutrophil trafficking to tumors [9]. Thereafter, exposure of neutrophils to HCC 
environment resulted in sustained survival of cells [76]. The accumulated neutrophils in the 
peritumoral stroma were the major source of MMP-9, which in turn triggered the angiogenic 
switch at the adjacent invading edge [9]. These data, therefore, provide direct evidence that 
neutrophils play an important role in human tumor progression by serving as a link 
between the pro-inflammatory response and angiogenesis in the tumor milieu. This notion 
is supported by the findings that the density of neutrophils in the peritumoral stroma was 
correlated with advanced disease stages and could serve as an independent predictor of 
poor survival in HCC patients (Figure 1 in Ref. 9). Consistent with these results, tumor 
angiogenesis is often more active at the invading edge, which is close to the peritumoral 
stroma, than intratumoral areas. 
4.4 Activated CD69+ T cells foster immune privilege by regulating Mφ IDO expression 
in the cancer nest of HCC 
IDO is a rate-limiting enzyme for tryptophan catabolism. In humans and mice, IDO inhibits 
antigen-specific T cell proliferation in vitro and suppresses T cell responses to fetal 
alloantigens during murine pregnancy [71, 77, 78]. Expression of IDO is often induced or 
maintained by many inflammatory cytokines, of which IFN-γ is the most potent [71]. In 
addition to being expressed in APCs, most human cancers also express high levels of IDO 
protein which correlates with poor prognosis in some cases [78]. In contrast, low or rare IDO 
expression is observed in most mouse and human tumor-cell lines, possibly due to the lack of 
a complete cancer microenvironment in cell lines in vitro [78, 79]. At present, little is known 
about the regulating mechanisms of IDO in TAMs at stroma of human tumors in situ.  
Experimental studies indicate that the IDO proteins are selectively high expressed by Mφ in 
several types of human tumors, including HCC (Zhao Q, et al. J Immunol. doi: 
10.4049/jimmunol.1100164). However, exposure to hepatoma cell culture supernatants did not 
elicit the IDO expression in monocytes/Mφs, which suggests that additional factors within the 
tumor milieu are required for inducing IDO expression in tumor Mφs. CD69 is an 
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immunoregulatory molecule expressed by early activated leukocytes at sites of chronic 
inflammation and CD69+ T cells have been found to promote human tumor progression [80, 
81]. Upon encountering autologous CD69+ T cells, tumor Mφs acquired capabilities to produce 
greatly higher amount of IDO protein. The T cells isolated from the HCC tissues expressed 
significant CD69 molecules than those on paired circulating and non-tumor-infiltrating T cells; 
and these tumor-derived CD69+ T cells could induce considerable IDO in monocytes. 
Interestingly, the tumor-associated monocytes/Mφ isolated from HCC tissues or generated by 
in vitro culture effectively activated circulating T cells to express CD69. IL-12 derived from 
tumor Mφ was required for early T cell activation and subsequent IDO expression (Zhao Q, et 
al. J Immunol. doi: 10.4049/jimmunol.1100164). Consistent with this, another recent study has 
shown that intratumoral delivery of exogenous IL-12 could elicit an IFN-γ-dependent IDO 
counter-regulation in mouse model [82]. Moreover, the conditioned medium form IDO+ Mφ 
effectively suppressed T cell responses in vitro; an effect which could be reversed by adding 
extrinsic IDO substrate tryptophan or by pre-treating Mφs with an IDO-specific inhibitor 1-
MT. Such an active induction of immune-tolerance should be considered for the rational 
design of effective immune-based anti-cancer therapies. 
4.5 Increased intratumoral Treg cells are related to intratumoral Mφs and poor 
prognosis in HCC patients 
Treg cell-mediated immunosuppression is a crucial strategy of tumor immune evasion and a 
main obstacle for successful cancer immunotherapy [12]. Several recent studies have 
demonstrated that FoxP3+ Treg cells with immunosuppressive properties were concentrated 
within HCC tumors and that the intratumoral prevalence of FoxP3+ Treg cells was 
associated with disease progression and poor prognosis [10, 11]. However, the source of 
Treg cells in HCC is still unclear. By analyzing the association between the densities of Treg 
cells and Mφs in HCC tissue, Zhou et al observed that the elevated intratumoral FoxP3+ 
Treg population was correlated with high-intratumoral Mφ density in HCC patients [26]. 
Depletion of liver Mφs thus decreased the frequency of liver FoxP3+ Treg cells in hepatoma-
bearing mice. Additionally, Mφs exposed to TSNs from hepatoma-derived cell lines 
augmented the FoxP3+ Treg population, partially via IL-10. However, in the absence of Mφs, 
culture supernatants derived from hepatoma cells could not increase the percentage of 
FoxP3+ Treg cells upon anti-CD3/CD28 stimulation. These data indicated that HCC-
associated immunosuppressive Mφs can increase the intratumoral FoxP3+ Treg population. 
Cross talks between monocytes/Mφs and other stroma cells are summarized in Figure 3. 
Notably, the regulatory mechanisms of monocytes/Mφs are less well understood in human 
HCC. Besides interacting with TH17, TC17, Treg, and CD69+ T cells, tumor-associated 
monocytes/Mφs also secrete molecules (eg, TGF-β, osteopontin), which directly induced 
epithelial-mesenchymal transition or transformation (EMT) of cancer cells [83]. Moreover, 
one of our latest finding indicated that monocytes/Mφs isolated from human HCC tissues 
induced NK cell dysfunction via a 2B4/CD48 interaction (Wu et al. Unpublished data). In 
addition, although not directly related to HCC, tumor-infiltrating Treg cells can trigger 
production of IL-10 by Mφs, which in turn stimulates such cells to express B7-H4 in an 
autocrine manner and renders them immunosuppressive via the B7-H4 molecules [84]. 
Therefore, manipulating the involved molecules may open new avenues for developing 
novel immune-based therapies to enhance antitumor immunity in human cancer. 
 




Fig. 3. Map of Cross talks between monocytes/Mφs and other immune cells in distinct 
niches of HCC.  
5. Summary 
Much research has been focused on tumor-mediated immunosuppression over the past 
decade. However, in spite of the generalized immunosuppressive status in cancer patients, 
many malignancies arise at sites of chronic inflammation, and inflammatory mediators are 
often produced in tumors [85, 86]. Human HCC tissues can be anatomically classified into 
areas of intratumoral and peritumoral stroma, each with distinct compositions and 
functional properties [20, 21, 54, 55]. Intratumoral environments of HCC usually contain 
abundant immunosuppressive molecules and cells to inhibit the T cell responses and create 
conditions that are conducive to tumor growth [20, 26]. In contrast, the peritumoral stromal 
areas of HCC contain a significant amount of leukocyte infiltrate, which are thereby situated 
close to the advancing edge of a tumor [21, 54]. Monocytes/Mφs represent an abundant 
population of APCs in HCC. Soluble factors derived from hepatoma cells can alter the 
normal developmental process of Mφs that is intended to dynamically regulate monocyte 
activation at distinct sites [20]. Hepatoma-activated monocytes in the peritumoral stroma 
induce sequential expansion of memory TH17 and TC17 cells and infiltration of neutrophils 
to promote inflammation and angiogenesis at invading tumor edge [54, 55]. Of note, these 
activated monocytes also express high level of B7-H1 to inhibit tumor-specific T cell 
immunity [21], and in that way repurpose the inflammatory response away from anti-tumor 
immunity (the sword) and towards tissue remodeling and pro-angiogenic pathways (a 
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plowshare). Furthermore, interactions between suppressive Mφs and T cells in the cancer 
nest of HCC lead to Mφ IDO expression and Treg cell expansion [26]. Thus, it is not 
inflammation per se but inflammatory “context” that determines the ability of pro-
inflammatory factors to facilitate or prevent tumor growth. Studying the mechanisms that 
can selectively modulate the functional activities of monocytes/Mφs might provide a novel 
strategy for anticancer therapy. 
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plowshare). Furthermore, interactions between suppressive Mφs and T cells in the cancer 
nest of HCC lead to Mφ IDO expression and Treg cell expansion [26]. Thus, it is not 
inflammation per se but inflammatory “context” that determines the ability of pro-
inflammatory factors to facilitate or prevent tumor growth. Studying the mechanisms that 
can selectively modulate the functional activities of monocytes/Mφs might provide a novel 
strategy for anticancer therapy. 
6. Acknowledgment 
This work was supported by the Fundamental Research Funds for the Central Universities 
(11lgzd12) and project grants from the National Natural Science Foundation of China 
(81000915 and 81171882) and the Education Department of Guangdong Province (LYM10008 
and sybzzxm201108). 
7. References 
[1] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. 
[2] Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of 
hepatocellular carcinoma.Nat Clin Pract Oncol. 2007;4:424-32. 
[3] Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular 
carcinoma. Hepatology. 2002;35:519-24. 
[4] Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence 
after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 
2002;20:1775-85. 
[5] Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 
2004;41:864-80. 
[6] Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and 
prognosis in hepatocellular carcinoma based on a unique immune response 
signature of the liver microenvironment. Cancer Cell. 2006;10:99-111. 
[7] Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. 
Langenbecks Arch Surg. DOI: 10.1007/s00423-011-0783-x. 
[8] Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T-
cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 
2011;41:2314-22. 
[9] Kuang DM, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to 
disease progression by fostering angiogenesis in hepatocellular carcinoma. J 
Hepatol. 2011;54:948-55. 
[10] Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell 
impairment and poor survival in hepatocellular carcinoma patients. 
Gastroenterology. 2007;132:2328-39. 
[11] Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is 
associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 
2007;25:2586-93. 
[12] Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 
2006;6:295-307. 
[13] Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are 
mediated by tumor cells. Annu Rev Immunol. 2007;25:267-96. 
 
Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma 
 
169 
[14] Zou W. Immunosuppressive networks in the tumour environment and their therapeutic 
relevance. Nat Rev Cancer. 2005;5:263-74. 
[15] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 
2008;454:436-44. 
[16] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat 
Rev Immunol. 2008;8:958-69. 
[17] Lewis CE, Pollard JW. Distinct role of macrophages in different tumor 
microenvironments. Cancer Res. 2006;66:605-12. 
[18] Pollard JW. Tumour-educated macrophages promote tumour progression and 
metastasis. Nat Rev Cancer. 2004;4:71-8. 
[19] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 
2005;5:953-64. 
[20] Kuang DM, Wu Y, Chen N, et al. Tumor-derived hyaluronan induces formation of 
immunosuppressive macrophages through transient early activation of monocytes. 
Blood. 2007;110:587-95. 
[21] Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of 
hepatocellular carcinoma foster immune privilege and disease progression through 
PD-L1. J Exp Med. 2009;206:1327-37. 
[22] Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor 
prognosis in patients with primary hepatocellular carcinoma after resection. Hum 
Pathol. 2009;40:381-9. 
[23] Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumor stroma in 
cancer. Nat Rev Cancer. 2004;4:839-49. 
[24] Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu 
Rev Pathol. 2006;1:119-150. 
[25] Ahmed F, Steele JC, Herbert JM, et al. Tumor stroma as a target in cancer. Curr Cancer 
Drug Targets. 2008;8:447-453. 
[26] Zhou J, Ding T, Pan W, et al. Increased intratumoral regulatory T cells are related to 
intratumoral macrophages and poor prognosis in hepatocellular carcinoma 
patients. Int J Cancer. 2009;125:1640-8. 
[27] Doskali M, Tanaka Y, Ohira M, et al. Possibility of adoptive immunotherapy with 
peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing 
antihepatocellular carcinoma and antihepatitis C virus activity. J Immunother. 
2011;34:129-38. 
[28] Abushahba W, Balan M, Castaneda I, et al. Antitumor activity of type I and type III 
interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010;59:1059-71. 
[29] Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-
associated antigen-specific t-cell responses in patients with hepatocellular 
carcinoma. Hepatology. 2011;53:1206-16. 
[30] Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of 
hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45:246-53. 
[31] Hiroishi K, Eguchi J, Baba T, et al. Strong CD8(+) T-cell responses against tumor-
associated antigens prolong the recurrence-free interval after tumor treatment in 
patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451-8. 
[32] Komita H, Homma S, Saotome H, et al. Interferon-gamma produced by interleukin-12-
activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse 
hepatocellular carcinoma. J Hepatol. 2006;45:662-72. 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
170 
[33] Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J 
Hepatol. 2011;54:830-4. 
[34] Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-9. 
[35] Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with 
hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 
1998;83:58-63. 
[36] Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with 
hepatocellular carcinoma relative to early development and tumor invasion. 
Cancer. 1990;65:926-30. 
[37] Miyagi T, Takehara T, Tatsumi T, et al. CD1d-mediated stimulation of natural killer T 
cells selectively activates hepatic natural killer cells to eliminate experimentally 
disseminated hepatoma cells in murine liver. Int J Cancer. 2003;106:81-9. 
[38] Nedvetzki S, Sowinski S, Eagle RA, et al. Reciprocal regulation of human natural killer 
cells and macrophages associated with distinct immune synapses. Blood. 
2007;109:3776-85. 
[39] Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-
associated squamous carcinogenesis. Cancer Cell. 2010;17:121-34. 
[40] de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic 
inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-23. 
[41] Chen X, Fu S, Chen F, et al. Identification of tumor-associated antigens in human 
hepatocellular carcinoma by autoantibodies. Oncol Rep. 2008;20:979-85. 
[42] Heo CK, Woo MK, Yu DY, et al. Identification of autoantibody against fatty acid 
synthase in hepatocellular carcinoma mouse model and its application to diagnosis 
of HCC. Int J Oncol. 2010;36:1453-9. 
[43] Nakano K, Orita T, Nezu J, et al. Anti-glypican 3 antibodies cause ADCC against 
human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 
2009;378:279-84. 
[44] Beckebaum S, Zhang X, Chen X, et al. Increased levels of interleukin-10 in serum from 
patients with hepatocellular carcinoma correlate with profound numerical 
deficiencies and immature phenotype of circulating dendritic cell subsets. Clin 
Cancer Res. 2004;10:7260-9. 
[45] Li L, Li SP, Min J, et al. Hepatoma cells inhibit the differentiation and maturation of 
dendritic cells and increase the production of regulatory T cells. Immunol Lett. 
2007;114:38-45. 
[46] Kuang DM, Zhao Q, Xu J, et al. Tumor-educated tolerogenic dendritic cells induce 
CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent 
pathways. J Immunol. 2008;181:3089-98. 
[47] Wei S, Kryczek I, Edwards RP, et al. Interleukin-2 administration alters the 
CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. 
Cancer Res. 2007;67:7487-94. 
[48] Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian 
carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 
2004;10:942-9. 
[49] Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing 
CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. 
J Immunol. 1999;163:5211-18. 
 
Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma 
 
171 
[50] Steitz J, Bruck J, Lenz J, et al. Depletion of CD25(+) CD4(+) T cells and treatment with 
tyrosinase-related protein 2-transduced dendritic cells enhance the interferon 
alpha-induced. CD8(+) T-cell-dependent immune defense of B16 melanoma. 
Cancer Res. 2001;61:8643-6. 
[51] Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen 
selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector 
functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8. 
[52] Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T 
cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo 
and in vitro. Int J Cancer. 2007;120:2723-33. 
[53] Li YW, Qiu SJ, Fan J, et al. Intratumoral neutrophils: a poor prognostic factor for 
hepatocellular carcinoma following resection. J Hepatol. 2011;54:497-505. 
[54] Kuang DM, Peng C, Zhao Q, et al. Activated monocytes in peritumoral stroma of 
hepatocellular carcinoma promote expansion of memory T helper 17 cells. 
Hepatology. 2010;51:154-64. 
[55] Kuang DM, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of 
IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol. 
2010;185:1544-9.  
[56] Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with 
poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980-9. 
[57] Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev 
Immunol. 2010;10:248-56. 
[58] Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and 
functional and clinical relevance of Th17 cells in the human tumor environments. 
Blood. 2009;114:1141-9. 
[59] Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev 
Immunol. 2000;18:767-811. 
[60] Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive 
macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871-81. 
[61] Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated 
macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends 
Immunol. 2002;23:549-55. 
[62] Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword 
in cancer progression. J Clin Oncol. 2005;23:953-64. 
[63] Katakura T, Miyazaki M, Kobayashi M, et al. CCL17 and IL-10 as effectors that enable 
alternatively activated macrophages to inhibit the generation of classically 
activated macrophages. J Immunol. 2004;172:1407-13. 
[64] Maeda H, Kuwahara H, Ichimura Y, et al. TGF-beta enhances macrophage ability to 
produce IL-10 in normal and tumor-bearing mice. J Immunol. 1995;155:4926-32. 
[65] Satoh T, Saika T, Ebara S, et al. Macrophages transduced with an adenoviral vector 
expressing interleukin 12 suppress tumor growth and metastasis in a preclinical 
metastatic prostate cancer model. Cancer Res. 2003;63:7853-60. 
[66] Watkins SK, Egilmez NK, Suttles J, et al. IL-12 rapidly alters the functional profile of 
tumorassociated and tumor-infiltrating macrophages in vitro and in vivo. J 
Immunol. 2007;178:1357-62. 
[67] Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages 
toward a tumor-associated phenotype. J Immunol. 2006;176:5023-32. 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
170 
[33] Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J 
Hepatol. 2011;54:830-4. 
[34] Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-9. 
[35] Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with 
hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 
1998;83:58-63. 
[36] Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with 
hepatocellular carcinoma relative to early development and tumor invasion. 
Cancer. 1990;65:926-30. 
[37] Miyagi T, Takehara T, Tatsumi T, et al. CD1d-mediated stimulation of natural killer T 
cells selectively activates hepatic natural killer cells to eliminate experimentally 
disseminated hepatoma cells in murine liver. Int J Cancer. 2003;106:81-9. 
[38] Nedvetzki S, Sowinski S, Eagle RA, et al. Reciprocal regulation of human natural killer 
cells and macrophages associated with distinct immune synapses. Blood. 
2007;109:3776-85. 
[39] Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-
associated squamous carcinogenesis. Cancer Cell. 2010;17:121-34. 
[40] de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic 
inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-23. 
[41] Chen X, Fu S, Chen F, et al. Identification of tumor-associated antigens in human 
hepatocellular carcinoma by autoantibodies. Oncol Rep. 2008;20:979-85. 
[42] Heo CK, Woo MK, Yu DY, et al. Identification of autoantibody against fatty acid 
synthase in hepatocellular carcinoma mouse model and its application to diagnosis 
of HCC. Int J Oncol. 2010;36:1453-9. 
[43] Nakano K, Orita T, Nezu J, et al. Anti-glypican 3 antibodies cause ADCC against 
human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 
2009;378:279-84. 
[44] Beckebaum S, Zhang X, Chen X, et al. Increased levels of interleukin-10 in serum from 
patients with hepatocellular carcinoma correlate with profound numerical 
deficiencies and immature phenotype of circulating dendritic cell subsets. Clin 
Cancer Res. 2004;10:7260-9. 
[45] Li L, Li SP, Min J, et al. Hepatoma cells inhibit the differentiation and maturation of 
dendritic cells and increase the production of regulatory T cells. Immunol Lett. 
2007;114:38-45. 
[46] Kuang DM, Zhao Q, Xu J, et al. Tumor-educated tolerogenic dendritic cells induce 
CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent 
pathways. J Immunol. 2008;181:3089-98. 
[47] Wei S, Kryczek I, Edwards RP, et al. Interleukin-2 administration alters the 
CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. 
Cancer Res. 2007;67:7487-94. 
[48] Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian 
carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 
2004;10:942-9. 
[49] Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing 
CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. 
J Immunol. 1999;163:5211-18. 
 
Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma 
 
171 
[50] Steitz J, Bruck J, Lenz J, et al. Depletion of CD25(+) CD4(+) T cells and treatment with 
tyrosinase-related protein 2-transduced dendritic cells enhance the interferon 
alpha-induced. CD8(+) T-cell-dependent immune defense of B16 melanoma. 
Cancer Res. 2001;61:8643-6. 
[51] Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen 
selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector 
functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8. 
[52] Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T 
cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo 
and in vitro. Int J Cancer. 2007;120:2723-33. 
[53] Li YW, Qiu SJ, Fan J, et al. Intratumoral neutrophils: a poor prognostic factor for 
hepatocellular carcinoma following resection. J Hepatol. 2011;54:497-505. 
[54] Kuang DM, Peng C, Zhao Q, et al. Activated monocytes in peritumoral stroma of 
hepatocellular carcinoma promote expansion of memory T helper 17 cells. 
Hepatology. 2010;51:154-64. 
[55] Kuang DM, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of 
IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol. 
2010;185:1544-9.  
[56] Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with 
poor survival in hepatocellular carcinoma patients. J Hepatol. 2009;50:980-9. 
[57] Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev 
Immunol. 2010;10:248-56. 
[58] Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and 
functional and clinical relevance of Th17 cells in the human tumor environments. 
Blood. 2009;114:1141-9. 
[59] Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev 
Immunol. 2000;18:767-811. 
[60] Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive 
macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871-81. 
[61] Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated 
macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends 
Immunol. 2002;23:549-55. 
[62] Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-edged sword 
in cancer progression. J Clin Oncol. 2005;23:953-64. 
[63] Katakura T, Miyazaki M, Kobayashi M, et al. CCL17 and IL-10 as effectors that enable 
alternatively activated macrophages to inhibit the generation of classically 
activated macrophages. J Immunol. 2004;172:1407-13. 
[64] Maeda H, Kuwahara H, Ichimura Y, et al. TGF-beta enhances macrophage ability to 
produce IL-10 in normal and tumor-bearing mice. J Immunol. 1995;155:4926-32. 
[65] Satoh T, Saika T, Ebara S, et al. Macrophages transduced with an adenoviral vector 
expressing interleukin 12 suppress tumor growth and metastasis in a preclinical 
metastatic prostate cancer model. Cancer Res. 2003;63:7853-60. 
[66] Watkins SK, Egilmez NK, Suttles J, et al. IL-12 rapidly alters the functional profile of 
tumorassociated and tumor-infiltrating macrophages in vitro and in vivo. J 
Immunol. 2007;178:1357-62. 
[67] Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages 
toward a tumor-associated phenotype. J Immunol. 2006;176:5023-32. 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
172 
[68] Wu K, Kryczek I, Chen L, et al. Kupffer cell suppression of CD8+ T cells in human 
hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. 
Cancer Res. 2009;69:8067-75. 
[69] Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with 
severity of liver damage in patients with chronic hepatitis B. Hepatology. 
2010;51:81-91. 
[70] Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-
specific regulatory T cells and tolerogenic APC. J Immunol. 2005;174:5907-14. 
[71] Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan 
catabolism. Nat Rev Immunol. 2004;4:762-74. 
[72] Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476-83. 
[73] Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of 
age. Blood. 2006;108:1435-40. 
[74] Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress 
experimental autoimmune thyroiditis by activation of thyroglobulin-specific 
CD4+CD25+ T cells. J Immunol. 2005;174:7433-39. 
[75] Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat 
Rev Immunol. 2008;8:467-77. 
[76] Wu Y, Zhao Q, Peng C, et al. Neutrophils promote motility of cancer cells via a 
hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011;225:438-47. 
[77] Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human 
dendritic cells revisited. Trends Immunol. 2006;27:68-73. 
[78] Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance 
mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. 
Nat Med. 2003;9:1269-1274. 
[79] Godin-Ethier J, Pelletier S, Hanafi LA, et al. Human activated T lymphocytes modulate 
IDO expression in tumors through Th1/Th2 balance. J Immunol. 2009;183:7752-60. 
[80] Wald O, Izhar U, Amir G, et al. CD4+CXCR4highCD69+T cells accumulate in lung 
adenocarcinoma. J Immunol. 2006;177:6983-90. 
[81] Han Y, Guo Q, Zhang M, et al. CD69+ CD4+ CD25- T cells, a new subset of regulatory T 
cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J 
Immunol. 2009;182:111-20. 
[82] Gu T, Rowswell-Turner RB, Kilinc MO, et al. Central role of IFNgamma-indoleamine 2, 
3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. 
Cancer Res. 2010;70:129-38. 
[83] Cheng J, Huo DH, Kuang DM, et al. Human macrophages promote the motility and 
invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 2007;67:5141-7. 
[84] Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: 
novel suppressive mode for regulatory T cells. J Immunol. 2006;177:40-44. 
[85] Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections 
to chronic inflammation and cancer. Cell. 2006;124:823-35. 
[86] Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev 
Immunol. 2004;4:641-8. 
9 
Macrophages and Microglia 
in Brain Malignancies 
Cristina Riccadonna and Paul R. Walker 
Geneva University Hospitals and University of Geneva, 
Switzerland 
1. Introduction  
Tumour and myeloid cell interactions that occur in the brain are exposed to unique 
microenvironmental conditions. While tumour outgrowth ultimately has a major impact, 
the intrinsic properties of the brain initially impose the framework on which subsequent 
cellular interactions must build. The particularities of the brain are partly anatomical, with 
strictly controlled traffic of cells and molecules from the blood by virtue of the blood brain 
barrier (BBB). But they are also due to a unique cellular composition not found outside the 
nervous system; this includes the neurons and glial cells which have potent 
immunoregulatory properties. Taken together, these factors have been used to attempt to 
explain the “immune privilege” of the brain, which is often used to describe low level 
adaptive immune responses. But in addition immune privilege also impacts on, and is 
influenced by, the brain myeloid cells which are the subject of this chapter.  
Our understanding of immune privilege must be defined and put into context, since it was 
originally used in the restricted field of the extended survival of allografts in the brain 
compared with that achieved in other sites (Barker & Billingham, 1977; Medawar, 1948). 
Over the years, the concept and terminology has often been used to apply to any situation of 
low or absent immune reactivity in the brain. Indeed, this seemed consistent with the 
overriding need to control inflammatory reactions in the brain because of their potentially 
deleterious consequences to critical neuronal functions with low regenerative capacity. 
Moreover, immune privilege also seemed consistent with an apparent isolation of the brain 
behind the BBB, and the absence of draining lymphatics and immune competent cells from 
much of the brain. However, this over simplistic interpretation of the brain as an immune 
privileged site has now been reassessed to define it as an immune specialized site, where 
immune cells are poised to respond to injury and infection, but in a highly regulated way 
(Carson et al., 2006; Galea et al., 2007). A further complexity of this updated concept of 
immune privilege is that this status is not uniform throughout the brain, and in addition, the 
myeloid cell populations are distinct in different brain regions. As argued by Perry and 
colleagues (Galea et al., 2007), the brain parenchyma is the brain compartment that exhibits 
most features associated with immune privilege. Other brain regions with distinct immune 
properties are the ventricles containing the choroid plexus and the cerebrospinal fluid (CSF), 
the meninges, and the perivascular space. Brain tumours can of course potentially invade 
any or all of these brain sites, but how this influences interactions with myeloid cells has not 
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1. Introduction  
Tumour and myeloid cell interactions that occur in the brain are exposed to unique 
microenvironmental conditions. While tumour outgrowth ultimately has a major impact, 
the intrinsic properties of the brain initially impose the framework on which subsequent 
cellular interactions must build. The particularities of the brain are partly anatomical, with 
strictly controlled traffic of cells and molecules from the blood by virtue of the blood brain 
barrier (BBB). But they are also due to a unique cellular composition not found outside the 
nervous system; this includes the neurons and glial cells which have potent 
immunoregulatory properties. Taken together, these factors have been used to attempt to 
explain the “immune privilege” of the brain, which is often used to describe low level 
adaptive immune responses. But in addition immune privilege also impacts on, and is 
influenced by, the brain myeloid cells which are the subject of this chapter.  
Our understanding of immune privilege must be defined and put into context, since it was 
originally used in the restricted field of the extended survival of allografts in the brain 
compared with that achieved in other sites (Barker & Billingham, 1977; Medawar, 1948). 
Over the years, the concept and terminology has often been used to apply to any situation of 
low or absent immune reactivity in the brain. Indeed, this seemed consistent with the 
overriding need to control inflammatory reactions in the brain because of their potentially 
deleterious consequences to critical neuronal functions with low regenerative capacity. 
Moreover, immune privilege also seemed consistent with an apparent isolation of the brain 
behind the BBB, and the absence of draining lymphatics and immune competent cells from 
much of the brain. However, this over simplistic interpretation of the brain as an immune 
privileged site has now been reassessed to define it as an immune specialized site, where 
immune cells are poised to respond to injury and infection, but in a highly regulated way 
(Carson et al., 2006; Galea et al., 2007). A further complexity of this updated concept of 
immune privilege is that this status is not uniform throughout the brain, and in addition, the 
myeloid cell populations are distinct in different brain regions. As argued by Perry and 
colleagues (Galea et al., 2007), the brain parenchyma is the brain compartment that exhibits 
most features associated with immune privilege. Other brain regions with distinct immune 
properties are the ventricles containing the choroid plexus and the cerebrospinal fluid (CSF), 
the meninges, and the perivascular space. Brain tumours can of course potentially invade 
any or all of these brain sites, but how this influences interactions with myeloid cells has not 
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generally been defined. However, it should be noted that most experimentally induced or 
grafted tumours are in the brain parenchyma, and so the initial contact will be with 
parenchymal myeloid cells. For the same reason, although most of the neuroimmunology 
described in this chapter could apply more generally to the central nervous system, we refer 
more specifically to the brain, to maintain a direct link to the vast majority of available 
information on malignancies.  
2. The myeloid cells of the brain  
Myeloid cells are abundantly present in the healthy brain, representing between 5% and 
20% of cells, depending on the specific location. Their histological appearance, their origin, 
and potentially their functions are distinct from those found in other tissues. The phenotypic 
classification of brain myeloid cells by defined markers is challenging, which has led to 
imprecise or changing nomenclature over the years. This terminology arose from 
histological studies around a century ago, which distinguished the small, ramified 
microglial cell of the parenchyma from the larger “macroglial” cells such as the astrocytes, 
oligodendrocytes and ependymal cells, as recently reviewed (Ransohoff & Cardona, 2010). 
Parenchymal microglial cells are considered to be the resident macrophages of the brain. 
Those myeloid cells populating other brain compartments are generally referred to as 
macrophages, prefixed with their localization (choroid plexus, meningeal, perivascular) 
(Hickey et al., 1992; Matyszak et al., 1992). Confusingly, the term microglia has also 
sometimes been used for these cell types (or even dendritic-like cells, or perivascular cells), 
although as we shall discuss, recent studies indicate that the origin of these macrophages is 
distinct from parenchymal microglia, and so in this chapter we retain the term microglia 
only for parenchymal cells.  
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blood vessels in the 
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presentation. 
Table 1. Principal myeloid populations in the healthy brain.  
Myeloid cells of each type in the listed location are identified in all species analysed (generally humans, 
rat, and mouse). The phenotypic markers may be species-specific. The function is often presumed rather 
than experimentally demonstrated in all species. 
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2.1 Parenchymal microglial cells – Origins and phenotypic definition 
The origins of microglial cells have been debated for many decades. The difficulties in 
reaching definitive conclusions are partially linked to the lack of unique markers to 
differentiate the microglia from other myeloid cells, and the inherent plasticity of myeloid 
cells to differentiate or modulate expression of many key markers (Geissmann et al., 2010; 
Santambrogio et al., 2001). From the 1990’s accumulating evidence finally assigned 
microglia to the myeloid lineage (Prinz & Mildner, 2011; Ransohoff & Cardona, 2010), thus 
distancing them from the neuroectoderm derived macroglia. The subsequent question that 
has been more elusive to answer is whether microglia derive from the bone marrow. Here a 
distinction must be made between the principle origin of parenchymal microglial cells in 
embryonic development, and their potential replenishment in the adult. Compelling 
evidence based on in vivo lineage tracing studies in mice indicated that microglia form an 
ontogenically distinct population in the mononuclear phagocyte system. The microglia that 
populate the adult brain parenchyma derive from myeloid progenitors in the yolk sac. This 
first primitive hematopoiesis temporally precedes and it is distinct from the definitive 
hematopoietic wave which gives rise to circulating hematopoietic precursors, including 
monocytes (Ginhoux et al., 2010).  
The mechanism by which the parenchymal microglial population is replenished during adult 
life or in pathological situations has been challenging to elucidate. First, as will be discussed, it 
is difficult to unambiguously differentiate parenchymal microglia from other macrophages. 
Second, the use of radiation bone marrow chimeras to conveniently replace bone marrow stem 
cells with labelled donor cells inevitably introduces artefacts such as vessel damage, and 
abnormal proportions and fluxes of donor stem cells in the circulation. With these limitations 
in mind, initial data suggested replenishment from bone marrow precursors (Flugel et al., 
2001). However, elegant experiments based on parabiosis rather than radiation indicated that 
self-renewal within the brain is sufficient to maintain the adult parenchymal microglial 
population (Ajami et al., 2007). Nevertheless, in certain pathologies, repopulation from bone-
marrow derived precursors remains a possibility (Soulet & Rivest, 2008). 
The original definition of parenchymal microglia was based on morphology and localization 
in brain parenchyma. Specific markers are clearly essential to objectively compare findings 
between research groups, and to manipulate microglial cells in vitro. However, most markers 
are shared with other tissue macrophage populations, thus CD11b/CD18 (integrin αMβ2) is 
expressed, as well as F4/80 in mouse microglia. Constitutive expression of MHC class II, and 
costimulatory molecules is generally low on parenchymal microglia. The low expression of 
many myeloid markers may be reinforced by neuron-microglial-cell inhibitory signalling 
through cell surface and soluble ligands (Ransohoff & Cardona, 2010). The principal tool to 
distinguish parenchymal microglia from other brain macrophages has been the level of CD45 
expression (leukocyte common antigen, Ly-5): microglia are characterized by low CD45 
expression, whereas other macrophages are CD45high (Ford et al., 1995). However, this 
distinction can only be achieved by flow cytometry, not by immunohistochemistry. 
Parenchymal microglia of human origin are more problematic to identify, and no markers 
have been consistently described to discriminate among the two cell populations (Wu et al., 
2010). Moreover, non-pathogical human brain tissue is infrequently studied, and so it is 
unclear what proportion of parenchymal microglia compared with other activated 
macrophage populations is to be expected. Nevertheless, at least one study has suggested that 
human parenchymal microglia can be identified as CD11b+, CD45low, and unlike other brain 
macrophages, negative for CD14 (Parney et al., 2009). 
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2.2 Non-microglial brain macrophages – Origins and phenotypic definition 
The myeloid populations in non-parenchymal regions of the brain are phenotypically closer 
to their extracranial counterparts than parenchymal microglia (Hickey et al., 1992). 
Moreover, whilst cranial irradiation does not deplete parenchymal microglial cells, other 
myeloid cells are radiosensitive and are readily replenished from bone marrow precursors 
within about 4 to 8 weeks (Chinnery et al., 2010; Hickey & Kimura, 1988).  
A wide diversity of phenotypes, in humans and rodents, is reported for choroid plexus 
myeloid cells: from classical tissue macrophages, to dendritic or “dendriform” like cells 
(Chinnery et al., 2010; Matyszak et al., 1992; McMenamin, 1999; Serot et al., 2000). In human 
tissue, there was an absence of co-stimulatory molecule expression (CD40, CD80, CD86) on 
these cells (Serot et al., 2000), but this was not studied in rodent origin choroid plexus 
derived cells. Similarly, in the meninges, pleomorphic myeloid cells with either macrophage 
or dendritic cell like features can be identified (Chinnery et al., 2010; McMenamin, 1999; 
McMenamin et al., 2003).  
The non-parenchymal site that has been the most thoroughly studied is the perivascular 
space, with myeloid cells strategically located to engage in dialogue with both blood-born 
immigrants and parenchymal residents. Moreover, these perivascular myeloid cells are 
proposed to contribute to BBB function (Bechmann et al., 2007). Phenotypically, perivascular 
myeloid cells can be macrophage-like or dendriform, although often this is based only on 
morphology, as dendritic cell specific markers have not been used in all studies (Flaris et al., 
1993; Platten & Steinman, 2005). 
2.3 Functions of microglia and brain macrophages in the healthy and diseased brain 
The spectrum of functional activities reported for myeloid cells in the brain is as wide as for 
conventional tissue macrophages, and will depend upon the stimulus or pathology that is 
inducing activation. Although the focus of this chapter is to understand myeloid cells and 
brain tumours, other pathologies (especially autoimmune and neurodegenerative diseases) 
have furnished a lot of basic information about myeloid cell function. These findings are 
therefore discussed first before considering the impact of malignancy on these complex 
cellular interactions.  
Attributing functions specifically to “microglial cells” or “brain macrophages” necessitates 
clarification of certain basic assumptions about the identity of these cells. A microglial cell 
assumes its overall morphology, its specific phenotype and its functions largely because of 
its localization in the brain parenchyma. If we wish to isolate brain myeloid cells using CD45 
staining intensity to differentiate microglia from other macrophages, we must accept the 
inherent limitations of this marker which is not necessarily expressed at a constant level in 
different in vivo pathologies, or in vitro. Moreover, cells cultured in vitro will be exposed to 
a microenvironment totally distinct from the brain parenchyma, and when cultured in 
serum containing medium, will be exposed to known microglial activators such as 
fibrinogen (Adams et al., 2007). These issues were thoroughly and quantitatively addressed 
using gene expression analysis of microglia activated by LPS/IFN-γ in vitro versus in vivo, 
with similar experiments performed for peritoneal and brain infiltrating macrophages 
(Schmid et al., 2009). This important study showed that brain-resident microglia are 
heterogeneous, with very different gene expression patterns after stimulation in vitro and in 
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vivo. Furthermore, the brain micro-environment was a more important factor in 
determining gene expression than the origin of the myeloid cells tested. The “microglia” and 
“brain macrophage” functions that we will now describe must therefore be interpreted with 
these complexities of terminology in mind, together with the limitations of in vitro tests that 
may not recapitulate the significantly overlapping properties of these cells in the in vivo 
brain microenvironment. 
2.3.1 Transition of parenchymal microglia from “resting” to “activated” 
In the healthy brain, parenchymal microglial cells are termed “resting” cells, 
morphologically identified as ramified cells with small soma and fine cellular processes. 
However, so called resting microglia have been proposed to be actively involved in 
maintaining synaptic integrity, indicating a different functional status than would be 
expected from a macrophage, as recently discussed (Graeber, 2010). With the advent of two-
photon microscopy able to visualize microglia in situ in the living mouse, the term “resting” 
is even more directly seen to be a misnomer, as these cells are dynamically surveying their 
microenvironment (Davalos et al., 2005; 2008; Nimmerjahn et al., 2005). Time-lapse imaging 
experiments demonstrated that microglial processes are motile and continuously (over 
periods of a few minutes) extend and retract to survey neighbouring astrocytes, neuronal 
cell bodies, and blood vessels. Upon tissue damage or signals that might mimic infection 
(application of LPS), microglia were capable of targeted movement of their processes 
towards the injured site, leading to a barrier of intertwined processes between damaged and 
healthy tissue (Davalos et al., 2005). Although not directly demonstrated, it is likely that the 
same processes can occur in malignant pathologies. A key signal that promoted this 
microglial activation was ATP, binding to the purinergic P2Y12 receptor on microglia. The 
source of ATP mediating these effects is proposed to be from both damaged cells and ATP-
induced ATP release from astrocytes.  
Microglial cell activation results in changes in morphology and function that are postulated 
to be directly linked to the consequences of initial chemoattraction by ATP (Orr et al., 2009). 
Extracellular ATP can be degraded to adenosine by microglia expressed ectonucleotidases, 
such as CD39 and CD73, which then leads to activation of the adenosine A2A receptor and 
process retraction by the microglia. Further activation of the microglial cell will occur when 
those elements maintaining their “resting” (but surveillant) status are removed. Since many 
of these inhibitory signals come from neurons, if tissue damage has perturbed neuronal 
function, this will remove or limit negative signalling, such as that mediated by CD200 
(Chitnis et al., 2007; Hoek et al., 2000) or CX3CL1 (fractaline) (Cardona et al., 2006). The 
activated microglial cell becomes amoeboid in shape, motile, and phagocytic, i.e., very 
similar to other macrophages.  
2.3.2 Functions of activated microglia and brain macrophages 
Microglia not only change in morphology upon activation, but also increase in number. 
Indeed, unlike most tissue macrophages, brain-resident microglia have a high potential for 
proliferation (Ajami et al., 2007; Graeber et al., 1998). Microglial functions can be potent, and 
so can either be beneficial or pathogenic according to the tissue targeted and when it is 
targeted. The products released by fully activated microglial cells include reactive oxygen 
species, nitric oxide (NO), and tumour necrosis factor (TNF), all of which can damage 
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those elements maintaining their “resting” (but surveillant) status are removed. Since many 
of these inhibitory signals come from neurons, if tissue damage has perturbed neuronal 
function, this will remove or limit negative signalling, such as that mediated by CD200 
(Chitnis et al., 2007; Hoek et al., 2000) or CX3CL1 (fractaline) (Cardona et al., 2006). The 
activated microglial cell becomes amoeboid in shape, motile, and phagocytic, i.e., very 
similar to other macrophages.  
2.3.2 Functions of activated microglia and brain macrophages 
Microglia not only change in morphology upon activation, but also increase in number. 
Indeed, unlike most tissue macrophages, brain-resident microglia have a high potential for 
proliferation (Ajami et al., 2007; Graeber et al., 1998). Microglial functions can be potent, and 
so can either be beneficial or pathogenic according to the tissue targeted and when it is 
targeted. The products released by fully activated microglial cells include reactive oxygen 
species, nitric oxide (NO), and tumour necrosis factor (TNF), all of which can damage 
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neurons and glial cells (Block et al., 2007), although whether this is directly linked to 
neurodegenerative disease is disputed by some (Graeber & Streit, 2010). The other side of 
the spectrum of microglial cell function is that of neuroprotection, in which there is 
abundant evidence for beneficial functions (Glezer et al., 2007; Hanisch & Kettenmann, 
2007). Probably most functions of an activated microglial cell could be carried out by other 
brain macrophages, and so unless specifically stated otherwise, the references to microglial 
cell function do not exclude this possibility. 
Migration. Proliferation is not sufficient to explain the high density of microglia around 
brain lesions; migration is also necessary (Carbonell et al., 2005a; 2005b). One study, using 
focal laser injury in ex vivo retinal explants, suggested that transition to a migratory 
phenotype could occur whilst microglia remain in the “resting” ramified morphology (Lee 
et al., 2008). However, in most pathologies, migratory microglia will be amoeboid and 
“activated”. Microglial migration is under control of several types of receptors: those found 
on other macrophages, as well as receptors such as purinergic receptors generally found on 
neural cells. Capacity to migrate towards certain stimuli is generally assessed using in vitro 
assays, and so their relative importance awaits in vivo validation. Among the key 
chemokine-chemokine receptor interactions, CCL21 produced by damaged neurons can 
attract microglia via CXCR3 (Biber et al., 2001); CX3CL1 (fractaline) produced by neurons 
and astrocytes signals through CX3CR1 on microglia (Cardona et al., 2006; Liang et al., 
2009); stromal cell derived factor-1α (SDF-1α) binds to CXCR4+ microglia (X. Wang et al., 
2008); and monocyte chemotactic protein 1 (MCP-1, CCL2) produced by many brain cells, 
including microglia themselves, signals through CCR2 (Simpson et al., 1998). The multiple 
non-chemokine receptors expressed by activated microglial cells facilitate migration 
towards other categories of stimuli present in the brain, including neurotransmitters, 
cannabinoids, lysophosphatidic acid (LSA), opioids, bradykinin, and various growth factors. 
These have recently been comprehensively reviewed (Kettenmann et al., 2011).  
Phagocytosis. A major function of activated microglia is phagocytosis: it is essential during 
brain development, for homeostatic debris clearance in the normal brain, and can tilt the 
balance towards neuroprotection or neurodegeneration. It can also provide a link to 
adaptive immune responses if phagocytosed antigenic proteins are processed and presented 
to T cells. Activated microglial cells can express a wide array of phagocytic receptors, both 
those responsible for pathogen recognition and clearance, and those facilitating removal of 
apoptotic cells (Kettenmann et al., 2011; Neumann et al., 2009). Of the former category, Toll 
like receptors (TLRs) 1-9, Fc receptors, scavenger receptors, and complement receptors can 
be expressed, ligation of which will generally lead to an inflammatory response, with 
release of TNF, IL-1 and nitric oxide. Receptors of the latter category include TREM2 
(triggering receptor expressed on myeloid cells-2), purine receptors (some of which are not 
found on other macrophages), and phosphatidylserine receptors. Ligation of this category of 
receptors can lead to anti-inflammatory signalling and release of TGF-β and IL-10.  
Antigen presentation. As microglia are certainly sentinel cells of the brain parenchyma, and 
they are the most abundant phagocyte, are they also antigen presenting cells (APCs) for T 
cells? A prerequisite is expression of MHC class II (for CD4 T cells) and MHC class I (for 
CD8 T cells), and costimulatory molecules. The level of expression of these molecules is 
totally dependent upon the activating and inhibitory factors perceived by the microglial cell 
(Aloisi et al., 2000). The antigen presenting capacity as tested in vitro (sometimes ex vivo) on 
 
Macrophages and Microglia in Brain Malignancies 
 
179 
CD4 T cells can vary from full to partial activation, to apoptosis induction (Ford et al., 1996; 
Frei et al., 1994; Matyszak et al., 1999; Platten & Steinman, 2005). The status of microglia as 
APC in vivo, in different pathologies, is therefore a key question. Accumulating evidence 
from rodent experimental autoimmune encephalomyelitis (EAE) models has now identified 
that the principal cell able to present antigen to restimulate infiltrating CD4 T cells resides in 
the perivascular space (Hickey & Kimura, 1988; McMahon et al., 2005), or the meninges 
(Bartholomaus et al., 2009). Unlike parenchymal microglia, these perivascular myeloid cells 
are radiosensitive, and may even have dendritic morphology and CD11c expression. The 
role of the parenchymal microglial cells in these EAE models was proposed to be to 
augment pathology by the release of T cell stimulating cytokines and toxic mediators such 
as IL-12, IL-23, osteopontin, and reactive oxygen species (Heppner et al., 2005; Platten & 
Steinman, 2005).  
Antigen presentation of exogenously acquired antigens on MHC class I molecules (cross-
presentation) is essential for CD8 T cell immune responses, but is an inefficient process in 
most cells. In vivo, certain subsets of dendritic cells (that are CD11c+CD8+ in the mouse) are 
considered to be the principle cross-presenting APC (Lin et al., 2008), but these have not 
been reported in the brain. However, one study showed that in the adult mouse, microglia 
can take up soluble ovalbumin and present processed antigen to CD8 T cells (Beauvillain et 
al., 2008), albeit with modest efficiency. These results are similar to earlier studies in the rat, 
although in this study the authors suggested that antigen presentation was very feeble and 
should be considered as compromised (Flugel et al., 1999). A further cross-presenting brain 
APC candidate is a ramified, radioresistant cell found in the parenchyma of mice that is 
CD11b+CD11c+MHCII-, termed a “brain DC” by the authors, but with a very similar 
phenotype to microglial cells. When activated in vivo with IFN-γ, then tested in vitro for 
stimulation of ovalbumin specific CD8 (and CD4) T cells, this APC could present and cross-
present soluble ovalbumin (Gottfried-Blackmore et al., 2009). The in vivo significance of 
these cells and their relation to other myeloid cells in the brain awaits clarification. 
The most stringent task for an APC is to prime naïve T cells. Since naïve T cells normally 
recirculate between blood and secondary lymphoid tissue, this can only occur efficiently in the 
T cell zones of lymph node (or spleen). Therefore, an APC having captured antigen in the 
brain must be able to migrate to the lymph node, which is facilitated by expression of the 
chemokine receptor CCR7, promoting lymph node entry through the high endothelial venules 
in response to a CCL21 chemokine gradient. Murine microglia have been reported to express 
CCR7 (Dijkstra et al., 2006), but functional homing experiments were not performed. Indirect 
evidence points towards dendritic cells (DCs) as being the principle APC candidate to migrate 
from the brain to lymph nodes (Hatterer et al., 2006; Hatterer et al., 2008; Karman et al., 2004), 
although definitive tracking of cell migration required intracranial injection of dendritic cells 
that may not precisely recapitulate endogenous cell behaviour.  
2.4 Brain tumours in humans and animal models  
Cellular heterogeneity has long been accepted to be a hallmark of most brain tumours, and 
even the earliest histological studies suggested that myeloid cells might be present in the 
tumour stroma and peritumoural regions. Multiple histological types of primary and 
metastatic brain tumour are described and are expected to vary in their myeloid cell 
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chemokine receptor CCR7, promoting lymph node entry through the high endothelial venules 
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even the earliest histological studies suggested that myeloid cells might be present in the 
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involvement. The commonest primary brain tumours are astrocytomas (Schwartzbaum et al., 
2006) and of these, the high grade malignant gliomas (WHO grade III and IV) are particularly 
lethal. Malignant glioma is profoundly resistant to conventional treatment modalities, and 
complete surgical resection is impossible because of their inaccessible location and highly 
infiltrative growth characteristics. Thus, even with the best resection possible and combined 
regimens of radiotherapy with new generation chemotherapy, the median survival of patients 
with glioblastoma multiforme (GBM: WHO grade IV glioma) is 14.6 months (Stupp et al., 
2009). For animal studies, the use of xenografted human glioma in immunodeficient mice 
cannot be expected to induce normal myeloid cell responses as the whole immune network is 
perturbed in the host mice. Instead, animal brain tumour models have focused on either 
orthotopically implanted models, historically often in rats (Barth & Kaur, 2009), but increasing 
in mouse models such as GL261 glioma, syngeneic to C57BL/6 mice (Szatmari et al., 2006) 
There is also considerable interest in the use of genetically engineered mouse models that may 
better recapitulate the pathology and heterogeneity of human glioma (Huse & Holland, 2009). 
However, these models were often designed and exploited for genetic studies; they have only 
recently been investigated for immunological parameters.  
2.4.1 Identification of microglia and macrophages in brain tumours  
Although thorough characterization of brain tumour associated myeloid cells had to await 
the advent of monoclonal antibodies, an early pioneering study determined that 
glioblastomas, meningiomas, medulloblastomas, and metastatic tumours were all infiltrated 
by Fc receptor-positive cells, i.e., predominately myeloid cells (Wood & Morantz, 1979). 
These macrophages or microglia were particularly abundant in glioblastoma, representing a 
mean content of 41% (range 5-78%) of the tumour tissue digested to give a single-cell 
suspension. Subsequent studies were able to profit from monoclonal antibodies to better 
define myeloid cells, not only in suspension, but also in tissue sections. In histological 
sections, quantification is somewhat more challenging and difficult to compare between 
studies, but reports from several groups using panels of different antibodies described 
significant myeloid cell infiltration in low grade glioma (Rossi et al., 1988; Shinonaga et al., 
1988), high grade glioma (Rossi et al., 1987; 1989; Shinonaga et al., 1988), as well as 
metastatic brain tumours (Shinonaga et al., 1988). Moreover, although flow cytometric 
analysis on single-cell suspensions of digested human tumour confirmed these findings, 
they did not allow an unequivocal distinction of microglia and other brain macrophages 
(Parney et al., 2009; Watters et al., 2005). Some of the histological studies on microglia and 
macrophage infiltration attempted to make correlations of type or intensity of myeloid cell 
infiltration and tumour type or grade (Nishie et al., 1999; Roggendorf et al., 1996; Rossi et al., 
1988; 1987): there was a tendency for greater infiltration of high grade tumours such as 
glioblastoma. Higher myeloid cell infiltration was proposed to correlate with peritumoural 
oedema (Shinonaga et al., 1988), but not with survival in one early study (Rossi et al., 1989). 
Our contemporary understanding of the complexity of the myeloid cell compartment in the 
brain that we have discussed in section 2 predicts that correlation of survival and simple 
myeloid cell phenotyping and quantification is improbable. A more recent study on a larger 
series of patients with glioblastoma examined polymorphisms in the gene encoding the 
CX3CR1 chemokine receptor, expressed on microglial cells and used in their migration 
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(Rodero et al., 2008). Based on genetic analysis of 230 patients, and immunohistochemistry 
of over 100 patients, expression of one common allelic variant was significantly associated 
with prolonged survival after surgery (23.5 vs 14.1 months; P < .0001), as well as reduced 
microglia/macrophage infiltration. 
In common with many other domains of cancer research, relevant animal models have 
played a major role in advancing our understanding of brain myeloid cells. For brain 
tumours in particular, the inaccessibility of the tumour site in patients often restricts 
studies to a single tumour sample, rodent models have therefore been widely exploited. 
Studies of myeloid cells infiltrating rat gliomas allowed intensity of CD45 expression on 
CD11b+ cells to be used to distinguish parenchymal microglia from other brain 
macrophages. The microglia and macrophage content varied somewhat according to the 
model (C6, 9L, RG-2), with CD45low microglial cells present in peritumoural areas and in 
the hemisphere contralateral to the tumour, and CD45high macrophages infiltrating the 
tumour bed (Badie & Schartner, 2001). In another study, orthotopically implanted Rat 9L 
glioma was also studied by immunohistochemistry, and compared with an intracranial 
carcinoma; both were comparably infiltrated by microglia or macrophages (Morioka et al., 
1992). Mouse glioma models have similarly been assessed for myeloid cell infiltration. In 
GL261 glioma, the infiltrate was predominately CD11b+F4/80+CD45high, considered as 
macrophages rather than microglia by the authors (Nakagawa et al., 2007). We have also 
analysed orthotopic GL261 glioma, a representative immune infiltrate is shown in Fig. 1. 
In the SMA-560 model, CD11b+ cells were identified by immunohistochemistry (Uhl et al., 
2004). A further study used an orthotopically implanted PDGF-driven glioma model to 
study myeloid cells (along with other immune cells) longitudinally (Kennedy et al., 2009). 
The frequency of CD11b+CD45+ cells was measured, without distinguishing the level of 
CD45 expression. These macrophages/microglia increased from 1.1% during the early 
phase, to 5.6% during the late stage. A further category of tumour model in which 
myeloid cells have been documented is genetically engineered “spontaneous” gliomas. 
The GFAP-V12HA-ras model is of particular interest, because astrocytomas form 
spontaneously in these mice, without the trauma (and potential microglial cell activation) 
associated with intracranial implantation (Ding et al., 2001; Shannon et al., 2005). We have 
explored immune parameters in these mice, analyzing the immune infiltrate from earliest 
stages of pathology, but without appearance of symptoms in mice (4, 8, and 12 weeks), to 
mice bearing advanced tumours producing symptoms (Tran Thang et al., 2010). Although 
there was a significant lymphocyte infiltrate in asymptomatic mice (at 12 weeks), myeloid 
cell augmentation correlated with appearance of terminal symptoms. Microglia 
(CD11b+CD45low) approximately doubled in number at this stage, whereas the previously 
minor population of CD11b+CD45high macrophages increased by more than 50 fold, 
becoming the major myeloid subset in the brain. The intriguing correlation of terminal 
progression of the brain tumour and the presence of these macrophages clearly raises 
issues about their origin and likely function; this is the subject of ongoing investigations. 
Myeloid cells were also investigated in another genetically engineered glioma model, in 
which de novo gliomas were generated by intracerebroventricuar transfection of NRas 
and a short hairpin RNA against P53 using the Sleeping Beauty transposon system (Fujita 
et al., 2011; 2010). The brain tumours of these mice were infiltrated by CD11b+ cells, 
although the authors focused particularly on the myeloid derived suppressor cell (MDSC) 
component, as described in section 3.2 below.  
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Fig. 1. Leucocyte populations in brain of healthy and tumour-bearing mice. 
Leucocytes isolated from brains of healthy (left) and glioma bearing mice (right) were stained for CD45 
and CD11b markers, and analysed by flow cytometry. The only highly represented leucocytes in 
healthy brain are CD11b+CD45low microglia. In mice bearing advanced brain tumours, there is also an 
infiltrate of CD11b+CD45high macrophages and CD11b-CD45high lymphocytes.  
2.4.2 Additional myeloid cell populations in brain tumours  
Studies of various malignancies in patients and in tumour-bearing mice demonstrated that 
the heterogeneous cells known as MDSCs can accumulate in secondary lymphoid tissue and 
at the tumour site (Gabrilovich & Nagaraj, 2009). The MDSC population includes immature 
macrophages, granulocytes and DCs, and these cells have the potential to suppress T cell 
immune responses. Proposed mechanisms differ in lymphoid tissue and the tumour site, but 
include reactive oxygen species, arginase 1 activity and nitric oxide production. 
Phenotypically, they are usually defined as CD11b+GR1+ in mice (although subsets exist); in 
humans, phenotyping is more complex but MDSCs may include CD14-CD11b+CD33+ cells.  
In patients with malignant glioma, MDSCs were detected in peripheral blood 
(Raychaudhuri et al., 2011; Rodrigues et al., 2010), and the phenotype could also be induced 
by exposure of normal monocytes to glioma cell lines (Rodrigues et al., 2010). However, the 
presence of MDSCs infiltrating human brain tumours has not yet been described. 
In rodents, presence of MDSCs within the brain tumour bed has been documented in 
several models. An early study using the T9 glioma model in Fischer 344 rats demonstrated 
that suppressive cells expressing both the rat granulocyte marker His48 and CD11b/c 
accumulated in the spleen and in the intracranial tumour bed (Prins et al., 2002). Moreover, 
this accumulation was enhanced by subcutaneous vaccination with irradiated glioma cells. 
These cells were further investigated in a recent study, in the same model, in which bone 
marrow replacement confirmed that the brain infiltrating MDSCs were of bone marrow 
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origin (Jia et al., 2010). Functionally, nitric oxide was determined to be the main suppressive 
molecule.  
In mice, MDSCs were described in both the GL261 orthotopically implanted glioma 
(Umemura et al., 2008), as well in genetically engineered models (Fujita et al., 2011; 2010; 
Tran Thang et al., 2010). The definition of MDSCs infiltrating GL261 glioma was discussed 
in some detail (Umemura et al., 2008). The authors concluded that there is substantial 
overlap with other tumour associated macrophages, and that moreover, these cells have 
considerable plasticity in their function and phenotype according to the microenvironment 
in which they function. These issues are probably central to most myeloid cells associated 
with tumours. A rather simpler observation of the presence of CD11b+GR1+CD45high cells 
was made in the GFAP-V12HA-ras model of spontaneous astrocytoma (Tran Thang et al., 
2010), but without further phenotyping or functional tests. However, elevated proportions 
of these cells were present in only a minority of ill mice. This may be a reflection of the 
inherent heterogeneity of tumours in this model (the genetic background is outbred, and 
tumours appear after stochastic accumulation of genetic mutations that vary between mice), 
or it may signify that MDSCs are of only minor functional significance in this model. In 
contrast, in the genetically induced glioma models studied by the Okada group (Fujita et al., 
2011; 2010), CD11b+Ly6Ghigh MDSCs were a major component of the brain tumour infiltrate, 
which was also explored functionally. Depletion of Ly6G+ cells prolonged survival of mice 
developing gliomas, as did COX-2 blockade with nonsteroidal anti-inflammatory drugs. The 
latter approach may have acted at two levels: by inhibiting the MDSC differentiation factor 
prostaglandin E2, and by limiting MDSC recruitment to the brain tumour site by reducing 
levels of the MDSC chemoattractant CCL2.  
A final type of myeloid cell that may be specifically recruited to brain tumours is an 
immunosuppressive CD11b+ DC. In the context of glioma, this cell type has been most 
thoroughly investigated in the GL261 mouse glioma model (Biollaz et al., 2009). The brain 
infiltrating dendritic cells were shown to be of bone marrow origin using bone marrow 
chimeric mice, and they had little or no expression of costimulatory molecules (CD40, B7.1, 
B7.2) and GR1. Functional tests in vitro showed that brain infiltrating DCs could induce 
regulatory T cells from naïve CD4 T cells, but were inefficient at inducing alloreactive or 
antigen specific CD4 T cell proliferation. Of particular interest was that the 
immunosuppressive functions of these GL261 infiltrating DCs were predominately found 
when the tumour was growing intracranially, but not with the same tumour implanted 
subcutaneously. Moreover, the overall tumour infiltrate and microenvironment was entirely 
different in the brain: intracranial GL261 had higher levels of DCs, regulatory T cells and 
TGF-β, and mice had shorter survival. Overall, this important study indicates how brain 
tumour-immune system interactions are a consequence of both the tumour and the 
specialized site of the brain.  
2.4.3 Microglia and macrophage function in the contest of malignant glioma 
The overall consequences of the appearance of malignant glioma in the brain have been 
extensively studied in patients as well as in animal models; there is progressive invasive 
(but non-metastatic) growth, no evidence for spontaneous immune-mediated regression, but 
substantial evidence for local immunosuppression (Walker et al., 2003). The local 
microenvironment is of course complex, and a product of multiple cell type and site-specific 
 




Fig. 1. Leucocyte populations in brain of healthy and tumour-bearing mice. 
Leucocytes isolated from brains of healthy (left) and glioma bearing mice (right) were stained for CD45 
and CD11b markers, and analysed by flow cytometry. The only highly represented leucocytes in 
healthy brain are CD11b+CD45low microglia. In mice bearing advanced brain tumours, there is also an 
infiltrate of CD11b+CD45high macrophages and CD11b-CD45high lymphocytes.  
2.4.2 Additional myeloid cell populations in brain tumours  
Studies of various malignancies in patients and in tumour-bearing mice demonstrated that 
the heterogeneous cells known as MDSCs can accumulate in secondary lymphoid tissue and 
at the tumour site (Gabrilovich & Nagaraj, 2009). The MDSC population includes immature 
macrophages, granulocytes and DCs, and these cells have the potential to suppress T cell 
immune responses. Proposed mechanisms differ in lymphoid tissue and the tumour site, but 
include reactive oxygen species, arginase 1 activity and nitric oxide production. 
Phenotypically, they are usually defined as CD11b+GR1+ in mice (although subsets exist); in 
humans, phenotyping is more complex but MDSCs may include CD14-CD11b+CD33+ cells.  
In patients with malignant glioma, MDSCs were detected in peripheral blood 
(Raychaudhuri et al., 2011; Rodrigues et al., 2010), and the phenotype could also be induced 
by exposure of normal monocytes to glioma cell lines (Rodrigues et al., 2010). However, the 
presence of MDSCs infiltrating human brain tumours has not yet been described. 
In rodents, presence of MDSCs within the brain tumour bed has been documented in 
several models. An early study using the T9 glioma model in Fischer 344 rats demonstrated 
that suppressive cells expressing both the rat granulocyte marker His48 and CD11b/c 
accumulated in the spleen and in the intracranial tumour bed (Prins et al., 2002). Moreover, 
this accumulation was enhanced by subcutaneous vaccination with irradiated glioma cells. 
These cells were further investigated in a recent study, in the same model, in which bone 
marrow replacement confirmed that the brain infiltrating MDSCs were of bone marrow 
 
Macrophages and Microglia in Brain Malignancies 
 
183 
origin (Jia et al., 2010). Functionally, nitric oxide was determined to be the main suppressive 
molecule.  
In mice, MDSCs were described in both the GL261 orthotopically implanted glioma 
(Umemura et al., 2008), as well in genetically engineered models (Fujita et al., 2011; 2010; 
Tran Thang et al., 2010). The definition of MDSCs infiltrating GL261 glioma was discussed 
in some detail (Umemura et al., 2008). The authors concluded that there is substantial 
overlap with other tumour associated macrophages, and that moreover, these cells have 
considerable plasticity in their function and phenotype according to the microenvironment 
in which they function. These issues are probably central to most myeloid cells associated 
with tumours. A rather simpler observation of the presence of CD11b+GR1+CD45high cells 
was made in the GFAP-V12HA-ras model of spontaneous astrocytoma (Tran Thang et al., 
2010), but without further phenotyping or functional tests. However, elevated proportions 
of these cells were present in only a minority of ill mice. This may be a reflection of the 
inherent heterogeneity of tumours in this model (the genetic background is outbred, and 
tumours appear after stochastic accumulation of genetic mutations that vary between mice), 
or it may signify that MDSCs are of only minor functional significance in this model. In 
contrast, in the genetically induced glioma models studied by the Okada group (Fujita et al., 
2011; 2010), CD11b+Ly6Ghigh MDSCs were a major component of the brain tumour infiltrate, 
which was also explored functionally. Depletion of Ly6G+ cells prolonged survival of mice 
developing gliomas, as did COX-2 blockade with nonsteroidal anti-inflammatory drugs. The 
latter approach may have acted at two levels: by inhibiting the MDSC differentiation factor 
prostaglandin E2, and by limiting MDSC recruitment to the brain tumour site by reducing 
levels of the MDSC chemoattractant CCL2.  
A final type of myeloid cell that may be specifically recruited to brain tumours is an 
immunosuppressive CD11b+ DC. In the context of glioma, this cell type has been most 
thoroughly investigated in the GL261 mouse glioma model (Biollaz et al., 2009). The brain 
infiltrating dendritic cells were shown to be of bone marrow origin using bone marrow 
chimeric mice, and they had little or no expression of costimulatory molecules (CD40, B7.1, 
B7.2) and GR1. Functional tests in vitro showed that brain infiltrating DCs could induce 
regulatory T cells from naïve CD4 T cells, but were inefficient at inducing alloreactive or 
antigen specific CD4 T cell proliferation. Of particular interest was that the 
immunosuppressive functions of these GL261 infiltrating DCs were predominately found 
when the tumour was growing intracranially, but not with the same tumour implanted 
subcutaneously. Moreover, the overall tumour infiltrate and microenvironment was entirely 
different in the brain: intracranial GL261 had higher levels of DCs, regulatory T cells and 
TGF-β, and mice had shorter survival. Overall, this important study indicates how brain 
tumour-immune system interactions are a consequence of both the tumour and the 
specialized site of the brain.  
2.4.3 Microglia and macrophage function in the contest of malignant glioma 
The overall consequences of the appearance of malignant glioma in the brain have been 
extensively studied in patients as well as in animal models; there is progressive invasive 
(but non-metastatic) growth, no evidence for spontaneous immune-mediated regression, but 
substantial evidence for local immunosuppression (Walker et al., 2003). The local 
microenvironment is of course complex, and a product of multiple cell type and site-specific 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
184 
factors. The role of certain cells infiltrating the tumour is unambiguous, such as Foxp3+CD4+ 
regulatory T cells that infiltrate both human and mouse glioma (Walker et al., 2009). 
Myeloid cells are less simple to define, but the unique myeloid cells constitutively present in 
the brain are likely to be central players in shaping the developing tumour stroma, 
potentially being the precursors of other brain macrophages, and able to influence the 
function of other immigrant myeloid cells (as described in section 2.4.2 above). Ultimately, 
in advanced tumours, myeloid cells of all origins will become the major non-tumoural 
component of the brain tumour bed (Fig. 2). Indeed, multiple chemokines secreted by 
glioma cells are known to attract microglia and other myeloid cells. These include CCL21 
(Biber et al., 2001; Zhai et al., 2011), MCP-3 (Okada et al., 2009), stromal cell derived factor-
1α (SDF-1α) (Rempel et al., 2000; X. Wang et al., 2008), and MCP-1 (Fujita et al., 2011; Platten 
et al., 2003). Moreover, the latter two factors may be particularly efficacious at attracting 
myeloid cells to hypoxic areas of the tumour. Whether myeloid cells associated with brain 
tumours are a cause or a consequence of tumour progression is still controversial. Indeed 
both pro- and anti-tumoural functions can be demonstrated on isolated cells, but in vivo 
there are complex mixed populations, functioning in a microenvironment totally different 
from that created in vitro. The conceptual framework for understanding these functions has 
developed both from neuroscience and macrophage biology. Myeloid cells in brain tumours 
may appear to display some aspects of microglial cell function, i.e., anti-inflammatory and  
 
 
Fig. 2. Heterogenous myeloid and lymphoid cells infiltrate tumour bearing brain.  
In healthy brain (top), the principle immune cells of the parenchyma are the microglia, which are 
resting, but active in brain surveillance. Appearance of malignancy (bottom) promotes activation of 
resident microglia and infiltration of diverse myeloid and lymphoid cells with potential for pro- and 
anti-tumoural functions (see text).  
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housekeeping roles, appropriate for maintaining healthy brain function (Kettenmann et al., 
2011), but not for combating a lethal tumour. On the other hand, it is tempting to model 
brain myeloid cells on current concepts of macrophage plasticity, in which classically 
activated macrophages (M1) may promote anti-tumoural responses, whereas alternatively 
activated macrophages (M2) are predicted to be pro-tumoural  (Biswas & Mantovani, 2010). 
This polarization concept is certainly helpful, as long as it can be associated with the specific 
dialect of neuroimmunology. 
Anti-tumoural functions of microglia and brain macrophages. Microglial cells and brain 
macrophages have the potential to exert anti-tumour effects, and this has been 
demonstrated in vitro (Hwang et al., 2009; Rosales, 1996). Normal rodent microglial cells can 
release nitric oxide and Cathepsin B, which together can promote glioma cell apoptosis, 
whilst sparing normal cultured astrocytes (Hwang et al., 2009). However, constitutive 
function of microglial cells in vivo is unlikely to achieve the same effect. Nevertheless, 
global depletion of CD11b+ cells in mice intracranially implanted with GL261 glioma 
resulted in increased tumour growth (Galarneau et al., 2007). The mechanisms were not 
fully elucidated, but were suggested to be T-cell independent. Moreover, the immune 
infiltrate was characterized as a type 1 response, with CD11b+ cells being the main source of 
TNF, with also high levels of MCP-1 and IL-1β. Levels of type 2 cytokines IL-4 and IL-10 
were low. One complexity in the interpretation of this study is that myeloid cell depletion 
(achieved by systemic administration of ganciclovir in CD11b-HSVTK mice) was 
incomplete, only up to 45%. Therefore, the result may be a consequence of the preferential 
elimination of pro-tumoural myeloid cells. This may also account for an apparently 
contradictory result in a more recent study using a virtually identical model, in which 
CD11b+ cell depletion reduced GL261 glioma growth (Zhai et al., 2011). The principle 
difference was that in this latter study, ganciclovir was administered intracranially, which 
would be assumed to give more efficient depletion of brain myeloid cells. 
Regarding brain APC, we have observed presentation of brain tumour antigens in different 
murine models. However, the cell type responsible for this function was not defined. In the 
MT539 murine glioma, brain APC were responsible for cross-presenting glioma derived 
antigens to CD8 T cells, and retaining them in the brain parenchyma (Calzascia et al., 2003). 
In a different model, tumour-specific CD8 T cell activation in the cervical lymph node was 
measured after intracranial tumour implantation, and in this case we determined that the 
responsible cells that had migrated from the brain were radiosensitive, and thus were not 
parenchymal microglia (Calzascia et al., 2005). In another independent study using a 
different mouse tumour model, presentation of tumour antigen to T cell populations 
including CD4 T cells was observed (Plautz et al., 2000). Overall, these observations indicate 
that the brain is either equipped or can recruit cells with potential to directly (cytotoxicity) 
or indirectly (antigen presentation) act against tumours, but in the most malignant tumours, 
these functions may be subverted or overwhelmed by pro-tumoural elements. 
Pro-tumoural effects of brain myeloid cells. Pro-tumoural effects of microglia and brain 
macrophages can be indirect or direct. In the former case, brain myeloid cells can participate 
in creating an immunosuppressive microenvironment, thus blocking immunity that could 
act against the tumour. In the latter case, they can directly act on the tumour or its 
microenvironment to promote tumour growth and invasion. As mentioned in the above 
subsection, overall support for the pro-tumoural role of brain myeloid cells can be 
concluded from one of the two CD11b+ cell depletion studies (Zhai et al., 2011), but such an 
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housekeeping roles, appropriate for maintaining healthy brain function (Kettenmann et al., 
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approach is arguably too extreme to either apply therapeutically, or to interpret in depth 
given myeloid cell heterogeneity. Based on the observations in malignant glioma that 
tumours progress in the presence of abundant myeloid cell infiltration (Nishie et al., 1999; 
Roggendorf et al., 1996; Rossi et al., 1988; Rossi et al., 1987), we will examine the evidence 
that this infiltrate supports tumour growth.  
Many pro-tumoural effects of myeloid cells can be associated with M2 polarization. 
Although one group studying the GL261 model has suggested that the glioma associated 
myeloid cells are not readily characterized by such terminology (Umemura et al., 2008), the 
concept can also applied less rigidly to determine the overall balance of the infiltrate. 
Indeed, another study on GL261 glioma claimed that the polarization balance of the tumour 
associated CD11b+ microglia or macrophages (mostly amoeboid) was distinctly towards a 
pro-tumoural M2 phenotype, with strong expression of IL-10 and arginase 1, both 
associated with dampening inflammation and T cell immunity. In human glioma, a 
histological study noted a malignancy-correlated infiltration of microglia or macrophages 
expressing the M2 associated markers CD163 and CD204 (Komohara et al., 2008). This 
infiltration was also associated with glioma production of M-CSF, and the proliferation 
index of the tumour. Based on additional in vitro experiments in which glioma supernatant 
induced CD163 and CD204 expression on macrophages, it was proposed, although not 
directly demonstrated, that glioma derived M-CSF is a key factor in M2 macrophage 
polarization.  
Several studies from the Heimberger group have chronicled the in vitro functions of 
myeloid cells isolated from patients with malignant glioma (Hussain et al., 2006a; 2006b). 
These glioma associated microglia/macrophages expressed multiple toll like receptors, 
MHC class II, but low levels of co-stimulatory molecules. They did not support T cell 
proliferative responses, and they did not constitutively express significant levels of 
inflammatory or anti-inflammatory cytokines when tested ex vivo. Phagocytic function was 
detectable in these experiments, however, other studies on rat microglia indicated that 
continued presence of glioma cells may inhibit this process (Voisin et al., 2010).  
Early demonstrations of microglia or macrophage modulation by glioma cells generally 
relied on co-culture with cell lines. More recent concepts in oncology have proposed that 
cancers, including glioma, arise from a small population of cells with stem-like properties, 
which can self-renew to produce tumourigenic daughter cells and more differentiated but 
non-tumourigenic cells (Singh et al., 2004). Glioma stem-like cells can be enriched in 
neurosphere cultures; these have now been assessed for their impact on human microglia 
and macrophage function (Wu et al., 2010). Supernatants from glioma stem-like cells were 
more potent at promoting monocyte recruitment than bulk glioma cells, potentially through 
CSF-1 and CCL2, and they inhibited macrophage phagocytosis. However, these 
supernatants also induced pro-tumoural characteristics, some of which may have been 
driven by phosphorylated STAT3 expression in monocytes. Treated macrophages and 
microglia secreted immunosuppressive cytokines (IL-10, TGF-β1, IL-23) and potentiated 
inhibition of T cell responses. Moreover, these functions were enhanced when glioma stem-
like cells were cultured under hypoxic conditions (Wei et al., 2011). Overall, these studies 
suggest that glioma stem-like cells acquire their central role in tumour malignancy not only 
through their intrinisic stem-like properties and ability to thrive in hypoxic areas of the 
tumour, but also by recruiting myeloid cells, recently confirmed in vivo (Yi et al., 2011), and 
reinforcing their pro-tumoural effects.  
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The lethality of malignant glioma is not due to metastasis as for most solid tumours, but due 
to its capacity to invade healthy brain tissue. This invasiveness is facilitated by 
metalloproteinases that degrade extracellular matrix. Membrane type 1 metalloprotease 
(MT1-MMP) is highly expressed in human glioma as well as in rodent models, and 
expression is concentrated within myeloid cells at the tumour borders. These cells were 
shown to be of amoeboid morphology and were derived from endogenous microglia 
(Markovic et al., 2009; Sliwa et al., 2007). In elegant in vivo and ex vivo experiments, 
membrane type 1 metalloprotease (MT1-MMP) was shown to be induced in microglial cells 
by soluble glioma-derived factors that were dependent on microglial expression of the toll-
like receptor adapter protein MyD88 and the p38 MAPK pathway. Glioma growth was 
promoted by microglial MT1-MMP activation of glioma-derived pro-MMP-2, whereas 
reduction in glioma volume was achieved either in MyD88-/- mice, or after microglial cell 
ablation (Markovic et al., 2009). A further route by which microglia can promote invasion is 
through TGF-β release, which can subsequently induce metalloproteinase release from 
glioma cells (Wesolowska et al., 2008). Although many cells (including glioma cells) can 
produce TGF-β in vivo, in vitro invasion tests with microglial and C6 rat glioma co-cultures 
showed that microglial cells were an important source. This latter observation, although not 
the specific subject of this study, also confirms the likely contribution of microglial derived 
TGF-β to the immunosuppressive tumour microenvironment.  
A further major pro-tumoural role of brain microglial cells and macrophages is achieved 
through their promotion of angiogenesis, a process essential for tumour progression. In an 
in vivo orthotopic mouse glioma model, hypoxia exposed glioma cells recruited CD11b+ 
myeloid cells in a hypoxia-inducible factor (HIF) 1 and SDF-1α dependent manner (Du et al., 
2008). Matrix metalloproteinase (MMP)-9 expression by these macrophages promoted 
angiogenesis by converting VEGF from a sequestered to a bioavailable state. Another central 
cytokine linked to angiogenesis in glioma is TNF, which can induce both VEGF (Ryuto et al., 
1996) and MMP9 (Esteve et al., 2002). Although TNF is considered a product of M1 
polarized cells, its expression was nevertheless described in perivascular and intratumoural 
macrophages in human glioma (Roessler et al., 1995) as well as in CD11b+CD45high 
macrophages infiltrating GL261 mouse glioma (Nakagawa et al., 2007). Angiogenesis may 
also be driven indirectly, through microglia/macrophage stimulated release of angiogenic 
factors from the glioma cells. In this regard, several studies in human glioblastoma 
correlated microglia/macrophage macrophage infiltration of glioma with the angiogenic 
factor IL-8 (Hong et al., 2009; Nishie et al., 1999; X. B. Wang et al., 2011), and in some cases 
vessel density (Nishie et al., 1999; X. B. Wang et al., 2011).  
2.4.4 Therapeutic modulation of microglia and macrophage in brain malignancy 
The balance of pro- and anti-tumour functions of brain microglia and macrophages is clearly 
not favourable in progressive brain tumours, and so their modulation could be an attractive 
therapeutic strategy. In view of their essential roles of microglial cell function in the healthy 
brain, ablation of all brain myeloid cells would appear unwise. Multiple possibilities for 
modulation of cancer promoting macrophages are being explored in non-cerebral 
malignancies. In this section we will concentrate on approaches already developed in brain 
tumours: blocking the infiltration of certain myeloid cells, targeting of key transcription 
factors, re-polarization with strong stimuli and TGF-β inhibition (Fig.3). 
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approach is arguably too extreme to either apply therapeutically, or to interpret in depth 
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tumours: blocking the infiltration of certain myeloid cells, targeting of key transcription 
factors, re-polarization with strong stimuli and TGF-β inhibition (Fig.3). 
 




Fig. 3. Therapeutic approaches to modulate myeloid cells in brain tumours. 
Examples of therapies having a major impact on myeloid cells are indicated. Promotion of M1 anti-
tumoural polarization of brain myeloid cells can be achieved by use of the TLR9 agonist CpG (A) and 
by inhibition of STAT3 in multiple cell types (B). Inhibition of TGFβ or its signaling diminishes 
immunosuppression and tumour progression by acting on multiple target cells (C). Infiltration of pro-
tumoural monocytes/macrophages and MDSCs can be reduced by antibody blockade of the MCP-
1/CCL2 (D).  
Blocking infiltration of pro-tumoural myeloid cells. Antibody inhibition of a myeloid cell 
chemoattractant is a straightforward and attractive approach to block immigration of 
deleterious cells. Based on the observations that MCP-1/CCL2 is expressed by human 
glioma and is associated with glioma aggressiveness and macrophage infiltration in animal 
models (Platten et al., 2003), antibody blockade was tested as a mono- and combination 
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therapy (Zhu et al., 2010). Macrophage and MDSC infiltration was decreased (but not 
abolished) in GL261 mouse glioma and a human xenografted model, although resident 
CD11b+CD45low microglia were less affected, perhaps because of limited antibody 
penetration into the tumour bed. Survival was only modestly increased, but this 
significantly improved in combination with the alkylating chemotherapy agent 
temozolomide. Such approaches may have a role in modulating infiltrating macrophages, 
but if a high proportion of pro-tumoural macrophages are derived from brain resident 
macrophages, efficacy will be limited.  
STAT3 inhibition. Although not a myeloid cell specific approach, targeting signal transducer 
and activator of transcription 3 (STAT3) is predicted to influence many immunosuppressive 
and pro-tumoural factors in the brain tumour microenvironment. Inhibition of STAT3 can be 
achieved with small molecular inhibitors, and is a particularly attractive therapeutic target in 
cancers such as glioma, because activated STAT3 is detected both in the tumour cells and in 
the infiltrating immune cells. Treating human microglia/macrophages isolated from glioma 
with a STAT3 inhibitor induced costimulatory molecule and type 1 cytokine expression 
(Hussain et al., 2007). Another compound that inhibits STAT3 is the plant-derived corosolic 
acid (Fujiwara et al., 2010). In vitro studies on human monocyte-derived macrophages showed 
that this compound prevented M2 macrophage polarization, as measured by inhibition of 
CD163 expression and IL-10 secretion (M2 markers); it also augmented glioblastoma cell 
apoptosis (Fujiwara et al., 2010). In mouse models, a STAT3 inhibitor or small interfering RNA 
blocked “immunosuppressive polarization”(principally  IL-10 and IL-6 secretion) of microglia 
stimulated by glioma cell supernatant (Zhang et al., 2009). Furthermore, in orthotopic GL261 
murine glioma in vivo, intratumoural STAT3 siRNA injection augmented TNF mRNA 
expression, and prolonged survival (Zhang et al., 2009).  
TLR Agonists. Pathogen stimulation of myeloid cells through pathogen recognition receptors 
such as toll like receptors (TLRs) can result in strong M1 polarization that would potentially 
be useful in anti-tumour immunity, but is not generally achieved during chronic tumour 
growth. However, it is predicted that use of synthetic TLR agonists can mimic such 
pathogen induced activation. CpG oligonucleotides as agonists of the intracellularly 
expressed TLR9 have been investigated in many glioma preclinical models as well as in 
patients. Intratumoural injection of CpG oligonucleotides in orthotopic rat glioma models 
reduced tumour volume and elicited therapeutic immunity in a proportion of animals. 
These successful preclinical experiments have led to a clinical trial, but the clinical results 
showed only marginal benefit (Carpentier et al., 2010). Indeed, other preclinical studies gave 
very variable results, ranging from tumour rejection to enhancement of tumour volume 
(Ginzkey et al., 2010). A recent approach has tried to improve the targeting of CpG 
oligonucleotides by conjugating CpG oligonucleotides to carbon nanotubes that are 
preferentially taken up by brain myeloid cells after intratumoural injection (Zhao et al., 
2010). In vitro experiments showed that monocytes were efficiently stimulated by the 
conjugated CpG to express high levels of type 1 cytokines (including IL-12 and TNF). In 
vivo, GL261 mouse glioma was eradicated by conjugated CpG injection in half of the mice. 
Overall, there seems to be considerable promise in the approach of stimulating brain 
myeloid cells with TLR agonists to reorient their functional polarization, although 
optimization to improve efficacy of the next generation of clinical trials will be essential. 
TGF-β inhibition. The central role of TGF-β in promoting tumour progression makes it a highly 
relevant therapeutic target in brain malignancy. The multiple targets and sources of this 
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cytokine makes interpretation of its therapeutic modulation complex, since of TGF-β acts 
directly on tumour cells, as well as on pro- and anti-tumoural myeloid and other immune 
cells. TGF-β inhibition through systemic application of neutralizing antibody (1D11) enhanced 
efficacy of therapeutic vaccination in mouse GL261 glioma, and promoted a type 1 immune 
response, although it was not effective as a single modality treatment (Ueda et al., 2009). In a 
further study, the same 1D11 antibody was tested on both subcutaneous and intracranial 
GL261; in the former site, there was total tumour regression, whereas the orthotopic glioma 
merely showed reduced invasion (Hulper et al., 2011) These results suggest that it will be 
challenging to achieve full efficacy with systemic use of blocking antibodies for tumours 
localised in the brain. Local TGF-β inhibition has been tested with intratumoural delivery of 
synthetic antisense oligonucleotides: in a rat intracranial glioma model this showed 
therapeutic benefit when combined with tumour vaccination (Liu et al., 2007). However, when 
tested clinically as a monotherapy in recurrent high grade glioma, the clinical effects were 
disappointing (Bogdahn et al., 2011). A potentially simpler approach is with small molecules 
targeting TGF-β receptor signalling pathways: these are predicted to have better penetration of 
the brain tumour bed. Early preclinical studies with a systemically delivered TGF-β receptor I 
kinase inhibitor (SD-208) indicated survival benefit on mice bearing syngeneic SMA-560 brain 
tumours; this also correlated with  enhanced infiltration of CD11b+ cells (in addition to CD8+ T 
cells and NK cells) (Uhl et al., 2004). Similar approaches are currently being tested in clinical 
trials. Overall, targeting TGF-β or its effects may be a valuable way of restoring antitumoural 
polarization of myeloid and other elements in brain tumours, particularly in the context of 
multimodal therapies.  
3. Conclusion 
The myeloid cells populating the brain in health and in malignant disease show a 
heterogeneity mirroring that found in other tissues, but the microglial cells have 
particularities that are found in no other tissue macrophages. Their unique features are most 
striking in the normal brain, when “resting” but highly surveillant ramified microglia are 
the principle myeloid cell of the brain parenchyma. Is this only of interest for neuroscience, 
or does it also impact on brain cancer, in which the myeloid infiltrate of advanced cerebral 
malignancies may superficially resemble that of extracranial tumours? Analysis of lower 
grade tumours in patients, or early stages of gliomagenesis in animal models reveals that 
endogenous parenchymal microglia are clearly detectable, and thus shape the 
microenvironment that influences tumour progression and the function of immune cells 
immigrating from the periphery. For primary brain tumours, endogenous microglia will 
also be the first to detect the malignant lesion, and it is possible that their default response of 
dampening inflammation leaves opportunity for tumour progression.  
Do these factors influence how we should treat brain tumours? We suggest that the 
particularities of the brain and its resident protective cells should be respected in treatment 
design. Pro-tumoural myeloid cells that we may wish to target will generally be of two 
sources: immigrating cells from the blood, and proliferating and differentiating microglia. 
Most systemically used drugs that aim to block myeloid cell infiltration will only efficiently 
target the former cells. The alternative approach of repolarizing pro-tumoural cells to release 
high levels of inflammatory cytokines may be promising, but it may not be advisable to 
convert all brain myeloid cells to highly pro-inflammatory cells, since uncontrolled brain 
inflammation can be as dangerous as the cancer we are aiming to treat. 
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Current results from treatment approaches for malignant glioma that impact on myeloid 
cells should offer hope, but should also impose caution. For example, the therapeutic 
potential of strong macrophage stimuli such as CpG is highly encouraging in certain 
preclinical trials. But what we now need to understand is why it is not always successful - 
either in different preclinical models, as well as for many patients in clinical trials. If we can 
better define those cells and polarizations that are deleterious, we can envisage better 
targeting of therapeutic agents to improve efficacy and safety of the next generation of 
cancer therapies. 
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1. Introduction 
Human oral squamous cell carcinoma (HOSCC) is the most common malignant neoplasm 
arising in the mucosa of the upper aerodigestive tract. It is an aggressive tumor that is 
difficult to treat with conventional therapies, including chemotherapy, radiation, and 
surgery. Because surgical treatment often affects profoundly the quality of life and activities 
of daily living of the affected patients with HOSCC, and thus new therapeutic strategies are 
necessary along with the other conventional therapy.  
In recent years considerable progress has been made in understanding the genetic basis of 
the development of HOSCC. It is well established that an accumulation of genetic alterations 
is the basis for the progression from a normal cell to a cancer cell, referred to as multi-step 
carcinogenesis (Califano et al., 1996). Progression is enabled by the increasingly more 
aberrant function of genes that positively or negatively regulate aspects of proliferation, 
apoptosis, genome stability, angiogenesis, invasion and metastasis (Hanahan et al., 2000). 
Gene function can be altered in different ways: tumor suppressor genes may be inactivated 
by mutation, deletion or methylation and oncogenes can be activated by mutation or 
amplification. A description of these alterations and how these are detected has previously 
been described (van Houten et al., 2000, Reid et al., 1997, Braakhuis et al., 2002). Oral cancers 
are characterized by a multitude of these genetic alterations and ongoing research is 
focusing on identifying the critical genetic events and the order in which they occur during 
carcinogenesis. Frequently occurring genomic alterations are supposed to contain the genes 
that are the most important for the development of a certain type of cancer (Albertson et al., 
2003). Common alterations for oral cancer are inactivation of TP53 (located at 17p13), gain of 
chromosomal material at 3q26 and 11q13, and losses at 3p21, 13q21 and 14q32 (Gollin, 2001, 
Forastiere et al., 2001). For most of these regions the putative tumor suppressor genes or 
oncogenes still need to be identified. In general, loss of chromosomal material (allelic losses) 
at 3p, 9q and 17p was observed in a relatively high proportion of dysplastic lesions and 
therefore these alterations were interpreted to be early markers of carcinogenesis. Several 
studies suggest, however, that early genetic changes do not necessarily correlate with 
altered morphology.  
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1. Introduction 
Human oral squamous cell carcinoma (HOSCC) is the most common malignant neoplasm 
arising in the mucosa of the upper aerodigestive tract. It is an aggressive tumor that is 
difficult to treat with conventional therapies, including chemotherapy, radiation, and 
surgery. Because surgical treatment often affects profoundly the quality of life and activities 
of daily living of the affected patients with HOSCC, and thus new therapeutic strategies are 
necessary along with the other conventional therapy.  
In recent years considerable progress has been made in understanding the genetic basis of 
the development of HOSCC. It is well established that an accumulation of genetic alterations 
is the basis for the progression from a normal cell to a cancer cell, referred to as multi-step 
carcinogenesis (Califano et al., 1996). Progression is enabled by the increasingly more 
aberrant function of genes that positively or negatively regulate aspects of proliferation, 
apoptosis, genome stability, angiogenesis, invasion and metastasis (Hanahan et al., 2000). 
Gene function can be altered in different ways: tumor suppressor genes may be inactivated 
by mutation, deletion or methylation and oncogenes can be activated by mutation or 
amplification. A description of these alterations and how these are detected has previously 
been described (van Houten et al., 2000, Reid et al., 1997, Braakhuis et al., 2002). Oral cancers 
are characterized by a multitude of these genetic alterations and ongoing research is 
focusing on identifying the critical genetic events and the order in which they occur during 
carcinogenesis. Frequently occurring genomic alterations are supposed to contain the genes 
that are the most important for the development of a certain type of cancer (Albertson et al., 
2003). Common alterations for oral cancer are inactivation of TP53 (located at 17p13), gain of 
chromosomal material at 3q26 and 11q13, and losses at 3p21, 13q21 and 14q32 (Gollin, 2001, 
Forastiere et al., 2001). For most of these regions the putative tumor suppressor genes or 
oncogenes still need to be identified. In general, loss of chromosomal material (allelic losses) 
at 3p, 9q and 17p was observed in a relatively high proportion of dysplastic lesions and 
therefore these alterations were interpreted to be early markers of carcinogenesis. Several 
studies suggest, however, that early genetic changes do not necessarily correlate with 
altered morphology.  
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Although recent improvements in the diagnosis and treatment of malignant tumors have 
extended the average length of patients’ lives, the incidence of multiple primary malignant 
tumors is increasing (Licciardello et al., 1989). In particular, it has been reported that 
patients with head and neck cancer often develop multiple primary neoplasms (Sakashita et 
al., 1996). This phenomenon has been attributed to ‘field cancerization’, a concept based in 
the hypothesis that prolonged exposure to certain risk factors, such as tobacco products, 
leads to the independent transformation of multiple epithelial cells at several distinct 
anatomic sites (Slaughter et al., 1953). In addition, it is now becoming clear that the tumor 
microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable 
participant in the neoplastic process, fostering proliferation, survival and migration. Recent 
data have expanded the concept that tumor microenvironments including hypoxia, and 
inflammation that are the critical components of tumor progression. Many cancers arise 
from sites of infection, chronic irritation and inflammation. Many tumors also contain 
hypoxic microenvironments, a condition that is associated with poor prognosis and 
resistance to treatment (Helmlinger et al., 1997).  
On the other hand, as is obvious, host has defense mechanisms against various 
carcinogenesis events like above. Host professional antigen-presenting cells (APCs) appear 
to play an important role in the presentation of tumor antigens and the induction of specific 
immune responses to tumors, a role that was initially attributed entirely to the tumor cells 
themselves (Huang 1994, Rock et al., 1993). However, despite their expression of these 
distinct APCs, attempts by the immune system to eliminate a tumor are often ineffective. It 
has recently been reported that in cancer patients the tumor cells themselves may also evade 
immune attack by expressing immunosuppressive cytokines.  
Thus, oral carcinogenesis is a highly complex multifactorial process that takes place when 
epithelial cells are affected by several genetic alterations. The use of molecular biology 
techniques to diagnose oral cancerous lesion might be markedly improved the detection of 
alterations that are invisible under the microscope.  
This chapter presents up-to-date evidence on molecular markers into the tumor 
microenvironment that have involved in the proliferation and progression mechanisms of 
the oral cancer. 
2. Role of myelomonocytic cells in tumor microenvironment 
Myeloid cells including monocytes and macrophages are key elements which regulate tissue 
homeostasis and local inflammation/immunity, differentiating into various cell types in 
response to provocative stimuli (Zeh et al., 2005, Demaria et al., 2010).  
Monocytes exist as the second recruited effectors of the acute inflammatory response after 
neutrophils and also migrate to the site of tumor microenvironment, guided by chemotactic 
factors. It is known that monocytes, in the presence of granulocyte–macrophage colony 
stimulating factor (GM-CSF) and interleukin (IL)-4, differentiate into immature dendritic 
cells (DCs) (Talmor et al., 1998). DCs migrate into inflamed peripheral tissue where they 
capture antigens and, after maturation, migrate to lymph nodes to stimulate T-lymphocyte 
activation. Soluble factors such as IL-6 and M-CSF, derived from neoplastic cells, push 
myeloid precursors towards a macrophage-like phenotype (Allavena et al., 2000).  
DCs are the most effective APCs in the induction of primary immune responses (Steinman 
1991, Knight et al., 1993) and are considered to be the best vehicle for the delivery of tumor-
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specific antigens in cancer immunotherapy (Austin 1993, Zitvogel et al., 1996, Mayordomo 
et al., 1995, Hsu et al., 1996). The existence of DCs in cancer-bearing hosts has attracted a 
great deal of interest because of their potential significance for tumor immunity. However, 
despite their expression of these distinct APCs, attempts by the immune system to eliminate 
a tumor are often ineffective. It has recently been reported that in cancer patients the tumor 
cells themselves may also evade immune attack by expressing immunosuppressive 
cytokines such as interleukin IL-10, transforming growth factor (TGF)-1, receptor-binding 
cancer antigen expressed on SiSo cells (RCAS1), IL-23, and vascular endothelial growth 
factor (VEGF), which induce defective immune cell function and a defective host immune 
response (Gabrilovich et al., 1996, Gabrilovich et al., 1998, Buelens et al., 1995, Mitra et al., 
1995, Brooks et al., 1998). Several studies have also described the defective function of APCs, 
including macrophages, DCs, and B cells, in tumor-bearing hosts (Tan et al., 1994, Watson et 
al., 1995, Alcalay et al., 1991, Erroi et al., 1989). A proposed mechanism for the inhibition of 
the activation of high-potency DCs ex vivo is represented in Fig. 1.  
Monocytes, which also differentiate into macrophages in tissues, are next to migrate to the 
site of tissue injury, guided by chemotactic factors. Once activated, macrophages are the 
main source of growth factors and cytokines, which profoundly affect endothelial, epithelial 
and mesenchymal cells in the local microenvironment.  
 
Fig. 1. A proposed mechanism for the DC activation and dysfunctional DC activation during 
the ex vivo. APC: antigen presenting cells, Th: helper T cell, cT: cytotoxic T cell, NK: Natural 
killer cell, DC: dendritic cell, Pc: plasma cell. 
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3. Role of cytokines in tumor microenvironment 
The reciprocal interactions between tumor cells and their microenvironment — extracellular 
matrix (ECM), growth factors, fibroblasts, immune and endothelial cells — play an essential 
role in the earliest stages of transformation to malignant progression and metastasis 
(Nyberg et al., 2008). Particularly, fibroblasts have many prominent roles in the cancer 
progression. In fact, in many carcinomas, the majority of the stromal cells are fibroblasts that 
possess myofibroblastic characteristics and are called cancer-associated fibroblasts. They 
produce ECM molecules, proteases, growth factors, and chemokines that crucially affect the 
carcinoma cell behavior (Kalluri et al., 2006, Orimo et al., 2006). Furthermore, the causal 
relationship between chronic inflammation, innate immunity and cancer is now widely 
accepted, and the similarities in the regulatory mechanisms have been suggested for more 
than a century. Many cancers arise at the site of chronic inflammation and inflammatory 
mediators are often produced in tumors. The frequent use of anti-inflammatory drugs 
reduces the incidence of a variety of human tumors. Although blockading some of these 
mediators has been shown to be efficacious in experimental settings, it is still unclear 
whether the inflammatory reaction at the tumor site promotes tumor growth or simply 
implies the failed attempt of the immune system to eliminate the rising malignancy.  
Neutrophils (and sometimes eosinophils) are the first recruited effectors of the acute 
inflammatory response. Monocytes, which differentiate into macrophages in tissues, are 
next to migrate to the site of tissue injury, guided by chemotactic factors. Once activated, 
macrophages are the main source of growth factors and cytokines, which profoundly affect 
endothelial, epithelial and mesenchymal cells in the local microenvironment. Mast cells are 
also important in acute inflammation owing to their release of stored and newly synthesized 
inflammatory mediators, such as histamine, cytokines and proteases complexed to highly 
sulphated proteoglycans, as well as lipid mediators. Thus, we have considered that various 
cytokines play the very important role by forming the cytokine cascades in the tumor 
microenvironment of the oral cancer. 
3.1 Receptor-binding Cancer Antigen expressed on SiSo cells (RCAS1) 
RCAS1 is a type II membrane protein isolated as a human tumor-associated antigen by a 
mouse monoclonal antibody (22-1-1 antibody) against a human uterine adenocarcinoma cell 
line, SiSo (Sonoda et al., 1995). RCAS1 acts as a ligand for a putative receptor present on 
immune cells such as T, B and NK cells and inhibits the growth of receptor-expressing cells, 
further induces apoptotic cell death (Nakashima et al., 1999). These observations suggest a 
role of RCAS1 in the immune escape of tumor cells. A variety of cancer tissues have been 
screened (Sonoda et al., 1996, Sonoda et al., 1998, Iwasaki et al., 2000, Izumi et al., 2001, 
Kubokawa et al., 2001, Noguchi et al., 2001, Takahashi et al., 2001, Hiraoka et al., 2002, 
Nakakubo et al., 2002, Fukuda et al., 2004) and were found to be positive for RCAS1 
expression, including human uterine, ovarian, esophageal SCCs, pancreatic 
adenocarcinomas, hepatocarcinomas, skin SCCs, gastric adenocarcinomas, lung cancer cells 
and HOSCCs, but not in normal tissues. 
We investigated whether tumor cells which are expressing RCAS1, induce apoptosis in its 
receptor-positive cells, PBLs. The apoptotic index (AI) of TILs was also examined in HOSCC 
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tissues. The correlations between RCAS1 expressions and clinicopathological variables in 
HOSCC and adenoid cystic carcinoma (ACC) tissues were examined, respectively. As the 
results, it was demonstrated that RCAS1 was frequently expressed both in HOSCC and 
ACC, in vitro and vivo, and its function on KB cells clearly led apoptosis to PBLs in vitro 
(Fukuda et al., 2004). Our results indicated that RCAS1 expression plays a key role in the 
immune escape mechanism of oral cancer, thus that RCAS1 expression could be used as a 
predictor of poor prognosis in patients with oral cancer. Further investigation of the role of 
RCAS1 will be required to clarify RCAS1-mediated tumor survival and to establish a 
strategy of RCAS1-based oral cancer therapy. 
3.2 Interleukin (IL)-12 & IL-23 
The causal relationship between chronic inflammation, innate immunity and cancer is now 
widely accepted, and the similarities in the regulatory mechanisms have been suggested for 
more than a century (Balkwill et al., 2001, Coussens et al., 2002). Many cancers arise at the 
site of chronic inflammation and inflammatory mediators are often produced in tumors 
(Coussens et al., 2002, Balkwill et al., 2005). The frequent use of anti-inflammatory drugs 
reduces the incidence of a variety of human tumors (Zha et al., 2004). Although blockading 
some of these mediators has been shown to be efficacious in experimental settings, it is still 
unclear whether the inflammatory reaction at the tumor site promotes tumor growth or 
simply implies the failed attempt of the immune system to eliminate the rising malignancy.  
IL-23, a heterodimeric cytokine with many similarities to IL-12, has recently been identified 
as a factor linking tumor-associated inflammation and a lack of tumor immune surveillance 
(Langowski et al., 2006). IL-23 comprises a p19 subunit that associates with the IL-12p40 
subunit (Oppmann et al., 2000), whereas IL-12 is a combination of IL-12p35 and the same IL-
12p40 subunit (Sospedra et al., 2005). Although p19 is expressed in various tissues and cell 
types, it lacks biological activity and only becomes biologically active when complexed with 
p40, which is normally secreted by activated macrophages and DCs (Oppmann et al., 2000). 
IL-23 uses many of the same signal-transduction components as IL-12, including the IL-12 
receptor (R) 1 subunit (IL-12R1), Janus kinase (Jak)2, Tyk2, signal transducer and activator 
of transcription (Stat)1, Stat3, Stat4, and Stat5 (Oppmann et al., 2000, Parham et al., 2002). IL-
23R, composed of the IL-12R1 and the IL-23R subunit, is also expressed in DCs, 
macrophages, and T cells (Parham et al., 2002). Consistent with the structural and biological 
similarities of IL-12 and IL-23, the IL-23R complex shares a subunit with that of IL-12 (IL-
12R1), however, it does not use or detectably bind to IL-12R2 (Oppmann et al., 2000). The 
ability of cells to respond to either IL-12 or IL-23 is determined by expression of IL-12R2 or 
IL-23R, respectively (Parham et al., 2002). Upon engaging IL-23, IL-12R1 and IL-23R 
associate, marking the beginning of the IL-23 signal-transduction cascade, many of whose 
components are now known (Fig. 2).  
Additionally, both cytokines promote the T helper cell type 1 (Th1) costimulatory function 
of antigen-presenting cells (Lankford et al., 2003) (Fig. 3).  
However, IL-23 does differ from IL-12 in the T cell subsets that it targets. IL-12 acts on naive 
CD4+ T cells, whereas IL-23 preferentially acts on memory CD4+ T cells (Lankford et al., 
2003). It has been reported that IL-12 has potent antitumor activity in a variety of murine  
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Fig. 2. Stat4 activation is a common feature of IL-23 and IL-12 signal-transduction pathways. 
IL-23 signal transduction is very similar to that of IL-12, they both use IL-12R1, Jak2, Tyk2, 
Stat1, Stat3, Stat4, and Stat5. This common feature may explain similarities in TH1 function 
among IL-12 and IL-23. 
 
Fig. 3. IL-23 acts on memory CD4+ T cells and DC. IL-23 stimulation leads to IFN- 
production and proliferative response in memory but not naive CD4+ T cells. IL-23 differs 
from IL-12, which acts on naive cells but has negligible effects on murine memory cells. IL-
23 and IL-12 share a similar function in promoting TH1 costimulation by inducing IL-12 and 
IFN- production by DC. MHCII, major histocompatibility complex class II. 
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tumor models, causing regression of established tumors (Brunda et al., 1993, Nastala et al., 
1994, Cua et al., 2003) and inhibiting the formation of experimental metastases (Brunda et 
al., 1993, Nastala et al., 1994) and spontaneous metastases (Murphy et al., 2003, Becher et al., 
2003). On the other hand, it has recently been reported that genetic deletion or antibody-
mediated elimination of IL-23 in mice leads to increased infiltration of cytotoxic T cells into 
the transformed tissue, rendering a protective effect against chemically-induced 
carcinogenesis (Langowski et al., 2006). So far, it has been reported that expression of IL-23 
and its receptors is detectable in activated macrophages, DCs, and keratinocytes in healthy 
skin (Piskin et al., 2006). We have previously reported that IL-23 is a potent and specific 
promoter of nuclear factor-kappaB (NF-B) activation in HOSCC cells, in vitro and in vivo 
(Fukuda et al., 2010). Finally, we noted that IL-23 was secreted not only by DCs and 
macrophages, as shown in previous studies (Sospedra et al., 2005), but also by autologous 
cancer cells. Consequently, we consider the existence of an autocrine mechanism, in which 
tumor growth is promoted by IL-23 produced by autologous cancer cells. From these 
combined data, we believe that IL-23 plays a significant role in the growth and proliferation 
of oral cancer. Thus, IL-23 could be used as a predictor of poor prognosis in patients with 
oral cancer, and its antibody might be able to use as an inhibitor of oral cancer progression. 
Identification of the signaling pathways underlying these events might provide the key to 
elucidating the mechanism of development of oral cancer. Further investigations into the 
role of IL-23 will be required to fully understand IL-23-mediated tumor proliferation and to 
establish an IL-23-based oral cancer therapeutic strategy. 
3.3 Vascular Endothelial Growth Factor (VEGF)  
Oral cancer is an important cause of worldwide morbidity and mortality, with substantial 
economic, physiological, and psychosocial impacts due to its treatment modality and a great 
risk for recurrences and second primary OSCC development. Therefore, it is very important 
to understand the underlying cell biology of such tumors. It is now a well-accepted fact that 
angiogenesis is essential for the growth and metastasis of solid tumors, including oral 
squamous cell carcinoma. The main factor responsible for angiogenesis is VEGF and its 
receptors. The expression of VEGF protein has been found in a wide variety of cancer 
tissues, including human prostate cancer, head and neck squamous cell carcinomas, skin 
squamous cell carcinomas, gastric adenocarcinomas, and lung cancer cells (Weidne et al., 
1993, Gasparini et al., 1993, Srivastava et al., 1998, Maeda et al., 1996, Kajita et al., 2001). It 
has also been shown that VEGF influences the differentiation, maturation, and function of 
DCs as an immunosuppressive cytokine (Gabrilovich et al., 1996, Banchereau et al., 1998). 
Interestingly, dendritic cells found in neoplastic infiltrates are frequently immature and 
defective in T-cell stimulatory capacity. It has been demonstrated that VEGFRs are also 
present on tumor cells themselves and other cells from the tumor microenvironment, in 
addition to tumoral endothelial cells (ECs) (Fukuda et al., 2010).  
Therefore between these cells take place numerous and different interactions mediated via 
paracrine/autocrine pathways that promote angiogenesis, uncontrolled tumor proliferation 
and metastasis. In consequence, estimation of VEGF expression and its receptors became a 
reliable prognostic tool in OSCCS, predicting the poor disease-free survival, poor overall 
survival, and metastatic disease.  
Furthermore, Saito et al. (1998, 1999) reported that the expression of VEGF is inversely 
related to the density of DCs in gastric adenocarcinoma tissue. In our study, it was found 
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tumor models, causing regression of established tumors (Brunda et al., 1993, Nastala et al., 
1994, Cua et al., 2003) and inhibiting the formation of experimental metastases (Brunda et 
al., 1993, Nastala et al., 1994) and spontaneous metastases (Murphy et al., 2003, Becher et al., 
2003). On the other hand, it has recently been reported that genetic deletion or antibody-
mediated elimination of IL-23 in mice leads to increased infiltration of cytotoxic T cells into 
the transformed tissue, rendering a protective effect against chemically-induced 
carcinogenesis (Langowski et al., 2006). So far, it has been reported that expression of IL-23 
and its receptors is detectable in activated macrophages, DCs, and keratinocytes in healthy 
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promoter of nuclear factor-kappaB (NF-B) activation in HOSCC cells, in vitro and in vivo 
(Fukuda et al., 2010). Finally, we noted that IL-23 was secreted not only by DCs and 
macrophages, as shown in previous studies (Sospedra et al., 2005), but also by autologous 
cancer cells. Consequently, we consider the existence of an autocrine mechanism, in which 
tumor growth is promoted by IL-23 produced by autologous cancer cells. From these 
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elucidating the mechanism of development of oral cancer. Further investigations into the 
role of IL-23 will be required to fully understand IL-23-mediated tumor proliferation and to 
establish an IL-23-based oral cancer therapeutic strategy. 
3.3 Vascular Endothelial Growth Factor (VEGF)  
Oral cancer is an important cause of worldwide morbidity and mortality, with substantial 
economic, physiological, and psychosocial impacts due to its treatment modality and a great 
risk for recurrences and second primary OSCC development. Therefore, it is very important 
to understand the underlying cell biology of such tumors. It is now a well-accepted fact that 
angiogenesis is essential for the growth and metastasis of solid tumors, including oral 
squamous cell carcinoma. The main factor responsible for angiogenesis is VEGF and its 
receptors. The expression of VEGF protein has been found in a wide variety of cancer 
tissues, including human prostate cancer, head and neck squamous cell carcinomas, skin 
squamous cell carcinomas, gastric adenocarcinomas, and lung cancer cells (Weidne et al., 
1993, Gasparini et al., 1993, Srivastava et al., 1998, Maeda et al., 1996, Kajita et al., 2001). It 
has also been shown that VEGF influences the differentiation, maturation, and function of 
DCs as an immunosuppressive cytokine (Gabrilovich et al., 1996, Banchereau et al., 1998). 
Interestingly, dendritic cells found in neoplastic infiltrates are frequently immature and 
defective in T-cell stimulatory capacity. It has been demonstrated that VEGFRs are also 
present on tumor cells themselves and other cells from the tumor microenvironment, in 
addition to tumoral endothelial cells (ECs) (Fukuda et al., 2010).  
Therefore between these cells take place numerous and different interactions mediated via 
paracrine/autocrine pathways that promote angiogenesis, uncontrolled tumor proliferation 
and metastasis. In consequence, estimation of VEGF expression and its receptors became a 
reliable prognostic tool in OSCCS, predicting the poor disease-free survival, poor overall 
survival, and metastatic disease.  
Furthermore, Saito et al. (1998, 1999) reported that the expression of VEGF is inversely 
related to the density of DCs in gastric adenocarcinoma tissue. In our study, it was found 
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that VEGF in the primary oral tumor is expressed more strongly in PN+ cases than in PN- 
cases, thus demonstrating that VEGF is associated with the metastasis to RLNs in oral 
cancer. We also found that in oral cancer the expression of VEGF is inversely related to the 
density of S-100+ and CD1a+ DCs, although it is also positively correlated with the density of 
CD83+ DCs (Kusama et al., 2005). Understanding the distribution and role of VEGF and its 
receptors in the progression of OSCC will be essential to the development and design of 
new therapeutic strategies. 
4. Role of transcriptional factors in tumor microenvironment 
The ancient stress response is the innate immune response, regulated by several 
transcription factors, among which NF-kappaB plays a central role. The hypoxic response is 
also ancient stress response triggered by low ambient oxygen (O2) and controlled by 
hypoxia inducible transcription factor-1, whose a subunit is rapidly degraded under 
normoxia but stabilized when O2-dependent prolylhydroxylases (PHDs) that target its O2-
dependent degradation domain are inhibited. Thus, the amount of HIF-1alpha, which 
controls genes involved in energy metabolism and angiogenesis, is regulated post-
translationally. So, NF-kappaB and hypoxia-inducible factor-1 were selected as the typical 
transcriptional factors in this section.  
4.1 Nuclear Factor (NF)-kappaB  
Transcription factor NF-B has key roles in inflammation, immune response, tumorigenesis 
and protection against apoptosis (Li et al., 2002, Karin et al., 2002, Orlowski et al., 2002). In 
most cells, NF-B is kept inactive in the cytoplasm as a heterodimeric complex composed of 
p50 and p65 (RelA) subunits bound to the inhibitory protein, inhibitor of B (IB) 
(Baeuerle et al., 1988, Baeuerle et al., 1989, Haskill et al., 1991). Insight into the signaling 
mechanisms that lead to IB phosphorylation have identified a high-molecular weight 
protein complex known collectively as the IB kinase (IKK) signalosome and including 
IKK, IKK and IKK also known as NF-B essential modulator (NEMO) (Karin, 1999, 
Mercurio et al., 1997). IKK and IKK have been identified as catalytic subunits, whereas 
IKK is a regulatory subunit (Karin, 1999, May et al., 1999). Generally, after stimulation by 
various reagents, IB is phosphorylated at serine residues 32 and 36 by IKK and IKK, 
together with the scaffold protein NEMO/IKK (Karin, 1999). Serine phosphorylation 
results in polyubiquitination of IB and its subsequent degradation by the proteasome, 
allowing NF-B to translocate to the nucleus and activate its target gene (Karin et al., 2002, 
Karin, 1999, Smahi et al., 2002). 
4.2 Hypoxia Inducible Factor (HIF)-1alpha 
Protection against hypoxia in solid tumors is an important step in tumor development and 
progression. One system in hypoxia protection of tumor cells is represented by the hypoxia-
inducible factor 1 (HIF-1) system which plays a crucial role in biologic processes under 
hypoxic conditions, especially in angiogenesis and carcinogenesis (Maxwell et al., 1997, 
Ryan et al., 1998).  
HIF-1 is a heterodimer, composed of HIF-1α (120 kDa) and HIF-1β (91, 93, 94 kDa) (Wang et 
al., 1995). HIF-1αsubunit, is a transcription factor in response to cellular hypoxia, plays an 
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important role in tumor growth and metastasis by regulating energy metabolism and 
inducing angiogenesis (Seagroves et al., 2001). However, under normoxic conditions, HIF-
1α is maintained at low levels due to continuous degradation via the ubiquitin-dependent 
proteosome pathway, and this pathway is inhibited by hypoxia and by p53 or von Hippel-
Lindau tumor-suppressor gene defects, leading to stabilization of the HIF-1α protein 
(Huang et al., 1996, Ravi et al., 2000, Maxwell et al., 1999, Stroka et al., 2001). Therefore, 
hypoxia can lead to a rapid increase in HIF-1α protein levels (Huang et al., 1996, Stroka et 
al., 2001, Wang et al., 1993, Wang et al., 1995). Furthermore, HIF-1α up-regulates a number 
of important factors for tumor expansion, including VEGF, a key factor in tumor 
angiogenesis (Akakura et al., 2001, Carmeliet et al., 1998, An et al., 1998). In several cancers, 
overexpression of HIF-1α protein has been found to be associated with tumor 
aggressiveness and with an unfavorable prognosis (Maxwell et al., 1997, Birner et al., 2000, 
Kuwai et al., 2003). Hypoxia has also been reported to induce wild-type p53 via a different 
pathway than DNA-damaging agents (Graeber et al., 1994). The hypoxic/anoxic induction 
of p53 selects for tumor cells that lack functional p53, and hence evidence diminished 
apoptotic potential (Graeber et al., 1996). Elevated levels of HIF-1α are noted in various 
malignant tumors (Maxwell et al., 1997), but it is unclear whether this is so in oral 
carcinoma. Therefore, we have examined the implications of HIF-1α expression in HOSCC, 
in vitro and in vivo. NanoCulture plate system was used to duplicate hypoxic condition 
within tumor mass of living organisms by the three-dimensional cell culture. As the results, 
we found that HIF-1αregulates the expression of VEGF, and that HIF-1αmay be regulated 
by p53 in SCC of the oral cavity (Fukuda et al., 2010). 
4.3 p53 
The p53 gene is a highly characterized tumor suppressor that encodes a protein with a 
molecular weight of 53 kilo Daltons. The p53 gene is also known as a transcription factor 
that can arrest the cell cycle at the late G1 phase in cells with sub-lethal damage in their 
genome until their complete repair, or induce apoptosis in cases of irreparable injury, and 
further activate the transcription of specific genes (El-Deiry et al., 1992, Cordon-Cardo, 1995). 
Hence, among the genetic changes involved, inactivation of the p53 tumor suppressor gene 
by point mutation and allele loss is considered to be the most common event underlying 
malignancies of every organ (Hollstein et al., 1991). These alterations also seem to be related 
to the multi-step processes of oral carcinogenesis (Crosthwaite et al., 1996, Stoll et al., 1998). 
Mutations of p53 must occur during early stages in the development of head and neck SCCs 
because they are already present in premalignant lesions (Shin et al., 1994). Mutations of p53 
gene are not necessarily the critical, sole, nor the consistent culprit in oral SCCs patients, 
however, between 30% and 50% of SCCs of this region have been reported to harbor p53 
gene alterations (Somers et al., 1992, Caamano et al., 1993, Nylander et al., 2000). By contrast, 
other markers are less suitable due to their lack of stability, variability, or difficulties with 
technical requirements for their detection. The genes that occur high frequent alterations 
more than p53 have not been found so far. Furthermore, it has been described that cancer 
with the mutated p53 gene is resistant to radio-/chemotherapy and the patient has poor 
prognosis than cancer patient with the wild-type p53 gene (Obata et al., 2000). Therefore, 
analysis of mutations in this particular gene gives a good indication of clonal expansion of 
malignancies and important prognostic information. Because the wild-type form of p53 has 
a half-life of only 6 to 30 minutes, the protein cannot be generally detected by 
immunohistochemistry; however, if the DNA is damaged, p53 protein accumulates and  
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cancer. We also found that in oral cancer the expression of VEGF is inversely related to the 
density of S-100+ and CD1a+ DCs, although it is also positively correlated with the density of 
CD83+ DCs (Kusama et al., 2005). Understanding the distribution and role of VEGF and its 
receptors in the progression of OSCC will be essential to the development and design of 
new therapeutic strategies. 
4. Role of transcriptional factors in tumor microenvironment 
The ancient stress response is the innate immune response, regulated by several 
transcription factors, among which NF-kappaB plays a central role. The hypoxic response is 
also ancient stress response triggered by low ambient oxygen (O2) and controlled by 
hypoxia inducible transcription factor-1, whose a subunit is rapidly degraded under 
normoxia but stabilized when O2-dependent prolylhydroxylases (PHDs) that target its O2-
dependent degradation domain are inhibited. Thus, the amount of HIF-1alpha, which 
controls genes involved in energy metabolism and angiogenesis, is regulated post-
translationally. So, NF-kappaB and hypoxia-inducible factor-1 were selected as the typical 
transcriptional factors in this section.  
4.1 Nuclear Factor (NF)-kappaB  
Transcription factor NF-B has key roles in inflammation, immune response, tumorigenesis 
and protection against apoptosis (Li et al., 2002, Karin et al., 2002, Orlowski et al., 2002). In 
most cells, NF-B is kept inactive in the cytoplasm as a heterodimeric complex composed of 
p50 and p65 (RelA) subunits bound to the inhibitory protein, inhibitor of B (IB) 
(Baeuerle et al., 1988, Baeuerle et al., 1989, Haskill et al., 1991). Insight into the signaling 
mechanisms that lead to IB phosphorylation have identified a high-molecular weight 
protein complex known collectively as the IB kinase (IKK) signalosome and including 
IKK, IKK and IKK also known as NF-B essential modulator (NEMO) (Karin, 1999, 
Mercurio et al., 1997). IKK and IKK have been identified as catalytic subunits, whereas 
IKK is a regulatory subunit (Karin, 1999, May et al., 1999). Generally, after stimulation by 
various reagents, IB is phosphorylated at serine residues 32 and 36 by IKK and IKK, 
together with the scaffold protein NEMO/IKK (Karin, 1999). Serine phosphorylation 
results in polyubiquitination of IB and its subsequent degradation by the proteasome, 
allowing NF-B to translocate to the nucleus and activate its target gene (Karin et al., 2002, 
Karin, 1999, Smahi et al., 2002). 
4.2 Hypoxia Inducible Factor (HIF)-1alpha 
Protection against hypoxia in solid tumors is an important step in tumor development and 
progression. One system in hypoxia protection of tumor cells is represented by the hypoxia-
inducible factor 1 (HIF-1) system which plays a crucial role in biologic processes under 
hypoxic conditions, especially in angiogenesis and carcinogenesis (Maxwell et al., 1997, 
Ryan et al., 1998).  
HIF-1 is a heterodimer, composed of HIF-1α (120 kDa) and HIF-1β (91, 93, 94 kDa) (Wang et 
al., 1995). HIF-1αsubunit, is a transcription factor in response to cellular hypoxia, plays an 
 
The Role of Tumor Microenvironment in Oral Cancer 
 
209 
important role in tumor growth and metastasis by regulating energy metabolism and 
inducing angiogenesis (Seagroves et al., 2001). However, under normoxic conditions, HIF-
1α is maintained at low levels due to continuous degradation via the ubiquitin-dependent 
proteosome pathway, and this pathway is inhibited by hypoxia and by p53 or von Hippel-
Lindau tumor-suppressor gene defects, leading to stabilization of the HIF-1α protein 
(Huang et al., 1996, Ravi et al., 2000, Maxwell et al., 1999, Stroka et al., 2001). Therefore, 
hypoxia can lead to a rapid increase in HIF-1α protein levels (Huang et al., 1996, Stroka et 
al., 2001, Wang et al., 1993, Wang et al., 1995). Furthermore, HIF-1α up-regulates a number 
of important factors for tumor expansion, including VEGF, a key factor in tumor 
angiogenesis (Akakura et al., 2001, Carmeliet et al., 1998, An et al., 1998). In several cancers, 
overexpression of HIF-1α protein has been found to be associated with tumor 
aggressiveness and with an unfavorable prognosis (Maxwell et al., 1997, Birner et al., 2000, 
Kuwai et al., 2003). Hypoxia has also been reported to induce wild-type p53 via a different 
pathway than DNA-damaging agents (Graeber et al., 1994). The hypoxic/anoxic induction 
of p53 selects for tumor cells that lack functional p53, and hence evidence diminished 
apoptotic potential (Graeber et al., 1996). Elevated levels of HIF-1α are noted in various 
malignant tumors (Maxwell et al., 1997), but it is unclear whether this is so in oral 
carcinoma. Therefore, we have examined the implications of HIF-1α expression in HOSCC, 
in vitro and in vivo. NanoCulture plate system was used to duplicate hypoxic condition 
within tumor mass of living organisms by the three-dimensional cell culture. As the results, 
we found that HIF-1αregulates the expression of VEGF, and that HIF-1αmay be regulated 
by p53 in SCC of the oral cavity (Fukuda et al., 2010). 
4.3 p53 
The p53 gene is a highly characterized tumor suppressor that encodes a protein with a 
molecular weight of 53 kilo Daltons. The p53 gene is also known as a transcription factor 
that can arrest the cell cycle at the late G1 phase in cells with sub-lethal damage in their 
genome until their complete repair, or induce apoptosis in cases of irreparable injury, and 
further activate the transcription of specific genes (El-Deiry et al., 1992, Cordon-Cardo, 1995). 
Hence, among the genetic changes involved, inactivation of the p53 tumor suppressor gene 
by point mutation and allele loss is considered to be the most common event underlying 
malignancies of every organ (Hollstein et al., 1991). These alterations also seem to be related 
to the multi-step processes of oral carcinogenesis (Crosthwaite et al., 1996, Stoll et al., 1998). 
Mutations of p53 must occur during early stages in the development of head and neck SCCs 
because they are already present in premalignant lesions (Shin et al., 1994). Mutations of p53 
gene are not necessarily the critical, sole, nor the consistent culprit in oral SCCs patients, 
however, between 30% and 50% of SCCs of this region have been reported to harbor p53 
gene alterations (Somers et al., 1992, Caamano et al., 1993, Nylander et al., 2000). By contrast, 
other markers are less suitable due to their lack of stability, variability, or difficulties with 
technical requirements for their detection. The genes that occur high frequent alterations 
more than p53 have not been found so far. Furthermore, it has been described that cancer 
with the mutated p53 gene is resistant to radio-/chemotherapy and the patient has poor 
prognosis than cancer patient with the wild-type p53 gene (Obata et al., 2000). Therefore, 
analysis of mutations in this particular gene gives a good indication of clonal expansion of 
malignancies and important prognostic information. Because the wild-type form of p53 has 
a half-life of only 6 to 30 minutes, the protein cannot be generally detected by 
immunohistochemistry; however, if the DNA is damaged, p53 protein accumulates and  
 




p53 gene alteration: 14/33 cases (42.4%) 
Table 1. The correlations between p53 expression, p53 gene alteration and 
clinicopathological variables in 40 cases of oral squamous cell carcinomas. 
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becomes detectable (Langdon et al., 1992). So, to assess the frequency of p53 mutations in 
HOSCCs and the correlations between p53 immunohistochemical detections and p53 gene 
alterations, we examined them by use of the formalin-fixed, paraffin-embedded specimens 
from 40 patients with oral SCC treated in the Department of Oral and Maxillofacial Surgery, 
Meikai University Hospital, Saitama, Japan, from 1970 to 2001. Diagnosis of oral lesions was 
based on histological examination of hematoxylin and eosin-stained slides. Of the 40 SCC 
patients, there were 34 men and 6 women, whose ages ranged from 48 to 92 years, with a 
mean age of 66.2 years. A majority of the patients were over 50 years of age. All specimens 
were obtained from surgical biopsies that no patients had undergone chemotherapy or 
radiotherapy preoperatively. As the results of immunohistochemistry using MAb p53 
antibody, 22 of 40 cases (55%) were positive. Then the alterations in exons 5 to exon 8 of the 
p53 gene were analyzed by PCR-SSCP and direct sequencing. The p53 point mutations were 
detected in 14 of 33 cases (42.4 %) (Table 1). However, it had no correlations between p53 
immunoreactivity, the detection of p53 gene alterations and clinico-pathological variables. 
These findings support those of previous reports (Kärjä et al., 1997).  
It has recently been reported that in combination with an overexpression of p53 protein, 
HIF-1 protein overexpression tends to indicate a dismal prognosis (Sumiyoshi et al., 2006). 
In addition, it has also described that p53 inhibits expression of the p65 subunit of NF-κB 
and its gene product Bcl-2 (Amin et al., 2009). For these reasons, it has been suggested that 
there is close relationship between p53 and tumor microenvironment. 
5. Conclusions 
The efficient elimination of cancer cells via immunodefense mechanisms remains the most 
ideal therapy. However, it is important to recognize that the dysfunctional immune state 
that exists in cancer patients will result in a poor response to vaccination procedures. 
Therefore, in order to enable an immunotherapy challenge, it is necessary to restore the 
increased levels of immunosuppressive factors, such as IL-10, IL-23, RCAS1, VEGF and/or 
TGF-1, in the tumor microenvironment of cancer patients to normal levels. In addition, 
whether DCs function normally and efficiently remains an important key for the induction 
of anticancer immunity.  
Further investigation will be required to establish a strategy of basic molecular-mechanism-
based and clinical studies to determine the most effective oral cancer therapy, which should 
be tailor-made for the individual patient. 
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1. Introduction 
microRNAs (miRNAs) have rapidly emerged as a widespread and important regulatory 
layer of gene expression (Ambros, 2004; Bartel & Chen, 2004). miRNAs can coordinately 
modulate the expression of hundreds of target genes, mainly by negatively affecting mRNA 
stability and/or protein output (Baek et al., 2008; Bentwich et al., 2005; Kozomara & 
Griffiths-Jones, 2011; Lim et al., 2005; Selbach et al., 2008). With this mode of gene expression 
control, a single miRNA can concomitantly influence multiple cellular programs under 
physiological and pathological conditions. Examples abound in which perturbation of 
miRNA functions can have catastrophic consequences for proper execution of 
developmental programs, for maintenance of cellular homeostasis, and for optimal 
performance of cellular processes (De Smaele et al., 2010; Garzon et al., 2010; Saba & Schratt, 
2010; Sempere & Kauppinen, 2009; Ventura & Jacks, 2009).  
Only one year after the discovery of miRNAs in 2001, Croce and colleagues found the first 
association between miRNAs and cancer when they noted the frequent occurrence of 
chromosomal deletion and the concurrent downregulation of two miRNA genes, miR-15a 
and miR-16-1, in B-cell chronic lymphocytic leukemia patients (Calin et al., 2002). Since that 
time, progress towards understanding the basic molecular and biological mechanisms of 
miRNA biogenesis, their normal patterns of temporal and spatial expression, and their roles 
in development and physiology has unfolded slowly compared to the rapid path towards 
translational and clinical applications of miRNAs, especially in cancer.  
A particular active area of research has been high-throughput expression profiling of 
miRNAs in a variety of cancer types (Barbarotto et al., 2008; Sempere, 2011). The general 
interpretation of these expression profiling experiments has been to assign altered miRNA 
expression to the cancer cells and promptly labelled the implicated miRNA as having tumor 
suppressive or oncogenic properties depending on whether miRNA levels were detected a 
lower or higher levels, respectively, in tumor tissues compared to normal. However, the 
cancer cell compartment of many of the most aggressive types of solid tumors represents a 
minority of the variety of cell types in cancer lesions (Sempere, 2011). A tumor 
microenvironmental (TME) cell type invariably associated with cancer progression is the 
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leukocyte. Immune cells are the site of cancer origin in leukemias and lymphomas, whereas 
epithelial cells are the site of cancer origin in carcinomas and the immune cells constitute the 
inflammatory component of TME. Thus, inflammation and infiltrating leukocytes present as 
co-disease or co-morbidity in solid tumors and are a major confounding factor to correctly 
interpret expression profiling experiments. A salient example to illustrate this dichotomy 
between cancer cell and immune cell infiltrate is miR-155 in solid tumors. miR-155 resides in 
non-protein coding B-cell integration cluster (BIC) gene (Faraoni et al., 2009; Tili et al., 2009). 
miR-155 is frequently detected at high levels in leukemias, lymphomas and solid tumors 
(e.g., carcinomas) and overexpression of miR-155 causes rapid and aggressive disease 
progression in a mouse model of B cell lymphoma (Faraoni et al., 2009; Tili et al., 2009). 
Thus, miR-155 has been regarded as a master oncogenic miRNA in hematological and solid 
tumors. However, a large body of evidence also attributes important roles to miR-155 as a 
mediator of lymphoid and myeloid cell responses to infection and inflammation, which is 
further supported by immunological deficiency exhibited by mir-155 knockout mouse 
models (Faraoni et al., 2009; Tili et al., 2009). We recently showed that expression of miR-155 
was confined to a subpopulation of infiltrating immune cells in breast, colorectal, lung, 
pancreas and prostate tumor lesions (Sempere et al., 2010). Importantly, these results 
indicated that the majority of miR-155 signal detected by RT-PCR assays in whole tissue 
biopsies or blood samples likely emanates from TME cells, drawing into question whether 
miR-155 plays any role within the cancer cells in these carcinomas. In the light of these 
findings, we revisit here altered expression of miR-155 and other leukocyte-expressed 
miRNAs (e.g., miR-17-5p, miR-20a, miR-21, miR-25, miR-29a, miR-142-3p, miR-146a, miR-
150, miR-181a, miR-221, miR-223) in solid tumors, which are likely to reflect, at least in part, 
immune cell responses in the TME rather than molecular aberrations within the cancer cells 
per se. We review the emerging roles of these leukocyte-expressed miRNAs in the immune 
system with an especial emphasis on myelomonocytic-derived cells, and discuss their 
implications in the modulation of cancer initiation and progression in the context of a 
reactive and/or permissive TME.  
2. Physiological roles of microRNAs in the immune system 
In the bone marrow, pluripotent hematopoietic stem cells give rise to common progenitors 
of the lymphoid and myeloid lineages. In the blood, these progenitors will continue distinct 
differentiation paths to produce the principal cell types of the immune system: B and T 
lymphocytes and natural killer (NK) cells in the lymphoid branch, and basophils, 
neutrophils, eosinophils, mast cells and monocytes in the myeloid branch; other non-
immune cell types such as erythrocytes and thrombocytes are also produced in the myeloid 
branch. In tissues, further maturation awaits for lymphoid and myeloid lineages to mount 
innate and adaptive responses against bacterial, viral and other pathogens as well as against 
cancer cells and other aberrant cells not recognized as self. These differentiation programs 
are crucial to establish a fully functional immune system. Expression profiling and 
functional studies have implicated miRNAs as key regulators of specific stages of 
differentiation and maturation of specific immune cell lineages, which in general have overt 
deleterious consequences at the organismal level.  
Mature and biologically active miRNAs, ~21-23 nucleotides-long, function as guides to 
recognize and bind partially complementary elements (miRNA recognition element; MRE) 
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on the 3’ untranslated region (UTR) of target mRNAs. miRNA biogenesis and processing 
determine the total levels of mature miRNA and to a large extent miRNA function (however 
see these reviews for cooperative and competitive effects of RNA binding proteins (Van 
Kouwenhove et al., 2011) and competing endogenous RNAs (Salmena et al., 2011) on 
miRNA activity). Most miRNA genes are transcribed by RNA polymerase II, which 
produces a long primary transcript (pri-miRNA) with a 5’ cap and a 3’ poly(A) tail (Ketting, 
2011; van et al., 2011). In the nucleus the pri-miRNA is recognized by the microprocessor, a 
multiprotein complex that cleaves off a 70 nts-long precursor miRNA hairpin (pre-miRNA). 
The catalyzes this cleavage as DGCR8 recognizes structural features of the hairpin and 
accordingly position the pre-miRNA for cleavage by RNAse III endonuclease Drosha. The 
pre-miRNA is exported to the cytoplasm by Exportin-5 in a RAN-GTP dependent manner. 
Then, the pre-miRNA is cleaved by another RNAse III endonuclease Dicer in association 
with TARBP2 or PACT and the mature miRNA strand (guide) is loaded in Argonaute-
containing RNA-induced silencing complexes (Ketting, 2011; van et al., 2011). 
The expression of key components of the miRNA processing machinery such Dicer can be 
inhibited under physiological stress and disease states, including cancer (Tomasi et al., 
2010). Moreover, Dicer expression is affected by cortisone, interferon and other 
pharmacological agents prescribed for the treatment of immune disorders (Tomasi et al., 
2010). Thus, perturbation of global miRNA activity can have undesirable clinical 
implications. In mouse models, deleterious effects of global miRNA impairment by 
conditional removal of Dicer or DGCR8 in specific immune cell lineage using the Cre/LoxP 
system has pinpointed important roles of miRNAs in production of antibody diversity, 
terminal differentiation and survival of B cells (Belver et al., 2010; Koralov et al., 2008), 
function of regulatory T (Treg) cells and Treg-mediated control of autoimmunity (Liston et 
al., 2008; Zhou et al., 2008), the development and function of invariant natural killer T cells 
(Bezman et al., 2010; Seo et al., 2010; Zhou et al., 2009), and terminal differentiation, 
activation, migration and survival of CD8+ T cell (Muljo et al., 2005; Zhang & Bevan, 2010). 
Subsequent studies have uncovered a major role of a single or small subset of miRNAs for 
immunological phenotypes observed in animals deficient in miRNA processing machinery 
(see below). As we describe in the next subsections, high-throughput expression profiling 
has been a useful discovery tool to correlate expression with function and thereby highlight 
specific miRNAs for further mechanistic characterization.  
2.1 Dynamic expression of microRNAs during hematopoietic lineage differentiation 
Using primarily the mouse as a model system, several groups have characterized in detail 
changes of miRNA expression during immune cell lineage differentiation as a means to infer 
from this a functional involvement of specific miRNAs at key steps of these processes 
(Malumbres & Lossos, 2010; O'Connell et al., 2010b; O'Neill et al., 2011).  
2.1.1 microRNA expression in granulocyte differentiation and maturation 
There are several well-defined differentiation stages that mature granulocytes (PB-N) 
undergo from a common myeloid progenitor (CMP): granulocyte-monocyte progenitor 
(GMP), immature bone marrow neutrophils (BM-N). Expression of miR-223 gradually 
increases from CMP to BM-N stages, reaching the highest level of expression in PB-N cells 
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leukocyte. Immune cells are the site of cancer origin in leukemias and lymphomas, whereas 
epithelial cells are the site of cancer origin in carcinomas and the immune cells constitute the 
inflammatory component of TME. Thus, inflammation and infiltrating leukocytes present as 
co-disease or co-morbidity in solid tumors and are a major confounding factor to correctly 
interpret expression profiling experiments. A salient example to illustrate this dichotomy 
between cancer cell and immune cell infiltrate is miR-155 in solid tumors. miR-155 resides in 
non-protein coding B-cell integration cluster (BIC) gene (Faraoni et al., 2009; Tili et al., 2009). 
miR-155 is frequently detected at high levels in leukemias, lymphomas and solid tumors 
(e.g., carcinomas) and overexpression of miR-155 causes rapid and aggressive disease 
progression in a mouse model of B cell lymphoma (Faraoni et al., 2009; Tili et al., 2009). 
Thus, miR-155 has been regarded as a master oncogenic miRNA in hematological and solid 
tumors. However, a large body of evidence also attributes important roles to miR-155 as a 
mediator of lymphoid and myeloid cell responses to infection and inflammation, which is 
further supported by immunological deficiency exhibited by mir-155 knockout mouse 
models (Faraoni et al., 2009; Tili et al., 2009). We recently showed that expression of miR-155 
was confined to a subpopulation of infiltrating immune cells in breast, colorectal, lung, 
pancreas and prostate tumor lesions (Sempere et al., 2010). Importantly, these results 
indicated that the majority of miR-155 signal detected by RT-PCR assays in whole tissue 
biopsies or blood samples likely emanates from TME cells, drawing into question whether 
miR-155 plays any role within the cancer cells in these carcinomas. In the light of these 
findings, we revisit here altered expression of miR-155 and other leukocyte-expressed 
miRNAs (e.g., miR-17-5p, miR-20a, miR-21, miR-25, miR-29a, miR-142-3p, miR-146a, miR-
150, miR-181a, miR-221, miR-223) in solid tumors, which are likely to reflect, at least in part, 
immune cell responses in the TME rather than molecular aberrations within the cancer cells 
per se. We review the emerging roles of these leukocyte-expressed miRNAs in the immune 
system with an especial emphasis on myelomonocytic-derived cells, and discuss their 
implications in the modulation of cancer initiation and progression in the context of a 
reactive and/or permissive TME.  
2. Physiological roles of microRNAs in the immune system 
In the bone marrow, pluripotent hematopoietic stem cells give rise to common progenitors 
of the lymphoid and myeloid lineages. In the blood, these progenitors will continue distinct 
differentiation paths to produce the principal cell types of the immune system: B and T 
lymphocytes and natural killer (NK) cells in the lymphoid branch, and basophils, 
neutrophils, eosinophils, mast cells and monocytes in the myeloid branch; other non-
immune cell types such as erythrocytes and thrombocytes are also produced in the myeloid 
branch. In tissues, further maturation awaits for lymphoid and myeloid lineages to mount 
innate and adaptive responses against bacterial, viral and other pathogens as well as against 
cancer cells and other aberrant cells not recognized as self. These differentiation programs 
are crucial to establish a fully functional immune system. Expression profiling and 
functional studies have implicated miRNAs as key regulators of specific stages of 
differentiation and maturation of specific immune cell lineages, which in general have overt 
deleterious consequences at the organismal level.  
Mature and biologically active miRNAs, ~21-23 nucleotides-long, function as guides to 
recognize and bind partially complementary elements (miRNA recognition element; MRE) 
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on the 3’ untranslated region (UTR) of target mRNAs. miRNA biogenesis and processing 
determine the total levels of mature miRNA and to a large extent miRNA function (however 
see these reviews for cooperative and competitive effects of RNA binding proteins (Van 
Kouwenhove et al., 2011) and competing endogenous RNAs (Salmena et al., 2011) on 
miRNA activity). Most miRNA genes are transcribed by RNA polymerase II, which 
produces a long primary transcript (pri-miRNA) with a 5’ cap and a 3’ poly(A) tail (Ketting, 
2011; van et al., 2011). In the nucleus the pri-miRNA is recognized by the microprocessor, a 
multiprotein complex that cleaves off a 70 nts-long precursor miRNA hairpin (pre-miRNA). 
The catalyzes this cleavage as DGCR8 recognizes structural features of the hairpin and 
accordingly position the pre-miRNA for cleavage by RNAse III endonuclease Drosha. The 
pre-miRNA is exported to the cytoplasm by Exportin-5 in a RAN-GTP dependent manner. 
Then, the pre-miRNA is cleaved by another RNAse III endonuclease Dicer in association 
with TARBP2 or PACT and the mature miRNA strand (guide) is loaded in Argonaute-
containing RNA-induced silencing complexes (Ketting, 2011; van et al., 2011). 
The expression of key components of the miRNA processing machinery such Dicer can be 
inhibited under physiological stress and disease states, including cancer (Tomasi et al., 
2010). Moreover, Dicer expression is affected by cortisone, interferon and other 
pharmacological agents prescribed for the treatment of immune disorders (Tomasi et al., 
2010). Thus, perturbation of global miRNA activity can have undesirable clinical 
implications. In mouse models, deleterious effects of global miRNA impairment by 
conditional removal of Dicer or DGCR8 in specific immune cell lineage using the Cre/LoxP 
system has pinpointed important roles of miRNAs in production of antibody diversity, 
terminal differentiation and survival of B cells (Belver et al., 2010; Koralov et al., 2008), 
function of regulatory T (Treg) cells and Treg-mediated control of autoimmunity (Liston et 
al., 2008; Zhou et al., 2008), the development and function of invariant natural killer T cells 
(Bezman et al., 2010; Seo et al., 2010; Zhou et al., 2009), and terminal differentiation, 
activation, migration and survival of CD8+ T cell (Muljo et al., 2005; Zhang & Bevan, 2010). 
Subsequent studies have uncovered a major role of a single or small subset of miRNAs for 
immunological phenotypes observed in animals deficient in miRNA processing machinery 
(see below). As we describe in the next subsections, high-throughput expression profiling 
has been a useful discovery tool to correlate expression with function and thereby highlight 
specific miRNAs for further mechanistic characterization.  
2.1 Dynamic expression of microRNAs during hematopoietic lineage differentiation 
Using primarily the mouse as a model system, several groups have characterized in detail 
changes of miRNA expression during immune cell lineage differentiation as a means to infer 
from this a functional involvement of specific miRNAs at key steps of these processes 
(Malumbres & Lossos, 2010; O'Connell et al., 2010b; O'Neill et al., 2011).  
2.1.1 microRNA expression in granulocyte differentiation and maturation 
There are several well-defined differentiation stages that mature granulocytes (PB-N) 
undergo from a common myeloid progenitor (CMP): granulocyte-monocyte progenitor 
(GMP), immature bone marrow neutrophils (BM-N). Expression of miR-223 gradually 
increases from CMP to BM-N stages, reaching the highest level of expression in PB-N cells 
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(Johnnidis et al., 2008). This differentiation pathway is crucial for the mobilization of the 
massive amount of immature myeloid leukocytes typically found in cancer patients.  
2.1.2 microRNA expression in monocytic-macrophage differentiation and maturation 
There are several well-defined differentiation stages that mature macrophages (s) 
undergo from a CMP cell: GMP, monocyte. Using similar strategies, several groups 
independently profiled miRNA expression in in vitro cell culture systems that induce 
monocytic differentiation and maturation into s (Fontana et al., 2007; Ghani et al., 2011). 
Expression of miR-17-5p, miR-20a, miR-106a was downregulated during differentiation and 
maturation of unilineage monocytic cell culture (Fontana et al., 2007). Expression of miR-99, 
miR-146a, miR-155, miR-342 and others was upregulated and that of miR-20a, miR-25, miR-
26a, miR-223 and others was downregulated during differentiation and maturation of PU.1-
expressing PUER cells (Ghani et al., 2011). Downregualtion of miR-223 in monoctyes had 
been previously noticed (Johnnidis et al., 2008). 
2.1.3 microRNA expression in dendritic cell differentiation and maturation 
There are several well-defined differentiation stages that mature dendritic cells (DCs) 
undergo from a CMP cell: GMP, monocyte. Expression of miR-99a, miR-193b was 
exclusively upregulated during induced differentiation and maturation into DC of ex vivo 
culture of human blood-derived monocytes, whereas upregulation of miR-34a, miR-125a-5p, 
miR-99b, miR-511 expression was observed in both DC and s (Tserel et al., 2011). These 
results are in good, but not in complete, agreement with similar studies in which relative 
miRNA expression levels were compared between monocytes, immature and mature DCs 
(Hashimi et al., 2009; Lu et al., 2011a). Upregulation of miR-21, miR-342 expression and 
downregulation of miR-17-5p, miR-25, miR-93, miR-106a expression in immature and/or 
mature DCs was observed in both studies (Hashimi et al., 2009; Lu et al., 2011a). 
Upregulation of miR-146a and miR-155 expression in mature DC upon activation by various 
pro-inflammatory stimuli, including bacterial lipopolysaccharide (LPS) and interleukin (IL) 
1β, has been consistently observed by independent groups (Turner et al., 2011).  
2.1.4 microRNA expression in B cell differentiation and maturation  
There are several well-defined differentiation stages that mature memory B cell or plasma 
cells undergo from a common lymphoid progenitor cell (CLP): Pro-B, Pre-B, IM-B, Naive 
B and germinal center (GC) cell. When comparing relative expression levels between pro-
B and naive B cells (Monticelli et al., 2005), expression of the following miRNAs was 
enriched at a specific stage: miR-24, miR-93, miR-101, miR-107, miR-324 in pro-B cells; 
miR-26, miR-29a, miR-142-3p, miR-142-5p, miR-150 in naive B cells. When comparing 
relative expression levels between naive, GC and memory B cells (Malumbres et al., 2009; 
Tan et al., 2009), expression of the following miRNAs was enriched at a specific stage: let-
7a, miR-92, miR-95, miR-142-3p, miR-142-5p, miR-193 and others in naive cells; miR-15b, 
miR-16, miR-17-3p, miR-17-5p, miR-20, miR-25, miR-93, miR-106a, miR-181a, miR-181b 
and others in GC cells; miR-21, miR-23a, miR-24, miR-29c, miR-30b, miR-146, miR-150 and 
others in memory cells. 
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2.1.5 microRNA expression in T cell differentiation and maturation  
There are several well-defined differentiation stages that naive CD4+ or CD8+ T cells 
undergo from a CLP cell: double negative (DN) 1, DN2, DN3, DN4, double positive (DP). 
When comparing relative expression levels between DN1-DP to CD4+ or CD8+ cells 
(Neilson et al., 2007), expression of the following miRNAs was enriched at a specific stage: 
miR-21, miR-29b, miR-221, miR-223, miR-342 in DN1 cells; miR-191 in DN3 cells, miR-16, 
miR-20a miR-128b, miR142-5p in DN4; miR-92, miR-181a, miR-181b, miR-350 in DP cells; 
miR-297 and miR-669c in CD4+ cells; and miR-15b, mir-24, miR-27a, miR-150 in CD8+ cells. 
When comparing relative expression levels between antigen-specific naive, effector and 
memory CD8+ T cells (Wu et al., 2007), expression of the following miRNAs was enriched at 
a specific stage: let-7f, miR-16, miR-142-3p, miR-142-5p, miR-150 in naive cells; miR-21, miR-
221, miR-222 in both effector and memory cells; miR-18, miR-31, miR-146a, miR-146b in 
memory cells. 
2.2 Roles of microRNAs in cellular components of the innate immune system 
Inflammation is now recognized as a hallmark of established tumors (Hanahan & Weinberg, 
2011). Over the last years, multiple independent lines of research have identified 
inflammation as a promoter of both cancer initiation and malignant progression. The 
secretion of inflammatory cytokines and chemokines that drive inflammatory responses by 
cells of the innate immune system are primarily elicited by the recognition of common 
structures shared by many microorganisms by receptors that activate complex 
transcriptional programs. Toll-like receptors (TLR) are an important component of 
inflammatory responses in this context. They are present in various myeloid cell lineages 
and serve as sensor to pathogenic RNA and other molecules from parasites. However, TLRs 
can also recognize certain cellular components and promote inflammation under sterile 
conditions. For instance, HMGB1 (Tang et al., 2010) and several S100 proteins (Ehrchen et 
al., 2009; Hiratsuka et al., 2008) have been associated with TLR-dependent carcinogenic 
inflammation. TLRs have also been shown to regulate expression of specific miRNAs in 
s, DCs and other myeloid-derived cell types (O'Neill et al., 2011). Transcription and 
expression of miR-21, miR-146a and miR-155 among other miRNAs is regulated by several 
TLRs in different cellular contexts that we discuss in more detail below. In turn, miRNAs 
regulate TLR-dependent signalling by targeting mRNAs of TRLs, of downstream signalling 
proteins and/or of effector transcriptional factors (O'Neill et al., 2011).  
2.2.1 microRNA-mediated neutrophil responses  
Transcriptional repression of miR-21 and miR-196a expression by zinc finger factor 
independent-1 (Ggi1) is required for granulocytic development and differentiation as 
persistent high levels of these miRNAs in CMP cells block this program (Velu et al., 2009). 
Similarly, overexpression of miR-125b blocks granulocytic differentiation induced by 
granulocyte colony stimulating factor (G-CSF) in 32D cell lines (Surdziel et al., 2011). 
Conversely, upregulation of miR-27 expression by G-CSF3-induced C/EBPtranscriptional 
factor enhances granulocytic differentiation (Feng et al., 2009). High levels of miR-27 post-
transcriptionally repress expression of Runx1 transcriptional factor, which antagonizes 
differentiation of CMPs or myoblast cell lines into granulocytes (Feng et al., 2009).  
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(Johnnidis et al., 2008). This differentiation pathway is crucial for the mobilization of the 
massive amount of immature myeloid leukocytes typically found in cancer patients.  
2.1.2 microRNA expression in monocytic-macrophage differentiation and maturation 
There are several well-defined differentiation stages that mature macrophages (s) 
undergo from a CMP cell: GMP, monocyte. Using similar strategies, several groups 
independently profiled miRNA expression in in vitro cell culture systems that induce 
monocytic differentiation and maturation into s (Fontana et al., 2007; Ghani et al., 2011). 
Expression of miR-17-5p, miR-20a, miR-106a was downregulated during differentiation and 
maturation of unilineage monocytic cell culture (Fontana et al., 2007). Expression of miR-99, 
miR-146a, miR-155, miR-342 and others was upregulated and that of miR-20a, miR-25, miR-
26a, miR-223 and others was downregulated during differentiation and maturation of PU.1-
expressing PUER cells (Ghani et al., 2011). Downregualtion of miR-223 in monoctyes had 
been previously noticed (Johnnidis et al., 2008). 
2.1.3 microRNA expression in dendritic cell differentiation and maturation 
There are several well-defined differentiation stages that mature dendritic cells (DCs) 
undergo from a CMP cell: GMP, monocyte. Expression of miR-99a, miR-193b was 
exclusively upregulated during induced differentiation and maturation into DC of ex vivo 
culture of human blood-derived monocytes, whereas upregulation of miR-34a, miR-125a-5p, 
miR-99b, miR-511 expression was observed in both DC and s (Tserel et al., 2011). These 
results are in good, but not in complete, agreement with similar studies in which relative 
miRNA expression levels were compared between monocytes, immature and mature DCs 
(Hashimi et al., 2009; Lu et al., 2011a). Upregulation of miR-21, miR-342 expression and 
downregulation of miR-17-5p, miR-25, miR-93, miR-106a expression in immature and/or 
mature DCs was observed in both studies (Hashimi et al., 2009; Lu et al., 2011a). 
Upregulation of miR-146a and miR-155 expression in mature DC upon activation by various 
pro-inflammatory stimuli, including bacterial lipopolysaccharide (LPS) and interleukin (IL) 
1β, has been consistently observed by independent groups (Turner et al., 2011).  
2.1.4 microRNA expression in B cell differentiation and maturation  
There are several well-defined differentiation stages that mature memory B cell or plasma 
cells undergo from a common lymphoid progenitor cell (CLP): Pro-B, Pre-B, IM-B, Naive 
B and germinal center (GC) cell. When comparing relative expression levels between pro-
B and naive B cells (Monticelli et al., 2005), expression of the following miRNAs was 
enriched at a specific stage: miR-24, miR-93, miR-101, miR-107, miR-324 in pro-B cells; 
miR-26, miR-29a, miR-142-3p, miR-142-5p, miR-150 in naive B cells. When comparing 
relative expression levels between naive, GC and memory B cells (Malumbres et al., 2009; 
Tan et al., 2009), expression of the following miRNAs was enriched at a specific stage: let-
7a, miR-92, miR-95, miR-142-3p, miR-142-5p, miR-193 and others in naive cells; miR-15b, 
miR-16, miR-17-3p, miR-17-5p, miR-20, miR-25, miR-93, miR-106a, miR-181a, miR-181b 
and others in GC cells; miR-21, miR-23a, miR-24, miR-29c, miR-30b, miR-146, miR-150 and 
others in memory cells. 
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2.1.5 microRNA expression in T cell differentiation and maturation  
There are several well-defined differentiation stages that naive CD4+ or CD8+ T cells 
undergo from a CLP cell: double negative (DN) 1, DN2, DN3, DN4, double positive (DP). 
When comparing relative expression levels between DN1-DP to CD4+ or CD8+ cells 
(Neilson et al., 2007), expression of the following miRNAs was enriched at a specific stage: 
miR-21, miR-29b, miR-221, miR-223, miR-342 in DN1 cells; miR-191 in DN3 cells, miR-16, 
miR-20a miR-128b, miR142-5p in DN4; miR-92, miR-181a, miR-181b, miR-350 in DP cells; 
miR-297 and miR-669c in CD4+ cells; and miR-15b, mir-24, miR-27a, miR-150 in CD8+ cells. 
When comparing relative expression levels between antigen-specific naive, effector and 
memory CD8+ T cells (Wu et al., 2007), expression of the following miRNAs was enriched at 
a specific stage: let-7f, miR-16, miR-142-3p, miR-142-5p, miR-150 in naive cells; miR-21, miR-
221, miR-222 in both effector and memory cells; miR-18, miR-31, miR-146a, miR-146b in 
memory cells. 
2.2 Roles of microRNAs in cellular components of the innate immune system 
Inflammation is now recognized as a hallmark of established tumors (Hanahan & Weinberg, 
2011). Over the last years, multiple independent lines of research have identified 
inflammation as a promoter of both cancer initiation and malignant progression. The 
secretion of inflammatory cytokines and chemokines that drive inflammatory responses by 
cells of the innate immune system are primarily elicited by the recognition of common 
structures shared by many microorganisms by receptors that activate complex 
transcriptional programs. Toll-like receptors (TLR) are an important component of 
inflammatory responses in this context. They are present in various myeloid cell lineages 
and serve as sensor to pathogenic RNA and other molecules from parasites. However, TLRs 
can also recognize certain cellular components and promote inflammation under sterile 
conditions. For instance, HMGB1 (Tang et al., 2010) and several S100 proteins (Ehrchen et 
al., 2009; Hiratsuka et al., 2008) have been associated with TLR-dependent carcinogenic 
inflammation. TLRs have also been shown to regulate expression of specific miRNAs in 
s, DCs and other myeloid-derived cell types (O'Neill et al., 2011). Transcription and 
expression of miR-21, miR-146a and miR-155 among other miRNAs is regulated by several 
TLRs in different cellular contexts that we discuss in more detail below. In turn, miRNAs 
regulate TLR-dependent signalling by targeting mRNAs of TRLs, of downstream signalling 
proteins and/or of effector transcriptional factors (O'Neill et al., 2011).  
2.2.1 microRNA-mediated neutrophil responses  
Transcriptional repression of miR-21 and miR-196a expression by zinc finger factor 
independent-1 (Ggi1) is required for granulocytic development and differentiation as 
persistent high levels of these miRNAs in CMP cells block this program (Velu et al., 2009). 
Similarly, overexpression of miR-125b blocks granulocytic differentiation induced by 
granulocyte colony stimulating factor (G-CSF) in 32D cell lines (Surdziel et al., 2011). 
Conversely, upregulation of miR-27 expression by G-CSF3-induced C/EBPtranscriptional 
factor enhances granulocytic differentiation (Feng et al., 2009). High levels of miR-27 post-
transcriptionally repress expression of Runx1 transcriptional factor, which antagonizes 
differentiation of CMPs or myoblast cell lines into granulocytes (Feng et al., 2009).  
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Unlike these previous examples of miRNA-mediated granulocyte differentiation which 
primarily affect the overall number, but not function, of available neutrophils, miR-223 
controls differentiation and activation of neutrophils (Johnnidis et al., 2008). mir-223 
knockout mice have an increased number of neutrophils as a result of an abnormal 
expansion of the GMP cells due to dysregulation of transcriptional factor Mef2c (Johnnidis 
et al., 2008). Moreover, these miR-223-deficient neutrophils are hypermature and 
hyperactive causing spontaneous pulmonary inflammation and excessive tissue damage 
upon endotoxin challenge (Johnnidis et al., 2008).  
2.2.2 microRNA-mediated  responses  
Several pro-inflammatory mediators such as LPS, polyriboinosinic–polyribocytidylic acid 
(poly IC), Tumor Necrosis Factor (TNF) , interferon (IFN) , have been shown to induce 
miR-155 expression in monocyte and/or s (Faraoni et al., 2009). miR-155 enhances type I 
IFN signaling-mediated  responses against viral infection, mainly by downregulating 
expression of suppressor of cytokine signaling 1 (SOCS1) (Wang et al., 2010). miR-155 is also 
an important player in the interleukin (IL) 13-dependent fate determination between M1 
(classical, pro-Th1, tumoricidal) and M2 (alternative, pro-Th2, tumorigenic) s. As IL-13 
signalling via its cognate receptor IL13R1 and consequent phosphorylation of STAT6 
favors M2 programs, miR-155 antagonizes this process by directly repressing expression of 
IL13R1 mRNA as well as by repressing expression of IL-13 responsive genes such as 
SOCS1, DC-SIGN, CCL18, CD23, and SERPINE (Martinez-Nunez et al., 2011).  
Induction of miR-146a/b expression by IL-1, LPS, TNF- in monocytes is an NF-B-
dependent process (Taganov et al., 2006). miR-146 is engaged in a negative feedback loop 
with TLR and cytokine signalling via downregulation of IL-1 receptor-associated kinase 1 
(IRAK1) and TNF receptor-associated factor 6 (TRAF6) mRNA levels, which are transducers 
of these signals (Taganov et al., 2006). Several studies indicate the importance of miR-146 
regulatory role in s. mir-146a knockout mice develop lymphoid and myeloid 
malignancies as well as myeoloproliferation and myelofibrosis; dysregulated and increased 
activation of NF-B-mediated transcription is a major contributing factor to the observed 
phenotypes (Zhao et al., 2011). Some viruses such as vesicular stomatitis virus (VSV) can 
disrupt the miR-146 regulatory loop as a means to dampen IFN-(Hou et al., 2009). Mice 
infected with VSV upregulate miR-146 expression in s in a TRL-independent, but NF-B-
dependent manner, and thereby triggers miR-146-mediated downregulation of TRAF6, 
IRAK1 and IRAK2 target genes (Hou et al., 2009). 
In contrast, high levels of miR-125b expression potentiate IFN--mediated  responses 
(Chaudhuri et al., 2011). Enforced miR-125b expression enhances  activation and antigen 
presentation to T cells (Chaudhuri et al., 2011). miR-125b-mediated downregulation of IFN 
regulatory factor 4 (IRF4) explained in great part the observed phenotypes and the enhanced 
ability of miR-125b-overexpressing s to elicit more effective cancer cell rejection 
(Chaudhuri et al., 2011). 
2.2.3 microRNA-mediated DC responses  
mir-155 knockout mice exhibit impaired B cell, T cell, and DC immune responses 
(Rodriguez et al., 2007; Thai et al., 2007). Several evidences indicate that impaired B cell 
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responses result from disruption of intrinsic miR-155-mediated processes (Turner & 
Vigorito, 2008; Vigorito et al., 2007). However, impaired T cell responses may reflect 
functional defects in miR-155-deficient DCs, which have a decreased capacity to present 
antigens to T cells (Rodriguez et al., 2007), rather than intrinsic T cell proceses. 
Intriguingly, in vitro studies suggest that high levels of miR-155 interfere with antigen 
binding ability of DC, and therery antigen presentation to and activation of T cells (Mao et 
al., 2011; Martinez-Nunez et al., 2009). miR-155 has been shown to promote pro-
inflammatory or anti-inflammatory responses in DCs via downregulation, along with 
other targets genes, of SH2-containing inositol 5-phosphatase (SHIP) and SOCS1 or IL-1β 
and TAK1-binding protein 2 (TAB2), respectively (Ceppi et al., 2009; Lu et al., 2008; 
O'Connell et al., 2008; O'Connell et al., 2009). Thus, miR-155 may exert different roles in 
DCs that are context-dependent such as physiological resolution of viral infection or 
pathological interaction with cancer cells in solid tumors. 
As miR-146a/b and miR-155, expression of miR-148 family members (miR-148a, miR-148b, 
miR-152) is induced by TLR signalling in DCs (Liu et al., 2010b). By targeting expression of 
calcium/calmodulin-dependent protein kinase II (CaMKII), these miRNAs diminished 
antigen presenting capacity of DCs (Liu et al., 2010b). 
2.2.4 microRNA-mediated NK cell reponses 
NK mediate contact-dependent cytotoxicity and produce immunostimulatory cytokines that 
activate other immune cells. Cytotoxic granules contain perforin (Prf1) and granzymes 
(Gmzs), which are delivered by exocytosis into the target cells. miR-27a* modulates 
cytotoxic NK cell responses by regulating expression levels of both Prf1 and GzmB in 
resting and activated NK cells (Kim et al., 2011). Similarly, miR-29 dampens interferon (IFN) 
-mediate responsesin NK and other lymphocyte lineages as observed in animals infected 
with intracellular bacterial pathogens such as Listeria monocytogenes (Ma et al., 2011).  
2.3 Roles of microRNAs in cellular components of the adaptive immune system 
The adaptive immune system comprises lymphocytes and their products (e.g., antibodies). 
Although the role of innate immune cells (e.g., NK cells) may be crucial to prevent tumor 
initiation, adaptive immune responses, particularly those mediated by effector T cells, are 
responsible for exerting spontaneous (and clinically relevant) immune pressure against the 
progression of many established cancers (Dunn et al., 2005; Yu & Fu, 2006). While the role of 
miRNAs in the development and functions of T and B cells has only started emerging very 
recently, it is becoming increasingly clear that B and T cell responses are tightly regulated by 
a network of miRNAs (O'Connell et al., 2010b). 
2.3.1 microRNA-mediated B cell responses  
Genetic manipulation of miR-150 expression and activity indicate an important role of this 
miRNA in B cell development and function (Malumbres & Lossos, 2010). Unimmunized mir-
150 knockout mice exhibit an expansion in splenic and peritoneal B1 cells and enhanced 
humoral responses as determined by increased serum immunoglobulin levels (Xiao et al., 
2007). Conversely, enforced expression of miR-150 in B cell lineages caused arrested 
development at the pro-B to pre-B transition. miR-150-mediated processes largely impinge 
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Unlike these previous examples of miRNA-mediated granulocyte differentiation which 
primarily affect the overall number, but not function, of available neutrophils, miR-223 
controls differentiation and activation of neutrophils (Johnnidis et al., 2008). mir-223 
knockout mice have an increased number of neutrophils as a result of an abnormal 
expansion of the GMP cells due to dysregulation of transcriptional factor Mef2c (Johnnidis 
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miR-155 expression in monocyte and/or s (Faraoni et al., 2009). miR-155 enhances type I 
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(classical, pro-Th1, tumoricidal) and M2 (alternative, pro-Th2, tumorigenic) s. As IL-13 
signalling via its cognate receptor IL13R1 and consequent phosphorylation of STAT6 
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IL13R1 mRNA as well as by repressing expression of IL-13 responsive genes such as 
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with TLR and cytokine signalling via downregulation of IL-1 receptor-associated kinase 1 
(IRAK1) and TNF receptor-associated factor 6 (TRAF6) mRNA levels, which are transducers 
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regulatory role in s. mir-146a knockout mice develop lymphoid and myeloid 
malignancies as well as myeoloproliferation and myelofibrosis; dysregulated and increased 
activation of NF-B-mediated transcription is a major contributing factor to the observed 
phenotypes (Zhao et al., 2011). Some viruses such as vesicular stomatitis virus (VSV) can 
disrupt the miR-146 regulatory loop as a means to dampen IFN-(Hou et al., 2009). Mice 
infected with VSV upregulate miR-146 expression in s in a TRL-independent, but NF-B-
dependent manner, and thereby triggers miR-146-mediated downregulation of TRAF6, 
IRAK1 and IRAK2 target genes (Hou et al., 2009). 
In contrast, high levels of miR-125b expression potentiate IFN--mediated  responses 
(Chaudhuri et al., 2011). Enforced miR-125b expression enhances  activation and antigen 
presentation to T cells (Chaudhuri et al., 2011). miR-125b-mediated downregulation of IFN 
regulatory factor 4 (IRF4) explained in great part the observed phenotypes and the enhanced 
ability of miR-125b-overexpressing s to elicit more effective cancer cell rejection 
(Chaudhuri et al., 2011). 
2.2.3 microRNA-mediated DC responses  
mir-155 knockout mice exhibit impaired B cell, T cell, and DC immune responses 
(Rodriguez et al., 2007; Thai et al., 2007). Several evidences indicate that impaired B cell 
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responses result from disruption of intrinsic miR-155-mediated processes (Turner & 
Vigorito, 2008; Vigorito et al., 2007). However, impaired T cell responses may reflect 
functional defects in miR-155-deficient DCs, which have a decreased capacity to present 
antigens to T cells (Rodriguez et al., 2007), rather than intrinsic T cell proceses. 
Intriguingly, in vitro studies suggest that high levels of miR-155 interfere with antigen 
binding ability of DC, and therery antigen presentation to and activation of T cells (Mao et 
al., 2011; Martinez-Nunez et al., 2009). miR-155 has been shown to promote pro-
inflammatory or anti-inflammatory responses in DCs via downregulation, along with 
other targets genes, of SH2-containing inositol 5-phosphatase (SHIP) and SOCS1 or IL-1β 
and TAK1-binding protein 2 (TAB2), respectively (Ceppi et al., 2009; Lu et al., 2008; 
O'Connell et al., 2008; O'Connell et al., 2009). Thus, miR-155 may exert different roles in 
DCs that are context-dependent such as physiological resolution of viral infection or 
pathological interaction with cancer cells in solid tumors. 
As miR-146a/b and miR-155, expression of miR-148 family members (miR-148a, miR-148b, 
miR-152) is induced by TLR signalling in DCs (Liu et al., 2010b). By targeting expression of 
calcium/calmodulin-dependent protein kinase II (CaMKII), these miRNAs diminished 
antigen presenting capacity of DCs (Liu et al., 2010b). 
2.2.4 microRNA-mediated NK cell reponses 
NK mediate contact-dependent cytotoxicity and produce immunostimulatory cytokines that 
activate other immune cells. Cytotoxic granules contain perforin (Prf1) and granzymes 
(Gmzs), which are delivered by exocytosis into the target cells. miR-27a* modulates 
cytotoxic NK cell responses by regulating expression levels of both Prf1 and GzmB in 
resting and activated NK cells (Kim et al., 2011). Similarly, miR-29 dampens interferon (IFN) 
-mediate responsesin NK and other lymphocyte lineages as observed in animals infected 
with intracellular bacterial pathogens such as Listeria monocytogenes (Ma et al., 2011).  
2.3 Roles of microRNAs in cellular components of the adaptive immune system 
The adaptive immune system comprises lymphocytes and their products (e.g., antibodies). 
Although the role of innate immune cells (e.g., NK cells) may be crucial to prevent tumor 
initiation, adaptive immune responses, particularly those mediated by effector T cells, are 
responsible for exerting spontaneous (and clinically relevant) immune pressure against the 
progression of many established cancers (Dunn et al., 2005; Yu & Fu, 2006). While the role of 
miRNAs in the development and functions of T and B cells has only started emerging very 
recently, it is becoming increasingly clear that B and T cell responses are tightly regulated by 
a network of miRNAs (O'Connell et al., 2010b). 
2.3.1 microRNA-mediated B cell responses  
Genetic manipulation of miR-150 expression and activity indicate an important role of this 
miRNA in B cell development and function (Malumbres & Lossos, 2010). Unimmunized mir-
150 knockout mice exhibit an expansion in splenic and peritoneal B1 cells and enhanced 
humoral responses as determined by increased serum immunoglobulin levels (Xiao et al., 
2007). Conversely, enforced expression of miR-150 in B cell lineages caused arrested 
development at the pro-B to pre-B transition. miR-150-mediated processes largely impinge 
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on negative regulation of c-Myb transcriptional factor involved at multiple steps of 
lymphocyte development (Xiao et al., 2007). 
Similar to miR-150 enforced expression, mice deficient in the mir-17~mir-92 gene cluster 
(miR-17-5p, miR-18a, miR-19a, miR-19b-1 miR-20a, miR-92-1) also exhibit a disrupted B cell 
development at the pro-B to pre-B transition (Ventura et al., 2008). Dysregulated and 
increased levels of pro-apoptotic protein Bim are a key molecular alteration responsible for 
this defect (Ventura et al., 2008). 
2.3.2 microRNA-mediated T cell responses 
The importance of miRNAs in controlling T cell-mediated responses was first illustrated by 
the demonstration that specific deletion of Dicer in the T cell lineage resulted in impaired T 
cell development and aberrant T helper cell differentiation and cytokine production (Muljo 
et al., 2005). Subsequent studies have confirmed that Dicer controls CD8+ T-cell activation, 
migration, and survival (Zhang & Bevan, 2010). More recently, a unique signature of 71 
miRNAs has been identified in activated T cells (Grigoryev et al., 2011). In an independent 
study, seven miRNAs (let-7f, miR-15b, miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150) 
alone were shown to account for approximately 60% of all miRNAs in naive, effector and 
memory CD8+ T cells. Among the multiple miRNAs modulated by T cell activation, miR-155 
appears to be particularly important. miR-155 enhances inflammatory T cell development 
(O'Connell et al., 2010a), and it is known to be essential for the T cell-mediated control of 
Helicobacter pylori infection and for the induction of chronic gastritis and colitis (Oertli et al., 
2011). miR-155 is also crucial for T helper cell differentiation and generating optimal T cell-
dependent antibody responses (Thai et al., 2007).  
Robust T cell responses require the up-regulation of anti-apoptotic pathways, accelerated 
cell cycle progression, and efficient antigen presentation. miR-181a modulates these 
processes by regulating expression levels of anti-apoptotic protein BCL2, transmembrane C-
type lectin protein CD69 and T cell receptor (TCR)  during T cell binding to an antigen 
(Neilson et al., 2007). miR-181a exerts an important role for antigen sensitivity and selection 
during T cell development imparted by downregulation of TCR and phosphatases relaying 
TCR signalling (Li et al., 2007). These effects, however, have been mainly investigated in 
thymocytes, and further studies are needed to conclusively extend these results to 
peripheral T lymphocytes. 
CD69 is upregulated by antigen-specific T cells following acute infection, but CD69 
expression returns to basal levels after 72 hrs. CD69 regulates sphingosine 1-phosphate 
(S1P1) and controls the release and migration of activated T cell from central lymphoid 
organs (lymph nodes and spleen) to infection site (Shiow et al., 2006). Expression of miR-130 
and miR-301 is dramatically upregulated following CD8+ T cells activation in vitro by TCR 
stimuli. miR-130 and miR-301, in addition to miR-181a, inhibit CD69 expression via binding 
to an MRE in the 3'UTR of CD69 mRNA (Zhang & Bevan, 2010). These results suggest that 
this miR-130/mir-301-mediated process is important to establish the timing of activated T 
cells into circulation.  
Finally, miR-182 has been recently found to be induced by IL-2 to promote clonal expansion 
of activated helper T lymphocytes (Stittrich et al., 2010). 
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3. Pathological roles of microRNAs in cancer-related inflammation and 
immunity 
Twenty-five years ago Dvorak compared tumors with wounds that do not heal for the first 
time in a seminal paper (Dvorak, 1986). As in wounds, inflammatory cells are present in the 
microenvironment of virtually all solid tumors. In addition, chronic inflammation increases 
the risk of developing cancers in certain organs (e.g., in the digestive tract). Most 
importantly, inflammation is a hallmark of cancer (Hanahan & Weinberg, 2011), including 
those tumors that are not associated with chronic inflammatory conditions (Colotta et al., 
2009). Over the last years, the crucial role of TME inflammatory cells such as MDSCs, s 
and Tregs to the survival and proliferation of cancer cells, angiogenesis, metastasis, and, 
especially, immnosuppression, has been progressively unveiled.  
miRNA-mediated regulation is required for optimal functioning of the immune system. 
Impairment of global or specific miRNA activity in leukocyte subsets can lead a broad 
spectrum of diseases and pathological conditions from autoimmune disorders (destruction 
of normal self cells) to cancer (protection of abnormal non-self cells). We focus here on the 
emerging roles in initiation and progression of cancer of leukocyte-expressed miRNAs in the 
TME of most solid tumors. 
3.1 microRNA roles in anti-tumor immune surveillance and modulation of cancer 
progression 
The crucial role of immune surveillance in the prevention of cancer is today beyond 
question among immunologists (Zitvogel et al., 2006). However, we cannot detect the 
tumors that are rejected by the immune system during the course of our lives. This implies 
that tumors that become clinically noticeable are the result of failure of the immune system. 
Multiple mechanisms cooperate in the TME and at distal locations in tumor-bearing hosts to 
prevent the rejection of established cancers. Independent work from several laboratories has 
recently demonstrated that tolerance to tumor antigens in advanced malignancies is not a 
merely passive event but, rather, an active process whereby multiple immunosuppressive 
cell types confer immune privilege to tumors (Zou, 2005). How the phenotype and 
mobilization of these immunosuppressive leukocytes are regulated by miRNAs is only 
starting to be understood. 
3.1.1 Role of microRNAs in Myeloid-Derived Suppressor Cell (MDSC)-mediated 
immunosuppression 
MDSCs are one of the major components of the immune suppressive networks operating in 
cancer-bearing hosts (Gabrilovich & Nagaraj, 2009). Tumor-derived factors (e.g., S100, 
proteins) induce excessive myelopoiesis, resulting in the massive mobilization of immature 
myelomonocytic cells in virtually all solid tumor-bearing hosts (Sinha et al., 2008). These 
myeloid cells correspond to precursors of both monocytes and granulocytes, but are 
influenced by tumor-derived inflammatory signals that multiply their regular numbers and 
transform them into crucial contributors to immunosuppression. The specific abrogation of 
anti-tumor T cells in the absence of global immunosuppression in cancer patients has been 
elegantly explained via a mechanism of nitration of the T cell receptor on the T-cell surface 
(Nagaraj et al., 2007). How MDSCs specifically take up tumor antigen (thereby preventing 
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on negative regulation of c-Myb transcriptional factor involved at multiple steps of 
lymphocyte development (Xiao et al., 2007). 
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miRNAs has been identified in activated T cells (Grigoryev et al., 2011). In an independent 
study, seven miRNAs (let-7f, miR-15b, miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150) 
alone were shown to account for approximately 60% of all miRNAs in naive, effector and 
memory CD8+ T cells. Among the multiple miRNAs modulated by T cell activation, miR-155 
appears to be particularly important. miR-155 enhances inflammatory T cell development 
(O'Connell et al., 2010a), and it is known to be essential for the T cell-mediated control of 
Helicobacter pylori infection and for the induction of chronic gastritis and colitis (Oertli et al., 
2011). miR-155 is also crucial for T helper cell differentiation and generating optimal T cell-
dependent antibody responses (Thai et al., 2007).  
Robust T cell responses require the up-regulation of anti-apoptotic pathways, accelerated 
cell cycle progression, and efficient antigen presentation. miR-181a modulates these 
processes by regulating expression levels of anti-apoptotic protein BCL2, transmembrane C-
type lectin protein CD69 and T cell receptor (TCR)  during T cell binding to an antigen 
(Neilson et al., 2007). miR-181a exerts an important role for antigen sensitivity and selection 
during T cell development imparted by downregulation of TCR and phosphatases relaying 
TCR signalling (Li et al., 2007). These effects, however, have been mainly investigated in 
thymocytes, and further studies are needed to conclusively extend these results to 
peripheral T lymphocytes. 
CD69 is upregulated by antigen-specific T cells following acute infection, but CD69 
expression returns to basal levels after 72 hrs. CD69 regulates sphingosine 1-phosphate 
(S1P1) and controls the release and migration of activated T cell from central lymphoid 
organs (lymph nodes and spleen) to infection site (Shiow et al., 2006). Expression of miR-130 
and miR-301 is dramatically upregulated following CD8+ T cells activation in vitro by TCR 
stimuli. miR-130 and miR-301, in addition to miR-181a, inhibit CD69 expression via binding 
to an MRE in the 3'UTR of CD69 mRNA (Zhang & Bevan, 2010). These results suggest that 
this miR-130/mir-301-mediated process is important to establish the timing of activated T 
cells into circulation.  
Finally, miR-182 has been recently found to be induced by IL-2 to promote clonal expansion 
of activated helper T lymphocytes (Stittrich et al., 2010). 
Modulation of Cancer Progression 
by Tumor Microenvironmental Leukocyte-Expressed microRNAs 229 
3. Pathological roles of microRNAs in cancer-related inflammation and 
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Twenty-five years ago Dvorak compared tumors with wounds that do not heal for the first 
time in a seminal paper (Dvorak, 1986). As in wounds, inflammatory cells are present in the 
microenvironment of virtually all solid tumors. In addition, chronic inflammation increases 
the risk of developing cancers in certain organs (e.g., in the digestive tract). Most 
importantly, inflammation is a hallmark of cancer (Hanahan & Weinberg, 2011), including 
those tumors that are not associated with chronic inflammatory conditions (Colotta et al., 
2009). Over the last years, the crucial role of TME inflammatory cells such as MDSCs, s 
and Tregs to the survival and proliferation of cancer cells, angiogenesis, metastasis, and, 
especially, immnosuppression, has been progressively unveiled.  
miRNA-mediated regulation is required for optimal functioning of the immune system. 
Impairment of global or specific miRNA activity in leukocyte subsets can lead a broad 
spectrum of diseases and pathological conditions from autoimmune disorders (destruction 
of normal self cells) to cancer (protection of abnormal non-self cells). We focus here on the 
emerging roles in initiation and progression of cancer of leukocyte-expressed miRNAs in the 
TME of most solid tumors. 
3.1 microRNA roles in anti-tumor immune surveillance and modulation of cancer 
progression 
The crucial role of immune surveillance in the prevention of cancer is today beyond 
question among immunologists (Zitvogel et al., 2006). However, we cannot detect the 
tumors that are rejected by the immune system during the course of our lives. This implies 
that tumors that become clinically noticeable are the result of failure of the immune system. 
Multiple mechanisms cooperate in the TME and at distal locations in tumor-bearing hosts to 
prevent the rejection of established cancers. Independent work from several laboratories has 
recently demonstrated that tolerance to tumor antigens in advanced malignancies is not a 
merely passive event but, rather, an active process whereby multiple immunosuppressive 
cell types confer immune privilege to tumors (Zou, 2005). How the phenotype and 
mobilization of these immunosuppressive leukocytes are regulated by miRNAs is only 
starting to be understood. 
3.1.1 Role of microRNAs in Myeloid-Derived Suppressor Cell (MDSC)-mediated 
immunosuppression 
MDSCs are one of the major components of the immune suppressive networks operating in 
cancer-bearing hosts (Gabrilovich & Nagaraj, 2009). Tumor-derived factors (e.g., S100, 
proteins) induce excessive myelopoiesis, resulting in the massive mobilization of immature 
myelomonocytic cells in virtually all solid tumor-bearing hosts (Sinha et al., 2008). These 
myeloid cells correspond to precursors of both monocytes and granulocytes, but are 
influenced by tumor-derived inflammatory signals that multiply their regular numbers and 
transform them into crucial contributors to immunosuppression. The specific abrogation of 
anti-tumor T cells in the absence of global immunosuppression in cancer patients has been 
elegantly explained via a mechanism of nitration of the T cell receptor on the T-cell surface 
(Nagaraj et al., 2007). How MDSCs specifically take up tumor antigen (thereby preventing 
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cancer patients from being severely immunodeficient) remains to be clarified, but this 
mechanism provides a framework to explain the unresponsiveness of tumor-specific T cells 
in established tumors. In addition, other mechanisms such as production of Arginase are 
relevant for T cell tolerogenic function.  
These immature leukocytes migrate from the bone marrow where they are produced to the 
periphery, and differentiate into immunosuppressive s or regulatory DCs at tumor sites. 
This primarily occurs from cells of the monocytic lineage, as granulocytic MDSCs tend to 
disappear in the periphery. However, many tumors accumulate myeloid cells that, at least 
in terms of light scatter properties and phenotypic markers, show attributes of classical 
neutrophils (Rodriguez et al., 2009). A great deal of phenotypic overlap and heterogeneity 
among myeloid leukocytes is therefore typically found in the microenvironment of different 
tumors, and even within the same tumor specimen. What these cells have in common is a 
strong immunosuppressive activity and the production of angiogenic factors that are crucial 
for tumor neovascularization (Ahn & Brown, 2008; Conejo-Garcia et al., 2004; Huarte et al., 
2008; Mantovani, 2010; Mazzieri et al., 2011). Together, this heterogeneous mix of MDSCs, 
s, regulatory DCs and monocytes also contributes to the promotion of tumor growth and 
metastasis.  
Very little is known about how miRNAs regulate the mobilization and activities of this 
crucial and abundant tolerogenic population. The most compelling evidence for the 
contribution of miRNAs to MDSC-mediated immune suppression has recently arised from 
the demonstration that the expression of STAT3, which promotes the suppressive activity of 
MDSCs, is silenced by the combined activity of miR-17-5p and miR-20a. Correspondingly, 
ectopic expression of miR-17-5p or miR-20a significantly reduced the capacity of MDSCs to 
suppress antigen-specific CD4 and CD8 T cells, both in vitro and in vivo (Zhang et al., 2011). 
Further research is needed to understand the contribution of miRNAs to the activity of 
MDSCs, as well as to design potential therapeutic interventions based on delivery of 
miRNA mimetics to promote their differentiation into immunocompetent (or at least less 
immunosuppressive) cells types. 
3.1.2 Role of microRNAs in the function of Antigen-Presenting Cells (APCs)  
Another hallmark of adaptive immune responses against tumor antigens is the abrogation 
of the capacity of APCs to elicit strong T cell activation. Among the miRNAs that participate 
in this process, miR-155 appears to be particularly important, because miR-155-defficient 
DCs simply fail to activate T cells (Rodriguez et al., 2007). In addition, miR-155 expression in 
bone marrow-derived DCs increases upon LPS-induced maturation and miR-155 is the only 
miRNA substantially up-regulated in primary s stimulated with a TLR3 agonist plus 
IFN- (O'Connell et al., 2007; Rodriguez et al., 2007). Furthermore, our results indicate that 
tumor-derived regulatory DCs express very low levels of miR-155, and that delivery of miR-
155 mimetics (see Section 5) to these cells promotes their capacity to effectively present 
tumor antigens and elicit protective anti-tumor immunity (manuscript under consideration). 
Interestingly, DCs matured in the absence of miR-155 express levels of MHC–II and co-
stimulatory molecules similar to those seen on identically treated matured wild-type DCs, 
but they fail to present antigens or co-stimulate T cells. 
In contrast to miR-155, expression of miR-21 decreases Th1 responses by preventing IL-12 
secretion in activated DCs (Lu et al., 2011b).  
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3.1.3 Role of microRNAs in Treg-mediated immunosuppression  
One of the crucial cell players actively suppressing the anti-tumor activity of effector anti-
tumor T cells are Foxp3+ regulatory T cells (Treg). Treg are essential to prevent 
autoimmunity in healthy hosts by suppressing autoreactive T cells. Because most epitopes 
recognized by tumor-reactive T cells are self-antigens, advanced tumors co-opt their 
regulatory functions to suppress anti-tumor T cell responses, which specifically occurs in the 
TME (Curiel et al., 2004). Correspondingly, Treg infiltration is associated with accelerated 
tumor progression and reduced survival. Several miRNAs have been reported to contribute 
to the tolerogenic function of Treg, and therefore can only be important for 
immunosuppression in the TME. Among them, miR-146a, typically overexpressed in Treg, 
is critical for their suppressor function by controlling the expression of Stat1 (Lu et al., 2010). 
In addition, miR-155, miR-21 and miR-7, which are all targets of Foxp3, silence Satb1 and are 
also collectively required for the suppressive function of Treg (Beyer et al., 2011).  
3.1.4 Tumor-infiltrating T cells  
Infiltration of tumor islets by T cells has been associated with significantly improved 
outcomes in multiple histological types of cancer (Dunn et al., 2005; Yu & Fu, 2006). As 
many tumor-specific antigens have been identified and shown to induce the production of 
specific antibodies in cancer patients, the protective activity of these lymphocytes has 
provided a rationale for using them to treat cancer (Ertl et al., 2011). Over the last years, 
some authors have restricted the protective role of T cells to the activity of cytotoxic (CD8+) 
lymphocytes (Hamanishi et al., 2007; Sato et al., 2005), primarily because CD4+ T cells 
include significant proportions of Treg. The considerations about the immunostimulatory 
and immunosuppressive roles of the miRNAs described above are extensive to tumor-
associated lymphocytes. Other miRNAs that deserve further investigation specifically in 
tumor-associated T cells are miR-29, which suppresses immune responses by targeting IFN-
 (Ma et al., 2011); and miR-125b, which prevents differentiation of naive lymphocytes into 
effector T cells (Rossi et al., 2011).  
3.1.5 Antibody-mediated B cell/mast cell carcinogenic interactions  
B cells are another leukocyte subset crucially associated with the progression of at least 
certain epithelial cancer models through the production of antibodies with the collaboration 
of CD4+ T cells (Andreu et al., 2010). These antibodies against extracellular matrix 
components engage mast cells via Fc receptors and trigger secretion of pro-angiogenic 
factors and chemokines by mast cells. This induces the recruitment of myelomonocytic cells, 
including alternatively activated s (M2). Then, these M2 cells promote tumorigenicity in 
a completely Fc-dependent fashion (Andreu et al., 2010). The observation that mast cells, 
which are known to accumulate in the periphery of tumors, can contribute to 
immunosuppression has been solidly documented by elegant studies (de Vries et al., 2011; 
Lu et al., 2006; Wasiuk et al., 2009). The role of miRNAs in mast cells is particularly 
important in this context because mast cells actively release microparticles that transfer 
miRNAs and mRNAs to other cells (Valadi et al., 2007). This exosome-mediated exchange of 
genetic materials between tumor-infiltrating leukocytes and cancer cells in the TME, 
remains a poorly understood mechanism (Brase et al., 2010; Mostert et al., 2011; Scholer et 
al., 2010; Schwarzenbach et al., 2011). 
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IFN- (O'Connell et al., 2007; Rodriguez et al., 2007). Furthermore, our results indicate that 
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Interestingly, DCs matured in the absence of miR-155 express levels of MHC–II and co-
stimulatory molecules similar to those seen on identically treated matured wild-type DCs, 
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In addition, miR-155, miR-21 and miR-7, which are all targets of Foxp3, silence Satb1 and are 
also collectively required for the suppressive function of Treg (Beyer et al., 2011).  
3.1.4 Tumor-infiltrating T cells  
Infiltration of tumor islets by T cells has been associated with significantly improved 
outcomes in multiple histological types of cancer (Dunn et al., 2005; Yu & Fu, 2006). As 
many tumor-specific antigens have been identified and shown to induce the production of 
specific antibodies in cancer patients, the protective activity of these lymphocytes has 
provided a rationale for using them to treat cancer (Ertl et al., 2011). Over the last years, 
some authors have restricted the protective role of T cells to the activity of cytotoxic (CD8+) 
lymphocytes (Hamanishi et al., 2007; Sato et al., 2005), primarily because CD4+ T cells 
include significant proportions of Treg. The considerations about the immunostimulatory 
and immunosuppressive roles of the miRNAs described above are extensive to tumor-
associated lymphocytes. Other miRNAs that deserve further investigation specifically in 
tumor-associated T cells are miR-29, which suppresses immune responses by targeting IFN-
 (Ma et al., 2011); and miR-125b, which prevents differentiation of naive lymphocytes into 
effector T cells (Rossi et al., 2011).  
3.1.5 Antibody-mediated B cell/mast cell carcinogenic interactions  
B cells are another leukocyte subset crucially associated with the progression of at least 
certain epithelial cancer models through the production of antibodies with the collaboration 
of CD4+ T cells (Andreu et al., 2010). These antibodies against extracellular matrix 
components engage mast cells via Fc receptors and trigger secretion of pro-angiogenic 
factors and chemokines by mast cells. This induces the recruitment of myelomonocytic cells, 
including alternatively activated s (M2). Then, these M2 cells promote tumorigenicity in 
a completely Fc-dependent fashion (Andreu et al., 2010). The observation that mast cells, 
which are known to accumulate in the periphery of tumors, can contribute to 
immunosuppression has been solidly documented by elegant studies (de Vries et al., 2011; 
Lu et al., 2006; Wasiuk et al., 2009). The role of miRNAs in mast cells is particularly 
important in this context because mast cells actively release microparticles that transfer 
miRNAs and mRNAs to other cells (Valadi et al., 2007). This exosome-mediated exchange of 
genetic materials between tumor-infiltrating leukocytes and cancer cells in the TME, 
remains a poorly understood mechanism (Brase et al., 2010; Mostert et al., 2011; Scholer et 
al., 2010; Schwarzenbach et al., 2011). 
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3.1.6 Role of microRNAs in immunosuppression-driven metastasis 
To be able to metastasize, sprouted cancer cells need to evade multiple mechanisms of 
immune surveillance. The role of miRNAs in this active process of immunosuppression has 
been recently illustrated by studies focused on miR-30b and miR-30d. Ectopic expression of 
miR-30b/d was shown to promote the metastatic behavior of melanoma cells by silencing 
the GalNAc transferase GALNT7 (Gaziel-Sovran et al., 2011). This resulted in the up-
regulation of the immunosuppressive cytokine IL-10, which impaired anti-tumor immunity 
and promote metastatic spreading at these locations. 
4. microRNA signatures in cancer 
Whole tissue profiling is a powerful discovery tool to identify differential expression of 
miRNAs in cancerous tissues. Changes of miRNA expression in tumor samples compared to 
normal samples or between groups of tumor samples with a favourable and poor clinical 
outcome have been used to generate miRNA signatures with potential prognostic and/or 
predictive value. Differential miRNA expression in tumor samples has also been used to 
infer molecular alterations in miRNA-mediated processes within cancer cells, but without 
carefully considering the contribution of other cellular components of the TME to these 
changes of miRNA levels.  
Similar experimental designs, approaches, statistical analyses and data interpretations have 
been applied to the study of leukemias and lymphomas, in which immune cells are the site 
of cancer, and solid tumors such as carcinomas (e.g. breast and lung cancer), in which 
immune cells are the inflammatory component of TME and epithelial cells are the site of 
cancer. The techniques employed in the majority of these profiling experiments did not 
allow to identify specific cell type(s) as the source of altered miRNA expression. Altered 
expression of leukocyte-expressed miRNAs likely reflects the recruitment of inflammatory 
cells to the TME in solid tumors rather than molecular aberrations within the cancer cell per 
se. Nonetheless, most of these leukocyte-expressed miRNAs are also expressed to some 
extent in other cell types (including in some instances cancer cells) and consequently total 
contribution of each individual cell and cell type(s) to the overall RNA levels of these 
miRNAs cannot be ascertained with these experiments (see section 4.3). We review below 
cancer-associated miRNA signatures in hematological and solid tumors. It is apparent that 
many of these signatures contain leukocyte-expressed miRNAs. 
Consistent with its upregulation in several hematological cancers, including B cell 
lymphomas and acute myeloid leukemia, miR-155 is a contributor to malignant 
hematological progression when it is overexpressed in cancer cells (Xiao & Rajewsky, 2009). 
In mice, retroviral expression of miR-155 in bone marrow progenitors causes a 
myeloproliferative disorder (O'Connell et al., 2008) and constitutive overexpression of miR-
155 in the B cell lineage results in pre-B cell proliferation and eventually B cell malignancy 
(Costinean et al., 2006). Deletions and certain polymorphisms in BRCA1 promote 
carcinogensis by preventing epigenetic repression of miR-155 expression (Chang et al., 
2011). The paradoxical association between oncogenesis and effective immunity is not 
surprising, because robust adaptive immune responses require rapid expansion of 
leukocytes. For instance, T cell expansion requires the upregulation of anti-apoptotic 
mediators, including Bcl-x. Therefore, miR-155 plays a tumorigenic role when it is up-
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regulated in cancer cells of hematological origin and a protective, anti-tumor function when 
it is expressed by certain immune cell types, including APCs, in the TME of solid tumors. 
4.1 Altered microRNA expression in hematological tumors 
Altered miRNA expression has been reported in all studied hematological malignancies, 
including chronic lymphocytic leukemia (CLL), B cell lymphomas, acute myeloid leukemia 
(AML), multiple myeloma, acute lymphoblastic leukemia, myeloproliferative neoplasms 
and others (Calvo et al., 2011; Fabbri et al., 2009; Fabbri & Croce, 2011; Kotani et al., 2010; 
Marcucci et al., 2011b; Schotte et al., 2011; Wieser et al., 2010; Williams et al., 2011). It is 
common for many of these hematological malignancies to harbor recurrent chromosomal 
abnormalities that: serve to classify types and subtypes; affect specific molecular pathways; 
and have different disease progression dynamics, response to treatment and outcome. 
4.1.1 Altered microRNA expression in chronic lymphocytic leukemia 
CLL is the most common type of leukemia in the United States (Parker & Strout, 2011). Risk 
of contracting this clonal malignancy of immature/mature B cells increases exponentially 
with age, especially after age 50 (Parker & Strout, 2011). This heterogeneous disease has an 
indolent and an aggressive presentation. Patients afflicted with indolent disease will not 
progress clinical for years, but patient afflicted with aggressive disease can have rapid 
disease progression. Standard of care consists of chemotherapy-based treatment for patients 
with progressive or aggressive disease, with no obvious benefit of early treatment in 
patients with indolent disease. miRNA expression profiling has been used to improve 
prognostics based on expression of zeta-chain (TCR)–associated protein kinase 70kDa 
(ZAP70) and T-cell leukemia/lymphoma 1 (TCL1) as well as recurrent chromosomal 
abnormalities (Parker & Strout, 2011). As a matter of fact, decreased expression of miR-15a 
and miR-16-1 gene cluster as a consequence of 13q14.3 chromosomal deletion was the first 
link between miRNAs and cancer (Calin et al., 2002). Similarly, decrease of miR-34b and 
miR-34c gene cluster and TP53 expression is due to 11q and 17 p chromosomal deletions, 
respectively (Fabbri et al., 2011). This association between decreased miRNA expression and 
chromosomal deletion has uncovered a regulatory feedback loop between p53 that 
transcriptionally activates expression of miR-15a~miR-16-1 and miR-34b~miR-34c which in 
turn regulate post-transcriptionally the expression of p53 and ZAP70, respectively (Fabbri et 
al., 2011). This provides a mechanistic understanding for indolent CLL that could be applied 
as a prognostic tool and therapeutic target. Expression profiling experiments have also 
highlighted miRNA signatures that could be useful to separate indolent and aggressive CLL 
cases. Along with miR-15a, miR16-1, miR-34b/c, differential expression of miR-17-5p, miR-
21, miR-29b, miR-29c, miR-34a, miR-103, miR-155, miR-181a, miR-181b, miR-223, miR-342-
3p has been shown to have diagnostic and/or prognostic value (Asslaber et al., 2010; Calin 
et al., 2005; Fabbri et al., 2011; Li et al., 2011; Merkel et al., 2010; Mraz et al., 2009; Pekarsky et 
al., 2006; Rossi et al., 2010; Sampath et al., 2011; Stamatopoulos et al., 2009, 2010; Zhu et al., 
2011). Several mechanistic links have been proposed between these miRNAs and oncogenic 
pathways. Briefly, miR-15a and miR-16-1 inhibit expression of TP53, Bcl2, Mcl1 (Fabbri et 
al., 2011), miR-29 and miR-181 family members inhibit Tcl-1 expression (Pekarsky et al., 
2006), miR-34 family member inhibit expression of B-Myb, E2F1 and ZAP70 (Fabbri et al., 
2011; Zauli et al., 2011). 
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3.1.6 Role of microRNAs in immunosuppression-driven metastasis 
To be able to metastasize, sprouted cancer cells need to evade multiple mechanisms of 
immune surveillance. The role of miRNAs in this active process of immunosuppression has 
been recently illustrated by studies focused on miR-30b and miR-30d. Ectopic expression of 
miR-30b/d was shown to promote the metastatic behavior of melanoma cells by silencing 
the GalNAc transferase GALNT7 (Gaziel-Sovran et al., 2011). This resulted in the up-
regulation of the immunosuppressive cytokine IL-10, which impaired anti-tumor immunity 
and promote metastatic spreading at these locations. 
4. microRNA signatures in cancer 
Whole tissue profiling is a powerful discovery tool to identify differential expression of 
miRNAs in cancerous tissues. Changes of miRNA expression in tumor samples compared to 
normal samples or between groups of tumor samples with a favourable and poor clinical 
outcome have been used to generate miRNA signatures with potential prognostic and/or 
predictive value. Differential miRNA expression in tumor samples has also been used to 
infer molecular alterations in miRNA-mediated processes within cancer cells, but without 
carefully considering the contribution of other cellular components of the TME to these 
changes of miRNA levels.  
Similar experimental designs, approaches, statistical analyses and data interpretations have 
been applied to the study of leukemias and lymphomas, in which immune cells are the site 
of cancer, and solid tumors such as carcinomas (e.g. breast and lung cancer), in which 
immune cells are the inflammatory component of TME and epithelial cells are the site of 
cancer. The techniques employed in the majority of these profiling experiments did not 
allow to identify specific cell type(s) as the source of altered miRNA expression. Altered 
expression of leukocyte-expressed miRNAs likely reflects the recruitment of inflammatory 
cells to the TME in solid tumors rather than molecular aberrations within the cancer cell per 
se. Nonetheless, most of these leukocyte-expressed miRNAs are also expressed to some 
extent in other cell types (including in some instances cancer cells) and consequently total 
contribution of each individual cell and cell type(s) to the overall RNA levels of these 
miRNAs cannot be ascertained with these experiments (see section 4.3). We review below 
cancer-associated miRNA signatures in hematological and solid tumors. It is apparent that 
many of these signatures contain leukocyte-expressed miRNAs. 
Consistent with its upregulation in several hematological cancers, including B cell 
lymphomas and acute myeloid leukemia, miR-155 is a contributor to malignant 
hematological progression when it is overexpressed in cancer cells (Xiao & Rajewsky, 2009). 
In mice, retroviral expression of miR-155 in bone marrow progenitors causes a 
myeloproliferative disorder (O'Connell et al., 2008) and constitutive overexpression of miR-
155 in the B cell lineage results in pre-B cell proliferation and eventually B cell malignancy 
(Costinean et al., 2006). Deletions and certain polymorphisms in BRCA1 promote 
carcinogensis by preventing epigenetic repression of miR-155 expression (Chang et al., 
2011). The paradoxical association between oncogenesis and effective immunity is not 
surprising, because robust adaptive immune responses require rapid expansion of 
leukocytes. For instance, T cell expansion requires the upregulation of anti-apoptotic 
mediators, including Bcl-x. Therefore, miR-155 plays a tumorigenic role when it is up-
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regulated in cancer cells of hematological origin and a protective, anti-tumor function when 
it is expressed by certain immune cell types, including APCs, in the TME of solid tumors. 
4.1 Altered microRNA expression in hematological tumors 
Altered miRNA expression has been reported in all studied hematological malignancies, 
including chronic lymphocytic leukemia (CLL), B cell lymphomas, acute myeloid leukemia 
(AML), multiple myeloma, acute lymphoblastic leukemia, myeloproliferative neoplasms 
and others (Calvo et al., 2011; Fabbri et al., 2009; Fabbri & Croce, 2011; Kotani et al., 2010; 
Marcucci et al., 2011b; Schotte et al., 2011; Wieser et al., 2010; Williams et al., 2011). It is 
common for many of these hematological malignancies to harbor recurrent chromosomal 
abnormalities that: serve to classify types and subtypes; affect specific molecular pathways; 
and have different disease progression dynamics, response to treatment and outcome. 
4.1.1 Altered microRNA expression in chronic lymphocytic leukemia 
CLL is the most common type of leukemia in the United States (Parker & Strout, 2011). Risk 
of contracting this clonal malignancy of immature/mature B cells increases exponentially 
with age, especially after age 50 (Parker & Strout, 2011). This heterogeneous disease has an 
indolent and an aggressive presentation. Patients afflicted with indolent disease will not 
progress clinical for years, but patient afflicted with aggressive disease can have rapid 
disease progression. Standard of care consists of chemotherapy-based treatment for patients 
with progressive or aggressive disease, with no obvious benefit of early treatment in 
patients with indolent disease. miRNA expression profiling has been used to improve 
prognostics based on expression of zeta-chain (TCR)–associated protein kinase 70kDa 
(ZAP70) and T-cell leukemia/lymphoma 1 (TCL1) as well as recurrent chromosomal 
abnormalities (Parker & Strout, 2011). As a matter of fact, decreased expression of miR-15a 
and miR-16-1 gene cluster as a consequence of 13q14.3 chromosomal deletion was the first 
link between miRNAs and cancer (Calin et al., 2002). Similarly, decrease of miR-34b and 
miR-34c gene cluster and TP53 expression is due to 11q and 17 p chromosomal deletions, 
respectively (Fabbri et al., 2011). This association between decreased miRNA expression and 
chromosomal deletion has uncovered a regulatory feedback loop between p53 that 
transcriptionally activates expression of miR-15a~miR-16-1 and miR-34b~miR-34c which in 
turn regulate post-transcriptionally the expression of p53 and ZAP70, respectively (Fabbri et 
al., 2011). This provides a mechanistic understanding for indolent CLL that could be applied 
as a prognostic tool and therapeutic target. Expression profiling experiments have also 
highlighted miRNA signatures that could be useful to separate indolent and aggressive CLL 
cases. Along with miR-15a, miR16-1, miR-34b/c, differential expression of miR-17-5p, miR-
21, miR-29b, miR-29c, miR-34a, miR-103, miR-155, miR-181a, miR-181b, miR-223, miR-342-
3p has been shown to have diagnostic and/or prognostic value (Asslaber et al., 2010; Calin 
et al., 2005; Fabbri et al., 2011; Li et al., 2011; Merkel et al., 2010; Mraz et al., 2009; Pekarsky et 
al., 2006; Rossi et al., 2010; Sampath et al., 2011; Stamatopoulos et al., 2009, 2010; Zhu et al., 
2011). Several mechanistic links have been proposed between these miRNAs and oncogenic 
pathways. Briefly, miR-15a and miR-16-1 inhibit expression of TP53, Bcl2, Mcl1 (Fabbri et 
al., 2011), miR-29 and miR-181 family members inhibit Tcl-1 expression (Pekarsky et al., 
2006), miR-34 family member inhibit expression of B-Myb, E2F1 and ZAP70 (Fabbri et al., 
2011; Zauli et al., 2011). 
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4.1.2 Altered microRNA expression in B cell lymphomas 
B cell lymphomas are a heterogeneous group of diseases that more frequently present in 
older individuals and immunocompromised patients. These five types of B cell lymphomas 
accounts for more than 75% of all cases: Diffuse large B cell lymphoma (DLBCL), follicular 
lymphoma (FL), mucosa-associated lymphatic tissue lymphoma, small cell lymphocytic 
lymphoma and mantle cell lymphoma (MCL) (Jemal et al., 2010). A 10-miRNA signature 
(miR-17-5p, miR-92, miR-125b, miR-126, miR-135a, miR-150, miR-213, miR-301, miR-330, 
miR-338) and a 26-miRNA signature (including miR-34a, miR-92, miR-93, miR-150, miR-
199a, miR-200c, miR-634, miR-638) separed cases from the most common types of B cell 
lymphoma, DLBCL and FL (Lawrie et al., 2009; Roehle et al., 2008). Moreover, miRNA 
signatures with prognostic and/or predictive value in all or specific (sub)types of B cell 
lymphomas have been reported. An 8-miRNA signature (let-7g, miR-19a, miR-21, miR-23a, 
miR-27a, miR-34a, miR-127, miR-195) was associated with outcome in DLBCL cases (Roehle 
et al., 2008), a 21-miRNA signature (including miR-21, miR-23, miR-27a, miR-30e, miR-199b, 
miR-330) with outcome in de novo DLBCL cases (Lawrie et al., 2009), and a 23-miRNA 
signature (including let-7a, let-7f, miR-20a, miR-20b, miR-30b, miR-96, miR-195, miR-221*, 
miR-1260, miR-1274a) with treatment response to chemotherapy in FL cases (Wang et al., 
2011b). Differential expression of individual miRNAs has enough power to predict outcome 
as is the case for miR-18a, miR181a and miR-222 in DLBCL (Alencar et al., 2011), for miR-29 
family members in MCL (Zhao et al., 2010) and for miR-92a in plasma of patients afflicted 
with different types of non-Hodgkin’s B cell lymphomas (Ohyashiki et al., 2011). Several 
mechanistic links have been proposed between these miRNAs and oncogenic pathways. 
Briefly, miR-29 family members inhibit CDK6 expression in MCL (Zhao et al., 2010), and 
miR-34a inhibits FoxP1 expression in DLBCL (Craig et al., 2011). 
4.1.3 Altered microRNA expression in acute myeloid leukemia 
AML is the most common acute leukemia affecting adults in the United States (Jemal et al., 
2010). AML is a very heterogenous disease and different types have been tradictionally 
classified based on cytological and cytogenetic characteristics. Molecular studies have 
provided clinical useful prognostic and functional factors, including gene mutations in c-
KIT, Fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), and CCAAT enhancer-
binding protein- (CEBP) (Foran, 2010). A 27-miRNA signature (including let-7a, miR-21, 
miR-23a, miR-27a, miR-125a, miR-128a, miR-199b, miR-210, miR-221, miR-222, miR-223) 
separed AML cases from acute lymphoblastic leukemia (Mi et al., 2007). Moreover, miRNA 
signatures with diagnostic, prognostic and/or predictive value in all or specific (sub)types 
of AML have been reported (Marcucci et al., 2009, 2011a). A 57-miRNA signature (including 
let-7a, miR-29a, miR-15a, miR-16-1, miR-17-5p, miR-20a, miR-25, miR-92a) correlated with 
mutation status of NPM1 (Garzon et al., 2008a), a 3-miRNA signature (miR-1331a, miR-155, 
miR-302a) with mutation status of FTL3 (Garzon et al., 2008a), a 5-miRNA signature (miR-
20a, miR-25, miR-191, miR-199a, miR-199b) and a 2-miRNA signature (miR-29a, miR-142-3p) 
were associated with outcome in AML cases (Garzon et al., 2008b; Wang et al., 2011a). 
Differenntial expression of individual miRNAs has enough power to predict outcome as is 
the case for miR-181a, miR-191 and miR-199a (Garzon et al., 2008b; Schwind et al., 2010), to 
predict response to decitabine treatment as is the case for miR-29b (Blum et al., 2010). 
Several mechanistic links have been proposed between these miRNAs and oncogenic 
pathways. Briefly, CEBP-induced miR-29 family members inhibit expression of Mcl-1 and 
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Ski (Eyholzer et al., 2010; Garzon et al., 2009; Teichler et al., 2011; Xiong et al., 2011), CEBP-
induced miR-34a inhibits E2F3 (Pulikkan et al., 2010), miR-193b, miR-221 and miR-222 
inhibit c-KIT expression (Gao et al., 2011; Isken et al., 2008).  
4.2 Altered microRNA expression in solid tumors 
Altered miRNA expression has been reported in all studied solid tumors, including breast, 
brain, colorectal, gastric, lung, ovarian, pancreatic, prostate, skin, and thyroid cancers 
(Barbarotto et al., 2008; Fabbri, 2010; Li et al., 2010; Liu et al., 2011; Pallante et al., 2010; 
Sempere, 2011). Carcinomas of the breast, colon and lung collectively account for more than 
247,000 cancer-related deaths per year in the United States (Jemal et al., 2010). We will use 
these solid tumors to exemplify the etiological contribution of TME leukoctyes and to 
expose the enrichment of leukocyte-expressed miRNAs in reported diagnostic and 
prognostic miRNA-based signatures.  
Immunohistochemical (IHC) characterization of cell type(s) present in the immune cell 
infiltrate in the TME can also be indicative of response to treatment. In breast cancer, the 
ratio of CD4+ T cells, CD8+ T cells and CD68+ monocytes/s is an independent 
prognostic indicator of recurrence-free and overall survival (DeNardo et al., 2011). A high 
number of infiltrating CD68+ cells, presumably with M2 attributes, in the TME is thought to 
decrease treatment response to chemotherapy (DeNardo et al., 2011). Recent gene ontology-
annotated mRNA signatures has uncovered the important contribution and prognostic 
value of immune cell signatures in breast, colorectal and lung cancer (Finak et al., 2008; 
Kristensen et al., 2011; Roepman et al., 2009).  
4.2.1 Altered microRNA expression in breast cancer 
Breast cancer is the most prevalent and second most common cause for cancer-related death 
of women in the United States (Jemal et al., 2010). There are four major intrinsic subtypes 
based on mRNA expression profiles (Sims et al., 2006; Sorlie, 2004) which closely correlate 
with expression status of estrogen receptor (ER), progesterone (PR) and Human Epidermal 
growth factor Receptor-like 2 (HER2) (Carey et al., 2006). Targeted therapies exist to 
interfere with ER and HER2 oncogenic signalling pathways (Caskey, 2010). Several groups 
have reported prognostic miRNA signatures, which include multiple leukocyte-expressed 
miRNAs (miR-7, miR-21, miR-150, miR-221, miR-222, miR-342). A 4-miRNA signature (miR-
7, miR-128a, miR-210, miR-516-3p), a 3-miRNA signature (miR-30a-3p, miR-30c, miR-182), 
and a 4-miRNA signature (miR-128a, miR-135a, miR-767-3p, miR-769-3p) were associated 
with outcome in ER+ cases (Buffa et al., 2011; Foekens et al., 2008; Rodriguez-Gonzalez et al., 
2011), a 6-miRNA signature (miR-27b, miR-30c, miR-144, miR-150, miR-210, miR-342) with 
outcome in ER- cases (Buffa et al., 2011), a 4-miRNA signature (miR-21, miR-210, miR-221, 
miR-222) with outcome in ER-PR-HER2- cases (Radojicic et al., 2011), and a 2-miRNA 
signature (miR-21, miR-181a) with outcome in all comers (Ota et al., 2011).  
4.2.2 Altered microRNA expression in colorectal cancer 
Colorectal cancer is the third leading cause of cancer-related death for both men and women in 
the United States (Jemal et al., 2010). There are two major molecular subtypes: microsatellite 
stable (MSS) and microsatellite instable (MSI). MSI phenotype is observed in about 15% of 
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4.1.2 Altered microRNA expression in B cell lymphomas 
B cell lymphomas are a heterogeneous group of diseases that more frequently present in 
older individuals and immunocompromised patients. These five types of B cell lymphomas 
accounts for more than 75% of all cases: Diffuse large B cell lymphoma (DLBCL), follicular 
lymphoma (FL), mucosa-associated lymphatic tissue lymphoma, small cell lymphocytic 
lymphoma and mantle cell lymphoma (MCL) (Jemal et al., 2010). A 10-miRNA signature 
(miR-17-5p, miR-92, miR-125b, miR-126, miR-135a, miR-150, miR-213, miR-301, miR-330, 
miR-338) and a 26-miRNA signature (including miR-34a, miR-92, miR-93, miR-150, miR-
199a, miR-200c, miR-634, miR-638) separed cases from the most common types of B cell 
lymphoma, DLBCL and FL (Lawrie et al., 2009; Roehle et al., 2008). Moreover, miRNA 
signatures with prognostic and/or predictive value in all or specific (sub)types of B cell 
lymphomas have been reported. An 8-miRNA signature (let-7g, miR-19a, miR-21, miR-23a, 
miR-27a, miR-34a, miR-127, miR-195) was associated with outcome in DLBCL cases (Roehle 
et al., 2008), a 21-miRNA signature (including miR-21, miR-23, miR-27a, miR-30e, miR-199b, 
miR-330) with outcome in de novo DLBCL cases (Lawrie et al., 2009), and a 23-miRNA 
signature (including let-7a, let-7f, miR-20a, miR-20b, miR-30b, miR-96, miR-195, miR-221*, 
miR-1260, miR-1274a) with treatment response to chemotherapy in FL cases (Wang et al., 
2011b). Differential expression of individual miRNAs has enough power to predict outcome 
as is the case for miR-18a, miR181a and miR-222 in DLBCL (Alencar et al., 2011), for miR-29 
family members in MCL (Zhao et al., 2010) and for miR-92a in plasma of patients afflicted 
with different types of non-Hodgkin’s B cell lymphomas (Ohyashiki et al., 2011). Several 
mechanistic links have been proposed between these miRNAs and oncogenic pathways. 
Briefly, miR-29 family members inhibit CDK6 expression in MCL (Zhao et al., 2010), and 
miR-34a inhibits FoxP1 expression in DLBCL (Craig et al., 2011). 
4.1.3 Altered microRNA expression in acute myeloid leukemia 
AML is the most common acute leukemia affecting adults in the United States (Jemal et al., 
2010). AML is a very heterogenous disease and different types have been tradictionally 
classified based on cytological and cytogenetic characteristics. Molecular studies have 
provided clinical useful prognostic and functional factors, including gene mutations in c-
KIT, Fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), and CCAAT enhancer-
binding protein- (CEBP) (Foran, 2010). A 27-miRNA signature (including let-7a, miR-21, 
miR-23a, miR-27a, miR-125a, miR-128a, miR-199b, miR-210, miR-221, miR-222, miR-223) 
separed AML cases from acute lymphoblastic leukemia (Mi et al., 2007). Moreover, miRNA 
signatures with diagnostic, prognostic and/or predictive value in all or specific (sub)types 
of AML have been reported (Marcucci et al., 2009, 2011a). A 57-miRNA signature (including 
let-7a, miR-29a, miR-15a, miR-16-1, miR-17-5p, miR-20a, miR-25, miR-92a) correlated with 
mutation status of NPM1 (Garzon et al., 2008a), a 3-miRNA signature (miR-1331a, miR-155, 
miR-302a) with mutation status of FTL3 (Garzon et al., 2008a), a 5-miRNA signature (miR-
20a, miR-25, miR-191, miR-199a, miR-199b) and a 2-miRNA signature (miR-29a, miR-142-3p) 
were associated with outcome in AML cases (Garzon et al., 2008b; Wang et al., 2011a). 
Differenntial expression of individual miRNAs has enough power to predict outcome as is 
the case for miR-181a, miR-191 and miR-199a (Garzon et al., 2008b; Schwind et al., 2010), to 
predict response to decitabine treatment as is the case for miR-29b (Blum et al., 2010). 
Several mechanistic links have been proposed between these miRNAs and oncogenic 
pathways. Briefly, CEBP-induced miR-29 family members inhibit expression of Mcl-1 and 
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Ski (Eyholzer et al., 2010; Garzon et al., 2009; Teichler et al., 2011; Xiong et al., 2011), CEBP-
induced miR-34a inhibits E2F3 (Pulikkan et al., 2010), miR-193b, miR-221 and miR-222 
inhibit c-KIT expression (Gao et al., 2011; Isken et al., 2008).  
4.2 Altered microRNA expression in solid tumors 
Altered miRNA expression has been reported in all studied solid tumors, including breast, 
brain, colorectal, gastric, lung, ovarian, pancreatic, prostate, skin, and thyroid cancers 
(Barbarotto et al., 2008; Fabbri, 2010; Li et al., 2010; Liu et al., 2011; Pallante et al., 2010; 
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these solid tumors to exemplify the etiological contribution of TME leukoctyes and to 
expose the enrichment of leukocyte-expressed miRNAs in reported diagnostic and 
prognostic miRNA-based signatures.  
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ratio of CD4+ T cells, CD8+ T cells and CD68+ monocytes/s is an independent 
prognostic indicator of recurrence-free and overall survival (DeNardo et al., 2011). A high 
number of infiltrating CD68+ cells, presumably with M2 attributes, in the TME is thought to 
decrease treatment response to chemotherapy (DeNardo et al., 2011). Recent gene ontology-
annotated mRNA signatures has uncovered the important contribution and prognostic 
value of immune cell signatures in breast, colorectal and lung cancer (Finak et al., 2008; 
Kristensen et al., 2011; Roepman et al., 2009).  
4.2.1 Altered microRNA expression in breast cancer 
Breast cancer is the most prevalent and second most common cause for cancer-related death 
of women in the United States (Jemal et al., 2010). There are four major intrinsic subtypes 
based on mRNA expression profiles (Sims et al., 2006; Sorlie, 2004) which closely correlate 
with expression status of estrogen receptor (ER), progesterone (PR) and Human Epidermal 
growth factor Receptor-like 2 (HER2) (Carey et al., 2006). Targeted therapies exist to 
interfere with ER and HER2 oncogenic signalling pathways (Caskey, 2010). Several groups 
have reported prognostic miRNA signatures, which include multiple leukocyte-expressed 
miRNAs (miR-7, miR-21, miR-150, miR-221, miR-222, miR-342). A 4-miRNA signature (miR-
7, miR-128a, miR-210, miR-516-3p), a 3-miRNA signature (miR-30a-3p, miR-30c, miR-182), 
and a 4-miRNA signature (miR-128a, miR-135a, miR-767-3p, miR-769-3p) were associated 
with outcome in ER+ cases (Buffa et al., 2011; Foekens et al., 2008; Rodriguez-Gonzalez et al., 
2011), a 6-miRNA signature (miR-27b, miR-30c, miR-144, miR-150, miR-210, miR-342) with 
outcome in ER- cases (Buffa et al., 2011), a 4-miRNA signature (miR-21, miR-210, miR-221, 
miR-222) with outcome in ER-PR-HER2- cases (Radojicic et al., 2011), and a 2-miRNA 
signature (miR-21, miR-181a) with outcome in all comers (Ota et al., 2011).  
4.2.2 Altered microRNA expression in colorectal cancer 
Colorectal cancer is the third leading cause of cancer-related death for both men and women in 
the United States (Jemal et al., 2010). There are two major molecular subtypes: microsatellite 
stable (MSS) and microsatellite instable (MSI). MSI phenotype is observed in about 15% of 
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cases, is associated with a better prognosis and exhibits a different chemosensitivity profile to 
therapeutic agents (Pino & Chung, 2011; Vilar & Gruber, 2010). Several groups have reported 
diagnostic and prognostic miRNA signatures, which include multiple leukocyte-expressed 
miRNAs (miR-17-5p, miR-20, miR-25, miR-142-3p, miR-155, miR-223). A 8-miRNA signature 
(miR-92, miR-93, miR-106a, miR-125a, miR-142-3p, miR-144, miR-151, miR-212) and a 14-
miRNA signature (miR-17-5p, miR-20, miR-25, miR-32, miR-92, miR-93, miR-106a, miR-125a, 
miR-155, miR-191, miR-192, miR-203, miR-215, miR-223) separated MSS and MSI cases (Lanza 
et al., 2007; Schepeler et al., 2008), a 2-miRNA signature (miR-320, miR-498) was associated 
with outcome in stage II MSS cases (Schepeler et al., 2008).  
4.2.3 Altered microRNA expression in lung cancer 
Lung cancer is the leading cause of cancer-related death for men and women in the United 
States (Jemal et al., 2010). There are two major histological subtypes: small-cell (SCLC) and 
non-small cell (NSCLC). NSCLC represent about 80% of all lung cancer cases and can be 
further divided in three histological groups: large cell carcinoma, squamous cell (SCC), 
adenocarcinoma (AdCa) (Wistuba & Gazdar, 2006). Several groups have reported diagnostic 
and prognostic miRNA signatures, which include multiple leukocyte-expressed miRNAs 
(miR-16, miR-17-5p, miR-20a, miR-20b, miR-29a, miR-29b, miR-29c, miR-106a, miR-106b, 
miR-146-5p, miR-146b, miR-155, miR-181a, miR-221). A 34-miRNA signature (including let-
7a, let-7e, miR-16, miR-17-5p, miR-19b, miR-20a, miR-29a, miR-29b, miR-29c, miR-30b, miR-
106a, miR-106b, miR-146-5p, miR-181a, miR-191, miR-195, miR-491-5p, miR-663) separated 
AdCa and SCC subtypes in male smokers (Landi et al., 2010), a 6-miRNA signature (let-7a, 
miR-221, miR-137, miR-182*, miR-372) was associated with outcome in NSCLC (Yu et al., 
2008), a 19-miRNA signature (let-7e, miR-17-5p, miR-20a, miR-20b, miR-21, miR-93, miR-
106a, miR-106b, miR-126, miR-146b, miR-155, miR-182, miR-183, miR-191, miR-200a, miR-
200c, miR-210, miR-224) with outcome in SCC cases (Raponi et al., 2009), and a 5-miRNA 
signature (let-7e, miR-34a, miR-34-5p, miR-25, miR-191) with outcome in male smoker SCC 
cases (Landi et al., 2010). 
4.3 Characterization of miRNA expression at single cell resolution in the TME 
Solid tumor tissues are a complex and heterogeneous mixture of different cell types, in 
which cancer cell interact and intermingle with other cellular components of the TME. We 
and others have implemented similar in situ hybridization (ISH) methods to identify the 
cellular compartment(s) of altered miRNA expression in a variety of solid tumors, including 
brain, breast, colorectal, lung, pancreatic, and prostate cancer (Dillhoff et al., 2008; Donnem 
et al., 2011; Gupta & Mo, 2011; Habbe et al., 2009; Jorgensen et al., 2010; Liu et al., 2010a; 
Nelson et al., 2006, 2010; Nelson & Wilfred, 2009; Nielsen et al., 2011; Preis et al., 2011; Qian 
et al., 2011; Rask et al., 2011; Schepeler et al., 2008; Schneider et al., 2011; Sempere et al., 2007, 
2010; Yamamichi et al., 2009). miR-21 and miR-155 are frequently detected at higher levels in 
solid tumors and their differential expression correlates with outcome (Barbarotto et al., 
2008; Sempere, 2011). Using a combined ISH/IHC multiplex assay, we determined that miR-
21 and miR-155 are expressed in different cellular compartments of the TME (Sempere et al., 
2010). miR-21 was predominantly expressed within reactive stroma (tumor associated 
fibroblasts) in breast and colorectal tumors, and within cancer cells in lung, pancreatic and 
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prostate tumors. Cellular co-localization of miR-155 and CD45 (leukocyte marker) signals, 
but not that of CK19 (epithelial cell marker) indicated a predominant expression of miR-155 
within a subset of immune cells in the TME (Sempere et al. 2010). Our unpublished 
observations suggest that miR-155 is predominantly expressed in a subset of myeloid-
derived immune cells (MPO+CD68-) in the TME of breast and colorectal tumors as 
determined by co-staining with cell type-specific and functional markers of major immune 
cell types (e.g., CD4, CD8, CD19). Further contextual characterization to identify the 
immune cells that upregulate or downregulate miR-155 and other leukocyte-expressed 
miRNAs in the TME should shed light on their etiological contribution to modulate cancer 
aggressiveness and progression.  
5. Manipulation of microRNA activity in the tumor microenvironment by  
non-viral synthetic compounds as a novel approach for cancer therapy 
The crucial role of miRNAs in the immunobiology of cancer makes them attractive targets 
for the design of novel interventions to modulate their activity. Delivery of miRNAs that are 
lost in cancer cells has been accomplished using viral vectors, which results in impressive 
therapeutic benefits (Kota et al., 2009). However, direct administration of viral vectors to 
cancer patients represents a major challenge in terms of clinical implementation. 
Alternatively, synthetic miRNA oligonucleotides or antagonistic compounds could be 
delivered through nanoparticles or microparticles, complexed to polymers or liposomes. 
The caveat of this approach is that, as commented above, a myriad of phagocytic cells with 
enhanced endocytic pathways are present in the microenvironment of virtually all solid 
tumors. Overcoming endocytosis by these abundant leukocytes and reaching cancer cells 
represents a barrier that, at least in our hands, has proven impossible (Cubillos-Ruiz et al., 
2009a, 2009b; Cubillos-Ruiz et al., 2010). Nevertheless, the myeloid leukocytes that 
spontaneously take up particulate materials are also optimal targets for miRNA mimetics-
based interventions. Thus, the crucial role of these cells in promoting the survival and 
proliferation of cancer cells, angiogenesis, metastasis and immnosuppression, as well as 
their plasticity and preferential homing to tumor sites facilitates their targeting as “Trojan 
Horses”. In proof-of-concept experiments, we have been able to deliver double-stranded 
RNA oligonucleotides specifically to myeloid leukocytes in TME of ovarian cancer mouse 
models, which transformed these myeloid leukocytes from an immunosuppressive to an 
immunostimulatory cell type, resulting in significant therapeutic activity (Cubillos-Ruiz et 
al., 2009a). More recently, taking advantage of this established delivery system, we have 
been able to deliver synthetic miRNAs to the same cells, which transformed more than a 
third of their transcriptional profile and turned them into effective antigen-presenting cells 
that elicit protective anti-tumor immunity (manuscript under consideration). Furthermore, 
synthetic miRNA mimetics, as double-stranded oligonucleotides, are recognized by TLR3 
and TLR7, which results in an additional non-specific activation stimulus. Because TLR 
agonists are known to synergize with CD40 activating reagents (Scarlett et al., 2009), which 
have demonstrated impressive effectiveness against pancreatic cancer (Beatty et al., 2011), 
their combined activity could be even stronger. Consequently, the abundance of natural 
phagocytic cells that avidly take up nanoparticles, which has been traditionally a major 
hurdle for targeted delivery of systemically administered nanoparticles, represents an 
advantage for effectively reaching this immunological-based therapeutic target.  
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cases, is associated with a better prognosis and exhibits a different chemosensitivity profile to 
therapeutic agents (Pino & Chung, 2011; Vilar & Gruber, 2010). Several groups have reported 
diagnostic and prognostic miRNA signatures, which include multiple leukocyte-expressed 
miRNAs (miR-17-5p, miR-20, miR-25, miR-142-3p, miR-155, miR-223). A 8-miRNA signature 
(miR-92, miR-93, miR-106a, miR-125a, miR-142-3p, miR-144, miR-151, miR-212) and a 14-
miRNA signature (miR-17-5p, miR-20, miR-25, miR-32, miR-92, miR-93, miR-106a, miR-125a, 
miR-155, miR-191, miR-192, miR-203, miR-215, miR-223) separated MSS and MSI cases (Lanza 
et al., 2007; Schepeler et al., 2008), a 2-miRNA signature (miR-320, miR-498) was associated 
with outcome in stage II MSS cases (Schepeler et al., 2008).  
4.2.3 Altered microRNA expression in lung cancer 
Lung cancer is the leading cause of cancer-related death for men and women in the United 
States (Jemal et al., 2010). There are two major histological subtypes: small-cell (SCLC) and 
non-small cell (NSCLC). NSCLC represent about 80% of all lung cancer cases and can be 
further divided in three histological groups: large cell carcinoma, squamous cell (SCC), 
adenocarcinoma (AdCa) (Wistuba & Gazdar, 2006). Several groups have reported diagnostic 
and prognostic miRNA signatures, which include multiple leukocyte-expressed miRNAs 
(miR-16, miR-17-5p, miR-20a, miR-20b, miR-29a, miR-29b, miR-29c, miR-106a, miR-106b, 
miR-146-5p, miR-146b, miR-155, miR-181a, miR-221). A 34-miRNA signature (including let-
7a, let-7e, miR-16, miR-17-5p, miR-19b, miR-20a, miR-29a, miR-29b, miR-29c, miR-30b, miR-
106a, miR-106b, miR-146-5p, miR-181a, miR-191, miR-195, miR-491-5p, miR-663) separated 
AdCa and SCC subtypes in male smokers (Landi et al., 2010), a 6-miRNA signature (let-7a, 
miR-221, miR-137, miR-182*, miR-372) was associated with outcome in NSCLC (Yu et al., 
2008), a 19-miRNA signature (let-7e, miR-17-5p, miR-20a, miR-20b, miR-21, miR-93, miR-
106a, miR-106b, miR-126, miR-146b, miR-155, miR-182, miR-183, miR-191, miR-200a, miR-
200c, miR-210, miR-224) with outcome in SCC cases (Raponi et al., 2009), and a 5-miRNA 
signature (let-7e, miR-34a, miR-34-5p, miR-25, miR-191) with outcome in male smoker SCC 
cases (Landi et al., 2010). 
4.3 Characterization of miRNA expression at single cell resolution in the TME 
Solid tumor tissues are a complex and heterogeneous mixture of different cell types, in 
which cancer cell interact and intermingle with other cellular components of the TME. We 
and others have implemented similar in situ hybridization (ISH) methods to identify the 
cellular compartment(s) of altered miRNA expression in a variety of solid tumors, including 
brain, breast, colorectal, lung, pancreatic, and prostate cancer (Dillhoff et al., 2008; Donnem 
et al., 2011; Gupta & Mo, 2011; Habbe et al., 2009; Jorgensen et al., 2010; Liu et al., 2010a; 
Nelson et al., 2006, 2010; Nelson & Wilfred, 2009; Nielsen et al., 2011; Preis et al., 2011; Qian 
et al., 2011; Rask et al., 2011; Schepeler et al., 2008; Schneider et al., 2011; Sempere et al., 2007, 
2010; Yamamichi et al., 2009). miR-21 and miR-155 are frequently detected at higher levels in 
solid tumors and their differential expression correlates with outcome (Barbarotto et al., 
2008; Sempere, 2011). Using a combined ISH/IHC multiplex assay, we determined that miR-
21 and miR-155 are expressed in different cellular compartments of the TME (Sempere et al., 
2010). miR-21 was predominantly expressed within reactive stroma (tumor associated 
fibroblasts) in breast and colorectal tumors, and within cancer cells in lung, pancreatic and 
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prostate tumors. Cellular co-localization of miR-155 and CD45 (leukocyte marker) signals, 
but not that of CK19 (epithelial cell marker) indicated a predominant expression of miR-155 
within a subset of immune cells in the TME (Sempere et al. 2010). Our unpublished 
observations suggest that miR-155 is predominantly expressed in a subset of myeloid-
derived immune cells (MPO+CD68-) in the TME of breast and colorectal tumors as 
determined by co-staining with cell type-specific and functional markers of major immune 
cell types (e.g., CD4, CD8, CD19). Further contextual characterization to identify the 
immune cells that upregulate or downregulate miR-155 and other leukocyte-expressed 
miRNAs in the TME should shed light on their etiological contribution to modulate cancer 
aggressiveness and progression.  
5. Manipulation of microRNA activity in the tumor microenvironment by  
non-viral synthetic compounds as a novel approach for cancer therapy 
The crucial role of miRNAs in the immunobiology of cancer makes them attractive targets 
for the design of novel interventions to modulate their activity. Delivery of miRNAs that are 
lost in cancer cells has been accomplished using viral vectors, which results in impressive 
therapeutic benefits (Kota et al., 2009). However, direct administration of viral vectors to 
cancer patients represents a major challenge in terms of clinical implementation. 
Alternatively, synthetic miRNA oligonucleotides or antagonistic compounds could be 
delivered through nanoparticles or microparticles, complexed to polymers or liposomes. 
The caveat of this approach is that, as commented above, a myriad of phagocytic cells with 
enhanced endocytic pathways are present in the microenvironment of virtually all solid 
tumors. Overcoming endocytosis by these abundant leukocytes and reaching cancer cells 
represents a barrier that, at least in our hands, has proven impossible (Cubillos-Ruiz et al., 
2009a, 2009b; Cubillos-Ruiz et al., 2010). Nevertheless, the myeloid leukocytes that 
spontaneously take up particulate materials are also optimal targets for miRNA mimetics-
based interventions. Thus, the crucial role of these cells in promoting the survival and 
proliferation of cancer cells, angiogenesis, metastasis and immnosuppression, as well as 
their plasticity and preferential homing to tumor sites facilitates their targeting as “Trojan 
Horses”. In proof-of-concept experiments, we have been able to deliver double-stranded 
RNA oligonucleotides specifically to myeloid leukocytes in TME of ovarian cancer mouse 
models, which transformed these myeloid leukocytes from an immunosuppressive to an 
immunostimulatory cell type, resulting in significant therapeutic activity (Cubillos-Ruiz et 
al., 2009a). More recently, taking advantage of this established delivery system, we have 
been able to deliver synthetic miRNAs to the same cells, which transformed more than a 
third of their transcriptional profile and turned them into effective antigen-presenting cells 
that elicit protective anti-tumor immunity (manuscript under consideration). Furthermore, 
synthetic miRNA mimetics, as double-stranded oligonucleotides, are recognized by TLR3 
and TLR7, which results in an additional non-specific activation stimulus. Because TLR 
agonists are known to synergize with CD40 activating reagents (Scarlett et al., 2009), which 
have demonstrated impressive effectiveness against pancreatic cancer (Beatty et al., 2011), 
their combined activity could be even stronger. Consequently, the abundance of natural 
phagocytic cells that avidly take up nanoparticles, which has been traditionally a major 
hurdle for targeted delivery of systemically administered nanoparticles, represents an 
advantage for effectively reaching this immunological-based therapeutic target.  
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6. Conclusion 
We have reviewed evidences of miRNA-mediated processes that modulate immune 
responses. The effects of miRNA-mediated regulation are cell type-, stage- and context-
dependent. Thus, cautions should be exercised when observed effects of miRNAs on clearly 
demarcated and controlled set of experiments in animal models are to be extrapolated from 
a physiological to a pathological context such as cancer and are to be generalized to human 
physiology and disease. This is of great importance when fragmentary knowledge of altered 
miRNA expression in whole tumor tissue biopsies is used to infer etiological roles and 
functional consequences of this presumed miRNA dysregulation in cancer cells.  
As commented above, hematological cells are the site of cancer origin in leukemias and 
lymphomas. Therefore, it is reasonable to assume that dysregulation of leukocyte-expressed 
miRNA-mediated developmental and differentiation programs can be exploited by the 
cancer cells to become malignantly transformed. However, immune cells are an inescapable 
and important component of the TME in solid tumors, in which epithelial cells or 
mesenchymal cells are the site of cancer origin, in carcinomas or sarcomas, respectively. 
Although it is possible that cancer cells dysregulate within themselves the activity of 
leukocyte-expressed miRNAs to hijack and stimulate tumorigenic immune responses in the 
TME of solid tumors, it is more parsimonious that cancer cells via cellular interactions and 
paracrine signals interfere with immunomodulatory properties of leukocyte expressed-
miRNAs such as miR-29 and miR-155 within specific subsets of infiltrating immune cells.  
Further investigations are needed to understand the role that miRNAs play in cancer, both 
in hematological and solid tumors. We hope that our reflections here serve to inform the 
experimental design of future pre-clinical and clinical studies, namely, that cell type-specific 
and context-dependent effects of miRNA-mediated immunomodulation are appropriately 
considered and distinguished from miRNA-mediated processes within cancer cells and 
other cellular compartments of the TME. This could have important clinical implications 
and applications since reprogramming a subset of immune cells to elicit anti-tumor 
responses is an appealing and potentially feasible approach for therapeutic intervention.  
7. Acknowledgment 
This work was supported, in part, by National Institutes of Health (NIH) and National 
Cancer Institute (NCI) grants: R03 CA141564 and R21 CA141017 (LFS), CA124515, 
CA124515S, CA132026 and P30CA010815 (JRC), and by DoD grant OC100059 (JRC). 
8. References 
Ahn, G. O. & Brown, J. M. Matrix metalloproteinase-9 is required for tumor vasculogenesis 
but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. 
Cancer Cell 13[3], 193-205. 2008.  
Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., 
Briones, J., Natkunam, Y., Sehn, L. H., Gascoyne, R. D., Tibshirani, R., & Lossos, I. S. 
MicroRNAs are independent predictors of outcome in diffuse large B-cell 
lymphoma patients treated with R-CHOP. Clin.Cancer Res. 17[12], 4125-4135. 6-15-
2011.  
Modulation of Cancer Progression 
by Tumor Microenvironmental Leukocyte-Expressed microRNAs 239 
Ambros, V. The functions of animal microRNAs. Nature 431[7006], 350-355. 9-16-2004.  
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., 
Tawfik, D., DeNardo, D. G., Naldini, L., de Visser, K. E., De, Palma M., & Coussens, 
L. M. FcRgamma activation regulates inflammation-associated squamous 
carcinogenesis. Cancer Cell 17[2], 121-134. 2-17-2010.  
Asslaber, D., Pinon, J. D., Seyfried, I., Desch, P., Stocher, M., Tinhofer, I., Egle, A., Merkel, O., 
& Greil, R. microRNA-34a expression correlates with MDM2 SNP309 
polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 
115[21], 4191-4197. 5-27-2010.  
Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. The impact of 
microRNAs on protein output. Nature 455[7209], 64-71. 9-4-2008.  
Barbarotto, E., Schmittgen, T. D., & Calin, G. A. MicroRNAs and cancer: profile, profile, 
profile. Int.J.Cancer 122[5], 969-977. 3-1-2008.  
Bartel, D. P. & Chen, C. Z. Micromanagers of gene expression: the potentially widespread 
influence of metazoan microRNAs. Nat.Rev.Genet. 5[5], 396-400. 2004.  
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, 
R. D., Song, W., Li, D., Sharp, L. L., Torigian, D. A., O'Dwyer, P. J., & Vonderheide, 
R. H. CD40 agonists alter tumor stroma and show efficacy against pancreatic 
carcinoma in mice and humans. Science 331[6024], 1612-1616. 3-25-2011.  
Belver, L., de, Yebenes, V, & Ramiro, A. R. MicroRNAs prevent the generation of 
autoreactive antibodies. Immunity. 33[5], 713-722. 11-24-2010.  
Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., Barzilai, A., Einat, P., 
Einav, U., Meiri, E., Sharon, E., Spector, Y., & Bentwich, Z. Identification of 
hundreds of conserved and nonconserved human microRNAs. Nat.Genet. 37[7], 
766-770. 2005.  
Beyer, M., Thabet, Y., Muller, R. U., Sadlon, T., Classen, S., Lahl, K., Basu, S., Zhou, X., 
Bailey-Bucktrout, S. L., Krebs, W., Schonfeld, E. A., Bottcher, J., Golovina, T., 
Mayer, C. T., Hofmann, A., Sommer, D., bey-Pascher, S., Endl, E., Limmer, A., 
Hippen, K. L., Blazar, B. R., Balderas, R., Quast, T., Waha, A., Mayer, G., Famulok, 
M., Knolle, P. A., Wickenhauser, C., Kolanus, W., Schermer, B., Bluestone, J. A., 
Barry, S. C., Sparwasser, T., Riley, J. L., & Schultze, J. L. Repression of the genome 
organizer SATB1 in regulatory T cells is required for suppressive function and 
inhibition of effector differentiation. Nat.Immunol. 12[9], 898-907. 2011.  
Bezman, N. A., Cedars, E., Steiner, D. F., Blelloch, R., Hesslein, D. G., & Lanier, L. L. Distinct 
requirements of microRNAs in NK cell activation, survival, and function. 
J.Immunol. 185[7], 3835-3846. 10-1-2010.  
Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, 
V., Becker, H., Schaaf, L., Mickle, J., Devine, H., Kefauver, C., Devine, S. M., Chan, 
K. K., Heerema, N. A., Bloomfield, C. D., Grever, M. R., Byrd, J. C., Villalona-
Calero, M., Croce, C. M., & Marcucci, G. Clinical response and miR-29b predictive 
significance in older AML patients treated with a 10-day schedule of decitabine. 
Proc.Natl.Acad.Sci.U.S.A 107[16], 7473-7478. 4-20-2010.  
Brase, J. C., Wuttig, D., Kuner, R., & Sultmann, H. Serum microRNAs as non-invasive 
biomarkers for cancer. Mol.Cancer 9, 306. 2010.  
Buffa, F. M., Camps, C., Winchester, L., Snell, C. E., Gee, H. E., Sheldon, H., Taylor, M., 
Harris, A. L., & Ragoussis, J. microRNA associated progression pathways and 
 
Tumor Microenvironment and Myelomonocytic Cells 238 
6. Conclusion 
We have reviewed evidences of miRNA-mediated processes that modulate immune 
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dependent. Thus, cautions should be exercised when observed effects of miRNAs on clearly 
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a physiological to a pathological context such as cancer and are to be generalized to human 
physiology and disease. This is of great importance when fragmentary knowledge of altered 
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mesenchymal cells are the site of cancer origin, in carcinomas or sarcomas, respectively. 
Although it is possible that cancer cells dysregulate within themselves the activity of 
leukocyte-expressed miRNAs to hijack and stimulate tumorigenic immune responses in the 
TME of solid tumors, it is more parsimonious that cancer cells via cellular interactions and 
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Further investigations are needed to understand the role that miRNAs play in cancer, both 
in hematological and solid tumors. We hope that our reflections here serve to inform the 
experimental design of future pre-clinical and clinical studies, namely, that cell type-specific 
and context-dependent effects of miRNA-mediated immunomodulation are appropriately 
considered and distinguished from miRNA-mediated processes within cancer cells and 
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1. Introduction 
Currently, there are many promising clinical trials using mesenchymal stem cells (MSCs) in 
cell-based therapies of diseases ranging widely from graft-versus-host to joint and cartilage 
disorders (Salem and Thiemermann 2010; Tolar, Le Blanc et al.). Increasingly, however, 
there is a concern over the clinical use of MSCs because they are also known to home to 
tumors and once resident in the tumor microenvironment (TME) to support tumor growth 
and spread (Karnoub, Dash et al. 2007; Kidd, Spaeth et al. 2008; Coffelt, Marini et al. 2009; 
Klopp, Gupta et al. 2010; Klopp, Gupta et al. 2011). Conversely, other studies have reported 
that MSCs found in the TME diminish tumor growth, which has further generated some 
controversy in this field (reviewed in (Klopp, Gupta et al. 2010; Klopp, Gupta et al. 2011). 
Either way as a result of the MSC propensity for the TME, genetically modified MSCs that 
can act as “Trojan horses” and deliver anti-cancer therapeutics into the tumor stroma are 
being evaluated as a promising new specific cell-based therapy for cancer. 
Our group established that MSCs in the ovarian tumor microenvironment promoted tumor 
growth and favored angiogenesis (Zwezdaryk, Coffelt et al. 2007; Coffelt and Scandurro 
2008; Coffelt, Marini et al. 2009). We also developed new methodology to induce the 
conventional mixed pool of MSCs into two uniform but distinct phenotypes, MSC1 and 
MSC2 (Waterman, Tomchuck et al. 2010). We based their classification on several parallel 
observations reported within the monocyte literature. Like MSCs, heterogeneous bone 
marrow-derived monocytes respond to stress or “danger“ inflammatory signals and home 
to tissue injury. Monocyte polarization into pro-inflammatory macrophages (M1) occurs 
early on in tissue repair whereas, monocyte polarization into anti-inflammatory 
macrophages (M2) follows later to help in tissue injury resolution (Mantovani, Sozzani et al. 
2002; Martinez, Gordon et al. 2006). Although, this is a much simplified view of what occurs 
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1. Introduction 
Currently, there are many promising clinical trials using mesenchymal stem cells (MSCs) in 
cell-based therapies of diseases ranging widely from graft-versus-host to joint and cartilage 
disorders (Salem and Thiemermann 2010; Tolar, Le Blanc et al.). Increasingly, however, 
there is a concern over the clinical use of MSCs because they are also known to home to 
tumors and once resident in the tumor microenvironment (TME) to support tumor growth 
and spread (Karnoub, Dash et al. 2007; Kidd, Spaeth et al. 2008; Coffelt, Marini et al. 2009; 
Klopp, Gupta et al. 2010; Klopp, Gupta et al. 2011). Conversely, other studies have reported 
that MSCs found in the TME diminish tumor growth, which has further generated some 
controversy in this field (reviewed in (Klopp, Gupta et al. 2010; Klopp, Gupta et al. 2011). 
Either way as a result of the MSC propensity for the TME, genetically modified MSCs that 
can act as “Trojan horses” and deliver anti-cancer therapeutics into the tumor stroma are 
being evaluated as a promising new specific cell-based therapy for cancer. 
Our group established that MSCs in the ovarian tumor microenvironment promoted tumor 
growth and favored angiogenesis (Zwezdaryk, Coffelt et al. 2007; Coffelt and Scandurro 
2008; Coffelt, Marini et al. 2009). We also developed new methodology to induce the 
conventional mixed pool of MSCs into two uniform but distinct phenotypes, MSC1 and 
MSC2 (Waterman, Tomchuck et al. 2010). We based their classification on several parallel 
observations reported within the monocyte literature. Like MSCs, heterogeneous bone 
marrow-derived monocytes respond to stress or “danger“ inflammatory signals and home 
to tissue injury. Monocyte polarization into pro-inflammatory macrophages (M1) occurs 
early on in tissue repair whereas, monocyte polarization into anti-inflammatory 
macrophages (M2) follows later to help in tissue injury resolution (Mantovani, Sozzani et al. 
2002; Martinez, Gordon et al. 2006). Although, this is a much simplified view of what occurs 
in the complex process of wound healing and repair, it provides a convenient paradigm to 
begin to dissect critical components within this biological process (Mantovani, Sica et al. 
2007; Mosser and Edwards 2008; Mosser and Zhang 2008). Likewise, we believe that pro-
inflammatory MSC1 and anti-inflammatory MSC2 provide convenient tools with which to 
begin to interrogate the role of MSCs in the tumor microenvironment. 
In recent studies we found that MSC2 supported ovarian cancer growth and spread while 
surprisingly MSC1 had an opposite anti-tumor effect (Waterman 2011). We suggest that by 
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more closely studying the distinct tumor effects observed for these MSC phenotypes we 
may figure out why in the studies mentioned above MSCs favor tumor growth while in 
others MSCs attenuate tumors. In other words, induction into each discrete but uniform 
phenotype may help resolve some of the controversies surrounding the use of MSCs in cell 
based-therapies.  
It is known that MSCs resident in the TME contribute mitogens, extracellular matrix 
proteins, angiogenic, and inflammatory factors. These contributions are not trivial to tumor 
growth and spread and serve to recruit specific subsets of leukocytes and endothelia to the 
TME that profoundly influence tumors. MSC1 in the TME are expected to attenuate tumor 
growth by secretion of anti-tumor factors and recruitment of anti-tumor immunity. MSC2 
found in TME should promote tumor growth and spread by secretion of mitogens and 
supressing anti-tumor immune responses. We expect that by identifying the differences 
between these two phenotypes we will shed some light on the growing controversy on the 
role of MSCs in tumors, and provide a means to safely deliver MSCs in cell-based therapies. 
We have attempted to provide all relevant information that is available concerning these 
issues in the sections included in this chapter. 
2. Current understanding of MSCs function in the TME 
Mesenchymal stem cells (MSCs) are a group of heterogeneous multipotent cells that can be 
easily isolated from many tissues throughout the body. Though initially isolated from the 
bone marrow, they are now recognized to be mostly in perivascular regions throughout the 
body (Feng, Mantesso et al. ; Zwezdaryk, Coffelt et al. 2007; da Silva Meirelles, Caplan et al. 
2008). The discovery of these cells dates back to the 1960s (Friedenstein, Piatetzky et al. 
1966). In recent years, MSCs have been widely studied due to their ability to be expanded in 
culture and stored without losing their capacity to differentiate into many different cells of 
mesodermal origin such as osteoblasts, chondrocytes, and adipocytes (Bruder, Jaiswal et al. 
1997; Jaiswal, Haynesworth et al. 1997; Digirolamo, Stokes et al. 1999; Phinney, Kopen et al. 
1999; Pittenger, Mackay et al. 1999). MSCs can also transdifferentiate into cells of ectodermal 
(Kopen, Prockop et al. 1999) and endodermal (Sun, Chen et al. 2007; Ju, Teng et al. 2010) 
origins. As a result, many preclinical studies have focused on evaluating the capacity of 
MSCs to repair and replace injured or diseased tissues of all origins.  
Despite these research efforts however, there is growing evidence that the clinical benefit of 
MSCs in cell-based therapies is not the replacement of the injured tissue, but rather their 
efficiency in modulating aberrant host immune responses (Pittenger, Mackay et al. 1999; 
Prockop 2003; Prockop 2009). Following the remarkable clinical observations by the Le Blanc 
group who used the successful delivery of MSCs as a last resort to stave off graft-versus-
host disease in a young boy, the immune modulating capability of MSCs is now more 
widely recognized (Le Blanc, Rasmusson et al. 2004). Further evidence indicating that 
immunomodulation is the primary activity of MSCs can be gleaned from the observation in 
many studies that although infused MSCs home to sites of injury and provide treatment 
benefit in widely ranging diseases, they can rarely be detected within the repaired tissue. 
Subsequent research efforts are beginning to identify the myriad ways that MSCs affect host 
immune responses. These appear to be mediated both by direct cell-to-cell contact and 
indirectly by the secretion of inflammatory factors (further discussed below) (Aggarwal and 
Pittenger 2005; Abdi, Fiorina et al. 2008; Uccelli, Moretta et al. 2008; Nemeth, Mayer et al. 
2009; Bunnell, Betancourt et al. 2010; Singer and Caplan 2011). 
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Thus far, the immune modulating effects of MSCs include inhibition of the proliferation of 
activated CD8+ and CD4+ T lymphocytes and natural killer (NK) cells, recruitment and 
support of regulatory T cells, suppression of Th17 lymphocytes and immunoglobulin 
production by plasma cells, inhibition of maturation of dendritic cells (DCs), as well as 
attenuation of mast cells (Aggarwal and Pittenger 2005; Abdi, Fiorina et al. 2008; Uccelli, 
Moretta et al. 2008; Nemeth, Mayer et al. 2009; Nemeth, Keane-Myers et al. 2010). MSCs 
secrete various inflammatory factors including TNF-α-induced protein 6 (TNAIP6 or TSG-
6), prostaglandin E2 (PGE2), human leukocyte antigen G5 (HLA-G5), hepatocyte growth 
factor (HGF), inducible nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO), 
transforming growth factor β (TGF-β), leukemia-inhibitory factor (LIF), and interleukin (IL)-
10 (Krampera, Pasini et al. 2006; Gur-Wahnon, Borovsky et al. 2009; Bunnell, Betancourt et 
al. 2010; Singer and Caplan 2011).  
MSCs express low levels of human leukocyte antigen (HLA) major histocompatibility 
complex (MHC) class I, do not express co-stimulatory molecules (B7-1/CD80 and -2/CD86, 
CD40, or CD40L), and must be induced to express MHC class II and Fas ligand that likely 
allows the safe delivery of these cells in non-self (allogeneic) hosts (Aggarwal and Pittenger 
2005; Bunnell, Betancourt et al. 2010). Indeed, MSCs stand alone among the other types of 
stem cells such as embryonic or induced pluripotent (iPS) cells being considered in 
regenerative medicine for their safe, non-immune provoking, allogeneic host delivery 
capability. This has prompted many new and established businesses to amass expanded 
stockpiles of MSCs ready for use in the treatment of many human diseases including cancer 
(Salem and Thiemermann 2010).  
Given the ability to deliver expanded, stockpiled clinical grade MSCs, knowing that they 
specifically home to the TME, and that they secrete mitogens, extracellular matrix proteins, 
angiogenic and inflammatory factors, it is not hard to conceive that MSCs might on the one 
hand influence tumors, and on the other hand, be used as vehicles to deliver anti-cancer 
agents. At issue is that despite intense study over the past few years, the effect of MSCs on 
tumors or their function in the TME is far from clear. Some studies report that MSCs 
promote tumor growth and spread while others report that MSCs attenuate tumor growth 
(Table 1). The distinct effects by MSCs on tumors has recently been attributed to differences 
in the experimental cancer model, the heterogeneity of MSC preparations, the dose or 
timing of the delivered MSCs, the animal host, or some as yet unknown factor (Klopp, 
Gupta et al. 2010; Klopp, Gupta et al. 2011). Also at play may be that the primary 
immunomodulatory function of MSCs is not realized in the context of most of these studies, 
which rely on immune compromised animal models. It is clear however, that with all of 
their unique properties MSCs make attractive candidates in cell therapies of cancer. In fact, a 
few promising pre-clinical reports have shown the delivery by MSCs of several anti-cancer 
therapeutics such as interferon (IFN)-, cytosine deaminase, tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), and oncolytic viruses to tumors (Pittenger, Mackay et 
al. 1999; Studeny, Marini et al. 2002; Prockop 2003; Studeny, Marini et al. 2004; Nakamizo, 
Marini et al. 2005; Ren, Li et al. 2007; Kim, Lim et al. 2008; Ren, Kumar et al. 2008; Ren, 
Kumar et al. 2008; Mader, Maeyama et al. 2009; Prockop 2009). Though it would seem from 
these reports that any pro-tumor MSC effect is outweighed by the anti-cancer strategy, it is 
important to fully understand all of the contributions that MSCs have in the TME of 
immune competent tumors to safely use them in cell-based therapies of human disease. 
It is appreciated that MSCs contribute in a number of ways within the TME. As mentioned 
above, it has long been documented that MSCs elaborate a number of factors directly, after 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
256 
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stimulation, or after contact with adjacent cells. These include mitogens, extracellular matrix 
(ECM) proteins, angiogenic factors, and inflammatory factors, all of which could potentially 
influence tumor growth and spread. These are summarized below along with some of the 
pro-tumorigenic and anti-tumorigenic evidence for MSCs. 
2.1 Pro-tumorigenic evidence 
There are a growing number of studies implicating a role for MSCs derived from various 
tissues in tumor growth and spread. Upon review of these studies and the anti-tumorigenic  
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Abbreviations: Hu- human, Mu- murine, ASC- adipose-derived MSCs, BMSCs- bone marrow-derived 
MSCs, Immune Status of animal model- - immune compromised +- immune competent, Br- breast, Lu- 
lung, Ov- ovarian, Pr- prostate, and Co- colon cancer cell lines. 
Table 1. Pro-tumorigenic evidence for MSCs in the TME. 
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ones below it is tempting to speculate that cancers of endo- and ectodermal tissue origin are 
likely supported by MSCs whereas cancers of mesodermal tissue origin are likely inhibited 
by MSCs. However, as stated above, the fact that most of the studies are for technical 
reasons conducted in immune compromised animals greatly limits these conclusions and 
our understanding of the final outcome of MSCs in cancer. Evidence that MSCs promote 
tumor growth and their stated mechanism(s) is given by the studies summarized in Table 1. 
MSCs supported growth of breast, brain, lung, ovary, prostate, and colon, as well as 
lymphoma and melanoma (Kucerova, Matuskova et al. ; Shinagawa, Kitadai et al. ; Djouad, 
Plence et al. 2003; Djouad, Fritz et al. 2005; Zhu, Xu et al. 2006; Karnoub, Dash et al. 2007; 
Galie, Konstantinidou et al. 2008; Yu, Ren et al. 2008; Coffelt, Marini et al. 2009; Muehlberg, 
Song et al. 2009; Lin, Yang et al. 2010). The MSCs delivered at high ratios to the experimental 
tumor cell lines most commonly promoted tumor growth and metastasis. Most studies 
reported an increase in angiogenesis as a result of increased VEGF production by the MSCs 
in the TME. Some studies reported attenuation of tumor apoptosis. Chemokines such as 
Chemokine Ligand-5 (CCL5 or RANTES) and stromal-derived factor-1 (SDF-1)-C-X-C 
chemokine receptor-4 (CXCR4) axis effects by the MSCs were associated with elevated 
tumor migration and spread. 
The secretion of pro-angiogenic molecules by the MSCs likely assist the tumors in capturing 
essential nutrients—perhaps also explaining the anti-apoptosis effects-- and in gaining the 
ability to spread to remote tissues—explaining the role of the chemokines. MSCs are known 
to secrete pro-angiogenic factors such as VEGF and possibly erythropoietin (Epo) thus this 
chief effect is not unexpected (Zwezdaryk, Coffelt et al. 2007; Singer and Caplan 2011). More 
studies are needed that focus on whether MSC conditioned medium is sufficient to elicit 
these responses and to test whether cell-to-cell contact by the MSCs, leukocytes, and/or 
cancer cells is required for the promotion of tumor growth and spread by MSCs. 
2.2 Anti-tumorigenic evidence 
While the pro-tumorigenic activity of MSCs is largely characterized by the secretion of pro-
angiogenic molecules, the anti-tumorigenic activity of these cells is exemplified by 
modulation of members of the Wnt-signaling family (Table 2). MSCs inhibited the growth of 
tumors in several different models (Maestroni, Hertens et al. 1999; Ohlsson, Varas et al. 
2003; Khakoo, Pati et al. 2006; Lu, Yuan et al. 2008; Qiao, Xu et al. 2008; Qiao, Xu et al. 2008; 
Cousin, Ravet et al. 2009; Otsu, Das et al. 2009; Zhu, Sun et al. 2009; Dasari, Kaur et al. ; 
Dasari, Velpula et al. ; Secchiero, Zorzet et al.). For instance, in studies that used fetal tissue 
derived MSCs, their secretion of the Wnt-signalling inhibitor Dickkopf-related protein-1 
(DKK-1) inhibited breast and liver cancer cell lines (Qiao, Xu et al. 2008; Qiao, Xu et al. 2008). 
When the researchers used a neutralizing antibody or small interfering RNA to block DKK-1 
within MSCs, the inhibitory tumor effects were attenuated. In the DKK-1 associated 
inhibition of primary leukemia by adipose-derived MSCs (ASCs), the stem cell transcription 
factor NANOG was also implicated (Zhu, Sun et al. 2009). 
Interestingly, in an immune competent model, MSCs typically believed to be immune 
suppressive, recruited leukocytes and appeared to favor pro-inflammatory 
monocyte/granulocyte infiltration, which promoted rat colon carcinoma growth (Ohlsson, 
Varas et al. 2003). In the other immune competent model studies, one reported lack of 
immune suppression or attenuation of T-cell activation by the admixed MSCs but did not 
report the changes in any other pro-inflammatory leukocytes, and the other study was 
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focused more on the effect on angiogenesis by the MSCs rather than on inflammatory cells 
(Lu, Yuan et al. 2008; Otsu, Das et al. 2009).  
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telomerase vectors, BpMSCs-c-myc-bone marrow-derived MSC progenitor cells immortalized with c-
myc, Immune Status of animal model- - immune compromised +- immune competent, Br- breast, Co-
colon, Li- liver, Lu- lung, NH- Non-Hodgkin’s lymphoma, and Pan- pancreas cancer cell lines. DKK-1-
dickkopf-related protein 1, GM-CSF-granulocyte/monocyte-colony stimulating factor, PTEN- 
phosphatase and tensin homolog 10, PI3K-phosphoinositol-3-kinase. 
Table 2. Anti-tumorigenic evidence for MSCs in the TME. 
 




Greater than a 100 clinical trials are underway or completed that investigate MSC-based 
therapy of human disease, and thus far the reports of adverse effects related to the therapy 
have been unremarkable (Salem and Thiemermann 2010; Tolar, Le Blanc et al. 2010; Singer 
and Caplan 2011). Therapy-related tumorigenicity has not been found, yet the preclinical 
studies presented above argue that we should carefully study this MSC potential. The 
question is why did MSCs promote cancer growth and spread in some studies, while in 
others MSCs diminished growth and spread? To begin to address this question there are a 
few important issues that have to be considered. First is the fact that surprisingly the chief 
effect of MSC-based therapies on disease is the modulation of the inflammatory host 
responses and not the replacement of injured tissue. Secondly, this observed therapeutic 
benefit is carried out by a few lingering MSCs that survive the relatively quick clearance of 
the cell bolus from the circulation—given that very small numbers of MSCs are ever 
detected at the sites of injury (Prockop 2009). Thirdly, it is known that both the adaptive and 
innate immune response arms profoundly influence tumor growth and spread by a complex 
interplay between inflammation and immunosurveillance (Frese and Tuveson 2007; Cheng, 
Ramesh et al. 2010). To resolve some of this controversy and to better understand the 
complex nature of the MSC-tumor interaction these issues need to be taken into account in 
future studies.  
It is difficult to accurately model tumorigenesis with human tumor xenograft models in 
immunodeficient mice to finally resolve the effect that MSC-based therapy will have on 
cancer (Frese and Tuveson 2007; Cheng, Ramesh et al. 2010). Moreover, the number of MSCs 
interacting with the tumor must reflect more closely what is observed by the clinical 
experience. To more precisely model tumorigenicity attempts have been made at 
humanizing the murine immune system by eliminating the endogenous immune system 
followed by engraftment of human bone marrow or immune cells (Frese and Tuveson 2007). 
The problem with this approach has been that species-specific differences in both arms of 
the immune system confound interpretations. Immunocompetent autochthonous mouse 
models of human cancer provide a valuable tool that better addresses some of these issues. 
Though far from perfect, these models more closely parallel human carcinogenesis by 
allowing intrinsic tumor formation with immune surveillance and offer a better alternative 
system to study MSC-tumor interactions. 
Apart from the limitations of current cancer models there are many other reasons that have 
been suggested to explain the divergent effects of MSCs in tumors (Klopp, Gupta et al. 2010; 
Klopp, Gupta et al. 2011). These include the heterogeneity of cells present in current MSC 
preparation protocols. Convention dictates that more homogeneous preparations of MSCs 
will also yield more consistent therapeutic outcomes with these cells. However, provided 
that we can overcome this hurdle and deliver more uniform cells, we may never get away 
from the variability that comes from the human donors. The age, gender, weight, and 
disease status of the donor may always affect efficacy outcomes and needs to be investigated 
more closely. Differences in the tissue source of the MSCs, whether bone marrow, adipose, 
umbilical cord, or other, also appear to affect a number of MSC functions (Sakaguchi, Sekiya 
et al. 2005; Hass, Kasper et al. 2011). Further complicating matters in all MSC-based therapy 
is the cell number and dosing frequency used to achieve a particular therapeutic efficacy. 
Cancer is a complex disease and to fully understand the contribution of MSCs, which are 
also intricate, more careful consideration of all these issues needs to be given. Despite these 
hurdles, MSCs remain an intriguing vehicle that can specifically target tumors. 
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3. Contributions by MSCs to tumors 
In spite of all the limitations described, there is agreement about certain factors that MSCs 
elaborate that are important to tumorigenesis. It has long been know that MSCs synthesize a 
broad spectrum of growth factors, extracellular matrix proteins (ECM), cytokines, 
chemokines, and angiogenic molecules that have effects on cells in their vicinity. The effects 
of the bioactive molecules that MSCs secrete can be either direct, indirect, or even both: 
direct by causing intracellular signaling or indirect by causing another cell in the vicinity to 
secrete a bioactive factor. The indirect activity is typically termed “trophic”, based on the 
original use of this word in neurobiology to distinguish neurotransmitters from other 
bioactive molecules released from nerve terminals (Caplan and Dennis 2006; Meirelles Lda, 
Fontes et al. 2009; Singer and Caplan 2011).  
Typically, the bioactive molecules that are released from MSCs are reported to be relatively 
constant between different donors, regardless of age or health status of the donor. However, 
there can be some donor-specific differences in the levels of the secreted molecules-- that can 
be as high as a ten-fold difference. Moreover, the specific bioactive agents secreted by 
individual MSCs are also controlled by their functional status, level of differentiation, and 
the influence of their local microenvironments (Phinney, Kopen et al. 1999; Djouad, Fritz et 
al. 2005; Caplan and Dennis 2006; Krampera, Pasini et al. 2006; Tomchuck, Zwezdaryk et al. 
2008; Nemeth, Mayer et al. 2009; Prasanna, Gopalakrishnan et al. ; Singer and Caplan 2011). 
It is expected that MSCs, as multipotent stem cells, will elaborate different levels and arrays 
of bioactive molecules as they differentiate into defined lineages. Additionally, the pattern 
and quantity of these secreted factors is well known to feed back on the MSC itself and 
change both its functional status and physiology. 
These MSC paracrine and autocrine factors can have profound effects on local cellular 
dynamics. For instance, the marrow stroma derived from MSCs not only provides the 
matrix that supports cell anchorage, but also helps to maintain nearby endothelia and 
hematopoietic cells. In stroma poor niches within the marrow the hematopoetic stem cells 
(HSCs) will begin distinct programs of differentiation. The interdependence of MSCs and 
HSCs in the marrow is governed by the secretion of bioactive molecules such as the stromal-
derived factor-1 (SDF1) to C-X-C chemokine receptor-4 (CXCR4) axis that helps support full 
hematopoietic lineage progression (Lopez Ponte, Marais et al. 2007). 
3.1 Soluble, Extracellular Matrix (ECM), and angiogenic factors 
The secretion of these broad range bioactive molecules is now believed to be the main 
mechanism by which MSCs achieve their therapeutic effect and that likely most affect the 
tumor microenvironment. These are typically divided by the processes they affect, such as 
mitogenic, angiogenic, apoptotic, or inflammatory/immune modulating (Table 3). We have 
added exosomes as a new category to these bioactive factors. Exosomes appear to be a 
previously unrecognized secretory vesicle that can affect neighboring cells. We include 
mitogens, Extracellular Matrix (ECM) proteins, and angiogens, exosomes and 
inflammatory/immune modulating bioactive factors as molecules potentially contributed 
by MSCs but caution that this is not an exhaustive list of all MSC products. Some of the 
molecules overlap in function, some of the molecules play greater roles in one species versus 
another (e.g.-mouse vs. human), and some of the molecules are released only following 
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specific stimulation or activation (Tomchuck, Zwezdaryk et al. 2008; Klopp, Gupta et al. 
2010; Waterman, Tomchuck et al. 2010; Klopp, Gupta et al. 2011). These have been recently 
reviewed (da Silva Meirelles, Caplan et al. 2008; Klopp, Gupta et al. 2010; Klopp, Gupta et al. 
2011; Singer and Caplan 2011). 
 
Molecule Types Molecules Study
Mitogens 
bFGF, G-CSF, GM-CSF, HGF, 
IGF-I, IL6, Leptin, LIF, SCF, 
SDF-1, stanniocalcin-1, TGF
VEGF 
(Zwezdaryk, Coffelt et al. 2007; Block, 
Ohkouchi et al. 2009; Meirelles Lda, Fontes 
et al. 2009[Tomchuck, 2008 #621; Klopp, 
Gupta et al. 2010; Waterman, Tomchuck et 





(Zuckerman and Wicha 1983; Hashimoto, 
Kariya et al. 2006; Zwezdaryk, Coffelt et 
al. 2007; Tomchuck, Zwezdaryk et al. 
2008; Meirelles Lda, Fontes et al. 2009; 
Waterman, Tomchuck et al. 2010) 
Angiogens 
Angiopoetin-1, bFGF, IL6, 
IL8, Leptin, stanniocalcin-1, 
VEGF 
(Zwezdaryk, Coffelt et al. 2007; 
Tomchuck, Zwezdaryk et al. 2008; 
Meirelles Lda, Fontes et al. 2009; 
Waterman, Tomchuck et al. 2010) 
Exosomes Pro-inflammatory molecules, miRNAs
(Anand 2010; Chen, Lai et al. 2010; Lai, 




galectin-3, galectin-1, HGF, 
HLA-G, IDO, IL1, IL1RA, 
IL6, IL8, IL12, iNOS, IP-10, 




(Zwezdaryk, Coffelt et al. 2007; Tomchuck, 
Zwezdaryk et al. 2008; Block, Ohkouchi et 
al. 2009; Meirelles Lda, Fontes et al. 2009; 
Bartosh, Ylostalo et al. 2010; Bunnell, 
Betancourt et al. 2010; Klopp, Gupta et al. 
2010; Waterman, Tomchuck et al. 2010; 
Danchuk, Ylostalo et al. 2011; Klopp, 
Gupta et al. 2011) 
Abbreviations: bFGF- basic fibroblast growth factor, CCL- C-C motif chemokine ligand, CXC- C-X-C-
motif chemokine, CXCL-CXC-ligand, G-CSF-granulocyte-colony stimulating factor, GM-CSF-
granulocyte-macrophage-colony stimulating factor, HGF-hepatocyte growth factor (scatter factor), 
HLA-G- human leukocyte antigen-G, IDO- indoleamine 2,3-dioxygenase, IGF-I-insulin-like growth 
factor-1, IL-interleukin, IL-1RA- interleukin-receptor 1 antagonist, iNOS-inducible nitric oxide synthase, 
IP-10-interferon-gamma-inducible protein 10 (CXCL10), LIF-leukemia inhibitory factor, MCP-1-
monocyte chemoatractant protein-1 (CCL2), MIP1-macrophage inflammatory protein-1 (CCL3), PGE2- 
prostaglandin-E2, PlGF-placental-derived growth factor, RANTES- regulated upon activation normal T 
cell expressed and secreted (CCL5), SCF-stem cell factor, SDF-1-stromal-derived factor-1, 
TGFtransforming growth factor TSG-6- TNF-alpha stimulated gene/protein 6, VEGF-vascular-
derived endothelial growth factor (vascular permeability factor, VPF). 
Table 3. Molecules Contributed by MSCs. 
3.2 Exosomes 
A recently described form of intercellular communication that may also be important in 
MSC-tumor exchanges is exosomes. These are endosome-derived vesicles of about 40–100 
nm that are formed by the involution of endosome membranes resulting in the formation of 
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multi-vesicular bodies (MVBs). Following certain physiological conditions, the MVBs fuse 
with the plasma membrane and release the exosomes into the circulation or tissue 
microenvironment. Exosomes have a “saucer-shaped” morphology as determined from 
electron microscopy analyses. Various methods have been developed to enrich for exosomes 
derived from a number of cell types including antigen-presenting cells (APCs), monocytes, 
T-lymphocytes, reticulocytes, mast cells, platelets, fibroblasts, tumor cells, and MSCs 
(Anand 2010; Lai, Arslan et al. 2010; Tan, De La Pena et al. 2010).  
Investigators studying the cardioprotective effect of human embryonic stem cell-derived 
MSC-conditioned medium (CM) on myocardial ischemia/reperfusion injury reasoned based 
on proteomic analyses that exosomes were responsible for the beneficial effect (Sze, de 
Kleijn et al. 2007; Lai, Arslan et al. 2010). Their unbiased proteomic profiling of proteins 
secreted by MSCs revealed an abundance of membrane and cytosolic proteins. This 
suggested to them that the trophic effects of MSCs were not mediated by soluble growth 
factors and cytokines alone. Sze et al. proceeded to enrich for particles by size-exclusion 
fractionation on HPLC. Based on the size and the composition of the particles they figured 
exosomes were present in the condition medium of MSCs. Moreover they demonstrated that 
the enriched fraction of exosomes reduced infarct size in a mouse model of myocardial 
ischemia/reperfusion injury.  
The particles could be visualized by electron microscopy and were shown to be 
phospholipid vesicles consisting of cholesterol, sphingomyelin, and phosphatidylcholine. 
Moreover, they were composed of known exosome-associated proteins-- CD81, CD9, and 
Alix. Exosomes are known to have a specific protein composition, including CD9, CD81, 
Alix, TSP-1, SOD-1, and pyruvate kinase. CD9 and CD81 are tetrapannin membrane 
proteins that are also localized in the membrane of exosomes. Consistent with the presence 
of exosomes in the CM of the MSCs this study further demonstrated that CD9 in the CM 
was a membrane-bound protein while SOD-1 was localized within a lipid vesicle. They 
eliminated the possibility of immune cells or platelets as sources of exosomes with an ex vivo 
mouse model of myocardial ischemia/reperfusion injury.  
Similarly in human ESC-derived MSC conditioned medium other investigators found 
exosomes that contained small RNAs (less than 300 nt) encapsulated in cholesterol-rich 
phospholipid vesicles. The small RNAs were identified by a number of biochemical and 
genetic criteria to be microRNAs (miRNAs). Of interest the Let-7 family of miRNAs figured 
prominently in these studies (Chen, Lai et al. 2010; Koh, Sheng et al. 2010). It is becoming 
increasingly clear that miRNAs are potent global gene regulators of many diverse cell 
functions including adaptation to mitogens, low oxygen (hypoxia), and inflammation. 
Perhaps this might explain why exosomes are potent immune modulators (Anand 2010). 
Apart from the molecules present inside the lumen of exosomes, it has been suggested that 
certain exosomal membrane molecules can interact with their surface receptors on the target 
cells thereby inducing an immunomodulatory response or activating the immune system. 
Consistent with this notion, exosome release is enhanced following pathologies where 
immune activation is required. It has been suggested that immunogenic molecules on the 
exosomal membrane can activate leukocytes. In support of this idea is the fact that exosomes 
are analogous to inverted endosomes and thus display inflammatory intracellular factors 
present normally within plasma membrane. Taking advantage of this inflammatory nature 
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of exosomes, clinicians are developing cancer vaccines based on loading dendritic cells 
(DCs) with tumor antigens, expanding the DCs ex vivo, and subsequently isolating their 
enriched exosomes (Tan, De La Pena et al. 2010). The tumor antigen loaded exosomes are 
then reintroduced into patients to elicit tumor specific anti-tumor immunity. 
Lastly, highlighting the interactions of tumors and MSCs, exosomes derived from tumors 
appear to drive adipose-derived MSC differentiation toward tumor associated myofibroblasts 
that can then contribute to tumor growth and spread (Webber, Steadman et al. 2010; Cho, Park 
et al. 2011; Cho, Park et al. 2011). Interestingly and perhaps providing a mechanism for the 
Wnt-signaling mediated anti-tumor effect of MSCs mentioned above, -catenin was found to 
be contained within exosomes (Chairoungdua, Smith et al. 2010). Furthermore, exosomal 
release of -catenin antagonized Wnt-signaling in the recipient cell. These studies emphasize 
the need for more intense investigations that clarify the role of both tumor- and MSC-derived 
exosomes in tumorigenesis. Besides identifying new components of tumor biology such 
studies may identify new therapeutic interventional agents. 
3.3 Immune modulation  
Apart from the ability of MSCs to contribute mitogens, ECM proteins, pro-angiogenic 
molecules, inflammatory agents, and exosomes to the TME, their most significant contribution 
may be modulating specific subsets of immune cells (Table 4)(Fibbe, Nauta et al. 2007; Nauta 
and Fibbe 2007; Bunnell, Betancourt et al. 2010; Roddy, Oh et al. 2011; Singer and Caplan 2011; 
Weiss, Bertoncello et al. 2011). The specific mechanism for this MSC role is not completely 
understood and may involve direct immune cell-MSC cell contact or indirect effects such as by 
the contribution of the factors just described or both. However, knowing the importance of 
immune and inflammatory cells in cancer growth and metastasis, the manner that MSCs in the 
TME might influence this process deserves closer attention and study. 
Though initially described as an ex vivo phenomena requiring the stimulation of the MSCs to 
lead to suppression of T-lymphocyte activation or proliferation, many clinical trials have 
asserted immune modulation to be a primary effect of MSC-based therapies (Di Nicola, Carlo-
Stella et al. 2002; Krampera, Glennie et al. 2003; Le Blanc, Rasmusson et al. 2004; Aggarwal and 
Pittenger 2005). In addition, these early observations prompted a number of studies to explore 
the distinct immune modulatory effects of MSCs derived from a variety of sources and species. 
Of note, although MSCs influence many immune cells, part of what makes them attractive 
candidates in cell-based therapies is their muted host immune responses even when delivered 
into a non-self (allogeneic) host. This is partly due to the fact that MSCs express low levels of 
human leukocyte antigen (HLA) major histocompatibility complex (MHC) class I, do not 
express co-stimulatory molecules (B7-1/CD80 and B7-2/CD86, CD40, or CD40L), and express 
MHC class II and Fas ligand only after specific stimulation.  
MSCs are now known to inhibit dendritic cell maturation, B and T cell proliferation and 
differentiation, attenuate natural killer cell and mast cell activity, as well as support the 
production of suppressive T regulatory cells (Tregs) while attenuating pro-inflammatory 
Th17 cells (Table 4) (Najar, Raicevic et al. ; Di Nicola, Carlo-Stella et al. 2002; Krampera, 
Glennie et al. 2003; Aggarwal and Pittenger 2005; Beyth, Borovsky et al. 2005; Ramasamy, 
Fazekasova et al. 2007; Ren, Zhang et al. 2008; Uccelli, Moretta et al. 2008; Gur-Wahnon, 
Borovsky et al. 2009; Meirelles Lda, Fontes et al. 2009; Nemeth, Mayer et al. 2009; Bunnell, 
Betancourt et al. 2010; Salem and Thiemermann 2010; Tolar, Le Blanc et al. 2010; Brown, 
Nemeth et al. 2011; Singer and Caplan 2011).  
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Cells MSC effects 
Innate 
Dendritic Cells (APC) 
Inhibition of maturation (CD80/86 expression) by 
STAT3 and IL10 (Beyth, Borovsky et al. 2005; Gur-
Wahnon, Borovsky et al. 2009; Mezey, Mayer et al. 2009; 
Nemeth, Leelahavanichkul et al. 2009) 
Monocyte/Macrophages 
(APC) 
PGE2 mediated increased IL10 secretion and 
attenuation of maturation (Beyth, Borovsky et al. 2005; 
Gur-Wahnon, Borovsky et al. 2009; Mezey, Mayer et al. 
2009; Nemeth, Leelahavanichkul et al. 2009) 
Natural Killer Cells Inhibition of proliferation and cytolytic activity (Giuliani, Oudrhiri et al. 2011) 
Mast Cells COX-2 mediated suppression (Brown, Nemeth et al. 2011) 
Adaptive 
Th1 
Inhibition of proliferation/activation (class switching) by 
HLA-G5, HGF, iNOS, COX2, IDO, PGE2, TGF and 
indirectly through support of immature APCs reviewed 
in (Singer and Caplan 2011) 
Th2 
Inhibition of proliferation/activation (class switching) by 
HLA-G5, HGF, iNOS, COX2, IDO, PGE2, TGF and 
indirectly through support of immature APCs reviewed 
in (Singer and Caplan 2011) 
Tregs Recruitent and support (class switching) IL10, TGFLIF 
Th17 
Inhibition of proliferation/activation (class switching) 
by COX-2 and PGE2 (Duffy, Pindjakova et al. 2011; 
Duffy, Ritter et al. 2011) 
B lymphocyte Suppression of terminal differentiation to plasma cell (Asari, Itakura et al. 2009) 
Abbreviations: COX-2- cyclooxygenase-2, HGF-hepatocyte growth factor (scatter factor), HLA-G- 
human leukocyte antigen-G, IDO- indoleamine 2,3-dioxygenase, iNOS-inducible nitric oxide synthase, 
IL10-interleukin-10, LIF-leukemia inhibitory factor, PGE2- prostaglandin-E2, STAT3- signal transducer 
and activator of transcription-3, TGFtransforming growth factor 
Table 4. Immune cells modulated by MSCs. 
3.3.1 MSCs and myelomonocytic cells 
Although the details of the interactions of MSCs with T lymphocytes, B lymphocytes, natural 
killer cells, and dendritic cells have been investigated in some detail, the effects of MSCs on 
cells of myelomonocytic lineages (MMCs) observed early on by the Rachmilewitz group 
remained under investigated until recently (Figure 1. Beyth, Borovsky et al. 2005). The 
growing clinical evidence for MSCs as major regulators of immune and inflammatory 
processes and the central role played by MMCs (including monocytes and granulocytes) 
within them has sparked new interest in studies on the interplay between MSCs and MMCs. 
Kim and Hematti (2009) reported that human macrophages generated in vitro after co-culture 
with MSCs assume an immunophenotype defined as IL-10–high, IL-12–low, IL-6–high, and  
 




Abbreviations: COX-2- cyclooxygenase-2, IL-interleukin, IL-1RA- interleukin-receptor 1 antagonist, 
iNOS-inducible nitric oxide synthase, MCP-1-monocyte chemoatractant protein-1 (CCL2), PGE2- 
prostaglandin-E2, STAT3- signal transducer and activator of transcription-3, TSG-6- TNF-alpha 
stimulated gene/protein. 
Fig. 1. The Consequences of the Interaction Between MSCs and Myelomonocytic Cells. 
Though still in their infancy the studies that have begun to identify the effect of the 
interactions between MSCs and MMCs whether cell-cell contact dependent or not have so 
far described those included in the figure. Please refer to the text for details.  
TNF-a–low secreting cells (Kim and Hematti 2009). They proposed that these MSC-educated 
monocytes represent a unique and novel type of alternatively activated macrophage with a 
potentially significant role in tissue repair. Initially, Beyth et al. reported that human MSCs 
affect monocytes or dendritic antigen-presenting cell (APC) maturation in a contact-
dependent manner (Beyth, Borovsky et al. 2005). Later, it was reported that the MSCs co-
cultured with the APCs induced the expression of the anti-inflammatory IL10 and that 
activation of the signal transducer and activator of transcription 3 (STAT3) within APCs is 
linked to abnormal APC differentiation and function by a new contact-dependent 
mechanism, that plays a critical role in mediating the immunomodulatory effects of MSCs 
(Gur-Wahnon, Borovsky et al. 2007; Gur-Wahnon, Borovsky et al. 2009). In order to 
understand this process better, they further extended their studies to tumor cells since 
tumors secrete a variety of bioactive factors that activate STAT3 within infiltrating APCs. 
Their studies demonstrated that in at least certain cellular microenvironments, cell-to-cell 
dependent interactions represent a novel way to activate STAT3 signaling different from the 
activation of STAT3 seen with soluble bioactive factors. As such this observation suggests an 
uncoupling of APC activation events and that may consequently independently regulate 
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immunity and tolerance. In agreement with these studies, the Mezey group identified other 
pathways involved in MSC-murine macrophage interactions (Nemeth, Leelahavanichkul et 
al. 2009). They also showed that LPS-stimulated macrophages produced more IL-10 when 
cultured with MSCs, but this effect was eliminated if the MSCs lacked the genes encoding 
TLR4, myeloid differentiation primary response gene-88 (MyD88), TNF-receptor-1 or 
cyclooxygenase-2 (COX-2). Their observations demonstrated that MSCs reprogram 
macrophages by releasing PGE2 that then acts on the macrophages through the 
prostaglandin EP2 and EP4 receptors. A unique population of MSCs isolated from human 
gingiva (GMSCs) with similar stem cell-like properties, immunosuppressive, and anti-
inflammatory functions as bone marrow-derived MSCs were also studied in this context 
with similar effects (Zhang, Su et al. 2010).  
When co-cultured with GMSCs, macrophages acquired an anti-inflammatory M2 phenotype 
similarly characterized by an increased expression of IL10 and IL6, mannose receptor (MR; 
CD206), a suppressed production of TNF, and also decreased the ability to induce Th-17 
cell expansion. Interesting to the discussion on tumors and their microenvironments, they 
demonstrated that systemically infused GMSCs could home to wounds-- specifically to sites 
where host macrophages were found-- promoted M2 polarization of the co-localized 
monocytes, significantly enhanced wound repair, and thus presumably could promote 
tumor growth by similar mechanisms. In addition, they noted that GMSC treatment 
suppressed local inflammation by reducing the infiltration of inflammatory cells and the 
production of IL6 and TNF, and by increased expression of IL10. Another complementary 
study used muine macrophages stimulated with LPS and co-cultured with MSCs and found 
the suppression of TNF, IL6, IL12p70 and interferon but increased levels of secreted IL10 
and IL12p40. They noted that the murine MSC effect could be reproduced with MSC 
conditioned medium suggesting that bioactive factors constitutively released by the murine 
MSCs may be sufficient for the monocyte effect in this animal species (Maggini, Mirkin et al. 
2010). They also found in cell-based therapy of mouse models that MSCs supported 
macrophages that showed a low expression of CD86 and MHC class II, and with a high 
ability to secrete IL10 and IL12p40, but not IL12 p70. They suggested in agreement with the 
other studies, that MSCs switch monocytes into a regulatory profile characterized by 
enhanced IL10 secretion, reduced inflammatory cytokine elaboration and enhanced 
phagocytic activity. Apart from elevated IL10 and related signaling mechanisms, other new 
players in the effects observed for MSCs on monocytes were recently advanced (Block, 
Ohkouchi et al. 2008; Block, Ohkouchi et al. 2009; Danchuk, Ylostalo et al. 2011; Prockop and 
Youn Oh 2011)]. Anti-inflammatory effects supported by MSC-monocyte interactions were 
suggested to also be partly mediated by elevated IL1 receptor antagonist (IL1RA) and by a 
negative feedback loop in which TNF and other pro-inflammatory cytokines from resident 
macrophages activate MSCs to secrete the anti-inflammatory protein TNF stimulated 
gene/protein 6 (TSG-6). These reports demonstrate that MSC derived TSG-6 acts to repress 
NF-κB signaling in the resident macrophages causing attenuation of pro-inflammatory 
cytokine synthesis. The investigators of these studies also proposed that MSC secreted PGE2 
promotes monocytes toward an IL10 secreting phenotype as well as, that anti-inflammatory 
effects may also be mediated by stanniocalcin-1.  
Finally, in another recent report using pre-clinical murine models it was shown that MCP1 
secreted by activated MSCs contributes to the bone marrow egress, trafficking, and 
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recruitment of monocytes towards remote sites (Shi, Jia et al. 2011). This elegant study 
demonstrated the intimate and complex cooperation that exists between MSCs and 
myelomonocytic cells that occurs not only in peripheral tissues or tumors but also in their 
originating bone marrow niche. It is widely recognized that tumor infiltrating cells can 
include macrophages, myeloid-derived suppressor cells (MDSCs), MSCs, and TIE2-
expressing monocytes that are all mostly derived from the bone marrow. MDSCs represent 
a heterogeneous population of cells of myeloid origin that are expanded and activated in 
response to growth factors and cytokines released by tumors much like MSCs. The details of 
the effects of MDSCs on tumors are better understood. It is known that once MDSCs are 
activated, they accumulate in lymphoid organs and tumors where they exert specific T cell 
mediated immune suppression. However, not much is known about whether MDSCs and 
MSCs cooperate at tumor sites or the nature of that interaction. It is tempting to suggest that 
MSC-myelomononocytic cell interactions including MSC-MDSC ones represent an 
intriguing new target for cancer therapies that would break the anti-inflammatory tumor 
tolerance mechanisms established by these two cell types however, there is still much left to 
learn before this can come to fruition. Furthermore, while the vast majority of these reports 
demonstrate the ability of MSCs to suppress immune responses or act in an anti-
inflammatory manner, there is emerging evidence that supports their contrasting ability to 
elicit pro-inflammatory responses-- which may also be mediated by their interaction with 
myelomonocytic cells. Both anti-inflammatory and pro-inflammatory effects will be 
important to know in dissecting their specific roles in tumors. This information will 
ultimately help in the design of more effective and targeted cancer therapeutics. 
3.3.2 Immune suppressive or anti-inflammatory responses 
The expression of IDO and iNOS by MSCs has been associated with its immune suppression 
of T-cell proliferation. Recently, secretion of IDO by MSCs therapeutically delivered in an 
experimental autoimmune myasthenia gravis model inhibited the proliferation of 
acetylcholine receptor-specific T cells and B cells and normalized the distribution of Th1, 
Th2, Th17 and Treg cells (Kong, Sun et al. 2009). IDO catalyzes the conversion of 
tryptophan, an essential amino acid for T-cell proliferation, into kynurenine. Immune 
suppression by IDO results from the local accumulation of tryptophan metabolites, rather 
than through tryptophan depletion (Ryan, Barry et al. 2007). Expression of IDO by MSCs 
was thought to be IFN-γ dependent (Krampera, Cosmi et al. 2006; Ryan, Barry et al. 2007; 
Bunnell, Betancourt et al. 2010). However, Opitz and colleagues recently demonstrated that 
IDO expression in MSCs can also be induced by activation of Toll-like receptor 3 (TLR3) and 
TLR4 via induction of an autocrine IFN-β signaling loop involving protein kinase R and 
independent of IFN-γ (Opitz, Litzenburger et al. 2009). Interestingly, when MSCs were 
treated with IFN-γ in vitro, they expressed extremely high levels of IDO and very low levels 
of iNOS, whereas mouse MSCs expressed abundant iNOS and very little IDO. These data 
suggest there is species variation in the mechanisms of MSC immunosuppression (Opitz, 
Litzenburger et al. 2009). 
Prostaglandin E2 (PGE2) is emerging as a central mediator of many of the anti-inflammatory 
properties of MSCs (Nauta and Fibbe 2007; Uccelli, Moretta et al. 2008). PGE-2 is 
synthesized from arachidonic acid by cyclooxygenase (COX) enzymes COX-1 and COX-2. 
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gene/protein 6 (TSG-6). These reports demonstrate that MSC derived TSG-6 acts to repress 
NF-κB signaling in the resident macrophages causing attenuation of pro-inflammatory 
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recruitment of monocytes towards remote sites (Shi, Jia et al. 2011). This elegant study 
demonstrated the intimate and complex cooperation that exists between MSCs and 
myelomonocytic cells that occurs not only in peripheral tissues or tumors but also in their 
originating bone marrow niche. It is widely recognized that tumor infiltrating cells can 
include macrophages, myeloid-derived suppressor cells (MDSCs), MSCs, and TIE2-
expressing monocytes that are all mostly derived from the bone marrow. MDSCs represent 
a heterogeneous population of cells of myeloid origin that are expanded and activated in 
response to growth factors and cytokines released by tumors much like MSCs. The details of 
the effects of MDSCs on tumors are better understood. It is known that once MDSCs are 
activated, they accumulate in lymphoid organs and tumors where they exert specific T cell 
mediated immune suppression. However, not much is known about whether MDSCs and 
MSCs cooperate at tumor sites or the nature of that interaction. It is tempting to suggest that 
MSC-myelomononocytic cell interactions including MSC-MDSC ones represent an 
intriguing new target for cancer therapies that would break the anti-inflammatory tumor 
tolerance mechanisms established by these two cell types however, there is still much left to 
learn before this can come to fruition. Furthermore, while the vast majority of these reports 
demonstrate the ability of MSCs to suppress immune responses or act in an anti-
inflammatory manner, there is emerging evidence that supports their contrasting ability to 
elicit pro-inflammatory responses-- which may also be mediated by their interaction with 
myelomonocytic cells. Both anti-inflammatory and pro-inflammatory effects will be 
important to know in dissecting their specific roles in tumors. This information will 
ultimately help in the design of more effective and targeted cancer therapeutics. 
3.3.2 Immune suppressive or anti-inflammatory responses 
The expression of IDO and iNOS by MSCs has been associated with its immune suppression 
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experimental autoimmune myasthenia gravis model inhibited the proliferation of 
acetylcholine receptor-specific T cells and B cells and normalized the distribution of Th1, 
Th2, Th17 and Treg cells (Kong, Sun et al. 2009). IDO catalyzes the conversion of 
tryptophan, an essential amino acid for T-cell proliferation, into kynurenine. Immune 
suppression by IDO results from the local accumulation of tryptophan metabolites, rather 
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was thought to be IFN-γ dependent (Krampera, Cosmi et al. 2006; Ryan, Barry et al. 2007; 
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IDO expression in MSCs can also be induced by activation of Toll-like receptor 3 (TLR3) and 
TLR4 via induction of an autocrine IFN-β signaling loop involving protein kinase R and 
independent of IFN-γ (Opitz, Litzenburger et al. 2009). Interestingly, when MSCs were 
treated with IFN-γ in vitro, they expressed extremely high levels of IDO and very low levels 
of iNOS, whereas mouse MSCs expressed abundant iNOS and very little IDO. These data 
suggest there is species variation in the mechanisms of MSC immunosuppression (Opitz, 
Litzenburger et al. 2009). 
Prostaglandin E2 (PGE2) is emerging as a central mediator of many of the anti-inflammatory 
properties of MSCs (Nauta and Fibbe 2007; Uccelli, Moretta et al. 2008). PGE-2 is 
synthesized from arachidonic acid by cyclooxygenase (COX) enzymes COX-1 and COX-2. 
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COX-1 is constitutively expressed in MSCs and COX-2 expression can be induced by 
inflammatory cytokines such as IL-1β, IL-6, IFN-γ, and TNF-α (Chen, Wang et al. 2010). 
Inhibitors of PGE2 synthesis attenuated MSC suppression of T cells and natural killer cells 
(Sotiropoulou, Perez et al. 2006; Chen, Wang et al. 2010). PGE2 is associated also with the 
MSC-mediated inhibition of dendritic cell maturation. Nemeth et al. reported that activated 
MSCs released PGE2 causing increased production of IL10 by macrophages, and decreased 
production of the pro-inflammatory cytokines TNF-α and IL-6 in a murine sepsis model 
(Sotiropoulou, Perez et al. 2006). Maggini et al. similarly reported macrophage alterations by 
PGE2 (Maggini, Mirkin et al. 2010). 
Mezey’s group demonstrated that COX-2 is also involved in MSCs ability to suppress mast 
cell activation (Brown, Nemeth et al. 2011). Mast cells (MCs) have a key role in the induction 
of allergic inflammation and contribute to the severity of certain autoimmune diseases. An 
increasing body of literature also implicates MCs in the TME to affect tumor inflammation, 
angiogenesis, and growth (Ribatti, Nico et al. 2011). To date, few studies have investigated 
the potential of mast cell-MSC interactions. Since MCs are critical effector cells in allergic 
inflammation and they represent an important cell type to therapeutically target using the 
immune modulatory properties of MSCs, Mezey’s group set out to study murine MC-MSCs 
effects. They reported that MSCs effectively suppressed specific MC functions in vitro and in 
animal models. MCs co-cultured with MSCs in direct contact, had dampened MC 
degranulation, pro-inflammatory cytokine production, chemokinesis, and chemotaxis. They 
also found that MC degranulation within mouse skin or the peritoneal cavity was 
suppressed following delivery of MSCs. Lastly, they discovered that these inhibitory effects 
were dependent on COX2 in MSCs (Brown, Nemeth et al. 2011). 
Transforming growth factor-β (TGFβ) is an anti-inflammatory cytokine that is constitutively 
expressed by MSCs. The immune modulatory function of MSCs on T cells and natural killer 
cells can be impaired by treatment with neutralizing antibodies to TGFβ (Di Nicola, Carlo-
Stella et al. 2002; Sotiropoulou, Perez et al. 2006). In contrast, several studies have also 
established that TGFβ had no effect on the immunosuppressive properties of MSCs (Tse, 
Pendleton et al. 2003; Xu, Zhang et al. 2007). These discrepancies are likely explained by 
differences in species or experimental conditions. The importance of TGFβ in MSC therapy 
was recently established in a mouse model of ragweed-induced asthma. Mezey’s group 
again demonstrated this assertion with neutralizing antibodies and the use of MSCs derived 
from TGFβ knockout mice (Nemeth, Keane-Myers et al. 2010). Notably, the number of Tregs 
in this model was elevated by the MSC-therapy. However, the role of TGFβ in this process 
was not directly studied, as was done by Patel et al. who showed that in co-cultures of 
peripheral blood mononuclear cells (PBMCs) with MSCs, TGFβ produced by MSCs resulted 
in increased numbers of Tregs (Patel, Meyer et al. 2010). 
Several other factors are associated with the potential anti-inflammatory properties of MSCs 
including HLA-G, hepatocyte growth factor (HGF), leukemia inhibitory factor (LIF), IL1 
receptor antagonist (IL1RA), CCL2, galectin-3, galectin-1 and semaphorin-3A, most of which 
attenuate T lymphocyte activation and are highly expressed by MSCs (Di Nicola, Carlo-
Stella et al. 2002; Ortiz, Dutreil et al. 2007; Di Ianni, Del Papa et al. 2008; Kang, Kang et al. 
2008; Nasef, Ashammakhi et al. 2008; Rafei, Hsieh et al. 2008; Lepelletier, Lecourt et al. 2009; 
Selmani, Naji et al. 2009; Sioud, Mobergslien et al. 2010; Volarevic, Al-Qahtani et al. 2010). A 
recently advanced culprit is TNF-α-induced protein 6 TNAIP6 or TSG-6 (Lee, Pulin et al. 
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2009; Prockop and Youn Oh 2011). TSG-6 secretion is known to suppress inflammation 
through the inhibition of the inflammatory network of proteases primarily by increasing the 
inhibitory activity of inter-α-inhibitor, sequestration of hyaluronan fragments, and 
decreasing neutrophil infiltration into sites of inflammation. In a model of acute 
inflammation induced by myocardial infarction, TSG-6 knockdown in MSCs significantly 
reduced their anti-inflammatory therapeutic effect. The administration of recombinant TSG-
6 protein largely duplicated the therapeutic effects of the delivered MSCs on inflammatory 
responses and infarct size (Getting, Mahoney et al. 2002; Wisniewski and Vilcek 2004; 
Milner, Higman et al. 2006; Forteza, Casalino-Matsuda et al. 2007; Lee, Pulin et al. 2009). 
Together these results make TSG-6 an interesting new factor in the anti-inflammatory effects 
of MSCs.  
3.3.3 Pro-inflammatory MSC responses 
Though we are beginning to better understand the many complex mechanisms associated 
with the secretion by MSCs of immune suppressive mediators like TSG-6, so far only a few 
reports have described a contrasting pro-inflammatory activity of MSCs that could be 
important in understanding the distinct role of MSCs in tumors. Indeed, the observation of 
this distinct MSCs immune effect came from studies primarily focused on the downstream 
consequences of TLR stimulation within these cells. TLRs are a conserved family of 
receptors that recognize pathogen- associated molecular patterns (PAMPs) and promote the 
activation of immune cells (Wright 1999-76; Triantafilou, Triantafilou et al. 2001; Sabroe, 
Read et al. 2003; Anders, Banas et al. 2004; Miggin and O'Neill 2006; West, Koblansky et al. 
2006; Bunnell, Betancourt et al. 2010). Many TLRs (TLR1 to TLR13) have been identified and 
characterized in a variety of immune cell types and species. Agonists for TLRs include 
exogenous microbial components, such as LPS (TLR2 and 4), lipoproteins and 
peptidoglycans (TLR1, 2, 6), viral RNA (TLR3), bacterial and viral unmethylated CpG-DNA 
(TLR9), and endogenous molecules shed following cell injury, including heat shock proteins 
and extracellular matrix molecules (Wright 1999-77; Triantafilou, Triantafilou et al. 2001; 
Sabroe, Read et al. 2003; Anders, Banas et al. 2004; Miggin and O'Neill 2006; West, 
Koblansky et al. 2006; Bunnell, Betancourt et al. 2010). Specific agonist engagement of TLRs 
leads to the expression of inflammatory cytokines or co-stimulatory molecules by a MyD88 
(a TLR adapter protein)-dependent or MyD88-independent signaling pathways and can 
promote chemotaxis of the stimulated cell. TLRs are differentially expressed on leukocyte 
subsets and non-immune cells and may regulate important aspects of innate and adaptive 
immune responses (Mempel, Voelcker et al. 2003; Hwa Cho, Bae et al. 2006; Nagai, Garrett 
et al. 2006; Pevsner-Fischer, Morad et al. 2006; West, Koblansky et al. 2006; Tomchuck, 
Zwezdaryk et al. 2008). 
MSCs are among the cells that express an array of TLRs, including TLR2, 3, 4, 5, 6 and 9 
(Hwa Cho, Bae et al. 2006; Pevsner-Fischer, Morad et al. 2006; Tomchuck, Zwezdaryk et al. 
2008). Furthermore, studies by our group established that the stimulation of MSCs with TLR 
agonists led to the activation of downstream signaling pathways, including NF-kB, AKT, 
and mitogen-activated protein kinase (MAPK). Consequently, activation of these pathways 
triggers the previously unreported induction and secretion of pro-inflammatory cytokines, 
chemokines, and related TLR gene products. Interestingly, the unique patterns of affected 
genes, cytokines, and chemokines measured identified the TLRs as potential players in the 
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established MSC immune modulatory properties, as well as their ability to migrate towards 
injured tissues. Surprisingly, we noted that TLR4 stimulation with LPS led to the secretion 
of primarily pro-inflammatory mediators, such as IL-1β and IL6 (Tomchuck, Zwezdaryk et 
al. 2008). Though unexpected, previous observations reported by Beyth et al. recognized that 
LPS priming affected co-cultures of leukocytes with human MSCs and attenuated the 
expected human MSC- mediated inhibition of T-lymphocyte activation as well as affected 
their capacity to secrete interferon (Beyth, Borovsky et al. 2005). More recently, Romieu-
Mourez et al. showed that TLR stimulation in murine MSCs similarly resulted in the 
production of inflammatory mediators, such as IL-1, IL-6, IL-8, and CCL5 (Romieu-Mourez, 
Francois et al. 2009). Furthermore, they demonstrated that TLR and IFN activated murine 
MSCs injected within Matrigel matrices into mice resulted in the formation of an 
inflammatory site attracting innate immune cells and resulting in a dramatic recruitment of 
neutrophils. Raicevic et al., studying the effect of TLR activation within MSCs in an 
inflammatory milieu, observed that this environment shifted the cytokine profile to a pro-
inflammatory one rather than the expected immunosuppressive one (Raicevic, Rouas et al. 
2010). They similarly observed an increase in IL-1β, IL-6, and IL-12 after TLR activation in 
this inflammatory context. 
Though somewhat confounding, this recent body of work on the downstream consequences of 
TLRs provides emerging evidence for a new pro-inflammatory immune modulating role for 
MSCs. The identification of the molecular details for this new pro-inflammatory MSC role, and 
whether it is innate or just an in vitro artifact, awaits further investigation. However, this novel 
observation is important to consider given the accelerated use of MSCs in anti-inflammatory 
cell-based therapies. Additionally, as Raicevic et al. suggest targeting of TLRs in MSCs, may 
avoid deleterious consequences in their use as anti-inflammatory therapies (Raicevic, Rouas et 
al. 2010). By contrast, TLR-activated pro-inflammatory MSCs could prove useful in breaking 
tolerance in the therapy of immune evasive diseases, such as cancer. 
4. New MSC paradigm: Pro-inflammatory MSC1 and anti-inflammatory MSC2 
Our recent studies are partly an attempt to resolve some of the controversy surrounding the 
potential of MSCs to be anti-inflammatory in some cases and pro-inflammatory in others or 
to be pro-tumor in some cancers and anti-tumor in others, as described above. These studies 
led us to propose a new paradigm for MSCs based on the premise that these heterogeneous 
cells can be induced to polarize into two distinct but homogeneously acting phenotypes--
that we modeled after monocytes, the other heterogeneous bone marrow-derived cells 
(Figure 2. Verreck, de Boer et al. 2006). 
It is established that stimulation of monocytes with known cytokines or agonists to their 
TLRs, including IFN-γ and endotoxin (LPS, TLR4-agonist), polarizes them into a classical 
M1 phenotype that participates in early pro-inflammatory responses. IL-4 treatment of 
monocytes yields the alternative M2 phenotype that is associated with anti-inflammatory 
resolution responses (Verreck, de Boer et al. 2006). We proposed that MSCs, like monocytes, 
are polarized by downstream TLR signaling into two homogenously acting phenotypes, 
classified as MSC1 and MSC2, following the monocyte nomenclature. We reported that 
TLR4 agonists polarized MSCs toward a pro-inflammatory MSC1 phenotype while the 
downstream consequences of TLR3 stimulation of MSCs was a skewing toward an anti-
inflammatory MSC2 phenotype. This novel MSC polarization paradigm is based on the 
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consistent but novel outcomes observed for MSC1 when compared with MSC2 for several 
parameters, including dissimilar patterns of secretion of cytokines and chemokines and 
differences in differentiation capabilities, extracellular matrix deposition, TGF-β signaling 
pathways, and Jagged, IDO and PGE-2 expression (Waterman, Tomchuck et al. 2010). The 
most compelling outcome was opposite effects of each cell type on T-lymphocyte activation 
(Waterman, Tomchuck et al. 2010).  
 
Fig. 2. Characteristics of the MSC1 and MSC2 Phenotypes. Short-term and low-level priming 
of TLR4 (left side) and TLR3 (right side) leads to the induction of heterogeneous hMSC 
preparations into a pro-inflammatory MSC1 phenotype or an anti-inflammatory MSC2 
phenotype. (adapted from (Tomchuck, Zwezdaryk et al. 2008; Waterman,  
Tomchuck et al. 2010)).  
4.1 Evidence for MSC1 and MSC2 
Our previous work, as well as that of others, established that MSCs reside in TMEs or tumor 
stroma, provide structural support for the malignant cells, modulate the tumor 
microenvironment, and consequently promote tumor growth and spread. Therefore, gene-
modified MSCs that can act as “Trojan horses” and deliver anti-cancer therapeutics into the 
tumor stroma are being evaluated as a promising new specific cell-based therapy for cancer. 
We also previously established that MSCs recruited to ovarian tumors by elevated secretion 
of LL-37 play a supportive role in ovarian tumor stroma. We found that specific induction of 
MSCs into MSC1 causes the secretion of pro-inflammatory mediators rather than anti-
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(Waterman, Tomchuck et al. 2010).  
 
Fig. 2. Characteristics of the MSC1 and MSC2 Phenotypes. Short-term and low-level priming 
of TLR4 (left side) and TLR3 (right side) leads to the induction of heterogeneous hMSC 
preparations into a pro-inflammatory MSC1 phenotype or an anti-inflammatory MSC2 
phenotype. (adapted from (Tomchuck, Zwezdaryk et al. 2008; Waterman,  
Tomchuck et al. 2010)).  
4.1 Evidence for MSC1 and MSC2 
Our previous work, as well as that of others, established that MSCs reside in TMEs or tumor 
stroma, provide structural support for the malignant cells, modulate the tumor 
microenvironment, and consequently promote tumor growth and spread. Therefore, gene-
modified MSCs that can act as “Trojan horses” and deliver anti-cancer therapeutics into the 
tumor stroma are being evaluated as a promising new specific cell-based therapy for cancer. 
We also previously established that MSCs recruited to ovarian tumors by elevated secretion 
of LL-37 play a supportive role in ovarian tumor stroma. We found that specific induction of 
MSCs into MSC1 causes the secretion of pro-inflammatory mediators rather than anti-
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inflammatory ones, as well as promotes collagen rather than fibronectin deposition into the 
extracellular matrix (Figure 1)(Waterman, Tomchuck et al. 2010). Our preliminary studies 
support the notion that MSC1 may be effective in new cell-based treatment of cancers. 
Indeed, ovarian cancer cell lines co-cultured with MSC1 formed smaller tumor spheroids 
and had markedly reduced tumor colony forming potential; whereas, co-cultures with 
MSC2 phenotype had the expected pro-tumor effect. Moreover, MSC1-treated ovarian 
cancer cells were less invasive than MSC2-treated ones in matrigel coated transwell 
migration assays. Pilot tests in murine ovarian cancer models were consistent with these 
findings. MSC1 delivered in mice with established tumors had attenuated growth and 
spread. Mice treated with MSC2 had larger and more metastatic tumors. 
MSC1 and MSC2 therapy has been successfully tested in several animal disease models and 
has resulted in predictable inflammatory responses and distinct effects on tumor growth 
and spread (Table 5).  
 
 
Table 5. Human MSC-based therapy of murine disease models.  
Please NOTE that for all of the data presented MSCs represent conventionally prepared 
human MSCs, MSC1 are defined as the hMSCs incubated for 1hr with 10 ng/mL LPS and 
washed prior to delivery. MSC2 are defined as the hMSCs incubated for 1hr with 1 mg/mL 
poly(I:C) and washed prior to delivery (provisional patent filed US 61/391,749). 
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Cancer models: Pilot studies with the mouse ovarian cancer model (MOSEC) and with a 
xenograft model demonstrate our assertions. A single delivery of MSC1-based therapy 
resulted in slower growing tumors, whereas comparable therapy with MSCs or MSC2 
resulted in larger tumors and metastasis at the end of the study (day 65, Figure 3). 
 
Fig. 3. MSC1 do not support tumor growth whereas MSC2 favor tumor growth and 
metastasis. The data show differences in tumor volume, CD45+leukocyte, and F4/80+ 
macrophage recruitment after the treatment of mice with established ovarian tumors, with 
human MSC1- and MSC2-based therapies. Methods The established syngeneic mouse model 
for epithelial ovarian cancer used is based upon a spontaneously transformed mouse 
ovarian surface epithelial cell (MOSEC) line ID8 that has been previously described (Roby, 
Taylor et al. 2000). 4-6 week-old female mice (n>10 mice/MSC-treatment) were injected 
subcutaneously  (s.c.) in the right hind leg with 1 X107 MOSEC cells. At approximately 4 
weeks a single dose of labeled human MSCs (hMSCs), MSC1, or MSC2 (1X106/per mouse) 
were injected intraperitonealy (IP) as indicated by red arrow . (A.) Tumor growth was 
measured with callipers as standard at weekly intervals until day of mouse sacrifice (Day 
65). Harvested tumors and metastasis were weighed, counted and processed for flow 
cytometry and immunohistochemical analysis (IHC, Coffelt et al., 2009). Metastasis was 
found only in MSC2-treated mice (data not shown). MSCs were detected by flow cytometry 
and IHC. All MSC-treated samples had similar detectable MSCs within the tumor tissue-
trending towards more MSC1 and MSC2 measured than hMSCs: approximately 15-25 cells 
counted per 200X field after 24hr of MSC-treatment and 2-5 cells at time of tissue harvest 
(day 65, data not shown). Sectioned tumor sample slides were stained with murine CD45 
(B.) or F4/80 (C.) antibodies and the number of positively stained immune cells per 200X 
field were scored as described previously (Coffelt et al., 2009). Data are expressed as average 
cells counted in 4 fields/slide relative to hMSC sample. Data indicate in vivo stability and 
predictably distinct effects by the MSC1 and MSC2. 
ALI model: In an established endotoxin-induced acute lung injury (ALI) mouse model, LPS, 
or endotoxin (0.1 mg/kg) was instilled intratracheally into adult Balb/C mice. After 24 hrs, 
mice were each treated with 0.5x106 MSCs, MSC1, MSC2, or HBSS vehicle. To characterize 
inflammation, the lungs of the animals were lavaged and bronchioalveolar lavage fluid 
(BALF) was analyzed after 24 hr for changes in neutrophil/monocyte recruitment 
(myeloperoxidase activity), total cell content by flow cytometry, and lung integrity by total 
protein leaked into the BALF (n=12). MSC1-therapy aggravated the disease and resulted in 
 
Tumor Microenvironment and Myelomonocytic Cells 
 
274 
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Cancer models: Pilot studies with the mouse ovarian cancer model (MOSEC) and with a 
xenograft model demonstrate our assertions. A single delivery of MSC1-based therapy 
resulted in slower growing tumors, whereas comparable therapy with MSCs or MSC2 
resulted in larger tumors and metastasis at the end of the study (day 65, Figure 3). 
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human MSC1- and MSC2-based therapies. Methods The established syngeneic mouse model 
for epithelial ovarian cancer used is based upon a spontaneously transformed mouse 
ovarian surface epithelial cell (MOSEC) line ID8 that has been previously described (Roby, 
Taylor et al. 2000). 4-6 week-old female mice (n>10 mice/MSC-treatment) were injected 
subcutaneously  (s.c.) in the right hind leg with 1 X107 MOSEC cells. At approximately 4 
weeks a single dose of labeled human MSCs (hMSCs), MSC1, or MSC2 (1X106/per mouse) 
were injected intraperitonealy (IP) as indicated by red arrow . (A.) Tumor growth was 
measured with callipers as standard at weekly intervals until day of mouse sacrifice (Day 
65). Harvested tumors and metastasis were weighed, counted and processed for flow 
cytometry and immunohistochemical analysis (IHC, Coffelt et al., 2009). Metastasis was 
found only in MSC2-treated mice (data not shown). MSCs were detected by flow cytometry 
and IHC. All MSC-treated samples had similar detectable MSCs within the tumor tissue-
trending towards more MSC1 and MSC2 measured than hMSCs: approximately 15-25 cells 
counted per 200X field after 24hr of MSC-treatment and 2-5 cells at time of tissue harvest 
(day 65, data not shown). Sectioned tumor sample slides were stained with murine CD45 
(B.) or F4/80 (C.) antibodies and the number of positively stained immune cells per 200X 
field were scored as described previously (Coffelt et al., 2009). Data are expressed as average 
cells counted in 4 fields/slide relative to hMSC sample. Data indicate in vivo stability and 
predictably distinct effects by the MSC1 and MSC2. 
ALI model: In an established endotoxin-induced acute lung injury (ALI) mouse model, LPS, 
or endotoxin (0.1 mg/kg) was instilled intratracheally into adult Balb/C mice. After 24 hrs, 
mice were each treated with 0.5x106 MSCs, MSC1, MSC2, or HBSS vehicle. To characterize 
inflammation, the lungs of the animals were lavaged and bronchioalveolar lavage fluid 
(BALF) was analyzed after 24 hr for changes in neutrophil/monocyte recruitment 
(myeloperoxidase activity), total cell content by flow cytometry, and lung integrity by total 
protein leaked into the BALF (n=12). MSC1-therapy aggravated the disease and resulted in 
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increased neutrophil recruitment and more compromised lungs than the conventional MSC 
or MSC2 therapy.  
Diabetes Model: Streptozotocin (STZ)-induced diabetic mice were procured from Jackson 
Laboratory (Bar Harbor, Maine). Blood glucose levels and animal weights were measured 
by standard methods. A month post STZ-injection, mice received intraperitonealy (IP) 
0.5x106 cells of MSCs, MSC1, MSC2, or HBSS vehicle for a total of 3 times in 10-day intervals. 
Established behavioral assays to evaluate hyperalgesia and allodynia were conducted one 
day prior to each MSC therapy, as well as prior to sacrifice. Inflammatory factors and 
immune cell changes were measured as before to characterize the treatment effects on 
inflammation (n=30). Again, all indicators were consistent with enhanced inflammation by 
MSC1-treatment and an improvement of disease by the MSC2- or MSC-treated animals. 
Manuscript in preparation. 
Additionally in vitro studies show divergent effects of MSC1 and MSC2 on cancer cells. Co-
culture of various human cancer cell lines with MSC1 and MSC2 in Colony Forming Units 
(CFU) assays and 3-D tumor spheroid assays agree with the in vivo tumor models with 
different MSC1 and MSC2 treatment effects (Figure 4). 
 
Fig. 4. MSC1 do not support tumor growth whereas MSC2 favor tumor growth: A. Data 
demonstrates that there are distinct effects on colony forming units (CFU) after coculture of 
different human cancer cell lines with untreated MSCs (hMSCs), MSC1, or MSC2. Methods: 
CFU assay was performed by culturing human tumor cells (200 cells/well) mixed with 
hMSCs, MSC1, or MSC2 (2 cells/well) at a ratio of 10 cancer cells per 1 MSC and plated in 
24-well plates in growth medium supplemented with 10% FBS as indicated in figure. 
Cultures were grown for 14 days at 37°C in a humidified atmosphere of 5% carbon dioxide 
balance air. Growth medium was changed every 3-4 days. Colonies were visualized by 
staining with a crystal violet solution (0.5% crystal violet/10% ethanol). The resulting 
colonies were enumerated by the colony counting macro in ImageJ software, SKOV3- 
ovarian cancer cell lines. Micrographs of the stained plates are shown. Colony counts are at 
right.(n=8) B. Data demonstrates that there are distinct effects on tumor spheroids after 
coculture of different cancer cell lines with unprimed MSCs, MSC1, or MSC2. Methods: 
Tumor spheroids were formed by culturing tumor cells (2000 cells/well) mixed without any 
other cells (--) or with hMSCs, MSC1, or MSC2 (20 cells/well) at a ratio of 10 cancer cells per 
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1 MSC and plated over 1.5% agarose in 96-well plates in growth medium supplemented 
with 10% FBS as indicated in figure. Cultures were grown for 14 days at 37°C in a 
humidified atmosphere of 5% carbon dioxide balance air. Growth medium was changed 
every 3-4 days. Micrographs shown represent 20X magnified field of the 96-well plate. 
Cancer cell lines used are: OVCAR-human ovarian cancer, SKOV3-human ovarian cancer 
cell lines, and MOSEC-murine ovarian surface epithelium carcinoma cells. Data indicate 
distinct effects by MSC1 and MSC2 on cancer cell growth and spread.  
5. Conclusion 
The unique pathology of individual tumors presents a huge problem for conventional 
mono-specific therapies. New approaches aiming at developing effective treatments against 
cancer include the use of MSC-based therapies. There are many features that make this new 
strategy attractive and feasible. First, MSC-based therapies are already in clinical use and 
thus far have not been associated with adverse effects. Second, MSCs can be easily 
expanded and stored without any impact to their capabilities—a phenomenom that has 
triggered the creation of many new biotech start-ups. Third, once delivered, MSCs 
preferentially home to tumors and affect tumor growth and spread. Fourth, MSCs from non-
self (allogeneic) or autologous (self) hosts can be safely delivered since they do not elicit 
immunity. Lastly, pre-clinical studies have demonstrated efficacy with genetically-
engineered MSCs that carry anti-cancer therapeutics that reached the tumors and prevented 
their growth. 
MSCs targeted to cancers are expected to contribute many soluble factors such as mitogens, 
extracellular matrix proteins, angiogenic and inflammatory factors, as well as exosomes 
with as yet poorly defined potentials, once resident in the TME. MSCs are also expected to 
affect tumor-associated leukocytes either directly by cell-cell contact or indirectly by the 
secretion of trophic factors. MSCs are known to affect the proliferation and differentiation of 
dendritic cells, monocytes/macrophages, B and T cells, NK cells, and even mast cells. There 
has been a great deal of debate in the field in trying to assert whether MSCs resident in the 
TME contribute to tumor growth and spread or prevent it, and if so, by what mechanisms. 
Many reasons have been advanced to explain the contradictory MSC role in cancer 
including the heterogeneity of MSC preparations, the age or health of the MSC donor, and 
the experimental model or condition, to name a few. Our group has suggested a new 
paradigm for MSCs that we believe will help resolve some of the conflicting issues. The 
induction of MSCs into uniform and consistently acting pro-inflammatory MSC1 or anti-
inflammatory MSC2 phenotypes should provide convenient experimental tools that dissect 
the potential pro- and anti-tumor contributions of MSCs. MSC-based therapies stand to 
revolutionize medicine with the myriad ways that they can be manipulated and guided to 
reach pathologic tissue sites such as tumors. The continued investigation of these cells will 
ensure safe and effective therapy of human disease. 
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Emerging evidence suggests that inflammation is one of the major contributing factors for 
tumor development and progression. In this context, myelomonocytic cells, as key 
mediators of inflammatory responses, are essential components of the malignant 
microenvironment. Numerous studies have provided evidence to show that infiltrating 
tumor-associated macrophages (TAMs) play a critical role in promoting tumor growth. 
Similarly, human studies also revealed that a high frequency of infiltration by TAMs is 
associated with poor prognosis in many human cancers (reviewed in (Bingle et al. 2002)). 
There is now substantial evidence that tumor-associated neutrophils (TANs), like TAMs, 
have a critical role in tumor development (reviewed in (Gregory and Houghton 2011)). 
Despite major research efforts in this area, the role of neutrophils in cancer pathogenesis 
remains controversial. This is likely due to the fact that neutrophils can play a dual role in 
primary tumors: neutrophils can mediate tumor rejection but also promote angiogenesis 
and tissue remodelling which favour tumor growth. Furthermore, emerging evidence 
suggests that neutrophils may also have the ability to promote metastasis. Hence there is 
great potential for novel neutrophil-based therapies in the treatment of cancer if the 
contrasting roles of neutrophils in tumor growth are fully elucidated.  
In this chapter, we will first briefly introduce the methodology of intravital multi-photon 
microscopy (MP-IVM), and then provide an overview of the application of MP-IVM for the 
visualisation of immune cells in tumor models. In addition, we will summarize how this 
technique has helped to reveal the unique interactive behavior of myelomonocytic cells, in 
particular neutrophils, during inflammatory responses. Our intention is to discuss the practical 
aspects of MP-IVM applications, with the aim of highlighting the features of MP microscopy 
that make it an ideal tool for investigating immune cell-tumor interactions in vivo.  
2. Neutrophils in immunity 
The immune system plays a well-established role in protecting the body from a wide variety 
of infectious diseases and in the elimination of endogenous tumors. In both cases, 
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associated with poor prognosis in many human cancers (reviewed in (Bingle et al. 2002)). 
There is now substantial evidence that tumor-associated neutrophils (TANs), like TAMs, 
have a critical role in tumor development (reviewed in (Gregory and Houghton 2011)). 
Despite major research efforts in this area, the role of neutrophils in cancer pathogenesis 
remains controversial. This is likely due to the fact that neutrophils can play a dual role in 
primary tumors: neutrophils can mediate tumor rejection but also promote angiogenesis 
and tissue remodelling which favour tumor growth. Furthermore, emerging evidence 
suggests that neutrophils may also have the ability to promote metastasis. Hence there is 
great potential for novel neutrophil-based therapies in the treatment of cancer if the 
contrasting roles of neutrophils in tumor growth are fully elucidated.  
In this chapter, we will first briefly introduce the methodology of intravital multi-photon 
microscopy (MP-IVM), and then provide an overview of the application of MP-IVM for the 
visualisation of immune cells in tumor models. In addition, we will summarize how this 
technique has helped to reveal the unique interactive behavior of myelomonocytic cells, in 
particular neutrophils, during inflammatory responses. Our intention is to discuss the practical 
aspects of MP-IVM applications, with the aim of highlighting the features of MP microscopy 
that make it an ideal tool for investigating immune cell-tumor interactions in vivo.  
2. Neutrophils in immunity 
The immune system plays a well-established role in protecting the body from a wide variety 
of infectious diseases and in the elimination of endogenous tumors. In both cases, 
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immediate but non-specific protection is mediated by the innate immune system, while the 
adaptive immune system provides more directed ‘antigen-specific’ responses and immune 
memory. Neutrophils, traditionally viewed as ‘first wave’ responders, can perform a diverse 
array of functions. Despite the central role of neutrophils in the acute inflammatory 
response, their role in immunity has only recently been “rediscovered”. It is possible that 
neutrophils have been overlooked because they were considered to be too short-lived to 
play a significant role in the immune response as it evolved over time. Based on in vitro 
assays, neutrophils were thought to have a lifespan <1 day, and only 4-8 hours for activated 
neutrophils (Dancey et al. 1976). However, more rigorous analysis using in vivo deuterium-
labeling has shown non-activated neutrophils to have a lifespan of 5.4 days under 
homeostatic conditions (Pillay et al. 2010). Although the major effector function of 
neutrophils is to induce rapid destruction of targets by phagocytosis and oxidative burst, 
emerging evidence suggests that neutrophils also play a crucial role in shaping the 
subsequent adaptive immune response. Neutrophils have a major effect on the recruitment 
and activation of additional immune cells via the release of soluble factors such as IL-8 and 
CXCL10. In certain circumstances, neutrophils were even shown to suppress the adaptive 
immune response by secreting anti-inflammatory cytokines (e.g. IL-10 and transforming 
growth factor-β) (reviewed in (Kasama et al. 2005)). Together, these data therefore point to a 
growing need to reassess the role of neutrophils in immunity. 
3. Neutrophils in cancer 
There is evidence to suggest that neutrophils play an important role in promoting human 
cancers. Clinical studies have shown that an increase in tumor-infiltrating neutrophils is 
correlated with a poorer outcome in bronchioalveolar carcinoma (Bellocq et al. 1998) and 
localized renal cell carcinomas (Jensen et al. 2009). Moreover, CD11b+ CD15+ neutrophils 
and monocytes with immunosuppressive properties were expanded in the peripheral blood 
of patients with malignant melanoma, and this correlated with disease stage (De Santo et al. 
2010). Similarly, elevated numbers of peripheral blood neutrophils and monocytes have 
been associated with poor prognosis in patients with metastatic melanoma (Schmidt et al. 
2005). Despite the clinical associations reported, the precise role of neutrophils in cancer 
remains controversial (Houghton et al. 2010; Granot et al. 2011).  
There is evidence from animal studies that under some circumstances neutrophils can 
contribute to tumor rejection whilst under other conditions neutrophils can promote tumor 
growth. These two opposing phenotypes have been termed N1 and N2 by analogy to M1 
and M2 polarised macrophages (Fridlender et al. 2009). Under “N1” conditions, neutrophil 
recruitment and activation can result in direct tumor cell killing by reactive oxygen species 
and further recruitment and activation of monocytes, macrophages, dendritic cells, natural 
killer and cytotoxic T cells (Fridlender et al. 2009). Under “N2” conditions, however, the 
non-specific tissue destruction and tissue remodelling induced by neutrophil-derived 
metalloproteases can create space, and angiogenesis induced by neutrophil-derived IL-8 and 
VEGF can ensure ongoing supply of oxygen and nutrients to support further tumor growth 
and also promote metastasis (reviewed in (Noonan et al. 2008; Gregory and Houghton 
2011)). Immunosuppressive cytokines such as IL-10 and TGF-beta secreted by neutrophils 
can dampen anti-tumor adaptive immune responses. Furthermore, neutrophil products, 
such as neutrophil elastase, can directly promote tumor growth (Houghton et al. 2010). 
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Consistent with this, depletion of Ly6G (Gr-1) positive neutrophils was shown to inhibit 
tumor growth and angiogenesis in the B16-F10 mouse melanoma model (Jablonska et al. 
2010). It is likely that the type of neutrophil response against a tumor is highly dependent on 
distinct temporal and anatomical factors. Consistent with this view, a study using 
melanoma cell lines transduced with the neutrophil chemoattractant IL-8 showed a biphasic 
dose-response curve between the number of infiltrating neutrophils and tumor growth 
(Schaider et al. 2003). Thus, it is possible that in the early stages of tumor development, 
neutrophils have an anti-tumor N1 phenotype and that later on neutrophils are conditioned 
to adopt a pro-tumor N2 phenotype.  
Like other cells of the immune system, neutrophils appear to rely on cues from the 
microenvironment to regulate their functional plasticity, i.e. switching between anti-tumor 
and tumor-promoting functions. For instance, TGF-β can skew the population towards N2 
phenotype, whilst blockade of this molecule induces an anti-tumor N1 phenotype 
(Fridlender et al. 2009). Inhibition of PPAR-α signals was found to switch tumor-promoting 
neutrophils into neutrophils with anti-tumor activities (Kaipainen et al. 2007). Delineation of 
neutrophil behaviour in different settings is therefore vital to our understanding of the 
precise role that these cells play in tumor growth and progression as well as to assess their 
potential as targets for therapeutic intervention.  
4. Neutrophils in tumor metastasis 
In addition to their role in primary tumors, neutrophils may also significantly influence 
tumor metastasis. Tumor metastasis is strongly associated with reduced survival of the host, 
making this process an important target for therapeutic intervention. Metastasis is a non-
random process in which tumor cells acquire the capacity to seed particular organs, a 
phenomenon first observed more than 100 years ago by Stephen Paget and known as the 
‘seed’ and ‘soil’ hypothesis (Paget 1889). Evidence that immunological factors (for example, 
cytokines, chemokines, and proteases) may direct metastasising cells to specific organs by 
creating permissive microenvironments for the tumor cells, led to the development of the 
‘pre-metastatic niche’ concept (reviewed in (Kaplan et al. 2006)). Neutrophils, together with 
other bone marrow derived cells, have been implicated in establishing such niches 
(Yamamoto et al. 2008), although the precise role of neutrophils remains to be elucidated. 
Neutrophils may play an important role during tumor metastasis by establishing specific 
microenvironments that promote tumor cell ‘seeding’ of secondary sites. For instance, 
neutrophils can release tissue-remodelling factors such as matrix metalloproteases, which may 
assist in the establishment of a physiological niche, and also secrete chemoattractants that may 
recruit other cells. Interestingly a recent study by Granot et al. suggests that at least in certain 
conditions neutrophils ‘entrained’ by the tumor may actually inhibit metastasis by generating 
hydrogen peroxide (Granot et al. 2011). This further emphasises the potential complexity of 
neutrophil functions in cancer and highlights the need for further investigation. 
5. Application of multi-photon microscopy in tumor-related research 
Imaging has become an important tool in cancer research. Perhaps one of the biggest 
advancements in recent years is in the field of fluorescence-based imaging. With the 
availability of a wide array of fluorescent reporter mice and the rapid development of cell- 
and tissue-specific labeling techniques (reviewed in (Germain et al. 2006; Hickman et al. 
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2009)), researchers can now address important questions in cancer biology in vivo. One 
fluorescence-based imaging approach that has received a lot of attention in recent years is 
MP microscopy. This technique has rapidly evolved beyond merely observational to address 
complex biological questions at a quantitative level. It is now possible to perform dynamic, 
multi-dimensional imaging to simultaneously track cell populations at the single cell level in 
living tissues or organs (Cahalan and Parker 2008). Consequently, anatomical, cellular, and 
molecular information can be obtained through this approach. For more detailed technical 
information about the general setup of a MP microscope, please refer to these publications 
(Germain et al. 2006; Phan and Bullen 2010).  
5.1 In vivo imaging of tumor development using multi-photon microscopy 
Over the past few years, a number of laboratories have applied MP microscopy to 
investigate tumor-related biological questions. In 2001, a seminal study from Jain laboratory 
showed the applicability of MP imaging for studying tumor cell development in vivo for the 
first time. In this study, MP-IVM was employed to investigate cell behavior in a dorsal skin fold 
chamber tumor model in mice. Jain and colleagues visualized tumor cell localization, 
angiogenesis, as well as leukocyte-blood vessel interactions and vessel permeability with high 
spatial and temporal resolution (Brown et al. 2001). Since then this approach has been adopted 
by researchers in the field of tumor biology to study tumor cell migration and tissue 
invasion, as well as angiogenesis, matrix remodeling and metastasis (reviewed in (Zal and 
Chodaczek 2010)). 
5.2 In vivo imaging of TAMs 
Although macrophages have been implicated in many aspects of tumor development, the 
spatial and temporal regulation of TAMs in the context of the tumor microenvironment is 
still poorly understood. In 2007, the Condeelis lab provided detailed information about the 
localization of macrophages and tumor cells in relation to blood vessels in a three-
dimensional (3D) context in vivo. TAMs were shown to be predominantly located in the 
tumor margin. In addition, Condeelis and colleagues reported the presence of a population 
of perivascular macrophages deep within tumors (Wyckoff et al. 2007). Importantly, this 
study provided evidence to support the notion that abluminally localized perivascular 
macrophages are important for the intravasation of tumor cells (Wyckoff et al. 2007). In 
another study of MP imaging of TAMs, Pittet laboratory demonstrated a novel method to 
specifically label M2 polarized TAMs with nanoparticles (AMTA680), thereby allowing the 
tracking of this subset of TAMs in vivo by MP-IVM (Leimgruber et al. 2009).  
5.3 In vivo imaging of tumor killing cytotoxic cells 
Arguably, the best-characterised immune imaging model during the early days of MP 
microscopy was that of B and T cell behaviour in lymph nodes. Most of these studies mainly 
focused on naïve T cells and their locomotion within the lymph node during priming 
(Bousso and Robey 2003; Mempel et al. 2004; Miller et al. 2002). Results from these 
experiments provided important framework for the subsequent studies of effector cells 
within target tissues. It is now well established that effector cells such as CD8 cytotoxic T 
cells (CTLs) and NK cells play a crucial role in host defence against malignant cells and 
viruses. In early MP imaging studies, three independent laboratories analysed the behaviour 
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of infiltrating cytotoxic CD8+ T cells (CTLs) in solid tumors (Boissonnas et al. 2007; Breart et 
al. 2008; Mrass et al. 2006)). These studies revealed for the first time the migratory and 
interactive behaviour of intratumoral CTLs at different stages of tumor development, for 
example during progressing or regressing stages. One key observation was that CTL 
motility and long lasting interactions with tumor cells were dependent on the presence of 
cognate antigen (Boissonnas et al. 2007; Mrass et al. 2006). In addition, the Weninger lab 
showed that physical interaction between CTLs and tumor cells preceded the initiation of 
the killing of the tumor cells (Mrass et al. 2006). A study by the Bousso lab further examined 
the kinetics of tumor cell killing by CTLs in vivo. Surprisingly, this study demonstrated that 
it required on average 6 hours for a CTL to destroy one tumor cell, which was much longer 
than expected based on previous in vitro results (Breart et al. 2008). A subsequent study from 
the same lab showed that Natural Killer (NK) cell dissemination and motility within the 
tumor were highly dependent on the presence of its ligand, Rae-1β. Although it is known 
that both CTLs and NK cells mediate similar cytotoxic activity (Russell and Ley 2002), this 
study showed that NK cells had a distinct intratumoral behaviour  compared to CTLs. 
Tumor infiltrating NK cells only formed transient contacts with target cells after initial 
interaction, whereas CTLs normally establish long lasting contacts that can last for more 
than 20 minutes (Deguine et al. 2011).  
6. Dynamic view of neutrophil responses 
As outlined in the previous section, there is now a wealth of knowledge about the behaviour 
of adaptive immune cells in primary tumors. Neutrophil dynamics in tumors and other 
inflammatory settings remain largely unexplored. However, recent studies utilizing 
intravital microscopy have provided some insight into the mechanisms of neutrophil 
adhesion and transmigration across the endothelium into the tissues, as well as the 
dynamics of neutrophil interstitial migration to or within their target sites (McDonald and 
Kubes 2011). Specifically intravital imaging studies including infection models in the skin, 
lymph nodes, and lungs have provided us with the first clues as to how neutrophil 
interstitial migration is regulated in vivo (Chtanova et al. 2008; Kreisel et al. 2010; Peters et al. 
2008; Zinselmeyer et al. 2008). A seminal study by Sacks and colleagues provided the first in 
vivo observations of neutrophil recruitment from the blood vessels into the skin in response 
to Leishmania Major transmitted by sand bite (Peters et al. 2008). Interestingly, neutrophils 
readily internalised the parasites but failed to destroy them, thus aiding parasite 
dissemination by acting as Trojan horses.  
Another important step in characterising neutrophil function in vivo came from a study of 
the immune response to Toxoplasma gondii infection in mice. Analysis of neutrophil 
behaviour in toxoplasma-infected lymph nodes revealed a strikingly coordinated pattern of 
migration with multiple cells simultaneously responding to an external signal to coalesce 
into dynamic swarms (Chtanova et al. 2008). Interestingly, neutrophil swarm formation 
coincided in space and time with the removal of the underlying tissue suggesting that 
swarm formation may present a mechanism for large scale tissue remodelling. This process 
could in turn provide a means for early and rapid removal of infected tissues preventing 
pathogen dissemination. Furthermore, these neutrophils also destroyed infected CD169+ 
subcapsular sinus (SCS) macrophages found in the lymph nodes. These SCS macrophages 
play a key role in sampling antigen from the periphery drained by the lymph, and are 
responsible for antigen presentation to B cells (Phan et al. 2007), CD8+ T cells (Chtanova et 
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al. 2009) and NK T cells (Barral et al. 2010). Thus, the results of this study imply that not 
only can neutrophils clear infected cells but may also indiscriminately destroy cells that are 
important for the initiation of anti-pathogen immune responses. Dynamic clustering (or 
swarming) of neutrophils was also observed in lung tissues in response to bacterial 
challenge (Kreisel et al. 2010) 
These findings suggest that specific molecular cues guide neutrophils through the compacted 
interstitial tissues towards the foci of infection/inflammation. Indeed, a recent study by Kubes 
lab using in vivo confocal microscopy to examine sterile liver injury has uncovered several 
molecular pathways involved in neutrophil sensing of injury. The authors showed that the exit 
of neutrophils from the circulation depended on ATP from the necrotic cells, and the Nlrp3 
inflammasome, whereas migration towards the site of injury required a chemokine gradient 
and formyl-peptide signals as guidance cues (McDonald et al. 2011).  
Using MP-IVM, we have recently characterised the cascade of events and molecular cues 
that guide neutrophils through the extravascular space within skin (Figure 1). In this 
study, we demonstrated that following confined physical injury, neutrophil accumulation 
at the injury site takes place in three distinct sequential steps (Ng et al. 2011). Initially,  
rare scouting neutrophils migrate in a directional manner towards the injury site. This  
is followed by the amplified attraction of additional waves of neutrophils in a highly  
 
 
Fig. 1. Multiphoton imaging of neutrophil responses in Lysozyme-GFP mice 
Time-lapse images showing the applicability of Lysozyme-GFP mice for studying neutrophil dynamic 
in vivo (skin), allowing co-visualization of neutrophils (green, tagged by green fluorescent protein), 
blood vessels (red, highlighted by Evans blue injection) and dermal collagen fibers (blue, detected 
through second harmonic generation signals). White arrows indicate the migratory path of an 
extravasating neutrophil over time. Time: min:sec. Scale bar: 30m. 
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synchronized manner, and finally there is a stabilisation of the neutrophil cluster around the 
injury. Interestingly, while neutrophil migration during steady-state conditions and during 
the scouting phase depended on G protein-coupled receptor signaling, the amplification 
phase was sensitive to interference with the cyclic adenosine diphosphate ribose pathway 
(Ng et al. 2011).  
Together, these studies show that neutrophil responses to pathogen or injury are regulated 
by complex mechanisms. These observations also clearly demonstrate that neutrophil 
responses are highly dependent on the nature of the initial stimuli, injury versus pathogenic. 
Understanding the molecular cues governing the distinct neutrophil behaviour in response 
to different stimuli may lead to new knowledge about neutrophil function.   
7. Mouse models and experimental considerations 
As outlined above are heavily involved in immune responses to pathogens and injury, and 
that their recruitment and behaviour are intricately controlled. Although neutrophil dynamics 
in the context of tumors remain to be visualised, it is likely that a similarly complex picture 
will emerge for neutrophils inside primary tumors and at potential sites of metastasis. Here we 
will provide information about the tools available for in vivo microscopic examination of 
neutrophil-tumor interactions. In addition, we will also several experimental considerations in 
applying MP microscopy to visualise intratumoral cellular activities.  
7.1 Visualizing neutrophils, blood vessels and extracellular matrix structures in 
tumors 
Currently, there is a wide array of fluorescent transgenic mice suitable for MP microscopy. 
Lysozyme-GFP (Faust et al. 2000) and MacGreen-GFP mice (MacDonald et al. 2005) are the 
most widely used mice for direct visualisation of neutrophils in vivo. Although all myeloid 
cells in these mice express GFP, neutrophils express the highest amount of the fluorescent 
protein (Ng et al. 2011), which makes them distinguishable from monocytes or macrophages 
based on the fluorescent intensity and cell morphology. To visualize blood vessels, quantum 
dots, fluorescent dextrans and lectins or Evans blue dye can be injected intravenously (Ng et 
al. 2011; Hickman et al. 2009; Germain et al. 2006; Li et al. 2012). Furthermore, changes in the 
extracellular matrix within tumors can be monitored by second and third harmonic generation 
signals (Friedl et al. 2007). Alternatively cells of implanted tumors can be labeled by genetically 
expressing a fluorescent protein of choice (Mrass et al. 2006; Wyckoff et al. 2007). 
7.2 In vivo versus explanted tumor imaging 
Most tumor imaging studies have been performed in vivo, either through skin flaps or the 
skin window chamber approach (Wyckoff et al. 2007; Boissonnas et al. 2007). Although these 
approaches are useful, they only allow a limited field of view of the tumor cells due to 
physical constraints. Furthermore, some tumors are inaccessible. These limitations can be 
circumvented by using tumor explant models (Mrass et al. 2008; Mrass et al. 2006), which 
allow imaging of multiple fields of view per explanted tumor. The ability to image multiple 
regions is important, as tumor tissues are highly heterogeneous in composition in terms of 
tumor cell density, extracellular matrix remodeling and angiogenesis, as well as cellular 
infiltration. However, important drawbacks of this approach include lack of blood 
circulation and lymphatic flow, as well as innervations.  
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important for the initiation of anti-pathogen immune responses. Dynamic clustering (or 
swarming) of neutrophils was also observed in lung tissues in response to bacterial 
challenge (Kreisel et al. 2010) 
These findings suggest that specific molecular cues guide neutrophils through the compacted 
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Fig. 1. Multiphoton imaging of neutrophil responses in Lysozyme-GFP mice 
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in vivo (skin), allowing co-visualization of neutrophils (green, tagged by green fluorescent protein), 
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allow imaging of multiple fields of view per explanted tumor. The ability to image multiple 
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infiltration. However, important drawbacks of this approach include lack of blood 
circulation and lymphatic flow, as well as innervations.  
 
Tumor Microenvironment and Myelomonocytic Cells 
 
294 
7.3 Choice of tumor models 
When selecting an appropriate tumor model for MP imaging in addition to the biological 
question being asked, it is important to review several technical considerations. For instance, 
we have observed that pigmented tissues and cells are highly sensitive to MP illumination due 
to their high MP absorption, and contribute to the generation of non-specific high intensity 
signals (“speckling”) (Ng et al. 2011; Li et al. 2012). This speckling not only compromises the 
image quality, but also induces heat injury that can trigger an inflammatory response and 
severely damage the tissue. We therefore recommend the use of non-pigmented tumor models 
in order to minimise artifacts caused by photodamage during imaging.  
8. Neutrophil dynamics in tumors – A prospective 
Great strides have been made in understanding the function of different immune cell 
subsets in cancer. Intravital MP imaging has played an important role in this process, and 
has allowed us to view CD8 T cells and NK cells killing tumor cells, and TAMs aiding tumor 
intravasation in vivo. However, many more questions remain unanswered. This is 
particularly true with regard to neutrophils. Recent technological advances in MP 
microscopy together with an ever-growing array of biological tools now make it possible to 
unravel the role that neutrophils may play in tumor growth and metastasis by directing 
visualising their activities within their native environment. 
Intravital imaging experiments have already demonstrated neutrophil recruitment and 
subsequent swarming in inflamed tissues during immune responses to injury and infection. 
We anticipate that a similarly complex picture will emerge for neutrophils inside primary 
tumors and also at potential sites of metastasis. We expect that N1 and N2 neutrophils might 
exhibit different patterns of behaviour. For instance, neutrophils of the anti-tumor phenotype 
might function as they do in infection, that is, by initiating cell recruitment followed by a 
coordinated response to external signals with formation of dynamic swarms, which remodel 
underlying tissue. On the other hand a change in neutrophil behaviour might reflect a 
conversion to a pro-tumor phenotype. Pro-tumor neutrophils maybe less motile reflecting 
their angiogenesis-promoting role. Thus, by directly observing the behaviour of these cells in 
tumors, we will be able to gain unique insight into their role in tumor growth. 
9. Conclusion 
In conclusion, although neutrophils are frequently dismissed as short-lived ‘foot-soldiers’ of 
immunity, recent studies point to an important contribution of these cells to cancer. 
Furthermore, the apparent functional plasticity of neutrophils makes them a great target for 
therapeutic intervention and further highlights the need to unravel the role of neutrophils in 
cancer pathogenesis. We envision that MP imaging will not only contribute to the basic 
knowledge related to tumor development, but also will gradually become an important tool 
for preclinical studies for assessing drug delivery to tumor cells as well as the effects of 
therapeutic agents on immune and tumor cells.  
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interplay of different cell types (e.g. tumor cells, stromal cells), their soluble products 
(e.g.cytokines, chemokines and growth factors) and varied physico-chemical 
conditions (e.g low oxygen concentration or hypoxia). Recent studies have identified 
myelomonocytic cells as key players in regulating the tumor microenvironment 
and hence, tumor progression in a variety of cancers. In view of these findings, the 
present book attemps to provide a comprehensive account of the diversity of tumor 
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